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Abstract(
Dupuytren’s disease (DD) is a fibroproliferative disorder causing deformity of 
fingers and disability.  Different treatments exist ranging from dividing cords 
(needle aponeurotomy) through disease excision (fasciectomy) to disease 
excision with resurfacing with a skin graft (dermofasciectomy).  A range of 
outcome measurements has been used in DD, including angular 
measurements of finger joints and patient-reported outcome measures 
(PROMs). 
This thesis hypothesised that the leading candidate outcome measures are 
inadequate (subject to bias, invalid, and/or uninterpretable) and that currently 
there is insufficient evidence to inform patient-centred treatment choice in DD. 
To investigate this, existing evidence was appraised and studies of validity 
and interpretability of outcomes were conducted.  This comprised a systematic 
review and meta-analysis of surgical trials, a systematic review of 
interpretability of outcome measures, cross sectional studies of the validity of 
leading candidate outcome measures (joint angles, the Disabilities of the Arm, 
Shoulder and Hand tool (DASH), and the Unité Rhumatologique des 
Affections de la Main scale (URAM)), and a prospective cohort study of 
outcome interpretability and variables associated with functional outcome. 
Key findings: 
• There were too few trials comparing treatments to inform practice in 
DD, and methodological quality was generally poor. 
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• There were limited interpretability data to guide the design of future 
studies.  
• Dynamism was present in 89% of digits, with mean MCPJ dynamism of 
6o and PIPJ dynamism of 14o; 11% of digits exhibited over 30 degrees 
of dynamism. 
• Patients had virtually unique goals for surgery, with 26% captured by 
the URAM 
• The DASH and the URAM were not structurally valid in factor analysis 
• The DASH was uninterpretable; the URAM’s minimal important change 
was 10.5 
• The factors associated with poor functional outcome differ from those 
associated with recurrence. 
Future work should examine validity for other outcome measures; qualitative 
investigation of patients’ experiences; and patient-centred high quality 
randomised controlled trials. 
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1 Introduction(
This chapter will describe the key features of Dupuytren’s disease, and 
explain why this project was required. 
 
1.1 What(Dupuytren’s(disease(is(and(why(it(matters(
Dupuytren’s disease is a condition in which fibrous changes occur in 
association with the palmar fascia, a subcutaneous layer in the hand.  This 
forms palpable nodules, which are believed to progress into cords and 
eventually flexion contractures of the fingers (Luck, 1959), preventing full 
extension at their metacarpophalangeal joints (MCPJs) and the proximal 
interphalangeal joints (PIPJs), and more rarely at their distal interphalangeal 
joints (DIPJs).  This results in impairment of function.  The reported 
prevalence of the condition varies widely.  Given that the prevalence of 
Dupuytren’s disease in the United Kingdom (UK) may be as high as 18% for 
men and 9% for women (Early, 1962), it may account for considerable 
morbidity. 
Furthermore, Hospital Episode Statistics (HES) data reveal that 12 191 palmar 
or digital fasciectomy surgeries were performed on National Health Service 
(NHS) inpatients in England alone in 2009-2010 (Hospital Episode Statistics, 
2011), thus management of Dupuytren’s disease constitutes a significant 
workload to healthcare services in the UK.  Data based on NHS tariffs 
estimate the cost of this treatment at £41 576 141 in 2010-2011 in England 
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alone (Gerber et al., 2011).  The actual number of procedures carried out for 
Dupuytren’s disease is probably much higher, as the HES data figure only 
captures inpatient operations from England, and not minor outpatient 
procedures, or data from other UK countries.  Thus the burden of the condition 
for the NHS across the UK is probably much greater.  The true socioeconomic 
‘cost’ of Dupuytren’s disease is not described by tariff alone, and the cost of 
ramifications of the condition and its treatment are almost certainly much 
greater than the figure described by Gerber and colleagues.  Functional 
impairment in the hand may affect employability of working age patients, and 
may increase dependence and the need for social care services in the elderly.  
These effects are difficult to capture accurately, and are not assessed in 
current UK national cost effectiveness analyses (NICE, 2008). 
As Dupuytren’s disease is a progressive condition, recurrence or progression 
are commonly encountered, even after successful treatment.  Both may result 
in a return to disability and/or need for further treatment for some patients.  
Additionally, different treatments exist, and vary in terms of recovery time, 
complication rate, early and late outcome, as well as “procedure” cost.  High 
quality comparative data are urgently required to inform treatment choice, and 
to establish the cost effectiveness of treating the condition at all. 
Published data do exist describing recurrence after individual treatment types.  
These typically are descriptions of return of angular deformity in non-
comparative studies (Armstrong et al., 2000, van Rijssen and Werker, 2006, 
Zachariae, 1969).  In comparative studies, either a similar definition was used 
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(van Rijssen et al., 2012), or the definition was not provided (Ullah et al., 
2009).  However, work that the candidate previously conducted for his MSc 
degree dissertation, and the findings of two different systematic reviews, 
demonstrated that there is no consistent definition of recurrence, and no 
consensus on when it should be assessed, between different studies (Ball et 
al., 2013, Becker and Davis, 2010, Rodrigues, 2010).  The two most likely 
candidates for primary outcome measure in future trials of Dupuytren’s 
disease treatment are: (a) an assessment of finger joint angles, as have been 
used in previous randomised controlled trials (Hurst et al., 2009, van Rijssen 
et al., 2006, van Rijssen et al., 2012); or, (b) a patient-reported outcome 
measure (PROM) assessing impairment of hand function, of which several 
have been previously used (Ball et al., 2013).  Angular deformity does not 
correlate well with the most commonly used of these measures of functional 
impairment (Engstrand et al., 2009, Jerosch-Herold et al., 2011, Zyluk and 
Jagielski, 2007), and whether either provides meaningful quantification of 
treatment efficacy is unclear.  This limits the applicability of study outcomes, 
prevents comparison of findings between studies and procedures, and 
compounds the paucity of high quality comparative trials in this condition. 
With new techniques such as collagenase injection being developed and 
launched to treat this common condition (FDA, 2010), there is an urgent need 
for robust and meaningful comparative data. 
In this project, the existing data comparing different surgical interventions for 
Dupuytren’s disease will be appraised, along with the tools used to assess 
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outcomes studied.  Outcome measure selection, early functional recovery, 
treatment failure rate, late outcome and complication rate will be considered 
for the most commonly employed surgical treatments of Dupuytren’s disease. 
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1.2 Anatomy(and(PathoWanatomy(
There are important aspects of the anatomy of the hand and other bodily sites 
affected by Dupuytren’s disease and its associated conditions that must be 
appreciated.  The complexity of the anatomy of the hand itself is also of 
relevance to treatment and expected outcome of treatment at different sites 
within the hand and even within a single digit. 
1.2.1 Palmar(fascia(anatomy(
Dupuytren’s disease is associated with the palmar fascia.  This consists of a 
continuum that spreads out distally from the tendon of palmaris longus at the 
wrist, forming a specific three-dimensional arrangement.  The components of 
these normal arrangements are referred to as fascia, ligaments or bands 
(Hurst, 2010).  In contrast, diseased tissue is referred to as nodules or cords 
(Hurst, 2010).  Understanding the normal anatomical arrangement of 
structures aids the surgeon in identifying and treating the disease. 
In the previous (fifth) edition of Green’s Operative Hand Surgery, McGrouther 
classifies these arrangements based on fibre orientation.  There are 
transverse fibres of Skoog crossing the distal palm, which are the deepest of 
all the fascial structures.  The neurovascular bundles are deep to them, and 
thus sheltered by them in the palm. 
Distal to Skoog’s fibres are longitudinal fibres, classified into three layers by 
McGrouther (McGrouther, 2005), referring to his own review of anatomical 
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descriptions of the palm, and McFarlane’s review of the digit, both in the same 
book (McFarlane, 1990, McGrouther, 1990).  These fan out distally when 
viewed in a sagittal plane through the hand.  The deepest ones pass lateral to 
both the flexor tendon and the bone around the metacarpophalangeal joint 
(MCPJ) level. 
The most superficial layer forms weak insertions into the palmar skin at 
proximal skin creases of the fingers, with some fibres continuing distally into 
the finger as the pretendinous band. 
The second layer also passes deep, around the side of the flexor tendon and 
deep to the neurovascular bundle.  These form the spiral bands, passing 
around the neurovascular bundle, and further distally to this, continue as 
retrovascular bands deep to the neurovascular bundle in the finger. 
The third layer passes deepest close to the MCPJ to insert into the extensor 
apparatus. 
The structural pattern summarised by McGrouther has implications for the 
surgeon.  For example, as the longitudinal fibres rest on the superficial surface 
of Skoog’s transverse fibres, with the neurovascular bundles deep to all of 
them, a longitudinal cord can be peeled off the transverse fibres without 
risking damage to the bundles.  Furthermore, as one moves into the finger, 
the wraparound relationship of the spiral band with the neurovascular bundle 
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means that as the contracture develops, the bundle will be displaced towards 
the midline and will become more superficial (McFarlane, 1974). 
In contrast to McGrouther, Hurst’s chapter in the most recent edition of 
Green’s Operative Hand Surgery divides the fascia into three regions based 
on surface landmarks.  Passing proximally to distally, these are the palm, the 
palmar-digital junction, and the digit (Hurst, 2010).  By classifying the disease 
into discrete surface anatomy regions, Hurst’s approach focuses the 
surgeon’s mind on the specific pathological structures likely to be relevant 
when managing disease at a particular site clinically.  Within the palm, central 
cords are encountered and extend distally through the other regions, with 
natatory cords at the palmar-digital junction, and retrovascular cords and 
lateral digital cords in the digit.  Spiral cords extend through the regions in a 
similar fashion to central cords (Hurst, 2010). 
It is apparent from both of these descriptions that Dupuytren’s disease is not a 
single anatomical entity.  At any site passing from the palm to the digit, one or 
more different cords may be encountered, in different planes, with different 
consequences in terms of contracture.  Furthermore, treating only some of the 
Dupuytren’s tissue present in a ray may or may not be adequate to release 
the contracture, depending on the pattern of disease present.  As a result, it is 
conceivable that the ‘same’ operation performed by different surgeons may 
have very different outcomes.  Furthermore, the exact pattern of disease 
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present in a ray may not necessarily be describable by surface clinical 
examination alone. 
1.2.2 Finger(joint(anatomy(
The joints involved in contractures must also be considered.  The MCPJs of 
the digits are synovial joints between the metacarpal head and the proximal 
phalanx.  The metacarpal head is not perfectly round, instead it is narrower 
dorsally, with a volar prominence (Tubiana et al., 1996).  Consequently, the 
radial and ulnar collateral ligaments that augment the lateral aspects of the 
joint capsule are relatively lax when the joint is in extension, allowing medial 
and lateral deviation (clinically this is abduction and adduction of the digits) 
and some degree of rotation.  They tighten when the joint flexes.  Thus, the 
joint only becomes stable when flexed.  An increasing contracture of the 
MCPJ (as occurs in Dupuytren’s disease) tightens the collateral ligaments and 
maintains their length.  As a result, when treatment releases the Dupuytren’s 
cord, the joint range of motion of the joint itself has been maintained by the 
increased tension on the ligaments, and the contracted joint can be 
straightened (Figure 1.1). 
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Figure 1.1: Metacarpophalangeal joint throughout its arc of motion 
In contrast, the proximal interphalangeal joint (PIPJ) is stable throughout its 
range of motion; hence it does not allow abduction or adduction.  This is 
achieved by maintaining even tension in the collateral ligaments throughout 
flexion and extension (Tubiana et al., 1996).  Furthermore, the volar plate (the 
palmar augmentation of the joint capsule) structure differs at the PIPJ from the 
MCPJ.  At the PIPJ, it inserts proximally into the flexor sheath via two strong 
‘check rein ligaments’, one on each side (Tubiana et al., 1996).  When the 
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joint is held flexed for a prolonged period (as in Dupuytren’s disease across 
the joint), the ligaments remain as tight as in any other position, but the volar 
plate contracts through its check rein ligaments.  Consequently, even if the 
Dupuytren’s cord is adequately treated at the PIPJ, the joint itself may not 
straighten until a ‘check rein ligament release’ has been performed.  As the 
proximal extent of the flexor sheath at the A1 pulley is level with the MCPJ, 
the MCPJ’s volar plate does not have proximal check rein ligaments.  As a 
result, MCPJs the mechanism of stiffness in flexion that occurs at the PIPJ 
does not occur at the MCPJ.  Such stiffness at the PIPJ is often incorrectly 
considered a collateral ligament effect, when it is instead a volar plate effect 
(Figure 1.2).  This explains why Dupuytren’s contractures of the PIPJ are 
harder to successfully correct than contractures of the MCPJ (Ritchie et al., 
2004, Smith and Breed, 1994). 
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Figure 1.2: Proximal interphalangeal joint throughout its arc of motion 
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SUMMARY 
Dupuytren’s disease is associated with the palmar fascia of the hand.  As 
there is a complex three-dimensional pattern to this structure, Dupuytren’s 
disease may present as a range of different cords in a digit, and more than 
one cord may be present in a digit, with implications for both clinical 
assessment and treatment.  The MCPJs and PIPJs respond differently to 
prolonged contracture and this may lead to differences in the expected 
treatment outcome of MCPJ and PIPJ disease.  
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1.3 Pathophysiology,(aetiology(and(epidemiology(in(relation(to(outcome(
Dupuytren’s disease is characterised by progressive fibroproliferative changes 
associated with the palmar fascia, or aponeurosis, of the hand (Hurst, 2010).  
McGrouther points out that this entity is neither truly palmar, nor is it strictly 
fascia (McGrouther, 2005).  Instead, it comprises the subcutaneous fibrofatty 
layer of the hand, deep to the glabrous skin and superficial to deeper 
structures such as the flexor tendons.  The three-dimensional structure of the 
palmar fascia that influences the pattern of Dupuytren’s disease has been 
discussed in the anatomy section.  There are aspects of the pathology, 
aetiology and epidemiology that may influence the risk of developing 
Dupuytren’s disease, the rate of progression and severity of any contractures 
that do occur.  Numerous studies have investigated the influence of variables 
on prevalence of Dupuytren’s disease as summarised by Hart and Hooper 
(Hart and Hooper, 2005), usually through cross-sectional and case-control 
study designs.  However, only a few studies have investigated factors 
influencing a high risk of recurrence after treatment (Abe et al., 2004, 
Hindocha et al., 2006, van Rijssen et al., 2012).  Identification of relevant 
factors that affect clinical outcome following treatment are important in trial 
design, as steps may then taken to match intervention and control cohorts, or 
to control for them.  A selection of particular factors putatively influencing 
treatment outcome will be discussed here to identify which will be studied in 
this project.  The likelihood that they influence functional outcome is 
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summarised (Table 1.1: Summary of likelihood that factors influence functional 
outcome). 
Throughout any discussion of such scientific work, it must be appreciated that 
this is a very common, but late onset, condition.  This poses a particular 
challenge for researchers conducting case-control studies.  Obtaining true 
‘controls’ from within a population itself at significant risk of developing the 
condition later is problematic – how does one know that a member of the 
‘control’ group is not actually a pre-clinical ‘case’?  The answer may lie in 
obtaining large enough sample sizes such that these latent ‘cases’ within the 
‘control’ group become a small minority.  This may be possible for large, multi-
centre studies investigating human genetics (Dolmans et al., 2011).  However, 
much laboratory work is labour-intensive, and only capable of producing small 
sample sizes.  This issue must be borne in mind when analysing studies 
involving such case-control comparison with a small sample size. 
1.3.1 Studies(of(Dupuytren’s(diathesis(
The logical starting point for identifying factors influencing outcome is to 
review studies of Dupuytren’s diathesis.  The term diathesis was first coined 
by Hueston (Hueston, 1963). It describes a group of factors that are 
associated with a higher likelihood of recurrence or extension of Dupuytren’s 
disease after treatment.  Recurrence has been defined as the reappearance 
of disease within the treated field, and extension as the appearance of 
disease in a neighbouring previously normal area (Leclercq, 2000).  The 
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original factors proposed by Hueston included early onset of disease, 
ethnicity, family history of the condition, bilateral hand disease, and ‘ectopic’ 
lesions outwith the glabrous palmar skin.  Different groups have conducted 
further analysis of diathesis factors.  Abe and colleagues studied the factors 
associated with progression to revision surgery (Abe et al., 2004).  In their 
study, early onset of disease, bilateral hand disease, ectopic lesions, radial 
sided disease and little finger surgery were associated with increased risks of 
recurrence and extension requiring revision surgery in their Japanese 
population.  However, family history was not associated with either.  The 
authors went on to generate a formula for calculating a diathesis score to risk-
stratify preoperative patients.  There are some criticisms of this paper.  Firstly, 
it involved relatively small sample sizes (18 recurrences and 47 with no 
recurrence), and was based on retrospective case note review.  Therefore, 
data completion rate and accuracy may have been compromised.  The use of 
linear discriminant analysis is dependent on normal distributed data, in 
contrast to binary logistic regression (Spicer, 2004).  Abe and colleagues do 
not define their data distribution sufficiently for us to be sure of the legitimacy 
of this approach, an omission that limits the reader’s ability to support their 
conclusions.  Importantly, the use of revision surgery to dichotomise 
recurrence/extension may not be suitable.  Not all patients may choose to 
undergo revision surgery, even if their condition recurs, and some may not be 
fit for further surgery for unrelated reasons.  Furthermore, the generalizability 
of a small Japanese study to Northern European population may not be 
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appropriate.  Indeed, there is growing evidence of an underlying genetic 
predisposition to Dupuytren’s disease amongst Northern Europeans (Dolmans 
et al., 2012). In keeping with this, Hindocha and colleagues’ UK-based study 
identified family history as a factor associated with recurrence (defined as 
reappearance of palpable disease) (Hindocha et al., 2006).  This larger study 
of 322 patients also identified male gender and age of onset below 50 years 
as factors associated with recurrence.  Whilst this study may be more 
generalisable to the rest of UK NHS, there are still some limitations to the 
findings.  The endpoint of reappearance of palpable disease does not 
describe a clinically meaningful endpoint, as will be discussed below.  No 
patient would undergo further surgery simply for the reappearance of a 
nodule, in the absence of evidence that this reliably predicts future functional 
impairment or need for further treatment.  Furthermore, it is not applicable to 
treatment modalities involving division of disease tissue (such as needle 
aponeurotomy) rather than excision of disease tissue.  The particular surgical 
procedures that the patients had undergone are not discussed in the paper.  If 
any had undergone needle or blade aponeurotomy, then this may compromise 
the validity of their findings.  It is likely that the majority underwent 
fasciectomy, and while this is an excisional procedure, it is unclear whether 
recurrent disease activity can be reliably distinguished from postoperative scar 
tissue.  Indeed, hand surgeons’ diagnoses of Dupuytren’s disease outstrip 
those by other doctors (Noble et al., 1984).  Hindocha and colleagues’ work 
thus may be of limited value when informing clinical practice. 
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A recent randomised controlled trial comparing fasciectomy to needle 
aponeurotomy from the Netherlands also included an assessment of factors 
influencing outcome (van Rijssen et al., 2012).  In this paper, the definition of 
recurrence involved recurrent angular deformity, in contrast to reoperation as 
used by Abe and colleagues, or palpable disease reappearance as used by 
Hindocha and colleagues.  The only variable associated with greater 
recurrence was young age (<50) at time of treatment.  All other diathesis 
factors were not significantly associated with recurrence.  These data are 
perhaps the most useful to date.  However, the relatively small sample size of 
the study (93 patients) may have rendered their logistic regression 
underpowered to identify relevant factors associated with recurrence.  Van 
Rijssen and colleagues’ data still do not describe the factors associated with 
poor functional outcome after treatment, which might be expected to be most 
relevant to patients, treatment providers and treatment commissioners. 
1.3.2 Disease(stage(
The formation of additional tissue in cases of Dupuytren’s disease, rather than 
simply contraction of existing tissue, was first identified in the 19th century by 
Goyrand (Goyrand, 1833).  When clinically detectable upon inspection and/or 
palpation, this tissue is described as nodules or cords.  Inconsistently, at a 
microscopic level, the term ‘nodule’ is also used to describe a whorl of cells in 
diseased tissue (McGrouther, 2005).  In the past half-century, significant 
resource and energy have been focussed on better understanding the biology 
University of Nottingham          Introduction 
 18 
of this novel Dupuytren’s disease tissue.  Early in this line of work, Luck 
reviewed histology of tissue from over 200 affected hands in his widely-cited 
1959 paper (Luck, 1959).  His work remains the cornerstone of textbook 
discussions (McGrouther, 2005).  He proposed a sequence of progression 
from a nodule to a cord, and he classified the disease into three stages: 
proliferative, involutional and residual.  In the proliferative phase, nodules are 
composed primarily of disorganised fibroblasts, with little collagen.  During the 
involutional phase, the fibroblasts align in the direction of the predominant 
tension.  The cells mature, collagen production increases and contraction 
occurs, resulting in the classical joint contractures.  At the same time, the 
nodule becomes less well defined, eventually completing its involution to leave 
a fibrous and relatively acellular cord in the residual phase.  This sequence 
implies that cords may be relatively inert compared to the developing nodule. 
The purported culprit cell, Gabbiani’s ‘modified fibroblast’ (Gabbiani et al., 
1971), is today referred to as a myofibroblast, although its absolute distinction 
from smooth muscle cells still remains poorly defined.  Numerous markers 
have been suggested to separate the pair.  However, as Hinz summarises, all 
have failed to stand up to rigorous examination (Hinz, 2007).   Amongst 
others, the capacity to produce laminin was considered to be a smooth muscle 
cell capability, but the myofibroblast has since been shown capable of this in 
vivo too (Berndt et al., 1994). 
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The influence of disease stage on clinical outcome may be complex.  Whilst 
logic suggests that those with more advanced contractures may have more 
severe disease, contracture severity did not correlate with genetic burden in a 
large study (Dolmans et al., 2012).  Instead, preoperative contracture severity 
may be influenced by a variety of factors, including patient behaviour in terms 
of delayed presentation to health services.  Furthermore, angular deformity 
does not correlate well with functional impairment (Engstrand et al., 2009, 
Jerosch-Herold et al., 2011, Zyluk and Jagielski, 2007).  However, there are 
anatomical reasons why severe contractures may achieve poorer clinical 
outcomes in terms of contracture correction.  This will be discussed in the 
anatomy section. 
1.3.3 Age(
Early age of onset of Dupuytren’s disease has been proposed as a factor 
contributing to Dupuytren’s diathesis in terms of recurrent surgery and 
recurrent palpable disease (Abe et al., 2004, Hindocha et al., 2006).  
Additionally, this is associated with carriage of high genetic risk alleles 
(Dolmans et al., 2012).  However, it is unclear how reliable the data are.  
When a diabetologist assessed the prevalence of Dupuytren’s disease 
amongst a British diabetes clinic population, it was reported to be half of the 
prevalence obtained when assessments were made by a hand surgeon 
(Noble et al., 1984).  It might be expected that prior to diagnosis, patients’ own 
identification of early disease (and thus their estimation of their age at onset) 
will be at least as inaccurate as that of a non-specialist doctor, and probably 
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much worse.  As they may be much older by the time of questioning, they may 
also have issues with recall of their age at onset.  As a result, this may be an 
unreliable factor to attempt to study.  In contrast, age at surgery can be 
studied very accurately, and older age at surgery was associated with lower 
recurrence of angular deformity in a recent trial (van Rijssen et al., 2012).  
Patient expectation and level of activity is likely to vary with age, and so 
younger patients may be expected to have greater functional outcome 
demands.  Understanding the age at treatment might also be of more use in 
estimating outcome when a patient attends for surgery.  As a result, age at 
treatment will be studied here. 
1.3.4 Previous(Surgery(
Attending for repeated surgery might influence outcome in several ways.  
Patients who have undergone surgery for Dupuytren’s disease to a site may 
be expected to have more severe disease, which has progressed more rapidly 
requiring re-intervention.  Moreover, further surgery may compound risks of 
complications and potentially reduce hand function.  It is possible that 
requiring revision surgery at the same centre may also indicate that the first 
operation performed was inadequate, and therefore revision surgery by the 
same surgeon may pose a greater risk of inadequacy than average.  
However, a different surgeon at the same centre may have performed the first 
operation.  Alternatively, the patient may have changed to a different service 
provider, either due to previous dissatisfaction, or simply due to changes in 
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referral pathways and waiting times.  As such, it is likely to be a complex 
variable to interpret, but may be important to consider.  There are also aspects 
of basic science that may be relevant to the influence of previous surgery on 
outcome from current surgery. 
The sources of the transforming growth factor beta-1 (TGFβ1) that may drive 
myofibroblast differentiation in Dupuytren’s disease are likely to include a 
variety of immune system cells, as reviewed by Al-Qattan (Al-Qattan, 2006).  
Langerhans cells, the skin’s antigen-presenting cell, may coordinate this.  
Langerhans cells may be stimulated by interleukin-1 to migrate into 
Dupuytren’s tissue from the epidermis and orchestrate this effect (Qureshi et 
al., 2001).   
The role of TGFβ1 itself in the development of myofibroblasts has also been 
investigated.  Whilst one study demonstrated elevated levels of TGFβ1 in 
Dupuytren’s tissue compared to control tissues (Baird et al., 1993), 
examination of common polymorphisms in the TGFβ1 gene did not 
demonstrate significant differences between Dupuytren’s disease patients and 
controls (Bayat et al., 2002), nor did examination of a novel polymorphism by 
the same group (Bayat et al., 2002).  However, other in vitro work has 
suggested that Dupuytren’s tissue fibroblasts may be more sensitive to the 
effects of TGFβ1 (Alioto et al., 1994).  Furthermore, it has been proposed that 
recurrence of the condition after surgery may result from stimulation of 
quiescent fibroblasts by TGFβ1 (Bisson et al., 2003).  Thus, it may be that the 
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fibroblasts and myofibroblasts of Dupuytren’s patients that differ in their 
response to TGFβ1 compared to controls, rather than a difference in quantity 
or quality of the TGFβ1 itself in Dupuytren’s patients.  Furthermore, the 
potential mechanism by which surgery may actually stimulate recurrence may 
be of relevance to rapid recurrence observed in some cases. 
1.3.5 Family(history(and(surrogate(markers(of(genetic(risk(
A genetic component to the aetiology of Dupuytren’s disease is increasingly 
supported.  A large multi-centre, international, genome-wide association study 
has implicated nine different genome loci as being associated with 
Dupuytren’s disease (Dolmans et al., 2011).  Six of these nine are involved in 
the Wnt signalling pathway (Dolmans et al., 2011).  Wnt proteins are thought 
to contribute to processes as varied as embryogenesis and carcinogenesis, as 
reviewed by Logan and Nusse (Logan and Nusse, 2004).  It is striking that all 
such situations involve cell proliferation and its regulation, so it is feasible that 
Wnt dysfunction might contribute to Dupuytren’s disease development.  It has 
been proposed that in Dupuytren’s disease, Wnt’s action on frizzled receptor 
proteins drives beta-catenin production, which may stimulate cell proliferation 
(Dolmans et al., 2011).  Thus a genetic-based mechanism for driving fibroblast 
proliferation may be present.  Further work by the same group has suggested 
that patients with an early age of onset (<50), knuckle pads, and a family 
history of Dupuytren’s disease are more likely to carry these risk alleles 
(Dolmans et al., 2012).  This suggests that such clinical features may be 
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surrogate markers of high genetic risk of developing Dupuytren’s disease.  As 
has been discussed, such features have been shown to be associated with 
recurrent surgery (Abe et al., 2004), and recurrence of palpable disease 
(Hindocha et al., 2006), but only age at treatment was associated with 
recurrence of angular deformity in a recent randomised controlled trial (van 
Rijssen et al., 2012).  It is not clear whether genetic factors would influence 
functional outcome. 
1.3.6 Ethnicity(
The fact that the prevalence of Dupuytren’s disease is reported to be highest 
in men of Northern European origin is widely quoted.  Identification of this is 
attributed to Early’s 1962 paper, where he attributes its geographical 
distribution to the historical migration of people of Norse origin (Early, 1962).  
Other factors such as climate, or behaviour might be similar between such 
places and account for any higher prevalence.  Conversely, if it were the 
Norse genetics that were causative, then the term ‘Northern European’ may 
not be suitable, as it would include other genetic lineages beyond simply 
Viking genetics.  Furthermore, the condition is not purely one seen in those of 
Norse origin.  Dupuytren’s disease has been reported in other geographical 
areas, such as Bosnia, (Srivastava et al., 1989, Zerajic and Finsen, 2004).  
Such data demonstrate its occurrence in a population with different genetic 
heritages, as well as different climates and behavioural norms.  Some 
variation between ethnic groups within a region may be present.  For example, 
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Zerajic’s group investigated the incidence of Dupuytren’s disease in a sample 
of 1207 members of the population in Bosnia (Zerajic and Finsen, 2004).  
There was a significantly lower prevalence of Dupuytren’s disease in Muslim 
men compared to Serbs or Croats.  Whether this truly represents a genetic 
difference is not clear.  The same difference was not seen in the women 
evaluated.  This may represent a genetic variation in susceptibility to the 
influence of androgens in driving Dupuytren’s.  Certainly, a role for androgens 
at a molecular level has been investigated (Pagnotta et al., 2002, Pagnotta et 
al., 2003).  However, there may be other explanations.  There may be 
socioeconomic variation between men of different groups, for example in 
terms of rates of heavy manual occupation.  Alternatively, there may be 
cultural differences.  For example, alcohol consumption may be higher in Serb 
and Croat men compared to Muslims and women.  Such confounding 
variables limit the reliability of the findings of epidemiological work in general.   
Srivastava and colleagues described Dupuytren’s disease in a case series of 
ten people of Indian origin (Srivastava et al., 1989).  At the time, this was the 
first report of the condition on Indian Asians.  However, the cohort was all 
treated in the West Midlands in the United Kingdom.  Whilst this might 
demonstrate the presence of a genetic cause of Dupuytren’s disease in 
Indians, which has only been recognised in a free at the point of use 
healthcare service in the United Kingdom, alternatively it may be simply 
under-reported in India.  Another explanation is that it may support a strong 
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influence of climate, or cultural or social change, in terms of manual work or 
alcohol consumption. 
Saboeiro’s work standardised variables to allow inter-racial comparison.  The 
group compared the rate of surgery for Dupuytren’s disease between 
ethnicities in Veterans Affairs (VA) hospitals in the United States of America 
(Saboeiro et al., 2000).  This demonstrated that surgery rates were highest in 
Caucasians, followed by Hispanics with lowest rates in African Americans.  
Whilst this appears to be a controlled comparison on the basis of ethnicity, 
there are numerous confounding factors.  Whilst the VA services are free at 
the point of use, there may have been cultural and socioeconomic differences 
between racial groups affecting their uptake of services by veterans with 
Dupuytren’s disease.  Finally, there is no fixed indication for surgery for 
Dupuytren’s disease.  This racial variation could be accounted for by 
institutional bias in treatment on the basis of race.  Consequently, whilst this 
study design provides data on a large cohort, and eliminates some sources of 
bias, it is affected by several other potential biases.  Thus, the epidemiology of 
Dupuytren’s disease is not as clear as may be thought. 
1.3.7 Gender(
It is accepted that Dupuytren’s disease is more common in men, and that its 
prevalence increases with age.  Early’s paper suggests that the prevalence in 
British people over the age of 75 may be as high as 18.1% in men, and 9% in 
women (Early, 1962).  Certainly, a difference in prevalence between sexes 
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would fit with Pagnotta and colleagues’ work on the potential role of 
androgens in driving Dupuytren’s disease at a cellular level (Pagnotta et al., 
2002, Pagnotta et al., 2003).  This difference between sexes balanced out in 
old age in one widely-cited study (Ross, 1999).  In contrast, whilst the 
difference between sexes was also seen in Zerajic’s study from Bosnia, the 
difference was seen in every decade, and was still marked in those over 
eighty (Zerajic and Finsen, 2004).  This may be a racial difference or there 
may be other contributory factors.  Studying Dupuytren’s disease in very 
elderly patients is not straightforward; Gudmundsson’s group demonstrated 
increased mortality in Dupuytren’s disease patients, even once several 
confounders (such as smoking) were accounted for (Gudmundsson et al., 
2002).  Their study of Iceland’s death registry suggests that there may be an 
increased cancer incidence in those with the condition, which might explain 
such a finding.  The mechanistic explanation of this is not known.  
Nevertheless, if increased mortality were proportional to Dupuytren’s disease 
severity, or androgen-dependence, then the difference in Dupuytren’s 
prevalence between men and women might appear to decrease with age, due 
to relatively higher survival of women with the condition, whilst men with 
condition are more likely to have died.  Whilst gender differences in incidence 
exist and can potentially be explained, it is unclear whether gender would 
influence functional outcome specifically. 
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1.3.8 Diabetes,(alcohol(and(smoking(
Other factors may also contribute to pathophysiology.  The presence of free 
radicals may stimulate fibroblast proliferation, which have been demonstrated 
to increase fibroblast density in Dupuytren’s tissue cultured in vitro (Murrell et 
al., 1987).  Free radicals could arise from the impact of exogenous factors, 
such as alcohol, trauma and diabetes mellitus, as well as from ageing.  In his 
review article covering pathogenic factors, Al-Qattan suggests that such 
agents may give rise to free radicals by stimulating the conversion of xanthine 
dehydrogenase to xanthine oxidase (Al-Qattan, 2006).  No evidence is cited to 
support this suggestion.  If such an effect does exist, it might provide a 
mechanism for the potential (and controversial) aetiological effect of such 
factors.  There are numerous potential associations with Dupuytren’s disease 
that may relate to free radical stress: diabetes mellitus, tobacco and alcohol 
usage, and even epilepsy.  Not only might this free radical pathway affect 
disease progression, but also it may influence other aspects of functional 
outcome and recovery. 
Geoghegan and colleagues have shown that diabetes mellitus is associated 
with Dupuytren’s contracture, even following logistic regression to adjust for 
the influence of consulting behaviour (Geoghegan et al., 2004).  The 
association between Dupuytren’s disease and diabetes mellitus has also been 
suggested in numerous earlier studies, such as that by Chammas and 
colleagues (Chammas et al., 1995). 
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In Geoghegan’s study, the strongest association was between insulin therapy 
and Dupuytren’s contracture, compared to other diabetes treatments.  By 
demonstrating that medically controlled diabetics are more likely to have 
Dupuytren’s disease than diet-controlled diabetics, Geoghegan suggests that 
diabetes severity may contribute to the likelihood of developing Dupuytren’s 
disease (Geoghegan et al., 2004). 
If studying the relationship between Dupuytren’s disease and well-defined 
comorbidities such as diabetes mellitus is challenging, then studying some of 
the other purported risk factors for Dupuytren’s may prove even more difficult. 
Tobacco and alcohol use correlate with each other, as reviewed by Bien (Bien 
and Burge), thus population studies that attempt to examine either individually 
must account for this.  Alternatively, both might be examined together, given 
that they are thought to contribute to Dupuytren’s pathogenesis through the 
same mechanism of free radical generation (Murrell et al., 1987). 
Godtfredsen and colleagues recruited patients from the Copenhagen Heart 
study to investigate the relationship between alcohol and tobacco intake and 
Dupuytren’s disease.  They found a dose-dependent association for both 
variables (Godtfredsen et al., 2004).  However, their data were collected by 
nurses and medical students, and so may be subject to the same poor 
sensitivity as that described by Saboeiro and colleagues (Saboeiro et al., 
2000).  Furthermore, the non-expert assessors were trained specifically to 
identify contractures affecting the ring and little fingers.  This strategy might 
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overlook patients whose only present disease was radial, as is widely known 
to occur in diabetics.  Consequently, there is a risk that the accuracy of the 
data obtained was doubly inaccurate.  Also, the measure of alcohol and 
tobacco intake was based on self-reports by patients.  There is thus no 
guarantee that this variable has been accurately determined.  This raises the 
issue of reliable assessment of variables with potential stigma attached to 
them, such as alcohol and tobacco consumption, where a social desirability 
response may occur. 
1.3.9 Epilepsy(
Epilepsy has been suggested to be an association since the 1940s (Lund, 
1941).  This has remained controversial since.  For example, one large study 
of Dupuytren’s patient from Germany has suggested that Dupuytren’s patients 
with epilepsy are more likely to develop worse contractures (Loos et al., 
2007).  In contrast, no increased odds ratio of having Dupuytren’s disease 
was seen in epileptics in Geoghegan and colleagues’ study of the United 
Kingdom General Practice Research database (Geoghegan et al., 2004).  
Furthermore, epilepsy itself may not cause Dupuytren’s disease, but may be a 
confounding factor; certain antiepileptic medications are purported to 
contribute to is development based on different studies (Al-Qattan, 2006, 
Lund, 1941), in particular phenobarbitone (Critchley et al., 1976). 
Geoghegan and colleagues’ work looked at epilepsy-associated factors.  They 
demonstrated no association of specific antiepileptic medications being 
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associated with Dupuytren’s disease.  Lund had identified phenobarbitone, a 
barbiturate, as being particularly associated with Dupuytren’s (Lund, 1941).  
Geoghegan did not demonstrate statistical significance of such an effect, and 
could not find any mechanistic explanation as to why it might contribute to 
Dupuytren’s pathogenesis, and so disregards it (Geoghegan et al., 2004). 
However, Al-Qattan’s later review of pathogenesis does provide a potential 
mechanism.  It suggests that it may be due to increased lysophosphatidic acid 
levels from altered cholesterol metabolism, although without adequate 
justification of this suggestion (Al-Qattan, 2006).  An in vitro study by Rayan 
and colleagues provides the explanatory link missing from Al-Qattan’s 
algorithm (Rayan et al., 1996).  They studied Dupuytren’s myofibroblast 
contraction using a collagen matrix – a similar technique to that used to study 
contraction by Brown and colleagues (Brown et al., 1998).  They 
demonstrated a dose-dependent myofibroblast contraction in response to 
lysophosphatidic acid (Rayan et al., 1996).  Additionally, a study by Tripoli and 
colleagues considered cases of contractures in patients treated with 
phenobarbitone (Tripoli et al., 2011).  Three cases are considered that 
illustrate a potential dose-dependent effect of phenobarbitone on recurrence 
following surgery for Dupuytren’s contracture.  Regression of early recurrence 
was observed in two patients who had a dose reduction of the drug and 
changed to carbamazepine.  The third patient, who continued phenobarbitone, 
continued to develop recurrence (Tripoli et al., 2011).  Unfortunately, as a very 
small and retrospective observational study, little value can be placed on 
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these findings alone.  Phenobarbitone represented the highest odds ratio for 
association with Dupuytren’s disease (2.67 with 95% confidence intervals of 
0.93 and 7.69).  It is highly likely that this study was underpowered given the 
small sample size, as evidenced by the broad confidence intervals, but it may 
merit further attention. 
Furthermore, many of the more specific problems with the larger studies that 
have been discussed all arise due to frequent basic flaws.  One is that the 
datasets being used to study Dupuytren’s disease were actually gathered for 
another purpose.  This can be seen with Saboeiro’s study investigating race 
(Saboeiro et al., 2000), in which data were gathered from assessments by 
different clinicians in Veterans’ Affairs hospitals.  It is also the case with 
Geoghegan and colleagues’ work (Geoghegan et al., 2004), which used GP 
records.  Godtfredsen and colleagues’ work used assessment of nurses and 
medical students trained to identify disease in the fourth and fifth rays 
(Godtfredsen et al., 2004).  In these three studies, diagnostic inaccuracy 
becomes problematic, as has been demonstrated by Noble and colleagues 
(Noble et al., 1984).  Also, Gotfredsen’s paper used patients from the 
Copenhagen City Heart Study (Godtfredsen et al., 2004).  This gives rise to 
issues with selection bias, as well as inaccurate diagnosis of Dupuytren’s 
disease (with its resulting impact on false negatives within the control cohort).  
One clear way to avoid such issues would be to carry out a well-designed, 
multi-centre population study specifically intended to study Dupuytren’s 
disease. 
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1.3.10 Occupation(
Manual labour has also been controversially associated with the development 
of Dupuytren’s disease.  The first suggestions of this came from the historical 
works of Cooper and Dupuytren himself, both of whom considered 
occupational factors as contributory to the pathogenesis (Cooper, 1822, 
Dupuytren, 1834).  Examination of this potential association extends beyond 
medical interest alone; a causative association between specific occupations 
and Dupuytren’s disease would be of political and economic interest.  Indeed, 
a United Kingdom government report examined the potential link a century 
ago, and found no evidence of an association (Collis and Eatock, 1912).  As a 
result, Dupuytren’s disease was not entered onto the list of occupational 
diseases for which compensation could be claimed.  Proving or disproving a 
genuine causative association with manual work may be challenging: the type 
and duration of ‘trauma’ experienced by the glabrous skin of the hand is likely 
to vary between specific occupations, and between workers within a particular 
group.  Additionally, pastimes and changes in occupation may act as 
confounding factors.  The growing evidence of genetic associations with the 
disease provides an alternative, albeit a non-mutually exclusive, aetiology.  
However, the association with other fibroproliferative conditions such as 
Ledderhose’s disease in the soles of the feet and Peyronie’s disease in the 
tunica albuginea of the corpora cavernosa in the penis (Leclercq, 2000), 
suggests that a systemically-acting causative factor is at least partially 
responsible, rather than simply manual labour alone. 
University of Nottingham          Introduction 
 33 
1.3.11 Summary(of(candidate(factors(
There is not currently evidence to support the roles of all of the factors that 
comprise the Dupuytren’s diathesis.  Furthermore, some of the factors that are 
associated with disease development, progression or even recurrence, may 
not contribute to poor outcome when defined in terms of function.  The factors 
reviewed are summarised in Table 1.1. 
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Candidate 
factor 
Likelihood of 
influencing 
functional 
outcome 
Comment 
Disease stage +/- Poor correlation between deformity 
and existing function PROMs.  
Advanced disease may be less 
functionally limiting. 
Age + Younger patients expected to have 
higher functional demands 
Previous 
surgery 
+ Expected to adversely affect 
function 
Family history - May influence incidence, but 
unlikely to influence functional 
outcome.  Surrogate markers such 
as knuckle pads relatively 
straightforward to assess. 
Ethnicity - Difficult to define in a cosmopolitan 
society, and to distinguish from 
environmental and social 
confounders.  Both this and family 
history may be phenotypes of 
underlying genetic tendencies, 
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which are becoming more apparent. 
Gender - Gives rise to differences in 
incidence, but not for difference in 
functional outcome 
Diabetes 
mellitus 
+ Likely to affect disease progression, 
complications and thus function. 
Alcohol intake + Likely to affect disease progression, 
complications and thus function.  
May be subject to social desirability 
response posing a challenge to 
accurate recording 
Smoking status + Likely to affect disease progression, 
complications and thus function.  
May be subject to social desirability 
response posing a challenge to 
accurate recording. 
Epilepsy - Unclear whether this influences 
disease incidence, and probably 
does not influence functional 
outcome 
Occupation - Unclear whether this does influence 
disease progression.  It is likely to 
be confounded by differences 
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between occupations and by other 
activities (e.g. hobbies).  Unlikely to 
affect functional outcome in a 
predictable manner 
Table 1.1: Summary of likelihood that factors influence functional 
outcome 
Key: 
+ Probably influences functional outcome in reliable manner 
- Probably does not influence functional outcome in reliable manner 
+/- May influence functional outcome, but not in a reliable manner 
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SUMMARY 
Whilst some studies have investigated factors that might influence 
Dupuytren’s diathesis, there are no data describing which factors influence 
functional outcome following surgery.  Of the candidate factors discussed 
here, some are more likely to affect function in a predictable manner, and are 
amenable to being assessed.  Some factors that are traditionally associated 
with disease development or progression, such as ethnicity, may not affect 
functional outcome in those with Dupuytren’s disease. 
Others, such as diabetes, may affect disease progression in terms of 
postoperative recurrence, but also affect risk of complications and so are likely 
to affect functional outcome. 
 
 (
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1.4 Clinical(Assessment(&(Outcome(Measures(
Dupuytren’s disease is diagnosed and assessed through history and clinical 
examination.  There are no further investigative tests specific to making this 
diagnosis, or to assessing severity, in either clinical practice or research at 
present.  However, there are different approaches to the clinical assessment 
of Dupuytren’s disease.  As a result, there are several potential measures that 
could constitute the optimal technique for assessing outcome following 
treatment. 
1.4.1 Context(of(assessment(
Making the diagnosis involves history and examination, to identify the 
development and presence of palpable nodules and cords, with or without 
resulting joint extension deficits (Hurst, 2010).  Rarely, imaging techniques 
such as x-ray or magnetic resonance imaging may be used when associated 
conditions, such as arthritis, are suspected (Hurst, 2010), but no specific 
diagnostic tests exist.  Once the diagnosis is made, an assessment of the 
‘severity’ of the condition could be made using a number of strategies, ranging 
from patient-reported history of limitation, to objective measures of angular 
deformity.  The measures used will be required to assess early outcome 
following treatment, and also long-term outcome, particularly as recurrence 
may occur following even ‘successful’ treatment.  Both are of importance for 
research purposes as well as clinical assessment of follow up cases.  As a 
condition that is not terminal, other commonly used biomedical research 
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endpoints, such as mortality, are not relevant to Dupuytren’s disease.  
Instead, assessments of disease state, morbidity and cost effectiveness are 
required.  However, Dupuytren’s disease is a slowly progressive condition, 
and so identifying a late outcome such as recurrence itself may require an 
impractically long follow-up for a study.  Thus, an outcome measure that 
predicts later deterioration might be advantageous, but this would need to be 
appropriately validated. 
The situation is made more complicated by several variables.  Patients’ 
opinion and experience may influence behaviour.  As a non-terminal condition, 
some patients may elect to decline treatment for primary disease.  
Alternatively, patients who experience recurrence or complications may refuse 
further intervention. 
Furthermore, surgeons’ behaviour may influence treatment.  Treatment might 
be employed to prevent loss of function, rather than to treat it.  For example, it 
is considered that outcome from treating PIPJ contractures is often worse than 
MCPJ contractures, possibly due to the anatomical differences in ligament 
arrangements of these joints, as previously discussed.  There is a lower 
recommended threshold for treating PIPJ contractures, with surgery being 
considered for even mild contracture (BSSH, 2008).  Thus the surgeon might 
offer treatment at an early stage for a PIPJ contracture, to prevent subsequent 
worsening functional impairment that cannot be corrected.  As a result, if a 
patient subsequently develops a contracture, it is not classified as a 
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‘recurrence’, as he or she is experiencing a first episode of function loss.  
However, it is still not clear whether a significant proportion of patients 
undergoing NHS treatment at present are being treated ‘prophylactically’ 
based on medical advice rather than symptoms.  This will be investigated as 
part of this thesis.  A further question is whether such prophylactic treatment is 
cost effective, and therefore whether it should be funded. 
1.4.2 Primary(outcome(measure(for(future(research(
In a randomised controlled trial of Dupuytren’s disease surgery, a variety of 
assessments would be included as secondary outcome measures.  However, 
there is a need to select an appropriate primary outcome measure.  This will 
be the measure for which the study would be powered to identify a clinically 
significant difference.  This thesis will investigate some of the relevant 
parameters of validity and reliability to assist the selection of a future primary 
outcome measure. 
The main long-term outcome described in Dupuytren’s disease is ‘recurrence’ 
of the condition.  However, the definition of this is not standardised and varies 
widely (Ball et al., 2013, Becker and Davis, 2010, Rodrigues, 2010).  
Recurrence rate is reported in terms of recurrence per joint treated, per ray 
operated upon, per hand, and in others per patient.   
Furthermore, the length of follow up employed in studies is not standardised 
and has been shown to vary greatly (Rodrigues, 2010).  As Dupuytren’s 
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disease is a progressive condition, a gradual increase in ‘recurrence rate’ is to 
be expected with a longer follow up.  At the same time, lengthy follow up 
studies will delay translation into clinical practice, and may affect factors such 
as attrition from participant dropout. 
‘Recurrence’ in Dupuytren’s disease typically refers to the proportion of 
patients successfully treated at the early assessment, that has gone on to 
experience a deterioration.  However, it should be borne in mind that a 
proportion of patients experience treatment failure at the early assessment, 
and that these patients are not accounted for in recurrence rates.  This 
proportion can be large – in one recent randomised controlled trial of 
collagenase therapy for Dupuytren’s disease, 36% of those treated failed to 
reach the primary endpoint (Hurst et al., 2009).  Any subsequent description of 
this patient cohort should account for the fact that over a third of those treated 
had a suboptimal initial result, and will thus continue to have a poor outcome 
at the late follow up, regardless of what the recurrence rate is for those 
successfully treated. 
Thus, there is currently no accepted primary outcome measure for future 
research, and no consensus for when it should be assessed.  Furthermore, in 
future, it may be more meaningful to consider the rate of poor outcome 
following intervention rather than recurrence in those successfully treated. 
The choice of primary outcome measure is inextricably linked to the main 
question that a study would set out to answer.  Previous studies have 
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measures such as initial correction of angular deformity as the primary early 
outcome measure, with recurrent deformity as the primary late outcome 
measure (Rodrigues, 2010).  Such measures can answer questions about 
whether treatment options straighten a digit effectively, and how durable this 
straightening is.  However, this may not correlate with improvement in either 
hand function or quality of life.  Such data are required to for calculating 
quality adjusted life years (QALYs), which are central to the calculation of cost 
effectiveness endpoints such as the incremental cost effectiveness ratio 
(ICER) of introducing a novel treatment such as collagenase.  As a result, 
these metrics are of limited use in the kind of cost effectiveness analysis 
currently being employed in the UK by NICE (NICE, 2008).  For such 
processes, measures that assess health-related quality of life and hand 
function would be more useful, and answer questions investigating whether a 
treatment option has improved function or quality of life.  As discussed above, 
it is more informative to describe such changes across an entire study 
population, rather than just those for whom a good initial outcome was 
obtained.  Asking this genre of question, and employing the appropriate 
outcome measures needed to do so, might not only facilitate successful 
approvals for cost-effective Dupuytren’s disease interventions, but would also 
provide clinically relevant data that could inform patient choice. 
1.4.3 Assessment(strategies(
A range of different options could be chosen as the primary outcome measure 
for future research.  As has been discussed, a range of strategies have been 
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employed previously (Becker and Davis, 2010).  During work that the 
candidate conducted for an MSc previously, these were analysed for 33 
studies describing outcome from surgery for Dupuytren’s disease (Rodrigues, 
2010).  This dissertation was submitted in 2010, with the search performed 
that year.  The primary outcome measures in these studies are shown in 
Figure 1.3.  All studies considered ‘recurrence’, but in over a third, no 
definition of recurrence was given.  The most popular definition was 
reappearance of palpable disease in the operated field, which was employed 
by just under a third of studies.  This definition is cited from two different 
sources, most frequently Leclercq’s chapter in Tubiana’s book from 2000 
(Leclercq, 2000), and also Hueston’s 1984 article (Hueston, 1984). As many 
citations refer to Leclercq’s definition, it shall be referred to as this here.  
Besides these options, all other studies described some form of loss of 
extension or range of motion, be it self-report by the patient using diagrams of 
increasing deformity (Dias and Braybrooke, 2006), or angular measurements 
using a goniometer.  The relative merits and disadvantages of each of these, 
as well as other options, must be appreciated. 
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1.4.4 Assessing(palpable(disease(
Hueston and Leclercq define recurrence as the reappearance of Dupuytren’s 
disease in a zone previously operated on (Hueston, 1984, Leclercq, 2000).  In 
contrast, Leclercq defines extension as the appearance of Dupuytren’s 
disease in a zone previously unaffected (Leclercq, 2000).  This accounted for 
the primary outcome measure in 27% of studies included in the literature 
review discussed already (Rodrigues, 2010).  However, in even more studies, 
no definition of recurrence was provided at all.  A major limitation of Leclercq’s 
 
Figure 1.3: Definitions of recurrence used as primary outcome measure 
in studies of surgery for Dupuytren's disease. 
Reproduced from MSc dissertation (Rodrigues, 2010) 
13
9
6
2
1
1 1
None
Leclerq's 2000 defintion
Worsening contracture
Self report on questionnaire
Worsening Tubiana Stage
Hueston's table top test
Reduced Total Active Movement
University of Nottingham          Introduction 
 45 
definition is that it is not applicable to techniques that involve division of 
Dupuytren’s tissue (such as needle aponeurotomy or collagenase) rather than 
its excision, in that the diseased tissue is not removed, and so remains 
palpable throughout, even in ‘successfully’ treated cases.  Thus, this definition 
lacks rigour for future comparative studies involving these techniques.  
Furthermore, where does the ‘operated field’ end?  This might be apparent for 
a dermofasciectomy where a scar can be seen at the junction of the graft and 
the glabrous skin, but is not so after fasciectomy, where the skin has been 
elevated and undermined and closed back in place.  How far does the treated 
subcutaneous field actually extend?  Another issue with Leclercq’s definition is 
whether it is a relevant outcome at all.  No patient should be re-operated on 
simply for the reappearance of nodules in the operated field alone.  
Reappearance of nodules might predict subsequent functional deterioration, 
thus Leclercq’s definition might provide a ‘marker’ of impending poor outcome.  
However, this assumption is not proven.  Finally, Leclercq’s definition is not 
robust enough for high quality research.  It is possible that it was never meant 
to be; the definition is taken from the prose of a textbook, from the very 
opening paragraph on recurrence, rather than from the validation studies that 
other assessment tools have been subjected to.  Identifying recurrent nodular 
change of disease in a scarred post-operative field is not straightforward, and 
distinguishing this from acceptable post-operative scarring is likely to be 
biased and subjective.  As different procedures result in distinct patterns of 
scarring, it is very difficult to blind an assessor to the intervention that the 
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patient has undergone without covering the scarring on the palm and digit.  
This in turn may influence how readily recurrence is palpable.  This may 
contribute to the wide variation in reported recurrence rates seen in different 
studies.  Other issues may contribute to this apparent difference, as have 
been discussed already. 
1.4.5 Assessing(loss(of(extension(
In clinical practice, loss of extension is typically assessed as angular deformity 
using goniometry, or Hueston’s tabletop test (see page 56).  Surgery tends to 
be performed to correct this loss of extension (BSSH, 2008).  An assessment 
of the redevelopment of extension loss is a common endpoint to use for 
research purposes (Rodrigues, 2010).  There are different ways to quantify 
this: angular deformity can be measured at joints, or linear loss of extension of 
the entire digit can be assessed. 
1.4.5.1 Assessing+angular+deformity+of+joints+
Common practice includes using goniometry to quantify the degree of joint 
contracture, which is expressed as the angle in degrees away from full 
extension at the joint concerned (Tubiana, 2000).  This can be performed in 
many different ways.  Indeed, a review of outcome measures in Dupuytren’s 
disease surgery has shown that 17 categories of angle-based measure have 
been reported in 91 studies in the literature (Ball et al., 2013).  Some of these 
measures account for dynamism, which may be observed if contractures span 
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more than one joint of a digit (Hurst, 2010), but others do not.  Dynamism may 
be an important influence to  
consider when interpreting angle-based data.  If a patient has a contracture of 
both the MCPJ and PIPJ of the same finger, and the PIPJ angle is being 
measured, the position of the MCPJ will affect the angle of the PIPJ.  If the 
MCPJ is held in maximal extension, then the volar soft tissues (including the 
Dupuytren’s cord) will be relatively tightened, flexing the PIPJ.  However, if the 
MCPJ is held flexed, the volar soft tissues are relatively lax, allowing more 
correction of the PIPJ contracture.  This principle is illustrated in Figure 1.4. 
Amongst the range of objective measures reported, total passive extension 
deficit, often abbreviated to TPED, can be obtained from the sum of the 
passive extension deficit of the joints of the digit.  Dupuytren’s disease 
typically affects the MCPJ and PIPJ, but may rarely affect the distal 
interphalangeal joint (DIPJ) as well.  Whether the MCP and PIP joints have 
been assessed, or whether all three finger joints are measured, is not always 
specified.  Indeed, one of the most recent randomised controlled trials of 
treatment discusses total passive extension deficit of each joint individually 
(van Rijssen et al., 2012).  Furthermore, some goniometers may not be able to 
span the distal interphalangeal joint due to the relatively short length of the 
distal phalanx. 
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Tubiana’s classification uses TPED to identify four stages of increasing 
contracture.  However, as TPED is achieved by adding separate, optimised 
passive MCPJ and PIPJ contracture angles, the TPED itself is minimised, as 
the ‘best possible’ passive angles are obtained for each joint.  The patient 
cannot actually straighten the digit as much as this value suggests.  It is thus 
not a ‘real-world’ measurement, and not necessarily clinically relevant.  
Furthermore, TPED only accounts for extension loss at the MCPJ and PIPJ.  If 
  
Figure 1.4: Schematic diagram of contracture dynamism 
The Dupuytren’s cord is illustrated as the blue strip, and is inelastic.  On the 
left, the MCPJ is extended, resulting in increased flexion at the PIPJ.  On the 
right, the MCPJ is flexed, allowing correction of the PIPJ contracture 
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the patient develops a stiff DIPJ, which might affect grip, this is not 
incorporated in the measurement. 
Angular deformity can also be assessed without goniometry, by using pictures 
of contracted digits.  Patients then select the image they believe corresponded 
to their preoperative state and the image that corresponds to their current 
state.  This approach was adopted for a postal evaluation of surgery outcome 
for Dupuytren’s disease published by Dias and Braybrooke (Dias and 
Braybrooke, 2006).  This avoids some of the disadvantages of measuring 
angles with goniometers or other devices.  It avoids the inconvenience and 
cost of a clinic appointment for assessment.  It also allows retrospective data 
collection, with the patient self-reporting their preoperative state.  It also 
attempts to assess a more clinically relevant endpoint – the active extension 
that the patient can achieve (rather than the passive extension obtained by an 
assessor).  However, the reliability of the data obtained with this strategy is 
unclear.  How accurately and objectively patients assess their current state is 
not clear, and recall bias may be an issue when attempting to measure 
preoperative state.  Given the lack of validation data describing this technique, 
it has not been studied here. 
Besides TPED, the range of motion can be calculated as the difference 
between the joint angle in maximal flexion and this extension angle.  This also 
provides an assessment of flexion.  The importance of this should not be 
underestimated.  Whilst treating Dupuytren’s disease aims to restore loss of 
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extension, if this has the side-effect of significantly affecting flexion function, 
then the patient may experience a deterioration in hand function overall. 
An assessment of angular loss of extension is often the primary endpoint of 
research.  This is demonstrated by considering two of the most recent high 
profile randomised controlled trials in Dupuytren’s disease treatment.  In van 
Rijssen and colleagues’ trial of limited fasciectomy versus needle 
aponeurotomy, TPED was used (van Rijssen et al., 2012).  Hurst and 
colleagues used reduction in individual joint contracture to less than five 
degrees (Hurst et al., 2009).  The accuracy of these measurements needs to 
be assured.  Goniometry has been demonstrated as having a resolution of 5 
degrees (Boone et al., 1978).  A similar level of accuracy was found in a study 
of reproducibility of goniometry performed by surgeons, conducted for the 
candidate’s MSc thesis (Rodrigues, 2010).  There are disadvantages to the 
use of goniometry.  Firstly, whilst the measurements can be documented, they 
cannot be reassessed for validation purposes.  The assessment is a one-off, 
and the contracture is likely to change with time, and so the exact 
circumstances in which the recording is made will have changed.  Other 
factors may also impair goniometry results, such as infection, misshapen 
hands or post-operative swelling (Hamilton and Lachenbruch, 1969).  One 
solution that allows reassessment is to obtain digital photographs of the hand 
from a lateral aspect and then perform angular measurements on the 
photograph.  This has been described by Georgeu and colleagues (Georgeu 
et al., 2002).  However, this particular study used a large jig to fix both the 
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hand being measured, and also the camera itself.  As such, the equipment 
does not appear to be easily portable from the photograph shown in the 
paper.  The measurements themselves required specific computer software, 
adding to costs.  It is also unclear how measurements of joint angles can be 
made on the middle and ring fingers, when these may be obstructed from view 
by the index and little digits.  A further issue applies to all such angular 
measurements; whilst a change in contracture of greater than 5 degrees might 
be detectable by a goniometer, it may not represent recurrence rather than 
extension.  This may not matter.  If hand function deteriorates following 
treatment, it is unlikely that the semantics of this distinction will concern the 
patient’s appraisal of their condition. 
It is not clear whether angular deformity is truly clinically relevant; function 
may not necessarily be impaired by the development of a contracture of an 
arbitrarily defined severity, such as 20 degrees.  Draviaraj and Chakrabarti 
reported that improvement in contracture correlated with improvement in hand 
function as assessed using the Sollerman score, and the correlation between 
functional improvement and PIPJ angular improvement in particular was most 
pronounced (Draviaraj and Chakrabarti, 2004).  However, a systematic review 
of outcome assessment in Dupuytren’s disease demonstrated that this 
particular outcome tool has only been used in Dupuytren’s disease by this 
team, and in only one other Dupuytren’s study from the same institution (Ball 
et al., 2013, Sinha et al., 2002).  Its validation is not as well established as that 
of other measures (Ball et al., 2013).  In other studies, angular deformity only 
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correlated weakly with the most commonly employed patient-reported 
outcome measure used in Dupuytren’s disease research: the Disabilities of 
the Arm, Shoulder and Hand (DASH) tool (see page 59) (Ball et al., 2013, 
Jerosch-Herold et al., 2011).  A common interpretation of this was to suggest 
that the DASH is not a valid assessment of functional limitation in Dupuytren’s 
disease (Packham, 2011).  However, the relationship between angular 
deformity of the digits and functional limitation may not be linear.  It is possible 
that maximal limitation is the result of having approximately 90 degrees of 
extension deficit, and that having the fingertips closer to the palm may be 
associated with less functional impairment, as illustrated in Figure 1.5. 
 
Figure 1.5: Photographs illustrating ‘moderate’ and ‘severe’ contractures 
The contracture on the left is ‘less severe’ than that on the right, as defined by 
extension deficit.  However, hand function may be better with the posture on 
the right, as the ring and little fingers can be bypassed to allow an effective 
tripod grip using the thumb, index and middle fingers. 
Which% s%‘wor e’?%
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Furthermore, attempting to fully correct angular deformity may cause 
complications, such as a reduction in active flexion, and so might 
paradoxically impair hand function.  As a result, the conclusion that angular 
deformity is the gold standard for approximating functional impairment is not 
currently supported by evidence.  Comparing a range of measures, rather 
than just two, is required to arrive at such a conclusion.  When the two 
measures differ, as was the case is the studies discussed, it is not clear which 
is ‘right’ and which is ‘wrong’. 
In addition, functional impairment may arise from Dupuytren’s disease that 
does not cause angular deformity of MCPJs or PIPJs.  For example, a thumb-
index web cord may limit thumb abduction and thus grasp.  Alternatively, 
natatory cords preventing finger abduction may limit the span of the palm.  
This may be of consequence to those who use alphabetical or musical 
keyboards.  Neither of these problems is necessarily represented by angular 
deformity. 
1.4.5.2 Assessing+linear+loss+of+extension+
Mäkelä and colleagues described an approach measuring loss of extension as 
a linear measurement perpendicular to the metacarpal, though no detailed 
method for performing the measurement was described (Makela et al., 1991).  
A portable jig was designed to do this as part of previous work by the 
candidate, and is shown in Figure 1.6 (Rodrigues, 2010).  Mäkelä and 
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colleagues also quantified flexion function by measuring active flexion as the 
distance that the patient can flex to, short of the pulp of the fingertip reaching 
the distal palmar crease.  This provides a mirror ‘loss of flexion’ measurement 
as well as the loss of extension measurement.  As discussed with angular 
range of motion, flexion function is also likely to be important in hand function.  
One advantage of Mäkelä and colleagues’ strategy is that it may minimise the 
impact of dynamism of a contracture.  If a contracture crosses both the MCPJ 
and the PIPJ, then the position of one joint will affect the passive extension of 
the other (Hurst, 2010).  For this reason, goniometry should always be 
performed with the other joint held in maximum passive flexion, as discussed.  
This in turn gives the least contracted value for the joint being measured.  
However, whether all assessors reliably perform this is not clear.  Additionally, 
the passive angle obtained is not what the patient can achieve actively.  By 
measuring the entire digit’s active loss of extension as a linear measure, the 
influence of contracture dynamism is standardised.  Indeed, as the digits are 
extended actively, it standardises dynamism at a clinically relevant point, 
unlike measures such as TPED.  Thus, a more clinically realistic measure is 
obtained by using loss of active extension rather than passive angular 
deformity, as assessed by goniometry. 
There are still some issues with using linear loss of extension as an outcome.  
As with angular deformity, some patterns of Dupuytren’s disease, such as 
thumb-index web contracture, or limited palmar span are not quantifiable.  
Furthermore, some patients with a PIPJ contracture develop compensatory 
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hyperextension of the MCPJ and distal interphalangeal joint, possibly reducing 
the functional impact of the contracture.  Mäkelä and colleagues do not 
discuss whether this is accounted for in their measurements.  With the jig in 
Figure 1.6, it is not. 
 
 
 
Figure 1.6: Typical study photograph from MSc project 
From the candidate’s MSc dissertation (Rodrigues, 2010). 
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1.4.5.3 Hueston’s+tabletop+test+
The basis of Hueston’s tabletop test is loss of extension in general.  However, 
it is neither a true measure of angular deformity, nor is it a perpendicular loss 
of extension.  This test was proposed as a simple method for selecting 
patients with a severe enough contracture to merit surgery, by assessing 
whether they can place the palm of the hand flat on a table or not due to loss 
of extension (Hueston, 1974).  Whilst it is dichotomous rather than 
quantitative, it has been used in one study to assess recurrence (Rodrigues, 
2010).  Although this only provides binary data regarding recurrence, it may 
provides a clinically relevant outcome measure, as it is also used as the 
indication for surgery in many instances.  Thus, a positive test at follow up 
represents recurrence, extension or treatment failure severe enough to merit 
reoperation.  However, whether the indication for surgery should be an 
objective test of this nature that does not assess impact on function or quality 
of life in any way is contentious. 
1.4.6 Patient(Reported(Outcome(Measures(
Another approach to quantifying Dupuytren’s disease in research is to use 
patient reported outcome measure (PROM) tools, of which there are many.  
One database lists 580 different tools, excluding foreign language translations 
of tools (MAPI, 2013), and careful choice of appropriate and validated PROMs 
is important. 
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Such scales aim to assess patient impact of the condition or its treatment on 
function, activity or health-related quality of life.  In Dupuytren’s disease, they 
may be able to summarise the impact of disease at multiple sites, as they are 
not limited by pattern of disease.  Thus, they may provide a clinically relevant 
assessment.  For example, if a patient experiences functional impairment due 
to a loss of palmar span, then this might be detected, whereas it will be 
overlooked when looking at joint angular deformity.  Also, assessing the 
impact of treatment at different sites is complex.  For example, if a patient with 
combined MCPJ and PIPJ contracture has simply the former component 
corrected, the residual PIPJ contracture may be functionally compensated for 
by hyperextension at the MCPJ.  This again may not be reflected in objective 
assessments, but may be of importance to the patient. 
Furthermore, these tools can often be administered as a questionnaire, 
without requiring specialist assessment.  As a result, they may be performed 
with less cost than measuring palpable disease or loss of extension: the 
questionnaire may be posted to patients to return, without incurring the cost of 
and inconvenience of additional outpatient clinic attendances for assessment.  
Additionally, in the current economic climate, it is likely that evidence of direct 
patient benefit will be required to justify expenditure in health systems for 
treatments.  The use of patient-reported outcome has grown in recent years 
and is promoted directly in the UK by the Department of Health (Department 
of Health, 2010). 
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PROMs may be broadly separated into those that assess health-related 
quality of life non-specifically, those that are domain-specific, e.g. assess the 
upper limb as a whole, and those that are disease-specific (Szabo, 2001).  A 
variety have been used in studies of Dupuytren’s disease, including domain-
specific PROMs and a disease-specific one (Ball et al., 2013). Since then, a 
further disease-specific PROM has been published (Mohan et al., 2014).  
However, no report of the use of generic PROMs was found (Ball et al., 2013). 
One common problem for the development of all such tools is defining health-
related quality of life, or hand function, objectively.  What constitutes 
acceptable hand function to a nursing home resident may be considerably 
different to what is acceptable to a concert pianist.  Quality of life for patients 
with Dupuytren’s disease has been explored recently (Wilburn et al., 2013).  
However, neither concept can be measured directly. 
1.4.6.1 Generic+PROMs+
Non-specific questionnaires assessing general quality of life allow comparison 
between very different conditions.  An example is the EuroQol 5D™ (EQ5D), 
which is the preferred measure for assessing health related quality of life by 
NICE as part of its cost effectiveness analyses (NICE, 2008).  In theory these 
allow comparison to any other condition or treatment, at any anatomical site.  
However, they may not be sensitive enough to detect subtle differences in 
effect between different interventions for Dupuytren’s disease itself.  Instead 
they may experience ceiling or floor effects, whereby the pre-treatment and 
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post-treatment scores are both either very high, with little difference between 
them, or both are low due to the impact of comorbidities.  Furthermore, their 
lack of specificity may mean that they are influenced by other comorbidities.  
The latter may be of particular relevance given that Dupuytren’s disease 
becomes more prevalent with increasing age. 
1.4.6.2 DomainFspecific+PROMs+
Domain-specific tools are more specific.  They include the DASH (Hudak et 
al., 1996).  This 30-question tool is considered one of the most widely 
validated upper limb scales, with numerous studies assessing it in different 
conditions and languages, as summarised in a review of outcome measures 
by Dorwick and colleagues (Dowrick et al., 2005).  Furthermore, it has been 
the most popular PROM used in Dupuytren’s disease research to date (Ball et 
al., 2013), and has been previously used in studies of different aspects of 
Dupuytren’s disease, including treatment outcome and also for 
clinicopathological correlation (Degreef et al., 2009, Dias and Braybrooke, 
2006).  Whilst the DASH is supposed to be specific to upper limb function, 
there is evidence that it is responsive to disease at sites outwith the upper 
limb (Dowrick et al., 2006).  Its validity for comparing different interventions for 
Dupuytren’s disease has been questioned in one study of patient quality of life 
(Wilburn et al., 2013), where a review was cited to suggest that the DASH’s 
validation studies were flawed, and that its dimensionality was unproven.  
However, whilst this statement does appear in the review article’s abstract, the 
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main text (which considers PROMs for shoulder conditions only) actually 
concludes that the DASH is the best existing PROM (Bot et al., 2004).  
Several of the questions in the DASH assess pain symptoms in the limb.  As a 
typically painless condition, it is feasible that pain scores in Dupuytren’s 
disease may actually be worse soon after surgery.  It might be expected that 
this be the case for more invasive and extensive surgery, which might have 
lower long-term recurrence than less invasive treatments.  This may give an 
inappropriately negative evaluation of a treatment that gives patients long-
term recurrence-free function.  Although this might suggest that scores like 
DASH are not suitable for assessing a condition like Dupuytren’s disease, it 
should still be borne in mind that if a patient were to develop chronic pain 
following treatment, then this might reduce function.  Thus, appropriate timing 
of assessment using tools like DASH is important. 
As with quality of life scores, comorbidities may influence the score obtained 
for domain-specific tools, for example due to coexisting shoulder or elbow 
disease.  The impact of comorbidities can be neutralised by considering the 
change in the score after treatment compared to that before the treatment – 
the difference could be assumed to be the result of the treatment itself, as the 
comorbidity will remain constant.  Whilst this is valid for early outcome, it is not 
true for late outcomes, as the comorbidities cannot be assumed to have 
remained constant: degenerative conditions such as arthritis may worsen 
during the intervening period, or indeed might be treated themselves. 
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1.4.6.3 DiseaseFspecific+PROMs+
A disease-specific scoring system for Dupuytren’s disease has been recently 
developed and validated by the Unité Rhumatologique des Affections de la 
Main (URAM) (Beaudreuil et al., 2011).  It is perhaps of note that Pfizer, who 
recently launched collagenase for the treatment of Dupuytren’s disease, 
funded the study and employed two of the named authors (Beaudreuil et al., 
2011).  The theoretical advantage of such a scale is that it has been designed 
to sensitively assess the pertinent problems of this condition, which might be 
expected to differ from other upper limb conditions, such as arthritis.  
Furthermore, the impact of comorbidities on the score should be minimised, 
and the effect of less relevant upper limb symptoms, such as pain or 
paraesthesia avoided.  Indeed, the URAM authors highlight the apparent 
weakness of using scores that comprise an assessment of pain, such as 
DASH for measuring Dupuytren’s disease outcome (Beaudreuil et al., 2011).  
However, as has been discussed already, it seems inappropriate to ignore the 
fact that the treatment itself may result in chronic postoperative pain that in 
turn reduces post-operative function.  If Dupuytren’s disease is painless both 
before and after surgery, then ‘pain questions’ should not unduly influence the 
score achieved, so why not ask about pain?  A major disadvantage of 
disease-specific scoring systems is their specificity itself.  In an era in which 
health economics is increasingly important, it may be necessary to 
demonstrate how effective or cost-effective treating Dupuytren’s disease is 
compared to treating other conditions, such as carpal tunnel syndrome, for 
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example.  Whilst scores like URAM might allow a detailed comparison 
between different Dupuytren’s treatments, demonstrating that treating 
Dupuytren’s disease improves a disease-specific score is not of use when 
comparing to other conditions.  This would be possible when using domain-
specific and quality of life scores.  The design of the URAM involved item 
generation by French doctors and patients.  Once a list of tasks made 
troublesome by Dupuytren’s disease was created, this was narrowed by 
eliminating tasks that either correlated very closely to other tasks, or were 
‘never’ performed by over 5% of the patients involved.  The latter may affect 
the generalisability of the tool.  Its cultural sensitivity for use in populations 
other than the French group may need investigation, as the tasks included 
may be less relevant to other populations, and some of those excluded may 
be major issues elsewhere. 
1.4.6.4 Patient+rated+change+PROMs+
A variation of PROM not discussed in the review by Szabo (Szabo, 2001) is 
patient rated change.  Several such tools exist, including the Measure 
Yourself Medical Outcome Profile (MYMOP) (Paterson, 1996) and Global 
Rating of Change scales (GRC), such as that used Jaeschke and colleagues 
(Fitzpatrick et al., 1998, Jaeschke et al., 1989).  Such patient rated change 
measures may be of use in analyses of interpretability of more specific 
quantitative tools, as well as being options for stand-alone measures. 
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1.4.6.5 PatientFspecific+PROMs+
All of the above PROMs involve fixed scale, whereby all patients complete the 
same items.  An alternative strategy is to use patient-specific PROMs.  Rather 
than having rigid scales, these typically involve the patient specifying the items 
based on their own symptoms and goals, and then scoring these before and 
after treatment.  Examples do exist for use in niche areas of hand surgery 
(Law et al., 1990), but have not been used in Dupuytren’s disease (Ball et al., 
2013). 
1.4.6.6 Validity+and+Reliability+of+PROMs+
There are issues with the development and use of function and quality of life 
tools.  One is demonstrating validity.  An international standard has been set 
for the study of patient-reported outcome, via a Delphi consensus.  The 
resulting Consensus-based Standards for the Selection of Health Status 
Measurement Instruments (COSMIN) inform the design of studies of validity, 
responsiveness and, to a lesser extent, interpretability (Mokkink et al., 2010). 
These define different aspects of the validity of PROMs: 
• Content validity assesses whether the items that comprise a PROM are 
an adequate reflection of what is trying to be measured.  It involves 
assessing the relevance and comprehensiveness of the items in a 
PROM. 
• Construct validity examines hypotheses about the PROM.  Such 
hypotheses may relate to its structural validity (internal relationships 
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between items), hypothesis testing (assessing its relationship with other 
PROMs) and differences between patient groups (cross-cultural 
validity). 
• Internal consistency assesses how related the items in a PROM are to 
each other.  This assumes that all of the items that contribute to a 
summary score actually assess the same underlying entity, or factor 
(e.g. impairment of structures in the hand versus restriction of activity 
involving the shoulder), i.e. they are ‘unidimensional’. 
• Criterion validity tests a PROM against a ‘gold standard’.  The only 
accepted methodology for this is the comparison of a shortened PROM 
against the long version (e.g. the QuickDASH against the DASH). 
Responsiveness is the ability to detect change over time, as opposed to the 
single time point score assessed in ‘validity’. 
Interpretability is concerned with being able to interpret and understand the 
relevance of a change score. 
Much validation of older PROMs falls short of the standards set by COSMIN.  
For example, the Short Form 36’s (SF-36) validation in the UK involved 
comparison to the Nottingham Questionnaire (Brazier et al., 1992).  This 
strategy is limited, as the ‘gold standard’ that has been used as the reference 
is the existing flawed measure.  Indeed, this is explicitly condemned by 
COSMIN. 
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There is limited validation of the DASH in Dupuytren’s disease specifically 
(Kennedy et al., 2011), 
Validation of the URAM scale involved construct validity assessment against 
existing functional measures such as DASH, and also to Tubiana stage 
(Beaudreuil et al., 2011).  The URAM authors point out that their scale 
correlates better with the Tubiana stage than the DASH does.  This is cited as 
an advantage.  Furthermore, incorporating patient opinion as an outcome 
measure is currently considered important.  However, in this situation 
correlation with just one standard seems inadequate for an ideal test in the 
absence of a gold standard.  Indeed, if an outcome test only correlates well 
with one standard, such as Tubiana stage improvement, then there may be 
little incremental gain from this ‘functional assessment’, over and above the 
baseline clinical assessment except perhaps a façade of assessing patient 
opinion. 
The authors of the paper describing URAM do, however, make the good point 
that it can be conducted without a specialist present, as it involves a simple 
questionnaire.  This may allow simplification of assessing outcome in research 
studies of Dupuytren’s treatment. 
Even for an individual, there will be variability in functional compromise 
depending on the dominance and the affected hand.  It might seem that this 
can be tackled by subgroup analysis of dominant hand disease versus non-
dominant hand disease.  However, patients cannot be categorised so easily.  
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If the dominant hand is affected, this is likely to have more impact than the 
non-dominant hand being affected.  However, the ability of the patient to 
compensate for reduced function of their dominant hand will be affected by 
other variables.  For example, a right-handed patient with right-handed severe 
Dupuytren’s disease, but an unaffected left hand, might cope better than a 
patient with bilateral severe disease or a comorbid condition compromising the 
left hand.  The prevalence of comorbidities in the typical older Dupuytren’s 
patient may also affect this.  For example, if a walking aid is used, and one or 
both hands have reduced function, then independence might be reduced more 
than expected. 
Function and quality of life tools may effectively standardise this variation by 
quantifying the improvement or deterioration relative to the patient’s own 
baseline function, in the same way that this might seem to be a valid way of 
standardising for the influence of comorbidities on domain-specific or quality of 
life scores.  Assessing ‘change in hand function score’ would provide an 
elegant solution to standardising PROM changes from the treatment and 
might be easily applicable to other hand conditions, such as arthritis.  
However, in addition to the problems arising from changes in comorbidities 
and their treatment that have already been discussed, there are also issues 
pertaining to Dupuytren’s treatment itself that make this more complicated.  
Dupuytren’s disease is often treated in a prophylactic manner (unlike arthritis, 
for example).  Thus surgery may not actually change function relative to the 
patient’s preoperative state.  Function may even worsen with time, but this 
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might still represent a success – treatment may have prevented a more rapid 
future functional decline. 
‘Change in hand function score’ might still be a valid outcome measure, even 
if hand function tends to decline after treatment for the reasons discussed 
above, so long as it were interpreted appropriately.  If the rate of decline in 
hand function after a particular trial treatment were slower than after standard 
treatment, then this would demonstrate the superiority of the trial treatment 
over standard treatment (despite both cohorts experiencing a decline in hand 
function over time).  Indeed standardised change in hand function (relative to 
the patient’s own baseline function) might allow the generation of Kaplan-
Meier survival curves of hand function following intervention.  Changes in 
comorbidities (either deterioration or treatment) would still affect these, but the 
overall pattern may still prove useful. 
If this continuum of decline in hand function were to be used, several issues 
would need to be resolved, such as defining what constitutes a clinically 
important drop in function. 
1.4.7 Assessing(cost(effectiveness 
Another strategy in assessing the impact of Dupuytren’s disease would be to 
assess cost effectiveness of treatment.  This is likely to be increasingly 
important when attempting to justify future resource allocation to a particular 
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treatment or condition, particularly when the British National Health Service is 
undergoing cost-saving changes. 
Common cost effectiveness measures are available.  In particular, NICE 
employs the incremental cost effectiveness ratio (ICER). The ICER amounts 
to the cost per quality adjusted life years (QALYs) gained.  Although 
Dupuytren’s disease is not a terminal condition, QALYs can still be calculated.  
Alternatively, change in hand function might be used as the denominator, but 
this is also more complicated. 
Other approaches have been used.  Some data describing the cost of 
treatment in England has been published (Gerber et al., 2011).  Like the 
URAM validation work, Pfizer also funded this study, and three of the four 
authors declared conflicting interests with Pfizer.  Data describing the number 
of treatments performed were multiplied by the cost described in The National 
Schedule of Tariff.  Whilst this crudely estimates the cost of treatment, it 
cannot comment on cost effectiveness.  Furthermore, the true cost/benefit of 
treatment would need to incorporate far wider reaching data, such as return to 
work or change in occupation following treatment, as these factors also affect 
cost to society.   
Given the advantages and considerable disadvantages of all methods of 
assessing Dupuytren’s disease, it is likely that no single method will suffice.  
Considering the particular unsuitability of the previously most popular 
technique (Leclercq’s definition of palpable recurrence) for use in fasciotomy, 
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a new standard is needed.  The ideal would be consensus on what techniques 
should be used, and timing of use following the procedure. 
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SUMMARY 
Research on Dupuytren’s disease treatments requires an appropriate choice 
of outcome and a means to measure this.  There are many different ways to 
approach this.  The most common strategy has been to assess recurrence 
and/or extension.  At present there is no consensus on the definition of 
recurrence, or when it should be assessed.  The most commonly used 
strategy of palpating the reappearance of nodules is no longer relevant.  Other 
approaches, including assessing angular deformity, are not patient-specific.  
Measuring hand function or quality of life is probably more meaningful, and 
lends itself to cost effectiveness analysis.  The most popular PROM used is 
the DASH, though the URAM has been recently developed as a Dupuytren’s 
disease specific PROM that could be used.  Further work is required to 
identify the most appropriate outcome measure to do this, in terms of validity, 
responsiveness and interpretability. 
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1.5 Treatment(
A range of treatment options is currently available for Dupuytren’s disease.  
These include strategies that divide cords of disease, with the bevel of a 
hypodermic needle in an aponeurotomy, with a scalpel blade, or with 
enzymatic degradation of collagen via an injection of collagenase.  
Alternatively, disease may be removed surgically with skin retained in a 
fasciectomy, or skin replaced with skin graft in a dermofasciectomy.  
Comparison of these using the outcome measures discussed is necessary to 
establish the appropriate role of each. 
1.5.1 Observation(
As a condition that is not life threatening, observation of disease is an option.  
This is particularly for early or mild disease that is not limiting the patient 
functionally, and in the presence of significant comorbidities that would 
increase the risk of treatment. 
There is relatively little literature describing the progression of disease in 
patients who are observed rather than treated.  Progression from nodules to 
cords occurs in the majority of patients (Luck, 1959), but does not necessarily 
reach a severity for which surgery is indicated (Reilly et al., 2005).  A small 
minority of patients in the latter study experienced spontaneous resolution of a 
nodule. 
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1.5.2 Selection(for(Surgery(
The aim of treatment is to manage Dupuytren’s disease, as curative treatment 
does not currently exist.  Additionally, the optimal timing for treatment is yet to 
be established, but Hueston’s table top test has been used as a simple means 
of determining whether a contracture is severe enough to merit intervention 
(Hueston, 1974).  This may be an oversimplification as some patients may 
experience functional limitation prior to this point, whilst others with more 
severe contractures may not wish to undergo treatment.  More recent 
guidance from the British Society for Surgery of the Hand suggests that the 
minimum criteria for which intervention should be considered are functional 
problems, MCPJ contractures over 30 degrees, any PIPJ contracture or a first 
web contracture (BSSH, 2008).  Whilst these criteria seem reasonable, there 
is no evidence cited for the algorithm.  Such guidance is provided primarily to 
assist clinical practice, but indications for surgery need to be standardised for 
prospective trials.  Valid clinical indications for surgery such as ‘functional 
problems’ in the absence of a moderate or severe contracture may not be 
appropriate for inclusion in a trial, particularly if the primary study endpoint is 
return of an angular contracture.  Cases with a milder contracture initially may 
achieve a better postoperative correction, whereas those with a severe 
contracture that is only partially correctable may be at a disadvantage.  As 
with the variation seen in outcome measures and endpoints, this aspect of 
research might benefit from a consensus agreement on an international 
standard for Dupuytren’s disease trials.  However, any such consensus would 
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need to be informed by further research to establish the relationship between 
structural impairment, such as loss of extension, hand function limitation, and 
activity and participation restriction with its impact on health-related quality of 
life. 
Once active management has been deemed necessary, the specific treatment 
modality can be considered.  Often textbooks classify options as ‘operative’ 
and ‘non-operative’ strategies (McGrouther, 2005).  However, this may be 
misleading.  Some ‘non-operative’ techniques, such as needle aponeurotomy 
or collagenase therapy, require aseptic technique and are often performed in 
an operating theatre.  They also carry risks such as nerve or tendon injury, 
which are similar to ‘operative’ techniques.  Here, strategies for treating 
contractures will be classified into those aiming to remove disease, those 
aiming to divide disease and those aiming to prevent the formation or 
progression of disease. 
1.5.3 Removal(of(disease(
Surgery to excise disease may involve excision of nodules and cords with 
preservation of the overlying skin (fasciectomy), or excision of the Dupuytren’s 
tissue with the overlying skin en masse (dermofasciectomy).  Collagenase 
enzyme therapy lyses collagen, and thus may remove a segment of disease, 
rather than simply divide it.  However, its effect on the myofibroblasts within 
the cord is unclear, whereas other forms of disease removal, such as 
fasciectomy, will remove collagen and myofibroblasts en masse.  In the 
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absence of these concepts being formally investigated and documented, 
collagenase will be discussed as a treatment that divides disease. 
Fasciectomy is the most common procedure performed for the management 
of Dupuytren’s disease, accounting for 93% of day case procedures and 
91.6% of inpatient procedures for the condition in England in 2007-2008 
(including revision surgery) (Gerber et al., 2011).  However, the term 
describes a continuum of excisional procedures that occupy a spectrum 
between an open fasciotomy at the more conservative end and 
dermofasciectomy at the more extensive end.  Indeed, common terminology 
used to sub-classify ‘fasciectomy’ includes segmental, limited, regional, radical 
and total fasciectomies, in order of increasing extent of tissue excision.  
Alternatively, fasciectomy may be classified on the basis of the skin incision, 
and skin closure, used to approach the disease. 
Skin incisions have evolved from those used for very rapid access prior to the 
availability of anaesthesia, through a myriad of different historical options, to 
several commonly used today (Tubiana, 2000).  There is little evidence base 
for many historical incisions, and as they are not in common usage today, they 
will not be discussed.  One common technique is to perform a longitudinal 
incision along the axis of the ray, extending from the palm into the digit.  
Closing such a longitudinal incision might result in scar contracture, again 
limiting extension of the digit, so several incisions are made from the side of it, 
which can then be closed as a series of z-plasties, breaking up the straight 
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line scar and recruiting additional skin laxity into the straightened finger 
(Tubiana, 2000).  Alternatively, a zig-zag approach can be used, as suggested 
by Bruner (Bruner, 1951).  By making small darts from the apices of the 
triangular flaps, and then allowing these ‘Y’ shapes to open into ‘V’ shapes, 
additional skin length can also be recruited into the wound closure at the 
expense of skin width (Tubiana, 2000).  A prospective randomised controlled 
trial comparing these two approaches has been published (Citron and Nunez, 
2005).  This showed no significant difference in recurrence rate as assessed 
by a surgeon who had not performed the initial operation, using Leclercq’s 
definition (Leclercq, 2000), by 2 years.  However, no power calculation was 
provided.  The intention to treat analysis revealed that several patients were 
excluded from the Bruner cohort after randomisation due to administrative 
issues, such as having previously been enrolled for contralateral surgery.  
However, if intention to treat analysis is performed using Fisher’s Exact test 
and including those patients initially excluded, the difference in recurrence 
remains statistically insignificant (p=0.44, versus initial result of p=0.20). 
Another skin management strategy is the open palm technique, described by 
McCash in a 43-case series (McCash, 1964).  This is used for palmar disease, 
often involving two or more finger rays.  The palmar Dupuytren’s cords are 
excised through a transverse incision in the distal palmar crease.  This is left 
open to heal by secondary intention when there is inadequate skin laxity to 
close it, or when closing other incisions in the digits requires all available skin 
laxity.  Indeed, similarities between this and Dupuytren’s original description of 
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operative technique are highlighted by McCash (McCash, 1964).  A 
prospective non-randomised study investigated wound healing and early 
complications, comparing the open palm technique to z-plasty and zig-zag 
closures (Gelberman et al., 1982).  The study concluded that the open palm 
technique was the ‘most dependable’ of the three, though it took the longest to 
heal, and no statistical analysis was performed.  Along with the lack of 
randomisation, this reduces the value of these data.  A higher incidence of 
some transient early complications, such as delayed wound healing, might be 
tolerated, if the long term outcome was improved by adopting a particular 
operative strategy.  However, no high quality comparative data of recurrence 
rates are available.  A retrospective study by Foucher and colleagues showed 
a 34% rate of recurrence at an average of 5.6 years follow up for open palm 
surgery, which they deemed comparable to other published series of limited 
fasciectomy (Foucher et al., 1992).  However, recurrence was not defined in 
the study. 
Once the skin incision has been made, the next area of variation in 
fasciectomy practice is the extent of excision.  More conservative strategies 
include segmental fasciectomy.  This was popularised by Moermans, who 
prospectively studied his first 213 consecutive procedures (Moermans, 1991).  
The operative strategy involved short curvilinear incisions through which short 
sections of cord were excised.  In so doing, gaps in the cord were formed, 
creating a theoretical advantage over aponeurotomy.  The recurrence rate 
found by Moermans and colleagues was 35.7% at a mean of 2.6 years of 
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follow up.  Limited fasciectomy involves greater excision than segmental 
fasciectomy.  Typically this is the excision of all involved fascia (McGrouther, 
2005).  It has been popularised by Hueston following his publication of the 
technique and a series of 96 procedures with early and late (albeit a mean of 
less than 2 years) outcomes (Hueston, 1961).  A more aggressive approach is 
the radical fasciectomy.  This involves excision of uninvolved fascia from the 
palm in addition to diseased tissue, but still only diseased tissue from the 
digits (McGrouther, 2005).  McGrouther suggests it is more popular in central 
Europe (McGrouther, 2005).  Exactly where limited fasciectomy ends has 
been discussed (Zachariae, 1969).  A study comparing extensive and limited 
fasciectomy found similar long-term outcomes, though extensive surgery was 
associated with longer surgery and postoperative recovery (Zachariae, 1967).  
Thus, more extensive surgery may not necessarily be better. 
Dermofasciectomy may also be considered as a heterogeneous group of 
procedures.  Hueston proposed the concept of deliberate excision of the 
overlying skin, when he reported a series of 38 patients for whom he had 
performed this [sic] (Heuston, 1969).  All his skin grafts were full thickness 
skin grafts.  This concept built upon his previous observation that recurrence 
did not seem to occur under skin grafts in a series of 8 patients followed up for 
two years who had previously undergone multiple revision fasciectomies 
(Hueston, 1962).  Skin grafts may be used to resurface large areas of the 
digit, often running from the metacarpophalangeal skin crease to the distal 
interphalangeal skin crease and from the radial midlateral line to ulnar 
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midlateral line, thus replacing the entire glabrous skin of one or more digits 
(Seah et al., 2012).  Alternatively, smaller grafts may be placed strategically in 
an attempt to interrupt the development of a recurrent cord.  The latter are 
referred to as ‘firebreak’ grafts, a term coined by Hueston (Hueston, 1984).  A 
prospective randomised controlled trial conducted by Ullah and colleagues 
compared the three-year outcome between patients who had z-plasty skin 
closure at PIPJ level with those who received firebreak skin grafts (Ullah et al., 
2009).  They found a low recurrence rate of 12.5% - 15% per hand by 3 years, 
with recurrence defined as progressive angular deformity.  There was no 
significant difference between the cohorts in an appropriately powered study.  
Despite this being a relatively rare example of high quality evidence in 
Dupuytren’s disease, there are still some issues.  Precisely what constituted 
‘progressive angular deformity’ was not specified in their paper, nor was there 
any attempt to blind the assessor to the outcome or surgical procedure that 
had been performed.  The authors acknowledged this limitation.  Although 
they stated that the follow-up period used was adequate to detect recurrence, 
this may not have been enough to allow for the deterioration in a contracture 
that their vague definition of recurrence alluded to.  This might account for 
their reported low rate of recurrence.  Ullah and colleagues also pointed out 
that their findings were not applicable to more extensive skin grafting 
procedures.  An observational study of outcome following more extensive 
dermofasciectomy has been published by Armstrong and colleagues 
(Armstrong et al., 2000).  This reviewed 143 dermofasciectomies in 103 
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patients, out of a total of 135 patients who had undergone this procedure over 
a nine-year period.  Although not explicitly stated, the description of the study 
design suggests that it was retrospective.  The dermofasciectomy procedure 
was well described and was extensive, stretching from the radial to the ulnar 
midlateral line, even when the cord being excised was more localised.  A 
recurrence rate of 8.4% per ray, and 11.6% per patient was reported after a 
mean follow up of 5.2 years.  Given the longer follow up than in Ullah and 
colleagues’ study, this suggests a lower recurrence for more extensive 
dermofasciectomy.  However, there are caveats in this study.  Armstrong and 
colleagues did not explicitly specify the definition of recurrence that they used.  
Their discussion of identifying nodules and cords implies the use of Leclercq’s 
definition of ‘the return of palpable disease within the operated field’ as their 
primary endpoint.  However, they also noted one case that progressed to re-
contracture in the results, but the severity of this was not discussed.  How this 
was determined as re-contracture, rather than incomplete initial correction is 
not clear.  It might be expected that palpable disease would appear prior to a 
progressive deterioration in angular deformity, as was assessed by Ullah and 
colleagues.  Thus, the true difference in recurrence rate between the two 
studies may be even more dramatic.  Including a fasciectomy cohort in 
Armstrong’s work would have been most appropriate, and would have avoided 
the need to extrapolate and compare between studies.  There are other 
limitations to Armstrong and colleagues’ study.  The length of follow up was 
not standardised.  Whilst the mean follow up of 5.2 years seems of reasonable 
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length, it conceals a range of follow up of 2.1 to 11.5 years.  This breadth of 
follow up renders the recurrence rate from this study much less useful, 
particularly as the distribution of follow up lengths is not shown.  There are no 
well designed prospective studies comparing dermofasciectomy to other forms 
of treatment, though at present dermofasciectomy is still widely considered to 
have a lower recurrence rate than other forms of treatment. 
Excisional strategies may need to be combined with secondary procedures, 
such as check rein ligament release, to tackle underlying joint contractures. 
This piece will focus on the main treatment modalities for tackling the 
Dupuytren’s tissue itself, but will also discuss these other procedures, as they 
have implications for the design of studies in Dupuytren’s disease. 
1.5.4 Division(of(disease(
This may involve dividing cords with a blade, as in the original historic 
descriptions by Astley-Cooper, Goyrand and Dupuytren.  More modern 
approaches tend to use the bevel of a hypodermic needle as a ‘blade’ to 
mechanically divide cords, or employ collagenase enzyme therapy for 
chemical cord division.  Other suggested approaches to disrupting cords 
include using shockwave therapy, though at present this remains a hypothesis 
under investigation (Knobloch et al., 2011). 
Open fasciotomy is the current version of the very original Dupuytren’s 
disease surgery, which has been historically termed the ‘Astley Cooper 
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procedure’ (Leclercq, 2000).  Small skin incisions allow the cord to be divided 
under direct vision without any excision.  It therefore might be considered 
between needle aponeurotomy and segmental fasciectomy on the spectrum of 
invasiveness.  As with fasciectomy, numerous different skin incisions have 
been adopted to approach the cord, some with theoretical advantages, but 
often without evidence for their use.  A prospective non-randomised study has 
compared two techniques used for fasciotomy of cords causing MCPJ 
contractures: direct closure of a transverse incision versus z-plasty closure of 
a longitudinal incision (Citron and Hearnden, 2003).  This small study was 
abandoned early as it showed that z-plasty closure was associated with 
markedly less recurrence than fasciotomy alone at 2 year follow up, but this 
did not reach statistical significance (p is quoted simply as <0.1).  With the 
absence of a power calculation for the study it is unclear whether this lack of 
significance reflects a tendency towards significance in an underpowered 
study, or a true lack of difference between the cohorts.  In spite of this lack of 
conventional statistical significance, a conclusion is made that the data 
support the theory that the development of Dupuytren’s disease may 
represent a response to skin tension.  However, it is notable that Leclercq’s 
definition of recurrence as palpable disease within the operated field was used 
as the primary endpoint, despite this being a trial of fasciotomy.  Thus it might 
be expected that only a relatively small gap in palpable disease would have 
been achieved by the procedure.  As the fasciotomy cohort will have a 
transverse scar overlying this gap in the cord, distinguishing recurrence from 
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skin scar may not be easy.  In contrast, the z-plasty cohort received a 
longitudinal incision, and the use of a z-plasty would rotate the scar out of the 
direction of the cord, but without rotating it through 90 degrees, i.e. the z-
plasty cohort would not be expected to have a scar running transversely 
across the gap in the cord, nor would they be expected to have one running 
parallel to the cord either.  This in turn might make scar-related lumpiness less 
likely to be palpated after a z-plasty, without actually affecting true recurrence.  
Such an effect may have been compounded by changes in assessors – five 
unblinded assessors were used over the course of the study.  Whilst blinding 
may be difficult in this context given the visible distinct appearance of the 
scars from the two closures, it would not be impossible as the patient’s hand 
could be covered with a latex glove.  Laying aside these concerns, if there is a 
true difference between closure of a transverse incision and z-plasty, it is not 
clear whether this truly represents the effect of reducing tension.  The 
approach to the fasciotomy differed between the cohorts; the z-plasty requires 
a longitudinal approach, as the geometry of the procedure then allows skin 
laxity to be recruited in this axis.  However, the longitudinal approach may 
have allowed for better visualisation.  This may have facilitated a more 
effective fasciotomy in this cohort, regardless of skin tension in closure. 
Fasciotomy may be performed using other techniques as well.  The concept of 
a closed fasciotomy is not new.  Indeed, needle aponeurotomy has recently 
increased in popularity, and has been studied in large volume (Pess et al., 
2012).  It involves a closed fasciotomy, in which the cord is divided by 
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repeatedly passing a hypodermic needle through it or across it.  The bevel of 
the needle divides fibres, and eventually breaks the cord.  This may then be 
combined with a steroid injection into the operated field, in an attempt to 
soften the residually diseased tissue (Badois et al., 1993).  Reported 
recurrence rates may be as high as 65% at 32 months (van Rijssen and 
Werker, 2006).  In this study, recurrence was defined as a reduction in TPED 
of 30 degrees or more.  As has been discussed, it is a more appropriate 
endpoint when investigating fasciotomy than Leclercq’s definition.  
Furthermore, it represents an indication for re-operation (BSSH, 2008), and 
thus is a clinically relevant endpoint.  The same team have conducted a 
prospective randomised controlled trial comparing needle aponeurotomy to 
limited fasciectomy with a 5 year follow up.  The early outcomes of this trial 
demonstrate better outcome in terms of TPED improvement for limited 
fasciectomy compared to needle aponeurotomy in severe contractures, but 
similar outcomes for mild contractures (van Rijssen et al., 2006).  Early patient 
satisfaction was better in the aponeurotomy cohort, and their DASH scores 
were significantly lower throughout the first six weeks of follow up.  However, 
recurrence rate was higher after aponeurotomy by 5 years, by which time 
patient satisfaction had reversed; it was higher after fasciectomy (van Rijssen 
et al., 2012).  Needle aponeurotomy has been the subject of an Interventional 
Procedure Overview by NICE, published in 2003 (NICE, 2003).  These 
overviews, by NICE’s Interventional Procedures Advisory Committee (IPAC) 
provide a rapid assessment of literature describing a new procedure, so that a 
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statement can be made about the procedure’s safety and efficacy only.  They 
do not aim to review the literature systematically, or to provide any guidance 
describing the role of that procedure in the management of a particular 
condition.  Seven case series were included in the review, and the specialist 
advisors noted variation in outcome measures.  However, it was 
acknowledged that it is an established practice.  It was considered that there 
was adequate safety and efficacy evidence to support the use of needle 
aponeurotomy in NHS practice. 
A more recent development has been the use of collagenase enzyme therapy, 
marketed as Xiapex™ in Europe.  Attempting to divide cords by enzymatic 
dissolution is not new (Hueston, 1971); however, it has recently undergone 
considerable development by Badalamente and Hurst, who have brought 
collagenase into clinical practice.  Their development process started with in 
vitro experimentation (Starkweather et al., 1996), and progressed through 
phase two trials to the Collagenase Option for the Reduction of Dupuytren’s 
(CORD) 1 study.  This was a phase three, double blind, placebo-controlled 
randomised controlled trial (Hurst et al., 2009), which demonstrated a highly 
significant difference between collagenase-treated contracted joints and 
placebo treated joints, in terms of the primary endpoint (correction to within 5 
degrees of full extension).  There were two flexor tendon ruptures and one 
case of chronic regional pain syndrome in the 203 joints treated with 
collagenase. 
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Data describing recurrence after collagenase treatment do exist.  Recurrence 
(defined as deterioration in contracture per joint of 20 degrees of more) in 
joints ‘successfully treated’ (corrected to 0-5 degrees following treatment) was 
35% at 3-year follow up (Peimer et al., 2013).  However, deterioration of 
contracture by 20 degrees in other joints that showed only partial initial 
response to treatment (contracture improved by 20 degrees or more, but not 
to the 0-5 degrees cut-off defined as ‘success’) was 50%.  This demonstrates 
the difficulty of extrapolating comparisons between studies, as there have 
often been variations in the definitions of early successful treatment, late 
recurrence or poor outcome, and the length of follow up has varied (Becker 
and Davis, 2010).  Indeed, the need for standardisation of definitions has been 
highlighted (Werker et al., 2012).  Other follow up studies have also 
demonstrated encouraging results (Warwick et al., 2014).  However, no trials 
comparing collagenase to needle aponeurotomy or open surgery have yet 
been performed.  Until such data become available, and the cost effectiveness 
of the agent compared to other treatment options is determined, the role of the 
former in managing Dupuytren’s disease cannot be established. 
It is also notable that collagenase treatment has a specific treatment protocol 
that must be adhered to.  The drug is injected directly into the Dupuytren’s 
cord using a hypodermic needle.  The clinician administering the injection 
must have received specific training in the procedure.  The patient then 
returns for a manipulation of the digit (in the initial studies this was 24 hours, 
though longer intervals are being studied), at which point an attempt to break 
University of Nottingham          Introduction 
 86 
the cord is made in order to correct the contracture (Hurst et al., 2009).  
Therefore, although the injection itself may be performed on an outpatient 
basis, the patient will need to return to the treating centre the next day for 
manipulation.  This may have implications when treating patients who live a 
long distance away from the treating centre.  The cost impact of this may only 
be partially captured by existing cost effectiveness analysis methodologies, 
which tend to assess direct healthcare costs only (NICE, 2008). 
1.5.5 Prevention(of(disease(formation(or(progression(
1.5.5.1 Radiotherapy+
Numerous strategies have been considered to try to prevent Dupuytren’s 
disease from developing, progressing or recurring.  The most widely 
discussed is radiotherapy.  As with needle aponeurotomy, this has been the 
subject of an Interventional Procedure Overview by NICE’s IPAC (NICE, 
2011).  The studies considered here were all published in English, though it 
was noted that other literature exists, particularly in German.  The publications 
included two describing one randomised controlled trial and two case series.  
The five specialist advisors who contributed to the overview were divided in 
opinions: two considered radiotherapy to be novel with unproven safety and 
efficacy, and two considered it to be established.  The fifth opinion is not 
described.  The NICE guidance provided is based on the same publications 
and acknowledges the lack of evidence available describing efficacy, 
mechanism of action and safety (NICE, 2011).  Consequently, it is limited to 
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concluding that radiotherapy ‘should only be used with special arrangements 
for clinical governance, consent and audit or research’. 
The randomised controlled trial cited in both the overview and guidance 
involved randomising patients with “early” Dupuytren’s disease to receive one 
of two protocols of radiotherapy (totalling 30 Grays in one group and 21 Grays 
in the other), without any control or placebo group (Seegenschmiedt et al., 
2001).  No description is provided for the method of randomisation, and it is 
not stated whether any blinding was used.  The adverse events are described 
as total numbers observed in the whole trial, rather than by treatment group.  
The primary endpoint used was ‘subjective improvement in symptoms’, which 
is vague and does not fit with commonly used outcome measures for 
Dupuytren’s disease.  Follow up was for a minimum of one year, which is 
likely to be inadequate to assess long-term efficacy on disease progression 
and safety.  Radiotherapy poses additional long-term risks to the patient, 
including dry palmar skin, but also secondary malignancy.  If a potentially 
harmful therapeutic modality is to be used to try to prevent a non-terminal 
condition like this, then obtaining more high quality evidence to support both 
its efficacy and safety profile are important. 
1.5.5.2 Steroid+injection+
Attempts to modify the disease with steroid injections into cords have been 
reported by Ketchum and Donohue, with the aim of softening cords in a 
manner akin to that seen when keloid scars are therapeutically injected with 
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corticosteroid (Ketchum and Donahue, 2000).  This cohort study reported a 
high level of subjectively assessed ‘regression’ of nodules following serial 
triamcinolone injection, though no controls were available and no attempt was 
made to assess improvement in angular contracture or hand function.  These 
data in isolation are not adequate to determine the effectiveness of this 
strategy. 
1.5.5.3 Splinting+and+Traction+
Extension splinting is often used following surgery as an adjunct.  Different 
regimens may be employed, including night only splinting, or day and night 
splinting.  The period of splintage may also vary.  Splints may need 
modification of revision during the rehabilitation period to maintain their effect 
(Jerosch-Herold et al., 2008).  However, relatively high quality studies have 
failed to identify clear evidence of benefit from this (Collis et al., 2013, 
Jerosch-Herold et al., 2011, Kemler et al., 2012).  Splinting as primary therapy 
has been studied, and may provide some benefit in terms of delaying 
deterioration when used in conjunction with soft tissue mobilisation (Larocerie-
Salgado and Davidson, 2012). 
Other strategies may be adopted to correct contractures without direct effect 
on the cord.  Bone traction using Kirschner wire-based devices has been 
described (Craft et al., 2011, Messina and Messina, 1993), by which gradual 
correction is achieved with skin elongation of 2 millimetres per day (Messina 
and Messina, 1993).  This may be used as a definitive strategy in isolation, or 
prior to other treatment techniques.  The developers claimed that the gradual 
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elongation of the contracture achieved with this technique might reduce the 
strain placed on neurovascular bundles and joints that might occur with 
sudden operative release.  Furthermore, the developers claim that this 
strategy may flatten nodules and induce regression of cords, although the 
method used to assess this was not described in detail and appears to be 
subjective (Messina and Messina, 1993).  This approach does result in a 
protracted course of treatment in comparison to other treatment modalities.  
However, it is possible that this time commitment would be offset if 
rehabilitation is accelerated and avoids more invasive surgery.  Furthermore, 
there may be complications from this strategy.  In one study, active flexion of 
the finger was completely lost at the time of removal of the device, and 
returned following a course of hand therapy (Messina and Messina, 1993).  
Although function was restored by therapy, the participants are likely to have 
experienced a further period of considerably limited hand function even after 
the distraction procedure has been completed. 
1.5.5.4 Other+modalities+
A review article raises the possibility of using interferon gamma to modulate 
the disease process as a scientific hypothesis, but does not provide any 
evidence of experimentation to support this (Tomasek et al., 1999).  Similarly, 
there are also other potential treatments currently lacking evidence for their 
efficacy.  These include ultrasound and massage (McGrouther, 2005). 
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1.5.6 Correction(of(associated(pathology(
Appropriately treating the Dupuytren’s disease cord or nodule may not 
necessarily achieve correction of the finger deformity, due to changes in other 
soft tissue structures.  As discussed already, the PIPJ may develop a joint 
contracture due to its arrangement of volar plate check reins.  This may limit 
correction of joint angles when treating disease at the PIPJ (Bryan and 
Ghorbal, 1988).  Release of structures besides the cord of Dupuytren’s 
disease may be performed.  However, this requires an open surgical 
approach, and so cannot be performed with minimally invasive techniques.  
Previous studies but PIPJ release may involve release of a range of the 
structures illustrated in Figure 1.7.  A typical strategy comprises identification 
and protection of the proper collateral ligament, then sequential division of the 
flexor sheath distal to the A2 pulley, the check rein ligaments proximal to the 
volar plate, the accessory collateral ligament and the remainder of the 
proximal part of the volar plate, until contracture release is achieved 
(Beyermann et al., 2004). 
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Figure 1.7: Schematic representation of structures at proximal 
interphalangeal joint 
During proximal interphalangeal joint (PIPJ) release, the proper collateral 
ligament (PCL) is preserved, and sequential release of other structures is 
performed, including the flexor sheath at the distal end of the A2 pulley, the 
accessory collateral ligament (ACL) and the volar plate. 
 
Several studies have investigated the value of PIPJ release in the treatment of 
Dupuytren’s disease, with some identifying improved outcome following joint 
release (Ritchie et al., 2004), whereas others did not demonstrate improved 
angular deformity outcome (Beyermann et al., 2004, Misra et al., 2007).  
Furthermore, joint release may pose further risk of complications such as 
injury to the digital nerves, joint instability, or further scarring and stiffness.  
The functional outcome of joint release may reflect a balance of the benefit of 
additional correction versus increased risk of complications.  Joint release has 
Proximal phalanx 
PIPJ 
Middle phalanx 
Volar plate 
PCL 
Flexor sheath 
ACL 
A2 pulley 
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been compared to bone traction using the Digit Widget device (Craft et al., 
2011). 
The different behaviour of disease affecting the PIPJ compared to cords 
affecting the MCPJ influences current recommendations regarding clinical 
practice, with the indications for surgery typically involving a 30 degree 
contracture at the MCPJ, or any contracture at the PIPJ (BSSH, 2008), as 
PIPJ contractures are harder to correct.  As alluded to earlier in the discussion 
of Selection for Surgery, the evidence supporting these particular cut-offs as 
the indications for treating Dupuytren’s disease is not robust. 
The role of joint release in treating PIPJ contractures requires further 
investigation.  However, it is likely that contractures of the PIPJ pose a greater 
challenge for surgical correction than do MCPJ contractures.  As a result, 
comparative clinical studies may need to match treatment arms in terms of 
proportions of participants with PIPJ contractures, the severity of such 
contractures, and the length of time that the digit has been deformed.  This 
may be particularly important when comparing different treatment modalities; 
needle aponeurotomy is often performed on MCPJ contractures, with more 
invasive fasciectomy and dermofasciectomy performed in cases with PIPJ 
contractures. 
1.5.7 Complications(
A range of complications can occur following treatment for Dupuytren’s 
disease (Hurst, 2010).  These can be categorised as early or late onset 
complications.  Early complications include infection, haematoma, wound 
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healing problems, tendon injury or nerve injury.  Some early complications 
persist for a prolonged period or are permanent, such as cold intolerance and 
altered sensation.  Symptoms following nerve injury may improve if the injury 
is identified and repaired.  However, even if a technically acceptable nerve 
repair is performed, then symptoms may persist indefinitely.  Furthermore, this 
requires an open surgical approach, and so may require a secondary 
operation if a percutaneous treatment such as aponeurotomy or collagenase.  
This will result in further morbidity at the time of treatment of the complication.   
Late complications arise at an interval after treatment and include recurrence, 
which is the focus of much of the literature describing outcome in Dupuytren’s 
disease (Crean et al., 2011).  However, there are other common 
complications.  The median reported rate of neurapraxia was 22% after 
excisional surgery, and 3% after aponeurotomy (Crean et al., 2011). 
A recent review identified that many complications are more common 
following more invasive treatment (Crean et al., 2011), which may influence 
functional outcome independently from recurrence.  Indeed, the reported rate 
of nerve injury after dermofasciectomy ranged from 41% to 51%, compared to 
0.8% to 5.3% after aponeurotomy (Crean et al., 2011).  As a result, the benefit 
of treatments such as dermofasciectomy in terms of low recurrence rate may 
be offset by increased risk of complications when hand function is considered. 
1.5.8 Relative(risks(and(benefits(of(different(treatments(
The theoretical pros and cons of different treatments suggest that different 
treatment modalities may have specific indications.  However, limited 
University of Nottingham          Introduction 
 94 
comparative data exists to confirm the roles of particular treatments.  The 
current theoretical benefits and limitations of the most common treatments 
discussed are summarised in Table 1.2. 
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Treatment type Treatment Sub 
groups 
Benefits Limitations Possible role 
Dermofasciectomy Firebreak skin graft 
‘Conventional’ 
dermofasciectomy 
Low recurrence rate 
(11.6%/patient at 5.2 years 
for conventional 
dermofasciectomy 
(Armstrong et al., 2000)) 
Higher rates of 
complications (e.g. 46% 
nerve injury vs 8.6% for 
fasciectomy (Crean et 
al., 2011). 
Replaces glabrous skin 
with less resilient non-
glabrous skin 
Used in severe or recurrent 
disease, or if strong risk of 
diathesis and therefore likely 
to recur (Armstrong et al., 
2000) 
Fasciectomy Segmental 
fasciectomy 
Most commonly used 
procedure so most 
Longer recovery period 
than aponeurotomy (van 
Currently most commonly 
used procedure in the UK 
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Limited fasciectomy 
Radical 
fasciectomy 
surgeons are experienced 
(Hospital Episode 
Statistics, 2011). 
Higher late patient 
satisfaction than 
aponeurotomy (van Rijssen 
et al., 2012). 
Lower recurrence rate than 
aponeurotomy (van Rijssen 
et al., 2012). 
Rijssen et al., 2006). 
Lower early patient 
satisfaction than 
aponeurotomy (van 
Rijssen et al., 2006) 
(Hospital Episode Statistics, 
2011) 
Aponeurotomy Needle 
aponeurotomy 
Blade 
Shorter recovery period 
than fasciectomy (van 
Rijssen et al., 2006). 
Higher recurrence rate 
than fasciectomy. 
Cannot perform 
Suitable for MCPJ disease 
with a well-defined cord (van 
Rijssen et al., 2006). 
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aponeurotomy Lower complication rate 
than fasciectomy or 
dermofasciectomy (Crean 
et al., 2011). 
secondary joint release 
as minimally invasive. 
Unable to treat painful 
nodules without 
contracture as disease 
not excised. 
Collagenase  Benefits unclear as no 
comparative data available 
Second patient contact 
required for 
manipulation. 
No comparative data 
describing long term 
outcome compared to 
other treatments. 
Role not defined, as no 
comparative data. 
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Table 1.2: Theoretical benefits and limitations of different common treatment options 
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SUMMARY 
Fasciectomy remains the most popular form of treatment for Dupuytren’s 
disease.  However, this term covers a range of different surgical approaches 
in terms of skin incision and management, and extent of excision of disease.  
Dermofasciectomy, with skin grafting is considered to have the lowest 
recurrence rate, though is more invasive, and probably poses a greater risk of 
complications.  Other strategies currently gaining popularity include needle 
aponeurotomy and collagenase therapy.  Whilst radiotherapy has been 
considered to attempt to slow disease progression or recurrence, its efficacy 
and safety are not universally accepted.  More high quality evidence is needed 
to determine the appropriate roles of each of these therapies in the 
management of Dupuytren’s disease.  In particular, the impact of other 
complications in addition to recurrence on function needs to be considered. 
 
 !
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1.6 Adoption!of!high!quality!evidence!
Once high quality evidence that reveals best practice has been generated, 
then it should be adopted.  Conventionally this may occur through 
presentation of research findings at scientific meetings, journal publications 
and through incorporation into clinical guidelines that are then implemented.  
However, adoption of best practice may not always occur.  Furthermore, 
guidelines may vary according to the quality of the process used in their 
development, and implementation of robust guidelines may be inconsistent.  
In England and Wales, the National Institute for Health and Clinical Excellence 
(NICE) was established with one of its objectives being to reduce variation in 
quality of clinical practice.  With The Health and Social Care Act 2012 coming 
into force (Health and Social Care Act c. 7, 2012), NICE’s remit expanded to 
include social care, and so its title changed to the National Institute for Health 
and Care Excellence.  This Act of Parliament also initiated changes to the 
architecture of the National Health Service (NHS) in England and Wales, 
some of which have the potential to facilitate adoption of best practice and to 
standardise the availability of evidence-based treatments. 
1.6.1 Changes!to!the!National!Health!Service!Architecture!
The organisation of secondary care, such as hand surgery, has changed since 
the introduction of the changes in the Health and Social Care Act.  Consortia 
based in primary care, entitled Clinical Commissioning Groups (CCGs), now 
commission services.  To incentivise appropriate commissioning, NICE has 
been charged with establishing a product that will assist commissioning, and 
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act as benchmark.  This has been entitled the Clinical Commissioning Group 
Outcome Indicator Set (CCGOIS).  The CCGOIS must be developed by 
assessments of practice that are derived from high quality evidence.  NICE is 
also developing a series of Quality Standards to serve this purpose.  Quality 
Standards are based upon NICE’s own clinical guidance, but also on clinical 
guidance that meets current international standards (NICE, 2013). 
1.6.2 Guideline!development!
NICE guidelines cover a broad range of areas of clinical practice.  However, it 
is acknowledged that other organisations may also produce robust guidance.  
If NICE were to also produce guidance for the same situation, then duplication 
would arise.  Furthermore, it would be unachievable for NICE to attempt to 
produce clinical guidance for every candidate topic across all aspects of 
clinical practice. 
As a result, NICE’s roles include appraisal of the guideline development 
processes of other organisations, in addition to developing NICE guidance.  
The standard for the development of clinical guidelines used to appraise 
processes is adapted from the Appraisal of Guidelines for Research and 
Evaluation (AGREE) II instrument (Brouwers M et al., 2010).  This comprises 
23 items spread across six domains that aim to comprehensively cover all 
areas of good practice in guideline development.  Processes submitted for 
appraisal by NICE that meet its standards receive NICE Accreditation, and 
can be used to inform Quality Standards (NICE, 2011).  Thus, a pathway is 
currently evolving by which an organisation, such as the British Society for 
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Surgery of the Hand, could systematically review high quality evidence and 
develop appropriate clinical guidance.  This guidance could then be 
implemented nationally through the process described that links Quality 
Standards to the CCGOIS.  This mechanism may become an important 
audience for high quality clinical outcome research.  Alongside the project, the 
candidate developed a process for the development of clinical guidelines that 
meet the standards set by NICE and specified in AGREE II. 
SUMMARY 
A process is emerging by which evidence from high quality studies of clinical 
practice, such as the treatment of Dupuytren’s disease could be adopted and 
implemented nationally.  The input to this process is through NICE Accredited 
guidance, and ensuring that clinical outcome evidence can be incorporated 
into such guidance is likely to become increasingly important in the United 
Kingdom. 
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2 Aim!and!Objectives!
 
2.1 Aims!
This thesis hypothesises that the leading candidate outcome measures are 
inadequate for future use in Dupuytren’s disease research, and that currently 
there is insufficient evidence to inform patient-centred treatment choice in DD. 
In particular, existing candidate outcome measures are hypothesised as being 
subject to bias, invalid, and/or uninterpretable to different extents, such that 
one or more may not be suitable for future use. 
The aim of this study was to investigate these hypotheses as part of the 
preparation to design future high quality clinical studies in Dupuytren’s 
disease.  Furthermore, this needs to be achieved in the context of the 
changes to NHS architecture brought about by The Health and Social Care 
Act 2012 (Health and Social Care Act c. 7, 2012) (Figure 2.1). 
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Figure 2.1: Simplified research pathway 
 
 !
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2.2 Objectives!
To achieve the aims, several objectives have to be achieved. 
 
1. Establish which surgical interventional trials have been conducted in 
Dupuytren’s disease and what outcomes were reported in them, by 
conducting a systematic review 
Firstly, existing evidence needs to be appraised so that the state of research 
comparing treatment options in Dupuytren’s disease is fully understood, and 
the need for further work established prior to continuing with other elements of 
the project.  By doing so, the outcome measures used to date in randomised 
controlled trials can be identified and compared to those used across all 
clinical studies of Dupuytren’s disease, as recently reviewed elsewhere (Ball 
et al., 2013). 
Therefore, this first review will identify high quality studies comparing 
treatments for Dupuytren’s disease to date, and identify which outcome 
measures have been reported in these trials. 
 
2. Investigate the validity of leading candidate outcome measures, by 
performing a cross sectional study 
Once the need for further clinical research in Dupuytren’s disease is confirmed 
by achieving Objective 1, then the behaviour of candidate outcome measures 
needs to be investigated to inform the choice of the primary outcome measure 
for future research.  The outcome measures studied will be based on the 
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findings of Objective 1, and a recent systematic review performed by others 
(Ball et al., 2013) 
Specifically, the following uncertainties need to resolved regarding existing 
outcome measures: 
a. Is dynamism in Dupuytren’s disease is significant enough to 
constitute a source of bias for passive angular measurements? 
b. What are the goals of British patients for the treatment of 
Dupuytren’s disease, and is the URAM scale cross culturally 
sensitive against British patients’ goals? 
c. Do the DASH and QuickDASH tools demonstrate acceptable 
structural validity when used in Dupuytren’s disease specifically? 
 
3. Study the interpretability of leading outcome measures in 
Dupuytren’s disease, by conducting a systematic review and cohort 
study. 
As interpretability is a different domain of the behaviour of outcome measures, 
it will be studied separately here.  Firstly, the existing data describing the 
interpretability of different outcome measures in Dupuytren’s disease will be 
appraised by conducting a systematic review.  Alongside the systematic 
review, a cohort study will provide original data, to resolve the following 
uncertainties: 
a. Is 6 weeks after surgery too early to measure outcome from 
surgery for Dupuytren’s disease? 
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b. What is the responsiveness and interpretability of the DASH and 
URAM when used in Dupuytren’s disease surgery? 
 
4. Estimate the late functional outcome after surgery for Dupuytren’s 
disease and the factors associated with poor functional outcome, by 
performing a cross sectional study 
Having studied the validity and interpretability of potential outcome measures 
to be used for future research, estimating functional outcome is also 
necessary as part of the preparation for future research.  As well as estimating 
the outcome itself, this will also allow investigation of the factors associated 
with poor outcome.  Such factors may need to be recorded in future studies to 
ensure cohorts are comparable.  This objective will clarify the following 
uncertainties: 
a. What is the late functional outcome of surgery for Dupuytren’s 
disease from a cross sectional study? 
b. What are the complication rates following the treatment of 
Dupuytren’s disease by needle aponeurotomy, fasciectomy and 
dermofasciectomy? 
c. Which factors discussed in the introduction are associated with 
poor functional outcome and complications, rather than with the 
tendency to recur, or ‘diathesis’? 
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3 General!Methods!
The methods for general data collection are described here.  Further methods 
specific to individual chapters are described in the relevant chapters. 
 
3.1 Studies!in!the!project!
Two groups of patients were recruited.  Early functional recovery was studied 
in a group of patients recruited in Nottingham prior to surgery, and then 
followed for 1 year after the procedure, as a cohort study.  A second group of 
patients was recruited from five centres including Nottingham, who had 
undergone treatment 1 year or 5 years previously.  The outcome of their 
treatment was evaluated as a cross sectional study. 
The candidate personally conducted all assessments of patients for both 
studies. 
 
3.2 Centre!Enrolment!for!cross!sectional!study!
Centres were identified and approached on the basis of perception of the 
estimated number of Dupuytren’s cases treated per year, willingness to 
support the project, and their treatment of choice for Dupuytren’s disease (with 
the aim of recruiting centres with a range of preferred treatments).  At each 
centre, a local consultant surgeon was appointed to act as principal 
investigator (PI) for that site by local consensus. 
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In addition to the Queen’s Medical Centre (QMC) (Nottingham University 
Hospitals NHS Trust), where the candidate was employed, other centres 
approached that met the above criteria were: 
 
• Rotherham General Hospital (RGH) 
(Rotherham NHS Foundation Trust) 
• The Pulvertaft Hand Centre within The Royal Derby Hospital (PHC) 
(Derby Hospitals NHS Foundation Trust) 
• Derriford Hospital (DH) 
(Plymouth Hospitals NHS Trust) 
• St John’s Hospital at Howden (SJH) 
(NHS Lothian) 
3.3 Generic!Approvals!&!Nottingham!Approval!
The candidate registered with the Information Commissioner’s Office 
(www.ico.gov.uk) as a Registered Data Controller (Z2200077), with approval 
for the specific purposes of the project (approval included: holding identifiable 
details including patient names and addresses, demographics, hand function, 
and digital images; transporting them between centres; storing paper copies of 
data capture in a secure environment in QMC; and storing electronic copies 
on a fully encrypted device).  However, the processes used for the project 
were designed to considerably reduce the risk of data protection being 
breached. 
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The original project processes were reviewed and approved as service 
evaluation by Dr Brian Thomson (Director of Research) and by Charlotte 
Davies (Operations Manager), of the Nottingham University Hospitals 
Research & Innovation team (see Appendix 1). 
As an employee of Nottingham University Hospitals NHS Trust, the candidate 
completed all required pre-employment checks mandated for work in the NHS.  
Employment as a Clinical Fellow in Trauma & Orthopaedics constituted 
membership of the ‘usual clinical care team’ for hand surgery patients.  
Photographic identification in the form of Nottingham University Hospitals NHS 
photographic ID was worn at all times. 
3.4 Cross!sectional!study!centre!approval!
With assistance from the PI at each centre, the project received approval from 
Research & Development departments (R&D) and Information Governance 
departments (IG). 
At one centre (SJH), IG referred the project for further approval by The 
Caldicott Guardian.  Data collection and handling processes were revised to 
meet The Caldicott Guardian requirements at this centre. 
One centre (PHC) was able to provide administrative support from a dedicated 
Research & Postgraduate Secretary, and the processes used at this centre 
were modified to account for this. 
Patient recruitment commenced at a centre once local approval was obtained. 
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3.5 Cross!sectional!study!patient!identification!&!contact!
The PI at each centre formally approached his or her clinical coding 
department.  Patients who had undergone treatment for primary Dupuytren’s 
disease either 1 year earlier or 5 years earlier were identified using the Office 
of Population Consensuses and Surveys Classification of Interventions and 
Procedures version 4 (OPCS-4) codes (Table 3.1). 
 
CODE! !DESCRIPTION!
T521! Palmar&fasciectomy&
T522! Revision&of&palmar&fasciectomy&
T525! Digital&fasciectomy&
T526! Revision&of&digital&fasciectomy&
T541! Division&of&palmar&fascia&
T548! Other&specified&
T561! Dermofasciectomy&
T562! Revision&of&dermofasciectomy&
Table 3.1: OPCS-4 codes used to identify prospective study participants 
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Lists were screened either by clinical coding staff, or by other workers at the 
local centre, to identify and exclude those who met the following criteria: 
• Deceased 
• Address over 20 miles from local centre by road 
• Nursing home residents 
3.6 Cross!sectional!study!recruitment!at!Nottingham! !
Patients who were not excluded from Nottingham were contacted by 
telephone to invite them to participate in the service evaluation.  An 
appointment was scheduled with those who agreed to participate in principle, 
at a mutually agreeable time and location.  At the start of the appointment, 
patients were provided with written information about the project (Appendix 2) 
and given the opportunity to withdraw their consent for participation. 
3.7 Cross!sectional!study!recruitment!at!other!centres!
The local centre PI wrote to all patients who were not excluded, using local 
centre NHS Trust headed paper to invite them to participate in the project.  
R&D at Rotherham General Hospital approved the content of the invitation 
letter (Appendix 3).  Thereafter, each centre’s consultant made only minor 
stylistic changes to the content of the letter.  A consent form (adapted from 
that used by R&D at RGH, and approved at each centre (Appendix 4) was 
enclosed with the letter of invitation.  A stamped addressed envelope for the 
return of the consent form was also enclosed.   
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The return address for the consent form was determined by local IG approval 
and the presence of administrative support, as listed in Table 3.2. 
 
Centre& Return&Address& Rationale&
PHC! PHC& Administrative&support&available&
RGH! QMC& Approved&by&local&centre&
DH! QMC& Approved&by&local&centre&
SJH! SJH& Stipulated&by&Caldicott&Guardian&
Table 3.2: Return postal arrangements for consent forms for different 
local centres 
 
Patients who consented to participate were contacted by telephone by the 
author to arrange an appointment at the local centre, under the nominal 
supervision of the local centre consultant hand surgeon.  If patients could not 
attend the local centre and yet wished to participate, an appointment at 
another location of their choice was arranged. 
All assessments were performed within a two-month window of the 
anniversary of their surgery (i.e. 10-14 months or 58-62 months post-surgery).  
If an appointment could not be made within the time frame, the patient was 
excluded from the study. 
3.8 Cross!sectional!study!data!capture!
During the single appointment, data were captured by targeted history and 
examination using a proforma approved by all centres (Appendix 5) and 
completion of PROMs.  Data captured included patient demographics, 
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purported risk factors for the development of Dupuytren’s disease, measures 
of outcome, and complications. 
Captured items included: 
• procedure type 
• hands and digits treated 
• age at surgery 
• postoperative splinting 
• gender 
• hand dominance 
• previous Dupuytren’s disease surgery 
• present occupation 
• main previous occupation and occupational impact of Dupuytren’s 
disease. 
Procedures were divided into aponeurotomy (with needle or blade), 
fasciectomy and dermofasciectomy.  Collagenase was not studied as part of 
this project, due its United States Food and Drug Administration (FDA) 
approval only being granted 1 year prior to the project commencing (FDA, 
2010).  Procedure type was determined by description of the procedure by the 
patient supported by clinical examination of scarring on the hand by the 
author, followed by reference to the OPCS-4 code for the procedure and the 
case notes if required. 
Information was recorded on procedures to all hands and digits treated on the 
date concerned.  If both hands were treated with the same procedure (e.g. 
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needle aponeurotomy to right and left ring fingers in one operation), then the 
one treated digit on each hand was assessed, as a separate entity. 
If more than one digit on a hand was treated with the same procedure on the 
date concerned, then only one digit was assessed.  The digit selected in such 
cases was the one that, at follow up, had the worst total active flexion deficit 
as assessed by eye.  For example, for a single procedure comprising 
fasciectomies to right ring and little fingers, after which the ring finger had 
remained straight, but little finger had contracted towards palm, then only little 
finger would be assessed. 
If more than one procedure was performed on a hand then both procedures 
were recorded as separate entities, for example a fasciectomy to the left ring 
finger and revision dermofasciectomy to the left little finger in one operation 
would be recorded independently.  Whether both events were used, or the 
patient was excluded from analysis, depended on the particular analysis 
concerned.  Such information is provided in the methods section of each 
chapter. 
Age at surgery was determined from the patient’s date of birth at the operation 
date provided by clinical coding. 
Whether the patient had undergone Dupuytren’s disease surgery previously 
was determined by a combination of patient recall, examination of the hands 
for additional scarring, and reference to case notes if uncertainty remained. 
Patients provided details of their current and significant previous occupational 
histories.  They were asked whether their occupation changed once 
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Dupuytren’s disease had become apparent, and whether it had changed 
following the surgical procedure under assessment or following any previous 
surgery. 
Risk factors included: 
• known family history 
• current smoking status 
• current alcohol consumption 
• epilepsy, and medications if currently treated 
• diabetes mellitus, and current treatment 
• knuckle pads 
• Ledderhose’s disease 
A positive family history was recorded only if the patient was confident that a 
biological relative had had Dupuytren’s disease, regardless of whether the 
relative was of a more senior or more junior generation, and irrespective of 
whether it was medically diagnosed or treated. 
Positive smoking status was only recorded if the patient described himself or 
herself as a current active smoker.  Previous smoking history was not 
recorded. 
Alcohol consumption was the patient’s self-report of the UK units consumed 
per week on average.  If the patient could not specify the number of units, 
then the product and volume were recorded, and number of units calculated 
using the tool available from the NHS Choices website (NHS, 2013).   
University of Nottingham     General Methods 
 117 
Epilepsy and diabetes mellitus were recorded if the patient reported a 
diagnosis of either condition made by a doctor.  Diabetes mellitus was then 
divided into type 1 or type 2 diabetes.  Current treatments were recorded. 
Specific clinical examination was carried out to identify knuckle pads.  Knuckle 
pads were considered to be present if there was at least one subcutaneous 
firm nodule separate from the skin overlying the PIPJ.  Cutaneous thickening 
of the skin alone was not counted as a knuckle pad. 
Ledderhose’s disease was described to patients as involving similar nodules 
affecting the soles of the feet.  If patients had clearly noted such lumps, this 
was recorded.  If they were unsure, the feet were examined to confirm the 
presence of Ledderhose’s disease. 
Outcomes included: 
• passive extension deficit at MCPJ and PIPJ by goniometry 
• one or more PROMs 
• further surgery for Dupuytren’s disease, either to the same digit or to 
the same hand 
Passive extension was measured at each joint individually, with the other joint 
of the ray held in passive flexion. 
All patients completed the DASH questionnaire.  The URAM questionnaire 
was published during the course of the project (Beaudreuil et al., 2011), and 
was added to the data capture once it had been reviewed.  After completing 
all PROMs, patients were asked to specify which PROM they considered to 
have been the most appropriate assessment of their hand function. 
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DASHs with more than 3 missing answers were excluded from analysis (in 
keeping with the developer’s instructions (Kennedy et al., 2011)).  URAMs 
with any missing answers were excluded from analysis. 
Complications included: 
• loss of active flexion at MCPJ and PIPJ  
• loss of active flexion recorded as fingertip-distal palmar crease distance 
in the same digit  
• altered two point discrimination sensation in the distribution of the radial 
digital nerve and the ulnar digital nerve 
• trauma-induced cold associated symptoms (cold intolerance) 
• complex regional pain syndrome (CRPS)  
CRPS was defined using the clinical criteria devised for use in orthopaedic 
surgery (Atkins, 2003), that are modified from those established by the 
International Association for the Study of Pain (IASP) (Stanton-Hicks et al., 
1995).  These comprise the presence of the following symptoms, none of 
which arise in uncomplicated Dupuytren’s disease (Atkins, 2003): 
• neuropathic pain 
• vasomotor instability 
• reduced joint mobility 
• soft tissue contractures 
Trauma-induced cold associated symptoms (cold intolerance) were identified 
using the scale described by Campbell and Kay (Campbell and Kay, 1998).  
This scale recognises five types of cold associated symptom: pain, numbness, 
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tingling, stiffness, and colour change.  Symptoms severity is scored as 
summarised in Table 3.3. 
 
GRADE DESCRIPTION 
1 Severe symptoms 
2 Troublesome symptoms 
3 Minor symptoms 
4 Symptoms present, but cause no 
trouble 
5 No symptoms 
Table 3.3: Campbell's scale of cold-associated symptom severity 
3.9 Cohort!study!recruitment!
Patients booked for fasciectomy or dermofasciectomy at QMC were invited to 
participate in the cohort study when attending the preadmission clinic.  Written 
information about the project was provided (Appendix 2) and patients were 
allowed ample time to read it.  If patients wished to participate, verbal consent 
was taken in keeping with local Nottingham University Hospitals NHS Trust 
policy for service evaluation. 
3.10 Cohort!study!data!capture!
Patients who consented to participate were reviewed during their 
preadmission clinic visit.  A standardised proforma was used to capture details 
of patient demographics, planned procedure and risk factors for poor early 
outcome (Appendix 6). 
University of Nottingham     General Methods 
 120 
A single observer measured finger joint angles.  When each MCPJ and PIPJ 
was measured, the other joint in the ray was held in maximum passive flexion. 
Patients completed PROMs to describe their preoperative state. 
Once each patient’s planned operation date had passed, confirmation that the 
operation had proceeded as planned was obtained through the Trust’s 
electronic appointment system.  If surgery was cancelled, this was noted and 
the patient excluded from further contact.  If surgery was postponed, 
confirmation that surgery had taken place on the revised date was ensured in 
the same way.  The specific procedure performed during the surgery was also 
identified from this system, in case a planned fasciectomy had been converted 
to a dermofasciectomy intraoperatively, and vice versa. 
DASH PROMs were posted to patients to be completed three weeks and six 
weeks after surgery and returned by post using a stamped addressed 
envelope enclosed.  The PROMs were posted to patients within the week 
preceding the three or six week time point to ensure receipt prior to the date 
concerned.  Patients were requested to complete the PROM on the 
appropriate date and to return to QMC using the stamped addressed 
envelope. 
Those who returned both three and six week PROMs, and those who 
completed the six week PROM but not the three week PROM, were sent a 
further DASH at one year following surgery.  Enclosed with the DASH was a 
PROM that assesses change in state: a Global Rating of Change (GROC) 
PROM.  Again, a stamped addressed envelope was enclosed to return 
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completed PROMs.  Clinical contact at Nottingham University Hospitals NHS 
Trust with patients who had returned one year PROMs was reviewed using 
the electronic appointments system, to identify those who had undergone 
further hand surgery since the fasciectomy or dermofasciectomy a year 
earlier. 
3.11 Data!handling!and!analysis!
All patients from both the cross sectional study and the cohort study were 
allocated a study reference number during initial contact for the cross 
sectional study, and during initial data capture for the cohort study.  This 
reference number, pseudo-anonymised the patients.  Names and hospital 
numbers were stored with the study code at the local centre where the patient 
was recruited. 
Data were entered into password-protected Microsoft Excel® spread sheets 
(Microsoft for Mac 2011 version, Microsoft®, Redmond, USA, 2010) with each 
patient identifiable by their study code.  The spreadsheets were stored on a 
laptop computer with an encrypted hard drive.  Paper copies of data collection 
sheets were stored securely at local centres.  Study code allocations for 
patients from each centre were also stored at that centre. 
Data analysis was performed using SPSS® Statistics version 21 (IBM® 
Software, Armonk, USA, 2012), and Prism 6.0 for Mac OS X (GraphPad® 
Software, La Jolla, USA, 2012). 
As data analyses were specific to the individual components of the project, 
they are discussed in the methods section of each chapter individually. 
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3.12 Accuracy!of!data!entry!
Prior to data analysis, a blinded independent observer assessed accuracy of 
data entry into Microsoft Excel® spreadsheets.  The independent observer 
was an orthopaedic surgery registrar from the hand surgery firm, and was 
therefore part of the usual clinical care team for hand surgery patients at 
Nottingham University Hospitals NHS Trust at the time concerned.  A target of 
less than 2% inaccurate data entry was set prior to the audit being carried out.  
If more than 2% of data entries were inaccurate, then all data entry from all 
centres would be audited.  If less than 2% of data entries were inaccurate, 
then this would be tolerated. 
An electronic random number generator provided five numbers.  The patient 
data corresponding to those row numbers in the master spreadsheet of 
patients recruited in Nottingham were extracted.  These five patient datasets 
comprised a total of 720 data items.  The independent observer reviewed the 
spreadsheet data against the original paper copies of data capture sheets on 
17th April 2013.  The observer identified one error of data entry, giving a data 
entry error rate of 0.14%.  Therefore, data entry was deemed accurate, and 
analysis proceeded as planned. 
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4 Systematic Review and Meta-analysis of Surgical 
Trials in Dupuytren’s Disease 
4.1 Preface!
The previous chapter described a new guideline development process to be 
used by the United Kingdom’s national hand surgery society, the British 
Society for Surgery of the Hand (BSSH).  It is likely that there is insufficient 
high quality comparative evidence to be able to produce a clinically useful 
guideline for the treatment of Dupuytren’s disease at present.  Furthermore, it 
is necessary to appraise the existing high quality studies prior to designing 
further research.  In addition to avoiding unintentional repetition of research, it 
will also identify aspects of trial design in Dupuytren’s disease that contribute 
to achieving high study quality, as well as aspects of design that have 
downgraded the quality of the study, based on the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) 
approach (Atkins et al., 2004).  This may be particularly important, as 
minimising risks of bias such as performance bias, may be difficult to achieve 
in surgical trials where blinding surgeons is difficult.  This chapter describes a 
systematic review of trials of the surgical treatment of Dupuytren’s disease, 
including a meta-analysis of trials investigating the role of postoperative 
splinting. 
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4.2 Background!
Comparative studies of the different treatment options for Dupuytren's disease 
are needed to determine the role of different procedures.  In particular, 
whether the benefits of more invasive procedures, such as dermofasciectomy, 
that are believed to have lower "recurrent contracture" rates outweigh 
potentially higher rates of adverse events (complications) or a less acceptable 
rehabilitation period.  Whilst comparison of different operative techniques is 
important, it must be recognised that surgery is only part of a complex 
intervention for the treatment of Dupuytren's contracture.  The outcome of this 
may not be exclusively determined by what surgery is performed, but also by 
the post-operative rehabilitation regimen (splinting and hand therapy) and 
other treatment factors such as patient selection and site of contracture 
(metacarpophalangeal joint alone, proximal interphalangeal joint alone, or 
both joints together).  Also the outcome of Dupuytren's surgery is usually 
defined by the "recurrent contracture rate", in contrast to "disease extension" 
to other digits, the rate of which is unaffected by surgery.  Only a few studies 
have assessed outcome in a patient-centred manner, or investigated the 
severity and length of the post-operative recovery from the surgery. 
4.3 Objectives!!!
The aim of this review was to assess the effects (benefits and harms) of 
different surgical procedures for the treatment of Dupuytren's contracture of 
the index, middle, ring and little fingers (the thumb will be excluded, where 
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disease is rarer, and where cords form on the radial aspect of the thumb, and 
thus are not readily accessible in terms of angular deformity.). 
4.4 Methods!
4.4.1 Criteria!for!considering!studies!for!this!review!!!
Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) were 
included, irrespective of sample size or language of publication. 
Participants could be adult men and women of any ethnicity, with or without 
risk factors for Dupuytren's disease, who had undergone surgery for 
Dupuytren's contracture of one or more of the index, middle, ring and little 
fingers. 
Interventions studied were any surgical intervention, including: 
• Percutaneous Needle Fasciotomy (Aponeurotomy) 
• Very Limited Fasciectomy 
• Limited Fasciectomy 
• Dermofasciectomy 
Comparators that would be included could vary from: 
• Different Surgical Procedures 
• Placebo/Sham Surgery 
• Other Active Non-Surgical Treatments (Collagenase Injection, 
Physiotherapy, Radiotherapy, Hand Therapy) 
It was not anticipated that there would be studies comparing treatment to 
observation alone.  If such studies were identified, they were discussed. 
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The validity and reliability of any outcome measure commonly used in 
Dupuytren's disease has not been well studied.  Anticipated outcomes have 
been listed below.  Hand function was selected as the key primary outcome, 
as this represents an important patient-centred measure.  In contrast, angular 
measurements are surgeon-centred measurements. 
4.4.2 Major!outcomes!
Change in hand function 
This could be determined by any appropriate assessment, such as the 
Disabilities of the Arm, Shoulder and Hand (DASH) patient-reported outcome 
measure (PROM) (Hudak et al., 1996), PEM (Macey et al., 1995), grip 
strength, Jebsen-Taylor Hand Function Test (Jebsen et al., 1969). It was 
uncertain which standardised outcome instruments would be encountered but 
all were reported. 
Patient satisfaction and other patient rated outcomes 
This could include pain or health-related quality of life (HRQoL). 
Early angles outcomes and other objective outcomes 
Possible outcomes in this group include 1) change in contracture after surgery 
- the difference between the finger angle measurement immediately after 
surgery and the preoperative finger angle measurements, or 2) residual 
contracture after surgery - as assessed by angle measurement (goniometry), 
or 3) early result (as above) at another relevant time point, such as time of 
discharge from care.  Active or passive angles may be reported.  Angles may 
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be presented per joint, or per ray (e.g. total extension deficit across the MCPJ 
and the PIPJ, or across the MCPJ, the PIPJ and the DIPJ. 
Recurrence of Dupuytren's disease/contracture where previously treated 
Given that recurrence is time-dependent, length of follow-up has not been 
standardised and there is no consensus definition of recurrence, recurrence 
rates and length of follow-up were described in narrative form.  Where 
appropriate data existed, time-to-event analyses would be performed.  
However, it was not expected that suitable data would be available.  Meta-
analyses would only have been performed for studies with similar definitions 
of recurrence and recurrence data at similar follow-up times after surgery.  
The minimum length of follow-up for eligibility in analyses of recurrence was 
18 months.  This was chosen for two reasons: firstly, shorter follow-up gives 
insufficient time for recurrence, and secondly, there was no current consensus 
to define minimum length of follow-up, and this varies widely, from 3 weeks to 
13 years (Becker and Davis, 2010). 
Adverse effects 
Anticipated adverse effects included loss of finger flexion, loss of finger 
sensation due to digital nerve injury, vascular compromise, delayed healing 
and infection.  As the completeness of reported adverse events was unknown, 
all adverse effects data were collected and reviewed.  This review focussed 
on key adverse events should there prove to be extensive reporting of 
numerous adverse effects. 
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4.4.3 Minor!outcomes!
Cost effectiveness 
Where provided this would be assessed using the total cost of the procedure 
and rehabilitation.  Where time-to-recurrence was documented, cost per year 
of recurrence-free survival would be calculated.  However, it was not 
anticipated that these data would be available. 
4.4.4 Search!methods!for!identification!of!studies!!!
All searches were performed on 17 September 2012, and re-run on 10th 
March 2014 to update the results. 
The following databases were searched to identify reports of relevant RCTs 
and CCTs: 
• The Cochrane Central Register of Controlled Trials (CENTRAL), The 
Cochrane Library, Issue 8 2012 
• BNI (British Nursing Index and Archive) - 1985 to September 2012 
• CINAHL - 1981 to September 2012 
• EMBASE - 1980 to September 2012 
• LILACS (Latin American and Caribbean Health Sciences) - 1982 to 
September 2012 
• Ovid MEDLINE - 1948 to September 2012 
• Ovid MEDLINE - In-Process and other Non-Indexed Citations - 1948 to 
September 2012 
• Proquest (ABI/INFORM Global and Dissertations & Theses)- all entries 
to September 2012 
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• ISI Web of Science 
• clinicaltrials.gov 
 
The full search strategy for CENTRAL was: 
 
#1 MeSH descriptor Dupuytren explode all trees 
#2 MeSH descriptor Fibromatosis explode all trees 
#3 Dupuytren*:ti, ab, kw 
#4 (#1 OR #2 OR #3) 
#5 MeSH descriptor surgery explode all trees 
#6 MeSH descriptor fascia explode all trees 
#7 (#5 OR #6) 
#8 (#4 OR #7) 
#9 MeSH descriptor Dupuytren surgery explode all trees 
#10 (dupuytren NEAR/3 surgery*): ti, ab, kw 
#11 (contracture NEAR/3 surgery*): ti, ab, kw 
#12 (#8 OR #9 OR #10 OR #11) 
 
The Ovid MEDLINE search was combined with the Cochrane Highly Sensitive 
Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and 
precision-maximizing version (2008 revision) (Lefebvre et al., 2011):  
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and 
Ovid MEDLINE(R) <1948 to Present>Search Strategy: 
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-------------------------------------------------------------------------------- 
1     randomised controlled trial.pt. (319496) 
2     controlled clinical trial.pt. (83719) 
3     randomised.ab. (224758) 
4     placebo.ab. (129278) 
5     clinical trials as topic.sh. (158838) 
6     randomly.ab. (161802) 
7     trial.ti. (96632) 
8     1 or 2 or 3 or 4 or 5 or 6 or 7 (742481) 
9     exp animals/ not humans.sh. (3701210) 
10     8 not 9 (685232) 
11     exp Dupuytren Contracture/ (2035) 
12     exp Fibroma/ (10932) 
13     Fibromatosis.tw. (2305) 
14     exp Fascia/ (8039) 
15     Fibroblasts/ (90308) 
16     (palmar adj3 fascia).tw. (186) 
17     Dupuytren*.tw. (1902) 
18     (palmar adj3 fibromatosis).tw. (63) 
19     (viking adj3 disease).tw. (1) 
20     or/11-19 (111278) 
21     10 and 20 (689) 
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 The EMBASE and CINAHL searches were combined with the trial filters 
developed by the Scottish Intercollegiate Guidelines Network (SIGN).  There 
were no language or date of publication restrictions. 
Variations of the Ovid MEDLINE search strategy were used to search the 
other databases. 
The reference lists of shortlisted articles were screened to identify further 
suitable studies and Web of Science was searched to identify studies citing 
the items in the shortlist.  No language restrictions were applied and 
potentially eligible foreign language studies were obtained and translated 
using electronic web-based translation. 
4.4.5 Selection!of!studies!!!
From the title, abstract or descriptor, two reviewers (the candidate and a 
second author) independently screened all abstracts to identify potential 
studies for review using a checklist of the criteria for inclusion: 
 
Q1.  Does the paper report the outcome of a clinical study?  (i.e. not a review 
article or just a paper describing an operative technique description)? 
Q2.  Have participants had a surgical intervention for Dupuytren's contracture 
of a finger? 
Q3.  Did the study report either the short term or long term outcomes 
(recurrence) of the surgery? 
Q4.  Did participants receive an intervention compared to a control group or 
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were at least two interventions compared? 
Q5.  Was the study randomised or quasi-randomised? 
 
The two authors compared their lists of potential studies and produced a 
consensus shortlist.  Copies of full papers on the shortlist were obtained. 
Two review authors (the candidate and a second author) independently 
reviewed the full text of the abstracts of the "agreed shortlist" papers and 
identified those suitable for inclusion using the checklist above.  
Disagreements were resolved by referral to a third author.  No masking of 
titles of journals, names of authors or supporting institutions was performed. 
4.4.6 Data!extraction!and!management!
Data describing source, study design, intervention, population and outcomes 
were extracted using a piloted form by two authors (the candidate and a 
second author) independently.  Disagreements were resolved by consensus 
after an additional review by a third author. 
4.4.7 Assessment!of!risk!of!bias!in!included!studies!!
Two authors (the candidate and a second author) independently used The 
Cochrane Collaboration's tool for assessing risk of bias (Higgins JPT and 
Green S, 2011).  All seven domains (sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome 
assessment, incomplete outcome data, selective outcome reporting and other 
University of Nottingham Systematic Review of Surgical Trials 
 133 
issues) were assessed and classified as 'high risk of bias', 'low risk of bias' or 
'unclear risk of bias'. 
Each outcome was judged upon the majority of the seven domains fitting 
either high or low risk.  Disagreements were resolved by referral to a third 
author (the supervisor).  As it was anticipated that few studies would employ 
blinding, the use of blocked randomisation in unblinded studies was assessed 
as a source of "other" bias risk. 
4.4.8 Measures!of!treatment!effect!!!
If appropriate, standardised mean differences (SMD) were used to combine 
different outcome measures from different trials (Hedges, 1982). 
If studies reported dichotomous data, risk ratios with 95% confidence intervals 
would be calculated.  For rare events (< 10%), Peto odds ratios with 95% 
confidence intervals were calculated. 
4.4.9 Unit!of!analysis!issues!!!
It was expected that the hand would be used as the unit of randomisation in 
most studies.  Assessing outcomes such as hand function would not be 
possible if individual digits on the same hand were used as the unit of 
randomisation.  The unit of randomisation (patient, hand, finger or unclear) 
was recorded for each included study. 
It was not expected that there would be any crossover studies, given that the 
interventions here are definitive treatments.  Cluster randomised studies were 
not expected to be encountered. 
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4.4.10 Dealing!with!missing!data!!!
Two types of missing data were anticipated: unreported and withdrawn.  If 
there were unreported data in included studies, the authors were contacted for 
assistance.  No imputation was attempted. 
4.4.11 Assessment!of!heterogeneity!!!
If appropriate, statistical heterogeneity was tested using visual inspection of 
graphs, Chi square and I square statistic tests.  A Chi square test result was 
considered significant when p < 0.10.  An I square test result greater than 50% 
was considered to demonstrate substantial heterogeneity. 
4.4.12 Assessment!of!reporting!biases!!!
To reduce the risk of reporting bias, multiple sources were searched, including 
Proquest (ABI/INFORM Global and Dissertations & Theses), to identify all 
unpublished results where possible. 
Funnel plots were drawn to assess the risk of publication bias. 
ISI Web of Science was searched to identify relevant results that had not been 
published.  If such work were identified, the authors were contacted and asked 
to provide a copy of the data. 
4.4.13 Data!synthesis!!!
Extracted data from included studies were compared using the Cochrane 
Collaboration's statistical software, Review Manager.  If studies were 
sufficiently similar, meta-analysis was undertaken. 
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When the same outcome measures were assessed with different scales, 
standardised mean differences (SMDs) were used. 
However, it was expected that data from different studies would be difficult to 
compare, such that meta-analysis might not be possible.  This would 
particularly be the case for "recurrence", because of variation in follow-up 
length (the recurrence rate increases longer follow-up) and differences in the 
definition of "recurrence" between studies. 
A random-effects model was used to combine data if outcomes were 
homogeneous.  If the results were heterogeneous, reasons for heterogeneity 
were identified through subgroup analysis.  If significant heterogeneity was 
found, the data was not pooled and a narrative (qualitative) summary of 
methodological quality and results was presented 
4.4.14 Subgroup!analysis!and!investigation!of!heterogeneity!!!
Reasons for heterogeneity were considered using subgroup analysis.  
Subgroup analysis was considered with regard to: 
• Length of time to follow-up 
• PIPJ and MCPJ outcomes separately 
As it is well recognised that contractures of the latter correct better than 
those of the former 
• Severity of disease prior to operation 
Where provided, it was expected that this would be in the form of total 
passive extension deficit at the MCPJ and PIPJ 
• Number of joints involved 
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• Postoperative treatment offered 
4.4.15 Sensitivity!analysis!!!
Outcome measures, such as the definition of recurrence, have been defined 
differently (Becker and Davis, 2010).  If required, sensitivity analyses were be 
performed to examine whether the result varied based on definitions. 
We also undertook sensitivity analysis for missing data, for example intention 
to treat versus per protocol analysis, to examine variations between different 
analytic approaches. 
4.5 Results!!!
4.5.1 Description!of!studies!
4.5.1.1 Search+Results+
The search strategy retrieved 2382 references.  One hundred and three 
duplicates were removed prior to abstract screening. 
For three studies, inadequate detail was available from the abstract and 
reference to make a decision, and the original paper could not be obtained 
(Gazdzik and Wasilewski, 1997, Slullitel, 1987, Yoshida et al., 1998).  They 
were excluded on this basis.  Two could not be classified as the full text article 
did not adequately describe the study design, such that it was not clear if they 
were randomised or pseudorandomised (Hazarika et al., 1979, Ward, 1976).  
Both of these articles are over 35 years old, and clarification could not be 
obtained from the authors. 
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Figure 4.1: Flow chart of article selection 
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Of the remaining 2279, 13 were included in the review (Bhatia et al., 2002, 
Bulstrode et al., 2004, Chignon-Sicard et al., 2012, Citron and Hearnden, 
2003, Citron and Nunez, 2005, Collis et al., 2013, Howard et al., 2009, 
Jerosch-Herold et al., 2011, Kemler et al., 2012, McMillan and Binhammer, 
2012, Ullah et al., 2009, van Rijssen et al., 2006, van Rijssen et al., 2012), 
and 2264 were excluded (see Figure 4.1). 
4.5.1.2 Included+studies+++
Ten studies were single centre studies, of which seven were based in the 
United Kingdom, one each in Canada, France and New Zealand and two were 
reports of one trial based in the Netherlands.  There were two multi-centre 
studies (Jerosch-Herold et al., 2011, Kemler et al., 2012).  All of the five 
centres in the former were from the UK.  Both centres in the latter were in the 
Netherlands.  All studies were published in English.  One study had an 
associated publication describing the trial protocol (Jerosch-Herold et al., 
2008). 
The 13 studies included 910 participants, of which the 93 reported in a 5-year 
outcome paper were participants in the same trial also described in the early 
outcome paper (van Rijssen et al., 2006, van Rijssen et al., 2012).  Thus 817 
individual patients were recruited across all studies. 
Three studies described the outcomes of two trials that compared different 
surgical procedures (Ullah et al., 2009, van Rijssen et al., 2006, van Rijssen et 
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al., 2012).  One trial compared using "firebreak" full thickness skin grafts (a 
form of dermofasciectomy) to z-plasty closure of a limited fasciectomy.  The 
authors refer to the original description of 'firebreak' grafts (Hueston, 1984). 
Here 'firebreak' grafts are described as small grafts strategically placed at 
flexion creases.  In contrast, traditional dermofasciectomy may involve 
resurfacing much larger areas of palmar skin (Seah et al., 2012).  This was 
achieved by conducting a limited fasciectomy, and then excising palmar skin 
to accommodate the skin graft in those randomised to this cohort.  The other 
two papers reported early and late outcomes respectively for a trial comparing 
needle fasciotomy to limited fasciectomy. 
Four of the other ten studies compared surgical incision and wound 
management options (Bhatia et al., 2002, Citron and Hearnden, 2003, Citron 
and Nunez, 2005, Howard et al., 2009).  These included studies that 
compared staple closure against suture closure, and absorbable versus no-
absorbable suture closures respectively, both in limited fasciectomy.  The 
other two studied types of incision for limited fasciectomy. 
Two publications studied adjunctive treatments to surgery: one investigated 
bathing the operation site in 5-fluorouracil prior to closure, versus saline 
(Bulstrode et al., 2004), and one compared the use of steroid injections in 
conjunction with needle fasciotomy versus no adjunctive treatment (McMillan 
and Binhammer, 2012). 
The four others studied non-invasive adjuncts to surgery, including the use of 
postoperative splints versus no splint, the use of a fibrin-and platelet-rich fibrin 
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plug as a primary dressing to open palm surgery versus conventional low 
adherence dressing, and comparing postoperative intermittent pneumatic 
compression to standard elevation of the limb (Chignon-Sicard et al., 2012, 
Collis et al., 2013, Jerosch-Herold et al., 2011, Kemler et al., 2012). 
These different interventions can be used to classify studies into: 
• Those studying different treatment options; 
• Those refining a treatment option (e.g. limited fasciectomy incisions, 
closure types, invasive adjuncts or equipment usage); 
• Those refining rehabilitation. 
4.5.1.3 Inclusion+and+exclusion+criteria+
Criteria were not always specified.  Two articles did not describe either 
inclusion or exclusion criteria (Bhatia et al., 2002, Howard et al., 2009).  Of the 
other eleven, four specified age-related cut offs for recruitment, of age under 
70 years (Bulstrode et al., 2004), and over 18 years (Chignon-Sicard et al., 
2012, Jerosch-Herold et al., 2011, Kemler et al., 2012). One study did not 
describe the ratio of participant genders (Howard et al., 2009).  None of the 
other studies explicitly excluded potential participants based on gender, 
though one study comprised only male subjects (Bulstrode et al., 2004). 
Patients undergoing revision surgery were excluded in three studies (Citron 
and Hearnden, 2003, Citron and Nunez, 2005, McMillan and Binhammer, 
2012).  Of these, one also excluded patients who had previously undergone 
other types of hand surgery (McMillan and Binhammer, 2012). 
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Site of disease within the hand was specified in three studies.  One study only 
included patients with palmar disease affecting the MCPJ (Citron and 
Hearnden, 2003).  In contrast, another only included those with at least 30 
degrees of contracture at the PIPJ (Ullah et al., 2009).  One splinting study 
excluded thumb and first web space treatments (Jerosch-Herold et al., 2011).  
Another recruited participants with Dupuytren's disease in one ray only (Citron 
and Nunez, 2005). 
Some studies used exclusion criteria relating to comorbidities that might 
influence outcome, such as bleeding tendencies (Citron and Nunez, 2005, 
Ullah et al., 2009, van Rijssen et al., 2006, van Rijssen et al., 2012).  Diabetes 
mellitus was an exclusion criterion (Chignon-Sicard et al., 2012, McMillan and 
Binhammer, 2012). 
Some specific criteria were related to study design.  In one study, patients had 
to receive treatment for two rays in the one procedure, as one was 
randomised to receive 5-fluorouracil, and the other to receive the control 
treatment of normal saline (Bulstrode et al., 2004).  In the Dutch papers 
describing fasciectomy versus aponeurotomy, participants had to have well-
defined cords of disease (van Rijssen et al., 2006, van Rijssen et al., 2012).  
This is a requirement for suitability for needle fasciotomy. 
4.5.1.4 Unit+of+analysis+
The predicted unit of analysis was that studies would be randomised by 
'hand'.  This could lead to the same patient being enrolled twice, for surgery to 
each hand on separate occasions in some studies (van Rijssen et al., 2006, 
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van Rijssen et al., 2012).  In contrast, one patient with bilateral disease was 
entered only once in another trial (McMillan and Binhammer, 2012).  Similarly, 
six patients presented for randomisation twice in another study (Citron and 
Nunez, 2005), for the treatment of bilateral disease.  They were only enrolled 
once in the trial.  In these studies, the unit of randomisation was by 'patient'.  
Other studies have specific individualised methodologies, such as using an 
internal control, with one digit on a hand randomised to treatment and another 
to control (Bulstrode et al., 2004). 
Reporting recurrence varied, including presenting the number of hands in the 
number of patients who had developed over 20 degrees of deformity in one 
joint (van Rijssen et al., 2012).  Other studies presented recurrence per 
patient (Citron and Hearnden, 2003, Citron and Nunez, 2005).  Only one study 
investigated recurrence (Ullah et al., 2009), in which recurrence was 
described as the percentage of fingers that showed recurrence, rather than 
the proportion of hands or patients. 
4.5.1.5 Outcome+measures+
The outcomes measured varied between studies.  Specific outcomes were 
used for particular studies. 
Length of follow-up varied between papers.  Those investigating rehabilitation 
and early recovery varied from two weeks follow up (Bhatia et al., 2002, 
Howard et al., 2009), to six weeks follow-up (van Rijssen et al., 2006).  Late 
outcome papers varied in length of follow-up from two years (Citron and 
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Hearnden, 2003, Citron and Nunez, 2005) to five years (van Rijssen et al., 
2012). 
Hand function 
Several trials presented patient-reported outcomes.  These included 
previously published PROMs such as the DASH (Collis et al., 2013, Jerosch-
Herold et al., 2011, van Rijssen et al., 2006, van Rijssen et al., 2012) or the 
PEM (Ullah et al., 2009). The design of studies with two digits on the same 
hand randomised to different groups (Bulstrode et al., 2004) would have 
prevented meaningful interpretation of hand patient-reported outcomes such 
as hand function. 
Patient satisfaction and other PROMs 
Patient satisfaction was reported in studies comparing procedure types (van 
Rijssen et al., 2006, van Rijssen et al., 2012).  However, whilst statistical 
significance was presented, full data were not.  Furthermore, the 
development, validity and reliability of the tools used to assess satisfaction 
were not described or referenced.  Satisfaction was also assessed in other 
studies (Collis et al., 2013, Jerosch-Herold et al., 2011), as was patient-
perceived change (Kemler et al., 2012). Some studies included self-reported 
pain assessed using a visual analogue scale (VAS) (Bhatia et al., 2002, 
Howard et al., 2009, Kemler et al., 2012).  Patient-assessed wound 
appearance was also reported in one study (Bhatia et al., 2002), though the 
development, validity or reliability of the tool used was not described or 
referenced. 
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Early angles and other objective outcomes 
Angular deformity was presented in different ways.  Some presented active 
finger angles (Bulstrode et al., 2004, Collis et al., 2013, Jerosch-Herold et al., 
2011, Kemler et al., 2012, McMillan and Binhammer, 2012), whilst others 
presented passive angles (van Rijssen et al., 2006, van Rijssen et al., 2012). 
In other studies, it was not clear whether the angles presented were active or 
passive (Citron and Hearnden, 2003, Citron and Nunez, 2005, Ullah et al., 
2009).  The presentation of angular measurements varied between the early 
and late outcomes of the same clinical trial (van Rijssen et al., 2006, van 
Rijssen et al., 2012).  Other objective outcomes measured included timings, 
such as time taken to perform key tasks involved in surgery or postoperative 
care (Bhatia et al., 2002, Howard et al., 2009, Ullah et al., 2009), time to 
healing (Bulstrode et al., 2004, Chignon-Sicard et al., 2012), and an analysis 
of grip strength (Collis et al., 2013, Ullah et al., 2009). 
Recurrence 
The studies that reported comparisons of operative technique considered 
recurrence in late outcome papers (Citron and Hearnden, 2003, Citron and 
Nunez, 2005, Ullah et al., 2009, van Rijssen et al., 2012), and extension deficit 
at early outcome points (Ullah et al., 2009, van Rijssen et al., 2006). The 
definition of recurrence varied from reappearance of palpable disease in the 
operated field (Citron and Hearnden, 2003, Citron and Nunez, 2005) to 
recurrent angular deformity (Ullah et al., 2009, van Rijssen et al., 2012). 
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Within the studies comparing different procedures, recurrence was defined as 
an increase in a joint angle, MCPJ or PIPJ, of 20 degrees or more (van 
Rijssen et al., 2012), or was not explicitly defined (Ullah et al., 2009).  
However, the latter paper does discuss "progressive recurrence of contracture 
of the PIP joint", suggesting that angular deformity was employed for this, 
rather than the reappearance of palpable disease. 
Adverse effects 
Adverse effect reporting varied from not studying complications in a study of 
rehabilitation adjuncts (Jerosch-Herold et al., 2011), through reporting "no 
intraoperative complications" (Bulstrode et al., 2004), or "no complications" 
(Citron and Hearnden, 2003), to describing and attempting to quantify specific 
complications (Chignon-Sicard et al., 2012). There was no standardisation of 
the choice of adverse effects studied, even between similar papers. 
Cost effectiveness 
No included studies presented formal cost effectiveness analysis, though it 
was noted that several articles did assess cost effectiveness.  However, none 
were randomised or pseudo-randomised studies, and so were excluded.  
Three studies presented analyses of time taken to perform key tasks involved 
in surgery or postoperative care (Bhatia et al., 2002, Howard et al., 2009, 
Ullah et al., 2009), which would be expected to have cost effectiveness 
implications. 
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SUMMARY 
The primary objective of this review was to study trials comparing different 
treatment options.  This group comprises only three papers describing two 
trials, and these two trials compared different interventions using different 
inclusion and exclusion criteria.  One compared small 'firebreak' full thickness 
skin grafting to z-plasty closure of limited fasciectomy for contracture involving 
the PIPJ (Ullah et al., 2009).  The other two described a trial comparing 
needle fasciotomy to limited fasciectomy, with inclusion criteria including 
contractures that may not necessarily affect the PIPJ (van Rijssen et al., 2006, 
van Rijssen et al., 2012). 
Amongst trials refining intraoperative techniques, all compared different 
interventions.  Amongst the trials refining rehabilitation adjuncts, two 
investigated the same intervention using comparable measures and 
timepoints, allowing meta-analysis (Collis et al., 2013, Jerosch-Herold et al., 
2011). 
The outcome measures studied varied and included a range of PROMs.  Of 
these, the DASH was one such PROM.  It was also identified as the most 
commonly reported PROM in Dupuytren’s disease research (Ball et al., 2013).  
This supports further research into the DASH’s behaviour in Dupuytren’s 
disease. 
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4.6 Risk!of!bias!in!included!studies!!!
Risks of bias for each study are summarised in Figure 4.2. 
4.6.1 Allocation!(selection!bias)!!!
Two trials did not explain the randomisation process used, and one used 
alternation.  The remaining nine provided information on appropriate 
randomisation processes, albeit with poor descriptions of allocation 
concealment in all but three studies that adequately described secure 
processes. 
Allocation concealment processes were robust in three studies only (Chignon-
Sicard et al., 2012, Citron and Nunez, 2005, Jerosch-Herold et al., 2011).  The 
former two described sealed, sequentially numbered opaque envelopes, 
whereas the latter used telephone randomisation from another site.  Three 
other studies also used numbered sealed envelopes, but did not describe 
whether these were opaque or not (Ullah et al., 2009, van Rijssen et al., 2006, 
van Rijssen et al., 2012).  Similar inadequate detail of concealment was 
provided in other studies. 
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Figure 4.2: Risks of bias in included studies 
+ indicates low risk of bias; - indicates high risk of bias; ? indicates inadequate 
detail to make judgement, or inconclusive 
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4.6.2 Blinding!(performance!bias!and!detection!bias)!!!
As the treatment involved is a surgical procedure, it is acknowledged that 
many trials are likely to be at high risk of performance bias, as the surgical 
team performing the procedure cannot always be blinded.  However, trials of 
wound closure and adjuncts could defer randomisation until after the 
corrective element of the procedure has been completed.  This was only done 
in one study (Ullah et al., 2009).  Several other studies (Bhatia et al., 2002, 
Bulstrode et al., 2004, Chignon-Sicard et al., 2012, Howard et al., 2009, 
McMillan and Binhammer, 2012) could have deferred randomisation in this 
way to reduce the impact of performance bias on other parts of the procedure, 
but did not. 
Few studies explicitly described blinding of assessment.  In one double 
blinding of the patient in addition to the assessor was employed (Bulstrode et 
al., 2004).  It is acknowledged that such blinding may be difficult to achieve 
when comparing procedures that leave distinctive and very different scar 
patterns on the hand (such as needle fasciotomy and fasciectomy).  One also 
described blinding of outcome assessment (Chignon-Sicard et al., 2012). 
4.6.3 Incomplete!outcome!data!(attrition!bias)!!!
Attrition was not formally described in several studies.  The study with the 
longest follow-up period (van Rijssen et al., 2012), had significantly different 
levels of attrition between the groups, which could have been influenced by 
the outcome of the treatment.  'Unclear' studies did not explicitly describe 
levels of attrition. 
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4.6.4 Selective!reporting!(reporting!bias)!!!
In one study (Howard et al., 2009), outliers were excluded despite formally 
testing the normality of the distribution of the data and electing to use non-
parametric statistics.  It is possible that the primary conclusion of the study 
could become invalid with these outliers included in the analysis.  No protocol 
for their exclusion was described.  One further study (Ullah et al., 2009) listed 
the highest number of secondary outcomes, but did not describe them all in 
detail, with some represented only graphically. 
4.6.5 Other!potential!sources!of!bias!!!
As many studies were expected to be unblinded, the risk from blocked 
randomisation in such studies was considered. 
SUMMARY 
Minimising risk of bias in trials of surgery of this nature can be difficult to 
achieve.  However, there are aspects of the included studies here that 
demonstrate that most common sources of bias could be controlled in a future 
trial of Dupuytren’s disease treatment. 
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4.7 Effects!of!interventions!!!
4.7.1 Comparing!procedure!types!
4.7.1.1 Comparing+needle+fasciotomy+with+fasciectomy+
One trial compared these procedures, with early and late outcomes reported 
separately (van Rijssen et al., 2006, van Rijssen et al., 2012).  The early 
outcome article reported 125 hands in 121 patients.  The late outcome article 
had 93 participants from the original cohort.  This comparison involved low 
quality evidence due to study design limitations and imprecision. 
 
Hand function 
There was low quality evidence that hand function, as determined by the 
DASH, may be significantly lower after needle fasciotomy than fasciectomy at 
all time points up to 5 weeks following surgery (van Rijssen et al., 2006).  
However, only 97/121 (80%) patients completed the PROM tool adequately to 
allow analysis.  There was no evidence describing later functional outcome 
(van Rijssen et al., 2012). 
Patient satisfaction and other patient rated outcomes 
The comparison of satisfaction between fasciotomy and fasciectomy was only 
described in terms of p values, without effect sizes.  There was low quality 
evidence that patient satisfaction may be significantly higher for the needle 
fasciotomy group compared to the fasciectomy group at 6 weeks (p = 0.003) 
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(van Rijssen et al., 2006).  Satisfaction reversed by five years; it was 
significantly higher for fasciectomy (p < 0.001) (van Rijssen et al., 2012).  
There was low quality evidence that, overall, satisfaction was lower in patients 
with recurrence (p < 0.001) (van Rijssen et al., 2012).  However, the tools 
used may not have been robustly developed or validated, as has been 
discussed already, and not all data was presented. 
Early angles and other objective outcomes 
There was low quality evidence that correction in total passive extension 
deficit was not different between procedures for milder contractures (Tubiana 
stage I and II, which equates to total passive extension deficit across all joints 
of less than 90 degrees) by six weeks, but limited fasciectomy achieved 
significantly better correction for more severe contractures (Tubiana III and IV, 
i.e. over 90 degrees of total passive extension deficit). 
Recurrence 
There was low quality evidence that recurrence may be significantly higher 
five years after needle fasciotomy (84.9% of hands after fasciotomy versus 
20.9% of hands after fasciectomy, p < 0.001) (van Rijssen et al., 2012). 
Adverse effects 
There was low quality evidence that complication rates were similar between 
procedures in terms of infection, haematoma, wound slough, skin fissure, 
sympathetic dystrophy, altered sensation, digital nerve injury, tendon injury, 
revision surgery.  The incidence of paraesthesia was significantly higher after 
limited fasciectomy than after fasciotomy. 
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Cost effectiveness 
There was no evidence identified comparing cost effectiveness of needle 
fasciotomy and fasciectomy. 
SUMMARY 
There was evidence that needle fasciotomy delivered better satisfaction and 
function at early outcome than fasciectomy, though poor rates of completion of 
the PROM were an issue.  Fasciectomy was more effective at correcting 
severe disease.  Recurrence was higher at five years after needle fasciotomy, 
though functional outcome had not been described.  The cost effectiveness of 
performing multiple needle fasciotomies over a period compared to a single 
fasciectomy had not been studied.  At present, there is insufficient evidence in 
key areas to determine which is a superior treatment overall.  These on going 
uncertainties justify further research into the treatment of Dupuytren’s disease. 
 +
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4.7.1.2 Comparing+dermofasciectomy+with+fasciectomy+
One study compared firebreak skin grafting to direct closure of fasciectomy 
(Ullah et al., 2009), which provided low quality evidence.  There were 79 
participants.  Much of the data were only presented graphically. 
Hand function 
Hand function, as determined by the PEM, was not different between 
fasciectomies and firebreak dermofasciectomies at 36 months.  Earlier time 
points were presented graphically only. 
Patient satisfaction and other patient rated outcomes 
There was no evidence identified comparing these outcomes for fasciectomies 
and firebreak dermofasciectomies. 
Early angles and other objective outcomes 
Grip strength, angular deformity and motion at the PIPJ all correlated at 36 
months.  No differences between groups were seen throughout the study, 
though the data supporting this were presented graphically only. 
Recurrence 
There was no difference between firebreak dermofasciectomies and 
fasciectomies in terms of recurrence, defined as progressive contracture, and 
time to recurrence. 
Adverse effects 
There was no difference between the procedures in terms of antibiotic 
requirement, skin necrosis, wound dehiscence, radial hypoaesthesia or reflex 
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sympathetic dystrophy.  There was a significantly greater incidence of ulnar 
hypoaesthesia after firebreak dermofasciectomy. 
Cost effectiveness 
There was no formal cost effectiveness analysis evidence.  However, 
firebreak dermofasciectomy took significantly longer to perform than a 
fasciectomy involving a z-plasty closure (79 versus 66 minutes, p = 0.01). 
 
SUMMARY 
There was high quality evidence that firebreak dermofasciectomy and 
fasciectomy with z-plasty closure performed similarly.  Given that firebreak 
dermofasciectomy took longer to perform, there was no evidence to support 
its routine use.  However, this conclusion cannot be extended to other 
approaches to dermofasciectomy involving larger skin grafts.  No evidence 
was identified to compare other approaches to dermofasciectomy with 
fasciectomy. 
 !
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4.7.2 Technical!refinements!
4.7.2.1 Type+of+incision+
Incisions were studied in two articles with 30 and 100 participants 
respectively.  The first compared z-plasty closure to direct closure of a 
transverse incision for fasciectomy (Citron and Hearnden, 2003).  The second 
compared a zig-zag (Bruner's) incision with direct closure to a longitudinal 
incision with z-plasty closure for fasciectomy (Citron and Nunez, 2005). They 
provided low quality evidence due to study design limitations and imprecision. 
Hand function 
There was no evidence identified to describe this. 
Patient satisfaction and other patient rated outcomes 
There was no evidence identified to describe this. 
Early angles and other objective outcomes 
There was no difference between a zig-zag incision and a z-plasty closure in 
terms of deformity or extension. 
Recurrence 
There was evidence that z-plasty closure of a palmar fasciectomy had 
significantly less recurrence (reappearance of palpable disease) than direct 
closure of a transverse incision (p < 0.01 when trial recruitment was stopped 
at the interim analysis point (Citron and Hearnden, 2003)).  There was no 
difference in recurrence defined this way between a zig-zag incision and a z-
plasty closure. 
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Adverse effects 
In one study, no complications were encountered (Citron and Hearnden, 
2003).  In the other, total complications, rates of algodystrophy and incidence 
of digital nerve injury were no different between a zig-zag incision and a z-
plasty, and digital nerve injury not different between a zig-zag incision and z-
plasty (Citron and Nunez, 2005). 
Cost effectiveness 
There was no evidence identified to describe this. 
SUMMARY 
There was evidence supporting z-plasty closure over direct closure of 
transverse incisions for MCPJ cords.  There was no difference between a zig-
zag incision and a z-plasty closure for fasciectomy.  However, the evidence 
was of poor quality. 
 +
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4.7.2.2 Wound+closure+
Two studies investigated wound closure (Bhatia et al., 2002, Howard et al., 
2009).  One compared staple closure to non-absorbable suture closure in 31 
participants (Bhatia et al., 2002).  The other compared absorbable suture 
closure with non-absorbable suture closure for fasciectomy in 62 participants 
(Howard et al., 2009).  Both provided level low quality evidence due to study 
design limitations and imprecision. 
Hand function 
There was no evidence identified to describe this. 
Patient satisfaction and other patient rated outcomes 
There was no difference in patient reported wound appearance at two weeks 
between those who received staples and those who received non-absorbable 
sutures (Bhatia et al., 2002).  Staples were more painful to remove than non-
absorbable sutures (p = 0.008) (Bhatia et al., 2002).  There was no difference 
in pain VAS at the first postoperative visit between absorbable and non-
absorbable suture groups (Howard et al., 2009). 
Early angles and other objective outcomes 
Staple closure was quicker to perform than non-absorbable suture closure (p 
< 0.001) (Bhatia et al., 2002).  Absorbable suture closure incurred less clinic 
time for management, once outliers were excluded, than non-absorbable 
suture closure (p = 0.003) (Howard et al., 2009).  However, excluding outliers 
from a non-parametric analysis may not have been appropriate, and may 
invalidate this finding. 
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Recurrence 
There was no evidence identified to describe this. 
Adverse effects 
No formal analysis of differences in complications between groups was 
performed in either study.  However, complication rates were low for both 
groups in both studies. 
Cost effectiveness 
There was no formal cost effectiveness analysis evidence.  The analysis of 
timings presented may not be robust, as explained above. 
 
SUMMARY 
Staple closure may be quicker to perform than suture closure, and may 
achieve a comparable early wound appearance.  However, staples may be 
more painful to remove. 
Absorbable sutures achieved comparable early outcomes to non-absorbable 
sutures, and were reported as requiring less clinic time for postoperative 
management.  However, the evidence was incomplete and of poor quality 
evidence.  In particular the main conclusion may not be valid, as the statistical 
analysis performed may have been inappropriate. 
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4.7.2.3 Intraoperative+adjuncts+
Two studies investigated intraoperative adjuncts to surgery.  Each considered 
a different intervention.  One investigated bathing a fasciectomy wound in 5-
fluorouracil compared to control, with 15 participants and provided low quality 
evidence (Bulstrode et al., 2004).  The second compared a postoperative 
series of steroid injections as an adjunct to needle fasciotomy versus no 
injections in 47 participants and provided low quality evidence due to study 
design limitations and imprecision (McMillan and Binhammer, 2012). 
Hand function 
There was no evidence identified to describe this. 
Patient satisfaction and other patient rated outcomes 
There was no evidence identified to describe this. 
Early angles and other objective outcomes 
There was no difference between 5-fluorouracil treatment and control 
treatment in terms of healing time, total active motion and loss of extension 
(Bulstrode et al., 2004). 
A series of steroid injections resulted in significantly greater percentage 
improvement in total active extension deficit at all time points (McMillan and 
Binhammer, 2012). 
Recurrence 
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There was no difference between 5-fluorouracil treatment and control 
treatment in terms of loss of extension or total active motion at 18 months 
(Bulstrode et al., 2004). 
There was a significantly greater percentage improvement in total active 
extension deficit at six months (65% correction for steroid group versus 41% 
for control group, p = 0.04), and in MCPJs and PIPJs when considered 
separately at six months (McMillan and Binhammer, 2012). 
Adverse effects 
Both studies reported no complications (Bulstrode et al., 2004, McMillan and 
Binhammer, 2012). 
Cost effectiveness 
There was no evidence identified to describe this. 
SUMMARY 
There was no evidence of benefit or harm from the addition of a 5-fluorouracil 
bath at the completion of a fasciectomy, though function and long-term 
outcome (beyond 18 months) have not been studied.  There was evidence 
that the addition of a series of steroid injections following needle fasciotomy 
may achieve and maintain better correction of contractures than needle 
fasciotomy alone, though no long term data were identified, and the quality of 
evidence available was poor. 
4.7.3 Rehabilitation!adjuncts!
The aim of this review had been to study operative techniques primarily.  
However, as rehabilitation adjuncts are components of hand therapy in 
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Dupuytren's disease, these trials met the inclusion criteria specified in the 
protocol, and so were included. 
Four studies were identified that investigated adjuncts that might aid 
rehabilitation.  Two studies compared three months of static postoperative 
splinting to no postoperative splinting (Collis et al., 2013, Jerosch-Herold et 
al., 2011).  One other study also investigated postoperative splinting, providing 
low quality evidence, though the intervention protocol differed from the former 
two studies: the arm underwent day and night splinting for a month then night 
splinting for a further two months (Kemler et al., 2012).  One hundred and fifty 
four participants were reported.  The final study investigated the application of 
fibrin- and platelet-rich fibrin plug to open palmar wounds after fasciectomy, to 
identify whether this improved healing (Chignon-Sicard et al., 2012).  These 
studies all provided low quality evidence due to study design limitations and 
imprecision. 
Not all relevant data in one study of splinting were available from the 
published article (Collis et al., 2013). The authors were contacted, and 
provided the necessary data for per protocol analyses. 
Hand function 
Hand function, as assessed with the DASH PROM, was not affected by 
postoperative splinting at three months, six months and twelve months 
(Jerosch-Herold et al., 2011).  No effect was also found in the other 
comparable splinting study (Collis et al., 2013), where individual time points 
were analysed up to three months postoperatively. In the latter, time points 
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were also combined based on there being no difference in a mixed effect 
model. 
Meta-analysis of these two studies demonstrated no significant heterogeneity 
at baseline between studies (see Figure 4.3).  There was also no difference in 
function between splint and no splint groups at three month follow up, in an 
intention to treat analysis (Figure 4.4).  In keeping with all intention to treat 
analyses, those presented in both papers had some limitations.  It had been 
considered ethically inappropriate to withhold a splint from patients who 
develop early deterioration in contracture.  Therefore, patients in the 'no splint' 
group' who experienced early recontracture were then given a splint.  
Furthermore, some patients in the splint group were not compliant with 
splinting (defined as self report of <50% compliance).  No difference between 
'splint' and 'no splint' groups was also seen when the data were analysed per 
protocol (Figure 4.5). 
Patient satisfaction and other patient rated outcomes 
Patient satisfaction was not different in those receiving postoperative splinting 
compared to patients not receiving splinting, as assessed using an 11-point 
verbal rating scale (Jerosch-Herold et al., 2011).  However, the validity and 
reliability of this scale is not described or cited.  Patient perceived change was 
also not significantly different between groups in one of the other splinting 
studies (Kemler et al., 2012). 
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Figure 4.3: Forest plot of baseline (preoperative) DASH summary score (scale: 0-100, higher score indicates worse 
function) 
SD – standard deviation, IV – inverse variance statistical method, 95% CI – 95% confidence intervals, random – random effects 
model 
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Figure 4.4: Forest plot of 3-month follow up DASH assessments of postoperative night splinting (Intention to treat) (scale: 
0-100, higher score indicates worse function) 
SD – standard deviation, IV – inverse variance statistical method, 95% CI – 95% confidence intervals, random – random effects 
model 
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Figure 4.5: Forest plot 3-month follow up DASH assessments following postoperative night-splinting (Per protocol) (scale: 
0-100, higher score indicates worse function) 
SD – standard deviation, IV – inverse variance statistical method, 95% CI – 95% confidence intervals, random – random effects 
model 
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Early angles and other objective outcomes 
As with hand function, there was no significant heterogeneity between studies 
at baseline, in terms of total active extension across the MCPJ, PIPJ and DIPJ 
(see Figure 4.6), and also in terms of total active flexion across all three joints 
in the ray (see Figure 4.7).  Total active flexion and total active extension were 
not different in those who received postoperative splinting, at three, six or 
twelve months (Jerosch-Herold et al., 2011).  No differences in total active 
extension or flexion were found in the second paper either (Collis et al., 2013).  
When the 3-month follow up results from both studies were meta-analysed, 
there was no difference in total active extension between splint and no splint 
groups (Figure 4.8).  However, there was a significant difference in total active 
flexion, with splint group participants achieving 8.42 degrees less total active 
flexion than no splint group participants (Figure 4.9).  As discussed with hand 
function, the intention to treat analyses were potentially affected by some of 
the 'no splint' group were given a splint if they experienced early re-
contracture, and some of the 'splint' group being non compliant.  When meta-
analyses were performed based on per protocol data, there was still no 
difference between groups in terms of total active extension (Figure 4.10), but 
the significant difference in total active flexion seen in the intention to treat 
analysis was more pronounced (Figure 4.11). 
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Figure 4.6: Forest plot of baseline (preoperative) total active extension in degrees (MCPJ+PIPJ+DIPJ) (higher value 
indicates more impairment) 
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SD – standard deviation, IV – inverse variance statistical method, 95% CI – 95% confidence intervals, random – random effects 
model 
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Figure 4.7: Forest plot of baseline (preoperative) total active flexion in degrees (MCPJ+PIPJ+DIPJ) (higher value indicates 
less impairment) 
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SD – standard deviation, IV – inverse variance statistical method, 95% CI – 95% confidence intervals, random – random effects 
model 
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Figure 4.8: Forest plot of 3-month follow up total active extension in degrees (MCPJ+PIPJ+DIPJ) following postoperative 
night splinting (Intention to treat) (higher value indicates more impairment) 
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SD – standard deviation, IV – inverse variance statistical method, 95% CI – 95% confidence intervals, random – random effects 
model  
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Figure 4.9: Forest plot of 3-month follow up total active flexion in degrees (MCPJ+PIPJ+DIPJ) following postoperative 
night splinting (Intention to treat) (higher value indicates less impairment) 
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SD – standard deviation, IV – inverse variance statistical method, 95% CI – 95% confidence intervals, random – random effects 
model  
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Figure 4.10: Forest plot of 3-month follow up total active extension in degrees (MCPJ+PIPJ+DIPJ) following postoperative 
night splinting (Per protocol) (higher value indicates more impairment) 
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SD – standard deviation, IV – inverse variance statistical method, 95% CI – 95% confidence intervals, random – random effects 
model 
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Figure 4.11: Forest plot of 3-month follow up total active flexion in degrees (MCPJ+PIPJ+DIPJ) following postoperative 
night splinting (Per protocol) (higher value indicates less impairment) 
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SD – standard deviation, IV – inverse variance statistical method, 95% CI – 95% confidence intervals, random – random effects 
model 
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There was a statistically significantly shorter healing delay from the application 
of fibrin- and platelet-rich fibrin plug to the open palmar wound compared to 
control group (median 24 days versus median 29 days), but no difference in 
secondary endpoints of pain, bleeding or wound exudate (Chignon-Sicard et 
al., 2012). 
Recurrence 
This was not assessed (Chignon-Sicard et al., 2012, Collis et al., 2013, 
Jerosch-Herold et al., 2011, Kemler et al., 2012). 
Adverse effects 
Bleeding and exudate were studied in one paper, but were not significantly 
different between intervention and control groups (Chignon-Sicard et al., 
2012).  Other adverse events, including wound and chest infections were rare, 
but were discussed. 
Cost effectiveness 
There was no formal cost effectiveness analysis evidence in any article. 
SUMMARY 
There is no evidence that postoperative splinting improves rehabilitation after 
fasciectomy or dermofasciectomy, but the meta-analysis conducted here has 
provided the first evidence that three months of night splinting reduces total 
active flexion at three months. 
Intermittent pneumatic compression may reduce postoperative oedema, 
though the quality of evidence to support this was poor, and the risks and 
benefits of this adjunct have not been studied. 
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4.8 Discussion+++
4.8.1 Present+study+findings+
4.8.1.1 Study*questions*
This systematic review has demonstrated that there are very few high quality 
studies of Dupuytren's disease surgery.  Amongst the trials included, fewer 
still compared different procedures, with others studying refinements of 
practice.  Despite many current treatment options being available for years or 
decades, the paucity of studies suggests that research in this field lacks 
direction. 
4.8.1.2 Outcomes*measured*
Variation in primary outcome measures assessed was found between studies.  
Whilst some of this might be expected, for example studying time taken for 
staple removal, rather than recurrence as a long-term outcome, the extent of 
variation within groups of studies limits the utility of the data presented, and 
their interpretation.  Such variation is seen across lower quality studies as 
well.  Providing no definition of recurrence is commonplace (Becker and 
Davis, 2010), and limits interpretation of data. 
Defining recurrence as the reappearance of palpable disease, as used in two 
papers here (Citron and Hearnden, 2003, Citron and Nunez, 2005), is 
acknowledged as generating qualitative data (Werker et al., 2012). When 
detection bias is a risk, the combination of an unblinded assessor defining 
outcome in a binary but subjective manner might be expected to be unsound.  
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This was the case in one study here (Citron and Hearnden, 2003).  This 
outcome may not be applicable to fasciotomy, as palpable disease is not 
cleared from the treated field. 
Even within studies that use angular deformity to define outcome and 
recurrence, wide variation is seen in what exactly is measured, and how it is 
described and presented (Ball et al., 2013).  Angles may be presented as the 
passive angle obtained by an assessor, or active extension, achieved 
unsupported by the patient.  Such angles may again differ, and influence 
study outcome. 
Whilst meta-analysis could not be performed to compare operation types due 
to the paucity of comparable trials, it is probable that even if more data were to 
be generated in future, without standardisation of follow-up length and 
outcome measures used, meta-analysis would still not be possible.  As 
Dupuytren's disease is a slowly progressive condition (Reilly et al., 2005), the 
incidence of recurrence is likely to rise with longer periods of follow-up. 
Furthermore, the natural history of the condition suggests that recurrence 
defined as reappearance of palpable disease is likely to be encountered 
earlier than a deteriorating angular deformity (Luck, 1959). The combination of 
these two inconsistencies contributes to the wide variation in reported 
recurrence rates in the existing literature, of 0% to 71% (Becker and Davis, 
2010).  Others have also highlighted the need for clarity and consistency 
(Werker et al., 2012). This review reiterates this, but also calls for more 
detailed study of the validity and reliability of outcome measures, to ensure 
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that the most appropriate outcomes are assessed, and at consistent and 
meaningful time points.  Furthermore, recurrence of palpable disease or 
angular deformity may not be truly relevant endpoints.  Instead, assessment of 
hand function as a patient-reported and patient-centred measure may be more 
appropriate.  Patient-reported outcomes were used as a secondary endpoint 
in some of the studies included in this review. 
There was marked variation in what was reported by study authors treated as 
secondary outcomes.  In part this related to the study question, though 
outcomes handled as 'secondary' measures in studies were classified as 
appropriate primary outcome measures in this review, for example, patient 
reported hand function.  However, trials of procedure type and technical 
refinement still varied between recording numerous secondary measures 
(Ullah et al., 2009), and recording virtually none other than complications 
(McMillan and Binhammer, 2012).  The value of capturing all of these 
outcomes is not clear.  One secondary outcome measure that is of importance 
is a measure of health-related quality of life.  Systems for analysing cost 
effectiveness are informed by data describing this, captured using PROMs 
such as the EuroQol-5D (NICE, 2008).  Determining functional outcome 
describes a patient-centred outcome, and may also be of pragmatic interest to 
commissioners of healthcare.  The use of patient-reported data has been 
promoted nationally in the UK (Darzi, 2008, Department of Health, 2010).  The 
variation in PROMs used in Dupuytren’s disease in general (Ball et al., 2013), 
and in the studies included in this review, demonstrates that there is no 
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consensus on which is most appropriate for use in future research. Three 
recent reviews have called for further study of outcome measures (Ball et al., 
2013, Becker and Davis, 2010, Werker et al., 2012).  To date, only a few 
studies included patient-reported hand function.  The data captured by the 
Patient Evaluation Measure in the study comparing firebreak 
dermofasciectomy to fasciectomy was not described in detail (Ullah et al., 
2009).  The DASH has been the most popular measure across all studies of 
Dupuytren's disease (Ball et al., 2013), and was used in studies included in 
this review (van Rijssen et al., 2012, van Rijssen and Werker, 2006).  The 
DASH data presented in the early outcome study of this trial did not support 
the same conclusions as measuring angles; needle fasciotomy fared better 
throughout early rehabilitation in terms of DASH scores, despite fasciectomy 
arguably providing better correction of angular deformity in general.  Thus, the 
conclusions drawn from this paper are likely to vary considerably depending 
on which outcome is considered to be of primary importance.  Corresponding 
late outcome function data were not presented (van Rijssen et al., 2012).  
Given the value of health-related quality of life data in accepted cost 
effectiveness analysis methodology (NICE, 2008), future pragmatic trials 
might consider the use of PROMs as the primary outcome measures, with 
joint angles demoted in importance.  Furthermore, such a change might 
support the design of pragmatic studies.  A variety of secondary outcomes 
were reported in the studies included.  However, separating the primary 
outcome from complications may limit the clinical applicability of research 
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findings.  If an intervention achieves low rates of recurrence, but does so with 
significant risks of complications such chronic regional pain syndrome, cold 
intolerance, and loss of grip strength or flexion, then it may still fail to achieve 
meaningful clinical improvement for patients, and cost effectiveness for 
commissioning bodies.  Patient satisfaction was considered in the reports of 
early and late outcome of the trial comparing fasciectomy and needle 
fasciotomy (van Rijssen et al., 2012, van Rijssen and Werker, 2006), though 
the validity and reliability of these assessments was not clear.  As already 
discussed for angular measurements, further work to establish the validity and 
reliability of candidate patient-reported outcome measures is urgently 
required. 
4.8.1.3 Comparing*procedure*types*
The only trial comparing aponeurotomy with fasciectomy demonstrated that 
needle fasciotomy may achieve comparable angular correction to limited 
fasciectomy for milder Tubiana I and II contractures, but inferior correction for 
Tubiana III and IV contractures (van Rijssen and Werker, 2006).  However, it 
caused less functional impairment in the early postoperative phase (up to five 
weeks), earlier recovery, and higher early patient satisfaction.  By five years it 
had significantly higher recurrence and lower satisfaction than fasciectomy.  
However, attrition bias may have affected late outcomes, with late functional 
outcome not recorded.  Patient satisfaction is an important outcome to 
measure, but perhaps ought to be measured in addition to, rather than instead 
of, valid measures of hand function, as the former might be influenced by 
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factors besides the functional efficacy of the treatment.  It is also not clear 
whether it is reasonable to expect needle fasciotomy, a demonstrably less 
invasive procedure that can be repeated for recurrent disease (van Rijssen 
and Werker, 2012), to achieve a comparably durable effect as the more 
invasive fasciectomy.  A more pragmatic study might be to consider early and 
late functional outcome in groups randomised to receive one fasciectomy or 
multiple needle fasciotomies over a period of years, with cost effectiveness 
then calculated based on functional outcome and treatment pathway expense. 
The comparison of fasciectomy with z-plasty closure to firebreak skin grafting 
found no differences between groups, other than prolonged operation time for 
skin grafting (Ullah et al., 2009).  This suggests that 'firebreak' skin grafting 
may not prevent recurrence compared to fasciectomy.  However, 
dermofasciectomy comprises a spectrum, with small skin grafts used as 
'firebreaks' at one end (Ullah et al., 2009), and much more extensive skin 
grafts at the other end (Seah et al., 2012).  Thus, further comparison between 
limited fasciectomy and dermofasciectomy is still required. 
4.8.1.4 Trials*investigating*postoperative*splinting*
This was the only area in which meta-analysis was possible.  It is noted that 
the earlier publication of a trial protocol facilitated standardisation (Jerosch-
Herold et al., 2008). Indeed, this was the only published trial protocol 
identified.  Advanced publication of trial protocols is encouraged as this may 
facilitate future standardisation of outcome assessment. 
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The functional outcome studied here was the absolute DASH score at three 
months (rather than change in DASH from preoperative to postoperative 
state), as preoperative DASH scores were not different between splint and no 
splint groups in either of the included studies (Collis et al., 2013, Jerosch-
Herold et al., 2011).  Furthermore, this final result represents the participants' 
functional performance at that time.  All three of the individual trial results 
showed no beneficial or adverse effect from postoperative splinting, but meta-
analysis demonstrated a statistically significant loss of flexion at three months 
from splinting.  Whether the magnitude of the difference seen is of clinical 
significance, or whether it persists later in the rehabilitation period is unclear.  
However, given the potential resource utilisation in producing and maintaining 
splints, their on going routine use is not supported. 
As discussed in the results, some of the ‘no splint’ group patients who 
developed early recontracture were issued with a splint.  The effect of this 
depends on the outcome considered.  If splinting improves loss of extension, 
then t might improve the average total active extension in the ‘no splint’ group.  
However, if splinting impairs total active flexion, then this outcome may be 
adversely affected in the ‘no splint’ group as a result.  Due to the potential for 
the above antagonistic effects, it is difficult to predict the effect of the protocol 
on functional outcome. 
4.8.1.5 Trials*investigating*other*questions*
The primary objective of this review was to identify trials comparing types of 
procedure.  However, our methodology has identified other trials within 
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Dupuytren's disease surgery, which have been grouped into those 
investigating technical refinements of procedures, and those investigating 
rehabilitation adjuncts.  Although these studies might be considered tangential 
to the central aim of this review, appraising these studies is important.  It has 
ensured that this review has been comprehensive, and aspects of study 
methodology and reporting have contributed to conclusions that can be made 
in this review.  In particular, analysing these studies informs the implications 
for future research in this field.  For example, only one study included 
adequately described a randomisation process using envelopes that had 
adequate allocation concealment (Citron and Nunez, 2005).  As with studies 
comparing types of procedure, the lack of comparable studies limited the 
performance of meta-analysis. 
4.8.1.6 Quality*of*evidence*
The overall quality of methodology varied between studies.  More modern 
studies were generally at less risk of bias.  The current assessment of 
performance bias might be controversial.  To minimise the potential for the 
surgeon to influence the quality of the procedure, blinding of the surgeon 
during the procedure was included as a desirable feature.  Achieving this 
blinding may be extremely challenging or even impossible in certain studies.  
However, clear efforts were made in some studies to standardise the surgical 
procedure as far as possible, with randomisation performed intraoperatively 
rather than preoperatively (Ullah et al., 2009), unlike other studies 
investigating an intervention of relevance to the closing stages of the 
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procedure.  By doing so, the excision of disease that might be considered to 
be the "correction" part of the surgery was not subject to lack of blinding, and 
only the wound closure was unblinded.  Taking such steps where possible 
may limit the effect of performance bias. 
In addition to risks of bias that related to study design limitations, the quality of 
evidence was further downgraded due to imprecision, with most comparisons 
based on one or two studies, with small sample sizes and wide confidence 
intervals. 
 
4.8.2 Limitations+
There were limited deviations from the protocol to the final review.  These 
differences were minor and did not influence the outcome of the review.  
Whilst explicit steps were taken to review conference proceeding abstracts, it 
is possible that unpublished data were missed.  However, given the paucity of 
trial data identified across all sources, it is unlikely that there is a significant 
volume of relevant data that has not been published. 
 +
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4.9 Conclusions+of+Systematic+Review+of+Trials+
There is a marked paucity of randomised controlled trials in Dupuytren's 
disease surgery.  The quality of design and reporting of trials in Dupuytren's 
disease surgery remains generally poor, with only some robust examples of 
good practice.  This is the case for comparing different treatment procedures, 
of which several are in current use, including needle fasciotomy, fasciectomy, 
dermofasciectomy and collagenase therapy.  The effectiveness and role of 
each of these treatments is currently based on poor quality evidence. 
The meta-analysis performed here questions the routine use of splinting 
following surgery for Dupuytren’s disease, and this warrants further research.  
It is possible that splinting may impair outcome, though this is not certain from 
the data presented here.  Furthermore, given the unclear role of splinting in 
early recontracture, splinting should still be considered on an individual patient 
basis until further evidence is available. 
Future trials should ensure that risks of bias are minimised.  As 
acknowledged, performance bias may prove difficult to minimise in some 
studies.  Certain components of the studies included here set precedents for 
processes by which risk of bias in random sequence generation, allocation 
concealment and outcome detection can be minimised.  Future studies should 
endeavour to employ such robust processes, and to report them clearly. 
However, prior to embarking on the trials needed in this area, it is clear that 
further study of outcome measures to establish their validity and reliability for 
use in Dupuytren's disease.  Once this has been done, consensus and 
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consistency of outcome choice and time point of assessment is needed, to 
ensure standardisation with other studies. 
 
SUMMARY 
This chapter described a systematic review of trials of the treatment of 
Dupuytren’s disease, including a meta-analysis of the effect of postoperative 
splinting as an adjunct to surgery. 
There have been relatively few randomised controlled trials to describe the 
roles for different surgical procedures in the treatment of Dupuytren’s disease. 
Most have been at risk of bias that could have been further minimised. 
The primary outcomes studied have often involved surgeon-centred objective 
measures, such as angular loss of extension, rather than patient-centre 
function. 
None of the studies included in this review included cost effectiveness 
analyses. 
The effect of postoperative splinting was meta-analysed here, and these 
analyses confirmed the findings of individual studies, in that it does not 
improve outcome, but this analysis demonstrates that impairs active flexion. 
This chapter demonstrates that further studies are urgently needed in 
Dupuytren’s disease.  Currently, there is insufficient high quality comparative 
data to inform the development of a meaningful clinical guideline in 
Dupuytren’s disease, or to best utilise the changes in NHS architecture that 
might promote standardisation of practice. 
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This chapter also highlighted the variation in outcome measures used to study 
Dupuytren’s disease.  To be able to design the required comparative study or 
studies, and to be able to interpret existing published data, better 
understanding of the most appropriate PROMs is required.  Within the PROMs 
previously used, the DASH was used in one trial comparing operative 
techniques.  This is the most common PROM in Dupuytren’s disease research 
(Ball et al., 2013).  Further study of the DASH is required. 
The following chapters will investigate aspects of validity, reliability and 
responsiveness of the DASH and other outcome measures that may be used 
as the primary outcome in future studies. 
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5 The+Dynamism+of+Dupuytren’s+Contractures+
5.1 Preface+
The previous chapter reviewed existing “interpretability” data for relevant 
clinical outcome measures used in Dupuytren’s disease.  Such data facilitate 
the interpretation of outcome measurements, by establishing what constitutes 
a clinically important change or difference.  The review demonstrated a 
paucity of such studies, which has implications for future study design, data 
interpretation and guideline development.  Passive extension deficit is an 
example of a measure that has been used as the primary outcome in 
randomised controlled trials of treatment of Dupuytren’s disease (van Rijssen 
et al., 2006, van Rijssen et al., 2012), but for which no interpretability data 
could be identified.  There may be limitations to the stability of this as an 
outcome measure, which have been previously overlooked.  Dynamism of 
contractures is discussed in the introduction, whereby for cases of 
Dupuytren’s disease in which a cord crosses more than one joint, the passive 
extension deficit at one joint is influenced by the position of other joints in the 
ray.  This is because the cord of Dupuytren’s disease is inelastic and so may 
limit the simultaneous extension of both joints (Hurst, 2010).  This could 
constitute a source of bias for passive finger joint angles in trials, and has not 
been studied. 
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If dynamism is frequently encountered and is of significant magnitude, this 
would support the adoption of a different primary outcome measure in future 
research, and caution the interpretation of previous studies reporting such 
angles.  This chapter examines the prevalence and severity of dynamism in 
preoperative Dupuytren’s contractures to determine whether this might 
constitute a source of bias that has been overlooked. 
 +
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5.2 Introduction+
Systematic reviews of Dupuytren’s disease have demonstrated no consistent 
definition of recurrence and that length of follow up varies between studies 
(Becker and Davis, 2010, Werker et al., 2012).  Common practice in studies of 
surgery for Dupuytren’s disease is to report ‘recurrence rates’ after treatment, 
but often without providing a definition of recurrence (Becker and Davis, 
2010). 
When recurrence is defined, a commonly employed definition is the 
recurrence of angular deformity.  Seventeen variations, such as an angular 
deformity of 30°, are reported (Ball et al., 2013).  Improvement in angular 
deformity was the primary endpoint of the two most recent and high profile 
randomised controlled trials (RCTs) of Dupuytren’s disease treatment (Hurst 
et al., 2009, van Rijssen et al., 2006).  Return of angular deformity was used 
to assess recurrence as the primary outcome in the 5-year follow-up of the 
latter trial (van Rijssen et al., 2012). 
If a Dupuytren’s contracture spans both the MCP and PIP joints, the severity 
of the passive flexion deformity of one of these joints may be influenced by the 
position of the other when the measurement is taken, through what is referred 
to as dynamism (Hurst, 2010).  Thus, if the metacarpophalangeal joint (MCPJ) 
is held in maximal passive flexion, then the flexion deformity at the proximal 
interphalangeal joint (PIPJ) may be partially or completely relieved.  
Conversely, if the MCPJ is held in maximal passive extension, then the PIPJ 
flexion deformity may be exaggerated (Figure 5.1).  To minimise the effect of 
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such dynamism, observers may hold the other joints of the finger in maximum 
passive flexion when measuring a flexion deformity of a joint, and thus report 
a minimised passive extension deficit, rather than the active deficit 
encountered by the patient, which might be larger due to dynamism. 
 
 
Figure 5.1: Schematic representation of dynamism 
The Dupuytren’s cord (shown in blue) is not elastic and has fixed attachments 
to the palmar aponeurosis in the palm and flexor sheath in the middle pulp 
space.  On the left, extension of the MCPJ tightens the cord at the PIPJ, 
pulling it into flexion, and generating the “worst” PIPJ angle.  Alternatively, 
passive flexion of the PIPJ relaxes the cord and allows increased extension at 
the MCPJ, giving the  “best” MCPJ angle. 
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On the right, flexion of the MCPJ relaxes the same cord at the PIPJ and 
allows increased extension, generating the “best” PIPJ angle.  Alternatively, 
passive extension of the PIPJ tightens the cord, and pulls the MCPJ into 
flexion, giving the “worst” MCPJ angle. 
 
Dynamism may also reduce the correlation between passive angles measured 
by an observer and the patient’s experience of the contracture, as the patient 
cannot achieve the milder contracture obtained by measuring passive 
extension angles at the MCPJ and PIPJ separately. 
We are not aware of any reports on the potential impact of dynamism on 
angular joint measurements.  Goniometry in general has good inter- and intra-
observer reproducibility when assessed in controlled situations.  When 
performed by hand therapists to measure joint angles in normal digits held by 
thermoplastic splints, inter-observer reproducibility was found to be 7°-9°, and 
intra-observer reproducibility was 4°-5° degrees (Ellis and Bruton, 2002).  
However, if common and significant, dynamism may introduce an important 
source of bias and error, which could influence reported recurrence rates. 
This study aimed to establish the extent of dynamism on Dupuytren’s 
contractures affecting PIPJs awaiting surgery (with or without MCPJ 
involvement). 
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5.3 Methods+
These data are derived from the baseline data collection from a study of early 
functional recovery following Dupuytren’s disease surgery.  They comprise a 
minor element of the study.  The local research and development department 
approved the overall project as service evaluation.  In keeping with National 
Research Ethics Service guidance, research ethics committee approval for 
this project component was not required (NRES, 2012). 
Data collection took place between February 2012 and May 2013.  The 
inclusion criteria were patients meeting of all of the following: 
• Awaiting fasciectomy or dermofasciectomy at a single United Kingdom 
hand surgery service 
• Primary or recurrent Dupuytren’s disease of one or more fingers 
• Extension deficit affecting the PIPJ of one of the digits when actively 
extending this digit 
• Able to attend a suitable pre-operative assessment clinic appointment 
scheduled for the candidate to perform the measurements 
 
Exclusion criteria were: 
• An isolated MCPJ contracture 
• Cognitive impairment preventing informed consent 
• Refusal of invitation to participate 
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Contractures that appeared to affect the PIPJ only were included, as in these 
cases there may have been MCPJ dynamism within the range of 
hyperextension.  However, as PIPJs do not typically hyperextend passively, 
MCPJ only contractures were excluded. 
Eligible patients who attended a routine orthopaedic preadmission clinic were 
issued with a letter explaining the project and inviting them to participate on a 
voluntary basis.  The candidate assessed all patients who consented to 
participate.  Demographic details, including previous surgery to the finger 
involved, were recorded.  Goniometry was performed to measure the 
extension deficits of the MCPJ and PIPJ of all digits that were to undergo 
surgery.  This was initially performed with the other joint of the digit held in 
maximum passive flexion, thus minimising the extension deficit measured and 
giving the ‘best’ measure.  It was then repeated with the other joint of the digit 
in maximum passive extension (thus maximising the extension deficit 
measured, giving the ‘worst’ measure).  When assessing an MCPJ in which 
hyperextension was present, this was recorded as 0°, in keeping with the 
methodology used in previous studies of goniometry in Dupuytren’s disease 
(Jerosch-Herold et al., 2011). 
Analysis was performed using Prism 6.0 for Mac OS X (GraphPad® Software, 
La Jolla, USA, 2012). 
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5.4 Results+
Eighty-four patients were considered for inclusion in this study but 14 were 
excluded as they had MCPJ only contractures.  A further six declined to 
participate and one was excluded as she had Alzheimer’s disease that 
prevented informed consent.  This left 85 digits on 72 hands from the 70 
patients, all of whom consented to participate. 
Of the 70 patients, 55 were men (79%) and the mean age was 67 years.  The 
digits studied were predominantly little fingers, followed by ring, middle and 
only three index fingers (Table 5.1). 
 
DIGIT SAMPLE SIZE 
(n=85) 
DIFFERENCE OF 
‘WORST’-‘BEST’ ANGLES 
AT PIPJ 
Mean (95%CIs) 
Little 55 (65%) 11o (9o to 14o) 
Ring 19 (22%) 20o (12o to 29o) 
Middle 8 (9%) 16o (5o to 27o) 
Index 3 (4%) 64o (30o to 99o) 
Table 5.1: Differences between ‘worst’ and ‘best’ angles at PIPJ by digit 
 
Thirty-five of 85 digits studied (41%) had PIPJ only contractures.  In these, the 
‘best’ and ‘worst’ MCPJ angles obtained were both within hyperextension.  By 
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finger, the proportions of PIPJ only contractures were significantly different 
(p=0.0225, Chi square test): 
• Index: 0/3 (0%) 
• Middle: 1/8 (13%) 
• Ring: 5/19 (26%) 
• Little: 29/55 (53%) 
Seventy-six digits showed dynamism at either the MCPJ or PIPJ (89%).  
Seventy-four showed dynamism at the PIPJ (87%), but only 35 (41%) MCPJs 
exhibited dynamism.  Other MCPJs may have had dynamism within the range 
of hyperextension, which was not captured here. 
In nine digits there was more than 30° of dynamism at one joint (11%).  
Overall, the mean ‘best’ MCPJ angle was 19° and the mean ‘worst’ MCPJ 
angle was 25°.  The mean range of dynamism for MCPJs was thus 6°, which 
represented a highly significantly difference between best and worst angles 
(p<0.0001, paired t test).  The mean dynamism seen increased to a mean of 
9° (95%CIs: 7-12) when those digits in which both ‘worst’ and ‘best’ MCPJ 
angles were 0° were excluded (as dynamism within the range of 
hyperextension might have been present in these, but was not assessed in 
this study).  The mean ‘best’ PIPJ angle was 49° and the mean ‘worst’ PIPJ 
angle was 63°.  Thus the mean dynamism for PIPJs was 14° (95%CI: 11° -
17°) which also represented a highly significant difference between best and 
worst angles (p<0.0001, paired t test).  The results are shown in Table 5.2. 
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JOINT BEST ANGLE 
Mean (95%CI) 
WORST 
ANGLE 
Mean (95%CI) 
DYNAMISM 
Mean (95%CI) 
MCPJ 19o (14o-25o) 25o (19o-31o) 5o (4o-7o) 
PIPJ 49o (44o-54o) 63o (58o-68o) 14o (11o-17o) 
Table 5.2: Best and worst angles (95% confidence intervals are in 
brackets) 
 
Twenty-one fingers had undergone previous Dupuytren’s surgery (25%).  
Fingers that had already had surgery for Dupuytren’s disease had comparable 
ranges of dynamism to those that had not undergone previous surgery.  For 
the MCPJ, the mean range of dynamism was 4.9o (95%CIs: 3.8o – 5.9o) for 
digits that had previously undergone surgery and 5.5 o (95%CIs: 1.8o – 9.2o) 
for those that had not had previous surgery.  For the PIPJ the mean range of 
dynamism was 12.6o (95%CIs: 9.7o – 15.5o) for fingers that had previously 
undergone surgery and 14.6o (95%CIs: 11.2o – 18.0o) for those that had not 
had previous surgery. 
Results from different digits are presented in Table 5.3.  The difference 
between ‘worst’ and ‘best’ MCPJ angles did not differ significantly between 
digits (p=0.137, one-way ANOVA).  However, the extent of PIPJ dynamism 
varied by digit (p<0.0001, one-way ANOVA).  When Tukey’s multiple 
comparisons test was applied, highly significant differences (p<0.0001) were 
seen between the index finger and all other fingers.  The only other significant 
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difference was between the ring and little fingers.  There was a difference in 
the proportion of PIPJ-only contractures between the ring and little fingers 
(ring: 5/19 (26%) versus little: 29/55 (53%), (p=0.0464, Chi square test), which 
may have contributed to this.  However, there were very few index fingers in 
the study, and so this finding merits further investigation. 
 
 Middle Ring Little 
Index 48o (70o to 26o) 
p<0.0001 
 
44o (64o to 23o) 
p<0.0001 
53o (72o to 33o) 
p<0.0001 
Middle  4o (-9o to 18o) 
NS 
 
5o (17o to -8o) 
NS 
Ring   8o (18o to 0o) 
p=0.042 
Table 5.3: Differences in dynamism at the PIPJ between different digits 
[mean (95%CIs), significance levels from Tukey’s multiple comparisons 
test] 
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5.5 Discussion+
5.5.1 Present+study+findings+
These data demonstrate that dynamism is common.  Frequently it can be of a 
large enough magnitude to potentially reclassify a contracture from 
“sufficiently large contracture (i.e. >30 degrees) to warrant surgical treatment” 
to “insufficient contracture (i.e. < 30 degrees) to warrant surgery” or from 
“recurred” to “not recurred” based on commonly used cut offs (i.e. 30 degrees) 
in Dupuytren’s disease research.  Therefore, it may constitute a source of 
inadvertent measurement error or systematic bias in clinical trials of 
Dupuytren’s disease management. 
Differences in technique for measuring angular deformity may result in some 
measurements being taken with passive flexion of the adjacent joint, such that 
dynamism may reduce the measured angular deformity of a joint.  In contrast, 
if the joint angle were measured with passive extension of the adjacent joint, 
then this would increase the joint angle measurement worse.  Furthermore, if 
observers were not blinded and were able to recognise the treatment that the 
patient has received, conscious or subconscious bias may influence the 
angular measurement.  Different treatment modalities for Dupuytren’s disease, 
such as needle aponeurotomy, fasciectomy and dermofasciectomy leave very 
visibly distinct scar patterns on the hand, which can be recognised by 
observers, even if they had been blinded to the treatment group allocation.  As 
goniometry may be considered a learned skill, acceptable reliability is likely to 
only be achieved if experienced observers perform assessments.  Such 
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observers are likely to be aware of the different treatment options and their 
scar patterns.  Dynamism was frequently capable of producing a 5°-10° 
change in a PIPJ measurement, and thus could move a finger from a “no 
recurrent contracture” to a “recurrent contracture” status, or vice-versa, if a 
definition of recurrence such as “20° or more increase in angular deformity” is 
used. 
In this study, index fingers showed the most dynamism.  However, there were 
only three index fingers in the series, and so this finding is probably not 
robust, and should be interpreted with caution. 
5.5.2 Limitations+
One limitation of the present study is that only preoperative and established 
recurrent contractures were measured.  In contrast, the results of trials 
typically also involve assessing early postoperative angular deformities to 
determine residual contractures after treatment.  However, 21 of the 85 fingers 
studied had undergone previous Dupuytren’s disease surgery, and these 
exhibited similar ranges of dynamism to the others.  Thus, we believe our 
findings can be reasonably extrapolated to postoperative situation. 
The results of the present study represent the maximum range of dynamism, 
given that the ‘worst’ angles were obtained by passively manipulating the digit 
to exaggerate a contracture at a particular joint.  This strategy was intentional, 
as the aim was to establish the maximum amount of dynamism achievable.  
However, it is unlikely that the maximum effect of dynamism identified here 
would be encountered in a trial, unless bias was very marked, or some 
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observers had been trained to measure angular deformities in a manner 
which, through dynamism, either maximised or minimised the angular 
deformity.  Nonetheless, this work demonstrates just how large the impact 
dynamism might have on individual joint measurements.  Even if only half the 
range of dynamism demonstrated in the present study actually occurred in 
routine clinical assessments of joint angles, altering nearly 90% of PIPJ 
measurements in a trial by a mean of 7° might create important shifts in the 
balances of success/failure or recurrence/no recurrence. 
The sub group analysis by digit involved small numbers of radial digits (index 
and middle fingers).  Consequently, this analysis is underpowered to make 
reliable comparisons between digits, as indicated by the broad 95% 
confidence intervals in Table 5.3.  However, the sub group data have been 
presented for completeness and to direct potential further study.  Disease 
affecting the radial side of the hand, including the index finger is relatively 
uncommon, and occurs more frequently in diabetics.  It is possible that there 
are differences between contractures affecting the radial digits compared to 
the ulnar digits. 
5.5.3 Relationship+to+existing+literature+
Accurate intra- and inter-observer reproducibility of goniometry measurements 
taken by therapists have been previously reported (Ellis and Bruton, 2002).  
However, the model used in that study did not reproduce the clinical situation 
as measurements were taken from the fingers of a normal hand that was held 
in a fixed flexed posture by a thermoplastic splint.  Thus there was no 
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possibility of measurement errors or differences due to dynamism or other 
patient and contracture factors, and the estimates of reproducibility are 
probably over-optimistic. 
In recent research in Dupuytren’s disease, unblinded surgeons performed the 
goniometric measurements (van Rijssen et al., 2006, van Rijssen et al., 2012).  
Such studies defined treatment success as correction of angular deformity at 
single joint level to less than 5°, with recurrence defined as a subsequent 
increase in angular deformity of 20° or more (Hurst et al., 2009, van Rijssen et 
al., 2012).  The 14° mean range of dynamism at the PIPJ, or even just 6° at 
the MCPJ demonstrated in the present study, could have markedly altered the 
proportions of patients classified as “successes” or “failures”, or “recurrences” 
or “no recurrences”. 
Reporting active (rather than passive) extension deficit might minimise the 
impact of dynamism on clinical outcome assessment.  Alternatively, using 
appropriate patient-reported outcome measures may provide a more 
meaningful description of hand function and the benefit of surgery, and align 
trial design with the growing use and study of patient-reported outcome 
measure (PROM) data across in the United Kingdom National Health Service 
and other countries (Darzi, 2008, Mokkink et al., 2010).  The correlation 
between angular deformity and patient-reported hand function in Dupuytren’s 
disease is typically poor.  It has been studied for the most popular PROM in 
Duputren’s disease (Ball et al., 2013), the Disabilities of the Arm, Shoulder 
and Hand (DASH), and no meaningful correlation was identified (Engstrand et 
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al., 2009, Jerosch-Herold et al., 2011, Zyluk and Jagielski, 2007).  This may 
be interpreted as evidence that the DASH is not valid (Packham, 2011).  
However, such a conclusion is not supported by a lack of correlation between 
the two.  As discussed by the Consensus-based Standards for the Selection 
of Health Status Measurement Instruments (COSMIN) collaboration, 
assessing a PROM against a ‘gold standard’ of hand function is not robust, as 
no such gold standard exists (Mokkink et al., 2010).  To conclude that the 
DASH is not valid based on poor correlation with angular deformity would only 
be appropriate if that the latter were the gold standard.  Instead, the 
performance of PROMs such as the DASH, or the recently developed Unité 
Rhumatologique des Affections de la Main (URAM) Dupuytren’s disease-
specific PROM (Beaudreuil et al., 2011), needs to investigated using accepted 
standards for validity (Mokkink et al., 2010). 
Despite dynamism, there is still likely to be value in measuring angular 
deformity.  In some circumstances, such as explanatory studies, correcting 
angular deformity at particular sites, such as the PIPJ, may be important.  
Furthermore, angular measurements probably ought to remain as secondary 
outcomes in pragmatic studies, but with an appropriate PROM as the primary 
outcome measure.  The data presented here support the use of active 
extension angles rather than passive extension angles, as the former are less 
likely to be influenced by dynamism.  Alternatively, composite loss of 
extension might be used, as has been previously described (Makela et al., 
1991). 
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5.6 Conclusions+of+study+of+dynamism+
Dynamism is common in preoperative contractures involving the PIPJ.  It 
occurs at both the MCPJ and PIPJ, and still affects MCPJ measurements 
when hyperextension is not studied.  Dynamism is of sufficient magnitude that 
it could represent a significant source of bias if passive joint angles are 
studied, especially if observers are unblinded, as is frequently the case in 
studies of Dupuytren’s disease (see Systematic Review and Meta-analysis of 
Surgical Trials in Dupuytren’s Disease). 
SUMMARY 
This chapter demonstrates that dynamism is encountered in 89% of digits 
when measuring passive extension deficit angles at either MCPJs or PIPJs.  It 
is frequently comparable in magnitude to widely used definitions of early 
correction of deformity and late recurrence of contracture.  The previous 
chapter identified that passive angles have been used in other studies, often 
as unblinded measurements, and with no evidence of consideration of the 
influence of dynamism (van Rijssen et al., 2006, van Rijssen et al., 2012).  
The data in those papers should be reassessed in light of the findings of this 
chapter.  This chapter supports the abandonment of passive extension deficit 
as the primary outcome measure in future studies of Dupuytren’s disease. 
 
Alternative outcome measures need to be considered.  It is possible that a 
PROM will be more appropriate than passive extension deficit as the primary 
outcome measure of future studies.  To investigate this, patients’ experience 
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of Dupuytren’s disease needs to be better understood.  The next chapter will 
consider patients’ goals for the treatment of their Dupuytren’s disease, and 
relate these to one of the candidate PROMs that has been designed for use in 
Dupuytren’s disease specifically. 
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6 British+ Patients’+ Goals+ for+ the+ Treatment+ of+ Dupuytren’s+
Disease,+ and+ their+ Relationship+ to+ the+ Unité+
Rhumatologique+des+Affections+de+la+Main+Scale+
6.1 Preface+
The previous chapter investigated dynamism as a potential source of bias in 
passive measurement of extension deficit.  Such angular measurements of 
finger joints have been used as quantitative outcome measures in high quality 
studies.  However, the incidence and magnitude of the effect of dynamism on 
the measurement of passive extension deficit angles may constitute an 
important and previously unmeasured source of bias.  Furthermore, the 
correlation between existing patient-reported outcome measures of hand 
function and angular deformity is poor (Jerosch-Herold et al., 2011).  To 
understand better which of these is more valid, it is essential to appreciate the 
goals of treatment.  These may be cited as ‘correcting angular deformity’, and 
this is typically used as the surgeon-centred endpoint of research.  However, 
patient expectation of treatment is poorly described.  In particular, surgery 
may be performed based on surgeon-centred indications relating to the 
technical challenges of correcting proximal interphalangeal joint (PIPJ) 
contractures that have been discussed in the introduction.  As a result, some 
guidelines recommend operating on any PIPJ contracture (BSSH, 2008).  It is 
possible that a proportion of patients are operated on prophylactically at a 
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stage at which they do not experience symptoms, but before their disease 
reaches a stage at which full correction becomes technically difficult due to the 
anatomical considerations.  It is not known whether this is the case. 
An understanding of patients’ goals can also be used to appraise existing 
patient-reported outcome measures, such as the recently developed 
Dupuytren’s disease-specific Unité Rhumatologique des Affections de la Main 
scale. 
  
University of Nottingham  British Patients’ Goals 
 213 
6.2 Introduction+
The use of patient-reported outcome measures (PROMs) in healthcare has 
been stimulated by recent UK Department of Health publications (Darzi, 2008, 
Department of Health, 2010).  PROMs may be of particular use in hand 
surgery, as patients’ functional requirements vary, as do their expectations of 
treatment and definitions of a satisfactory outcome.  PROMs used in hand 
surgery are classified into generic tools that assess global wellbeing (e.g. the 
EuroQol 5D), domain-specific tools that assess a particular region (e.g. the 
Disability of the Arm, Shoulder and Hand (DASH) tool (Hudak et al., 1996) or 
the Patient Evaluation Measure (PEM) (Macey et al., 1995)), and disease-
specific tools (Szabo, 2001).  Whilst generic and domain-specific tools can be 
used to assess outcome for upper limb conditions, they have low sensitivity 
and specificity, and may not detect changes in symptoms or hand function that 
are relevant to patients.  They can also be subject to ceiling or floor effects, 
which occur when many individuals’ scores are close to the upper or the lower 
scale limits respectively (Szabo, 2001).  This limits the scale’s ability to detect 
further improvement or deterioration respectively. 
Recently, a Dupuytren’s disease-specific tool was developed in France 
(Beaudreuil et al., 2011).  This Unité Rhumatologique des Affections de la 
Main, or URAM, scale comprises nine items, which are each scored between 
0 and 5 depending on the difficulty in performing that particular function (Table 
6.1).  Nine patients and seven healthcare professionals generated an initial 
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battery of items that were then reduced to the nine items comprising the final 
scale, via a process involving a further 85 patients. 
However, all were recruited at a single hand surgery centre in Paris, and may 
have been treated with the same type of intervention (Beaudreuil et al., 2011).  
It is unclear whether the URAM is broadly applicable and culturally 
generalisable, and therefore it is unclear whether it is valid for use elsewhere. 
This prospective study aimed to identify patients’ goals for Dupuytren’s 
disease surgery at a British hand surgery centre, and to compare these to 
URAM scale items. 
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1. Wash yourself with a flannel, keeping your 
hand flat? 
      
2. Wash your face?       
3. Hold a bottle in one hand?       
4. Shake someone’s hand?       
5. Stroke something or caress someone?       
6. Clap your hands?       
7. Spread out your fingers?       
8. Lean on your hand?       
9. Pick up small objects with your thumb and 
index finger? 
      
Table 6.1: URAM scale 
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6.3 Methods+
Data collection involved the baseline time point of a service evaluation, and 
took place between September 2011 and April 2013.  The inclusion criteria 
were: 
• Patients awaiting fasciectomy or dermofasciectomy at this UK hand 
surgery centre 
• Primary or recurrent Dupuytren’s disease 
• Available for a preoperative assessment at a time when the candidate 
was available. 
Exclusion criteria were: 
• Cognitive impairment preventing informed consent 
• Refusal of invitation to participate 
Eligible patients were issued with a letter, which explained the project and 
invited them to participate on a voluntary basis.  The candidate assessed all 
patients who consented to participate.  Details of patient demographics and 
planned procedure were captured. 
Patients were asked to specify up to three functional problems they were 
experiencing and wished their surgery to resolve.  Free text answers were 
recorded, so that participants were not restricted to grading their ability to 
specify tasks or the severity of particular symptoms.  They were not asked to 
rank these indications.  Indications were specified prior to the patients 
completing any established patient-reported outcome measures as part of 
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their service evaluation, to avoid them being influenced by the items in 
existing PROMs. 
The candidate then grouped the free text indications, so that different 
descriptions of the same task were consolidated into ‘types’ of problem.  For 
example, “difficulty washing my face” and “I catch my eye or nose with my 
finger when washing my face” were grouped together as “wash self”. 
The consolidated types of patient problem were mapped against the nine 
items that comprise the URAM scale.  When a patient problem would have 
been captured by the URAM, a positive result was recorded (+).  Where a 
problem was not captured by the URAM, a negative result was recorded (-).  
Where a patient problem was interpreted as having some overlap with a 
URAM item, this was recorded as unclear (+/-). 
As well listing the types of indication for their surgery, a question was posed to 
establish the relative importance patients assigned to issues such as speed of 
recovery or better long-term outcome of treatment.  The question asked them 
to rank the following characteristics of their ideal treatment: 
• Early recovery from surgery 
• Better long term outcome 
• Surgeon’s recommended treatment 
The third of these options was provided to gauge whether patients deferred to 
surgeon opinion or felt unable to prioritise speed of recovery against long-term 
outcome. 
 +
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6.4 Results+
There were 117 eligible patients.  Six declined to participate and one was 
excluded due to Alzheimer’s disease of a severity that precluded informed 
consent, leaving 110 patients.  Eighty of the 110 were awaiting limited 
fasciectomy, 28 dermofasciectomy, and two aponeurotomy.  Their mean age 
was 68 (range: 34-90).  Eighty-four (76%) were men, 69 (63%) were awaiting 
surgery to their right hand and 67 (61%) were awaiting surgery to their 
dominant hand.  The mean total passive extension deficit across the 
metacarpophalangeal and proximal interphalangeal joints of the fingers to 
undergo surgery was 68°.  In these measurements, the other joint in the ray 
was held in passive flexion, thus these were the ‘best’ passive angles when 
using the definition from the previous chapter. 
In total, patients provided 278 problems, a mean of 2.5 per patient.  Fifteen 
patients provided one problem, 22 gave two problems and 73 specified three 
problems. 
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PROBLEM Number (%) of 
patients citing 
problem 
Capture in 
URAM scale  
RELEVANT 
URAM 
SCALE 
ITEM 
Difficulty washing self  54 (49%) + 1, 2 
Difficulty picking things up 
(large or small items) 
27 (25%) +/- 9 
Finger hooking on things 26 (24%) -  
Difficulty putting on gloves 25 (23%) -  
Pain 17 (15%) -  
Difficulty gripping 16 (15%) -  
To prevent worsening 12 (11%) -  
Difficulty putting hands in 
pockets 
9 (8%) -  
Difficulty placing hand flat 7 (6%) +/- 8 
Difficulty with palmar hold of 
items 
7 (6%) -  
Difficulty opening bottle tops 7 (6%) +/- 3 
Table 6.2: The most common problems specified by patients 
 
Once consolidated by the authors, there were 43 types of problem, and 94 
different combinations of these amongst the 110 patients.  The most common 
problems, their frequencies and capture by the URAM, are shown in Table 
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6.2.  Less common problems included five problems that were specified by 
four patients each: difficulty using computer keyboard (unclear whether this 
was captured by the URAM, +/-), difficulty shaking hands (+), difficulty driving 
(-), difficulty clapping (+), and difficulty dressing oneself (-).  Nine further 
indications were specified by three patients each: difficulty playing piano (+/-), 
difficulty using cutlery (-), difficulty using the computer other than the keyboard 
(e.g. the mouse) (-), difficulty with fine grip (+), difficulty writing (+/-), finger 
knocks things over (-), difficulty playing bowls (-), difficulty playing golf (-), and 
non-specific difficulty at work (-).  Five more indications were common to two 
patients each: difficulty playing snooker (+), difficulty applying cream to body 
(+), difficulty cutting fingernails (-), appearance of finger upsetting (-), difficulty 
stroking (+).  There were also 13 indications specified by one patient each: 
paraesthesia (-), difficulty leaning on hand (+), difficulty placing hand into 
enclosed spaces (e.g. washing cup) (-), difficulty washing clothes (-), difficulty 
playing flute (-), difficulty using wheelchair (-), difficulty tying shoelaces (-), 
difficulty performing housework (-), unable to massage (+), difficulty cooking (-
), concerned about finger swelling (-), dropping items (-), and difficulty 
sleeping (-). 
Some problems might not relate directly to extension deficit (for example, 
difficulty using computer keyboards and difficulty playing piano may relate to 
reduction of palmar span, and difficulty using cutlery and dropping items may 
relate to fine motor control rather than loss of extension).  Seventeen patients 
(who had no comorbid painful condition) listed pain in the digit, despite pain 
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not being considered a relevant symptom in Dupuytren’s disease by the team 
that designed the URAM.  Two patients cited the unpleasant appearance of 
the digit as a problem, a symptom not assessed by the URAM or the DASH, 
but one which is captured by the PEM.  Of the 15 patients who only cited one 
problem, the problem was difficulty washing oneself for five, concern about 
future deterioration for four, difficulty putting on gloves for two, and one each 
for difficulty gripping, difficulty holding items in the palm of the supinated hand 
(for example when given coins in a shop), difficulty dressing oneself, and 
difficulty writing. 
URAM scale items would have directly assessed (“+”) nine of the 43 different 
types of problem obtained in this study.  When frequencies of these nine 
indications were considered, URAM items would have captured 73 of the 278 
problems specified by patients (26%).  A further six of the 43 types of problem 
showed some overlap (“+/-“) with URAM items, accounting for a further 51 of 
the 278 (18%) problems.  The remaining 28 indications showed no overlap 
with URAM items (“-“), and accounted for 154 of the 278 problems (55%). 
Long-term outcome and surgeon’s recommendation were relatively important 
to patients, whereas achieving rapid early recovery was of less importance 
(Table 6.3). 
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RANK OPTIONS 
Early recovery Long-term 
outcome 
Surgeon’s 
recommendation 
First 27 (24%) 42 (38%) 41 (37%) 
Second 35 (32%) 34 (31%) 40 (36%) 
Third 48 (44%) 34 (31%) 29 (27%) 
Table 6.3: The relative importance of various options to the patients 
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6.5 Discussion+
6.5.1 Present+Study+Findings+
This study demonstrates that preoperative patients have a wide range of goals 
for the treatment of their Dupuytren’s disease.  Individuals’ expectations were 
usually unique.  Relatively few considered the treatment to be prophylactic; 
most were expecting improvement in some functional limitation.  The URAM 
scale only captured a minority of these goals.  It specifically assesses 
Dupuytren’s disease, and its design used standard, contemporary 
methodology (Beaudreuil et al., 2011).  However, it failed to describe most of 
the problems that this study’s patients experienced.  This may be due to the 
URAM’s development, or due to cultural differences between its developers’ 
French patients and this British cohort.  The initial item generation phase of 
the URAM involved input from only nine French patients.  It is not clear from 
the paper whether item generation was conducted before or after treatment.  
Furthermore, the small French group may not have been representative of 
patients with Dupuytren’s contractures.  Reduction of these items was then 
achieved by removing: 
• Items never performed by at least 5% of patients 
• Items with a low spread of responses amongst preoperative patients 
• Items with low test-retest reliability 
• Items with redundancy (defined as a high correlation coefficient with 
another item) 
• Items showing poor factor loading in an exploratory factor analysis  
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Eliminating items never performed by 5% of their study population of patients 
might have removed problems that were very important to others.  
Additionally, removing items because of a small spread of responses obtained 
when administered to a small group of preoperative patients may not be 
appropriate.  Based on this methodology, a task that was commonly found to 
be severely limiting by all patients with the condition would be rejected. 
It is possible that some of the common goals identified in this study that are 
not present in the URAM relate to cross cultural differences.  For example, 
difficulty wearing gloves was a common problem for British patients, but may 
not be relevant if the French patients participating in item generation were 
based in a warmer climate. 
However, the absence of other British patients’ goals from the URAM is less 
easily understood.  The authors of the URAM scale state that Dupuytren’s 
disease is painless.  However, improving pain was a goal for 15% of the 
patients in this study, and pain has been previously documented in 
Dupuytren’s disease (Hueston, 1963, von Campe et al., 2012).  Furthermore, 
pain may be an important aspect of postoperative functional impairment.  The 
URAM scale appears unsuitable for the assessment of common complications 
of treatment of Dupuytren’s disease (Crean et al., 2011), which differ from 
preoperative disabilities.  Instead, the URAM scale items correlated most 
closely with Tubiana stage, a classification of loss of extension (Beaudreuil et 
al., 2011).  As a result, the use of the URAM to assess postoperative outcome 
of treatment, particularly in the first few weeks when differing treatments may 
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be expected to result in different levels of pain, may not be appropriate.  The 
developers of the URAM present interpretability data in the original paper 
(Beaudreuil et al., 2011), but this is performed in a cohort of patients 
undergoing aponeurotomy.  As a less invasive treatment, this has a lower risk 
of complications than fasciectomy (Crean et al., 2011), at the expense of a 
greater risk of recurrence (van Rijssen et al., 2012).  Whether the URAM’s 
interpretability is acceptable for more invasive treatments, after which 
complications are likely to be more common, is not known. 
The findings of the present study also suggest that the long-term outcome of 
treatment may be more important than quick recovery to the majority of 
patients.  A larger sample size would have allowed a meaningful sub group 
analysis, as it may comprise distinct patient types with different preferences.  
For example, self-employed working age people might prefer quicker recovery 
at the risk of greater recurrence whereas retired patients might prefer to 
minimise the likelihood of further treatment for recurrence. 
6.5.2 Limitations+
There are limitations to the study.  Only preoperative goals for treatment were 
considered in the present study.  It is implied that the patients involved in the 
development of the URAM were preoperative patients (Beaudreuil et al., 
2011).  Postoperative functional impairment may relate to complications.  As 
discussed, common postoperative complications differ from preoperative 
impairment, and may include features such as pain and altered sensation, 
which are not assessed by the URAM (Crean et al., 2011).  Preoperative 
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patients may be unlikely to appreciate the extent or effect of postoperative 
complications.  Studying goals in a mixed cohort of preoperative and 
postoperative patients might have generated two types of goal: disabilities to 
be improved by treatment, and complications or adverse effects to be avoided. 
The sample of patients included some who had already had treatment of 
Dupuytren’s disease in the past.  The problems that they reported, and their 
expectations of treatment, might have been influenced by their previous 
experiences.  However, as many patients with Dupuytren’s disease would be 
expected to undergo more than one procedure in their lifetime, this may 
increase the generalisability of the results.  Another potential issue is that 
most of the patients studied were awaiting fasciectomy or dermofasciectomy, 
rather than needle aponeurotomy.  Needle aponeurotomy has a quicker 
recovery (van Rijssen et al., 2006), but exhibits more recurrence (van Rijssen 
et al., 2012).  Patients who specifically sought quick recovery might have been 
referred elsewhere.  However, such a selection bias would not necessarily 
influence the symptoms reported by the patient. 
6.5.3 Relationship+to+existing+literature+
Alternative PROMs to the URAM do exist, and have been used to assess 
outcome of treatment for Dupuytren’s contracture (Ball et al., 2013).  The most 
commonly used PROM has been the DASH.  Like the URAM, it mainly 
assesses activity limitations, and so may also fail to capture the problems 
experienced by many patients.  However, it does capture a broad range of 
impairments affecting the upper limb that are not measured by the URAM.  In 
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particular, symptoms that might arise as complications of treatment (Crean et 
al., 2011), such as pain and paraesthesia are measured. 
The PEM outcome measure assesses impairments and generalised, rather 
than specific, activity limitations (Macey et al., 1995).  It also measures the 
psychological impact of the appearance of the hand.  Therefore, the PEM 
might better capture the broad range of specific problems that patients 
experience. 
An alternative solution would be to use individualised patient-reported 
outcome measures, which allow individual patients to specify tasks with which 
they have difficulty, or symptoms they find troublesome.  Most of the patients 
had unique personal combinations of problems that caused them to seek 
treatment.  A study from Sweden also reported a broad range of functional 
problems experienced by patients with Dupuytren’s contractures and found 
these self-defined tasks improved significantly following surgery (Engstrand et 
al., 2009).  This individualised approach to measuring outcome may represent 
a responsive, meaningful, patient-centred and pragmatic endpoint. 
Several other individualised tools exist, such as the Measure Your Medical 
Outcome Profile (MYMOP) (Paterson, 1996) and Canadian Occupational 
Performance Measure (COPM) (Law et al., 1990).  These have been used in 
other clinical areas, but have not been validated for use in Dupuytren’s 
disease. 
Finger joint angle measurements (passive extension deficit, active extension 
deficit and range of motion) have been used to measure outcome in many 
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previous studies (Ball et al., 2013).  However, angular measurements are not 
patient-centred outcomes, and the previously unmeasured influence of 
dynamism has already been studied.  The data in this study suggest that 
some patients experience problems from their Dupuytren’s contractures that 
might not relate directly to loss of extension or reduced range of motion. 
6.6 Conclusions+of+study+of+patients’+goals+
Patients had wide-ranging and often individualised goals for the treatment of 
Dupuytren’s disease.  These data suggest that the face validity of the URAM 
needs to be reassessed, and perhaps modified for general use.  However, in 
this study, patients experienced a broad range of problems specified, which 
may prove hard to capture with any existing rigid scale based on activity 
limitation. 
SUMMARY 
This chapter has demonstrated that patients’ goals for the treatment of 
Dupuytren’s disease are broad.  With 94 different combinations of goals 
provided by 110 patients, they often have distinct individual expectations of 
the treatment of Dupuytren’s disease.  A significant proportion of these goals 
are not captured by the URAM. 
Surgeons may believe that they are treating patients ‘prophylactically’, before 
contractures become severe.  However, only a very small proportion of 
patients underwent treatment for Dupuytren’s disease prophylactically; nearly 
all described a functional limitation that they wanted improved by the surgery.  
In this study, patients prioritised avoiding recurrence in the long term, rather 
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than rapid functional recovery after treatment.  However, this may reflect a 
selection bias as the cohort was undergoing more invasive surgery 
(fasciectomy or dermofasciectomy rather than aponeurotomy), which is 
believed to deliver better long-term outcome. 
Further study of the behaviour of the URAM scale in the treatment of 
Dupuytren’s disease is needed, and such work is presented in the next 
chapter.  Given the broad range of goals identified in this chapter, the URAM’s 
comprehensiveness will be examined in the next chapter.  Given that the 
DASH was used in the most contemporary trial of Dupuytren’s disease 
surgery (van Rijssen et al., 2006; van Rijssen et al., 2012), and that the DASH 
is the most popular PROM for studying Dupuytren’s disease (Ball et al., 2013), 
its validity will also be studied.  In this way, the next chapter a balanced 
consideration of its performance can be made. 
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7 Validity+of+ the+Disabilities+of+ the+Arm,+Shoulder+and+Hand+
tool,+ the+QuickDASH+ tool,+ and+ the+Unité+ Rhumatologique+
des+Affections+de+la+Main+scale+in+Dupuytren’s+disease+
7.1 Preface+
Earlier chapters have demonstrated that passive extension deficit, the primary 
outcome measure in previous randomised trials of the treatment of 
Dupuytren’s disease (van Rijssen et al., 2006, van Rijssen et al., 2012), may 
be subject to previously unmeasured bias in the form of dynamism.  
Furthermore, the first Dupuytren’s disease-specific patient-reported outcome 
measure (PROM), the Unité Rhumatologique des Affections de la Main 
(URAM) scale may still require further assessment of cross-cultural sensitivity 
and interpretability. 
The most popular PROM in Dupuytren’s disease, the Disabilities of the Arm, 
Shoulder and Hand tool (DASH) has been validated in a range of clinical 
scenarios, but not specifically against modern standards of validity (Mokkink et 
al., 2010), or in Dupuytren’s disease specifically.  Furthermore, its validity has 
been questioned (Packham, 2011), albeit on the basis of it poor correlation 
with angular deformity (Engstrand et al., 2009, Jerosch-Herold et al., 2011, 
Zyluk and Jagielski, 2007), which does not constitute a valid assessment of 
criterion validity according to current standards (Mokkink et al., 2010).  Also, 
the inclusion of items assessing pain has been criticised in Dupuytren’s 
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disease (Beaudreuil et al., 2011).  As a result, there is a need to assess the 
validity of the DASH in Dupuytren’s disease, to guide outcome measure 
selection for future research, but also to inform appraisal of the existing 
evidence base that has used it, in clinical guideline development, for example. 
This chapter considers some aspects of the performance of the DASH, its 
shortened version the QuickDASH, and the URAM. 
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7.2 Introduction+
Several PROMs have been used to evaluate Dupuytren’s disease, and the 30-
item DASH is the most popular (Ball et al., 2013).  However it has been 
suggested that the DASH may not be valid for use in Dupuytren’s disease 
(Beaudreuil et al., 2011, Packham, 2011), as neither it nor the QuickDASH 
correlates closely with angular deformity (Budd et al., 2011, Engstrand et al., 
2009, Jerosch-Herold et al., 2011, Zyluk and Jagielski, 2007).  Furthermore, 
both include items that assess pain whereas it is claimed that Dupuytren’s 
disease is not painful (Beaudreuil et al., 2011).  Other groups suggest that 
pain may be present (Hueston, 1963, Rodrigues et al., 2014, von Campe et 
al., 2012), and treatment-related pain may affect postoperative recovery of 
function. 
Much of the data describing the validity and reliability of the DASH was 
obtained from mixed cohorts involving upper limb conditions widely accepted 
as painful (Kennedy et al., 2011).  Much of the data describing the validity and 
reliability of the DASH was obtained from mixed cohorts involving upper limb 
conditions widely accepted as painful (Kennedy et al., 2011).  Other than the 
recent publication of the secondary analysis of a randomised controlled trial 
(Forget et al., 2014), there is limited data describing the DASH’s validity and 
reliability in Dupuytren’s disease specifically. 
PROMs have been developed to study Dupuytren’s disease specifically, such 
as the URAM (Beaudreuil et al., 2011) and the Southampton Dupuytren’s 
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scoring system (Mohan et al., 2014).  The latter was published since the 
completion of data collection for this project. 
Other PROMs that have been used to assess Dupuytren’s disease (Ball et al., 
2013), include the Michigan Hand Questionnaire (MHQ) (Chung et al., 1998), 
the Patient Evaluation Measure (PEM) (Macey et al., 1995), and the 
QuickDASH (Beaton et al., 2005) .  In a study of patients with a range of hand 
conditions, the DASH took longer to complete than the PEM, but was quicker 
than the MHQ (Dias et al., 2008).  Patients contributing to research, service 
evaluation or audit might be asked to complete more than one outcome 
measure.  For example, a specific PROM and a generic measure to assess 
health-related quality of life, such as the EuroQol 5 D (EQ5D) (Herdman et al., 
2011), may be required to facilitate cost effectiveness analysis (NICE, 2008).  
As a result, using PROMs that are quicker for the patient to complete may be 
more convenient and facilitate higher response rates. 
The QuickDASH comprises 11 of the 30 items in the DASH, and should be 
quicker to complete.  However, it has not been used extensively in 
Dupuytren’s disease (Ball et al., 2013). 
The URAM is the first Dupuytren’s disease-specific PROM to have been 
developed.  It has been subjected to assessments of its validity by the 
developer (Beaudreuil et al., 2011).  It purposefully does not assess domains 
such as pain.  As such, it may prioritise relevance of preoperative symptoms 
ahead of comprehensiveness for use in the postoperative setting. 
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Consensus-based standards for the selection of health status measurement 
instruments (COSMIN) have been developed (Mokkink et al., 2010).  These 
define different aspects of the validity of PROMs. 
Content validity assesses whether the items that comprise a PROM are an 
adequate reflection of what is trying to be measured.  It involves assessing the 
relevance and comprehensiveness of the items in a PROM. 
Construct validity examines hypotheses about the PROM.  Such hypotheses 
may relate to its structural validity (internal relationships between items), 
hypothesis testing (assessing its relationship with other PROMs) and 
differences between groups (cross-cultural validity).  For example, the former 
can be investigated by studying whether all items in a tool contributing to a 
summary score reflect the same underlying construct in a multivariate 
analysis. 
Internal consistency, considered part of the reliability of a PROM, is the 
interrelatedness of the items within a PROM.  It assumes that all of the items 
that contribute to a summary score intend to reflect the same underlying 
entity, or factor (e.g. impairment of structures in the hand versus restriction of 
function involving the shoulder), i.e. they are ‘unidimensional’.  If this 
assumption is met, internal consistency assesses how closely the items reflect 
the construct concerned. 
Criterion validity tests a PROM against a ‘gold standard’.  The only accepted 
methodology for this is the comparison of a shortened PROM against the long 
version (e.g. the QuickDASH against the DASH). 
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This cross sectional study assessed aspects of content validity, construct 
validity and reliability of the DASH and the URAM in Dupuytren’s disease, and 
studied the relationship between the DASH and the QuickDASH (i.e. the 
criterion validity of the QuickDASH).  Responsiveness (the ability to detect 
change over time) differs from ‘validity’, in that responsiveness assesses a 
change score, whereas validity assesses a single time point score.  This will 
be studied in the next chapter based on cohort study data. 
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7.3 Methods+
7.3.1 Patient+recruitment+and+data+collection+
The data presented in this study were gathered as part of a larger service 
evaluation. 
Patient recruitment took place between September 2011 and April 2013.  The 
inclusion criteria were primary or recurrent Dupuytren’s disease, and either: 
1. Patients awaiting fasciectomy or dermofasciectomy at one UK hand 
surgery centre or 
2. Patients available for assessment at five UK hand surgery centres 1 
year or 5 years (+/- 2 months) after their surgery when the candidate 
was available. 
 
Exclusion criteria were: 
• Cognitive impairment preventing informed consent 
• Refusal of invitation to participate 
For the first inclusion criterion group, preoperative patients were recruited at 
the routine preadmission clinic visit prior to surgery.  Those who were eligible 
and consented to participate completed the DASH prior to surgery.  These 
patients were also sent questionnaires for completion by post at 3 weeks, 6 
weeks and 1 year after surgery.  Patients who were scheduled for surgery to 
the left and right hand at different times during the study recruitment period 
were eligible for recruitment twice.  This happened on four occasions. 
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Patients in the second inclusion criterion group were invited to participate with 
a letter explaining the project and inviting them to participate on a voluntary 
basis, with a fixed stipend offered to cover travel expenses.  The candidate 
assessed those who consented to participate.  The assessment included 
collection of demographic data and completion of the 30-item DASH 
questionnaire. 
The URAM scale was published during the study period.  Patients recruited 
later in the study (August 2012 onwards) also completed the URAM at 
assessments. 
7.3.2 Angular+measurement:+total+passive+extension+deficit+(TPED)+
Patients who completed PROMs whilst a surgeon was present (as opposed to 
completion by post – which was the case for 3 and 6 week postoperative 
measurements) had the passive extension deficit of the treated digit assessed 
by a single examiner.  Total passive extension deficit (TPED) was calculated 
by adding the measured passive extension deficits of the 
metacarpophalangeal joint and proximal interphalangeal joint while the other 
joints of the digit were passively flexed.  The measurement thus minimised the 
influence of dynamism (Rodrigues et al., 2014). 
7.3.3 Content+validity:+relevance+of+pain+questions+in+the+DASH+
The relevance of items assessing pain was assessed by extracting and 
analysing responses to question 24 of the DASH (which assesses pain, and is 
question 9 of the QuickDASH) and question 25 of the DASH (which assesses 
pain during specific activity) at different time points.  It was hypothesised that if 
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pain items were relevant, they would change significantly through the recovery 
period. 
7.3.4 Construct+validity+and+reliability+
How the different items in the DASH related to each other (their internal 
relationships) for different patients was analysed.  This constituted a study of 
the structural validity of the DASH.  When used as instructed by the 
developer, the DASH generates a single summary ‘DASH score’, using all of 
the 30 items (in contrast to other tools such as the Michigan Hand 
Questionnaire, which generates several summary scores for different areas).  
For the single DASH score to be valid, all items contributing to the score 
should measure, or ‘reflect’, the same underlying entity or ‘factor’, in this case 
upper limb function, i.e. the tool should be unidimensional (Mokkink et al., 
2010).  To evaluate whether the DASH is unidimensional, exploratory factor 
analysis (EFA) was employed (Mokkink et al., 2010).  EFA analyses the 
relationship between items when completed by different people to identify 
underlying latent factors that explain the variance; the differences seen 
between individuals across a population.  Some of the relevant concepts 
involved are defined in Table 1.  It was expected that the responses obtained 
would have a tendency towards low scores and so not fit a normal distribution.  
This was examined by calculating the kurtosis and skewness for items.  If the 
responses were not normally distributed (defined as kurtosis or skewness >+2 
or <-2), then logarithmic transformation of all items was performed (Pallant, 
2010) and their distributions then reassessed prior to factor analysis.  EFA 
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may be performed using different statistical methods.  In this study, principal 
axis factoring was used to extract latent factors that were being reflected by 
the DASH’s items, and the number of factors extracted was determined and 
confirmed by using two different accepted techniques (scree plots and parallel 
analysis, see Table 1) (Cattell, 1966, Horn, 1965, Patil et al., 2007).  If the 
DASH were unidimensional, then there would only be one factor that could be 
extracted.  Cronbach’s alpha was calculated to assess internal consistency.  
However, this was interpreted with caution if unidimensionality had not been 
confirmed. 
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Aspect Studied Method(s) 
Used 
Concept(s) Description 
Content validity Cohort study of 
pain items 
Comprehensiveness & 
Relevance 
Content validity considers whether PROM items are relevant to what is being measured, and whether 
the scale overall is comprehensive. 
Distribution of item 
responses 
Kurtosis & 
skewness 
Kurtosis Defines the sharpness of the peak of a distribution of data 
  Skewness Defines the amount of asymmetry of a distribution of data 
Construct validity 
(structural validity) 
Exploratory 
Factor Analysis 
Unidimensionality All items contributing to a summary score reflect the same underlying factor (some PROMs generate 
more than one summary score, each describing a different subscale of the PROM) 
  Factor Factor analysis aims to describe the variation in measured items that correlate with each other in terms 
of fewer unobserved ‘factors’ 
  Principal axis factoring A form of factor analysis in which factors are extracted based on common variance, rather than total 
variance. 
  Eigenvalue Describes the amount of the total variance that is explained by a particular factor 
  Catell’s scree plot Determines the number of factors to extract.  All potential factors are plotted in order of Eigenvalues 
(see Chart 1).  The turning point where the connecting line flattens sharply is the point at which the last 
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significant factor has been passed, as further factors represent a flat level of background noise (Catell, 
1966). 
  Parallel analysis Determines the number of factors to extract.  A second set of Eigenvalues is generated, but which are 
based entirely on chance.  All factors in the real model with Eigenvalues greater than their counterparts 
in the chance model are significant and are then extracted.  Avoids the risk of bias that exists with scree 
plot interpretation (Horn, 1965). 
  Kaiser-Meyer-Olkin 
statistic 
Assesses sampling adequacy.  It lies between 0-1, describing the proportion of variance that is common 
variance.  The minimum acceptable level for analysis being 0.6, and >0.9 being described as 
‘marvellous’ (Kaiser, 1974). 
  Bartlett’s test of 
sphericity 
Assesses whether an identity matrix would result if correlations between the items included were 
studied, i.e. whether the correlation between all of the DASH items is zero.  Some correlation between 
items is needed for EFA.  A significant result is achieved if the data is suitable for EFA. 
  Factor loading The output of EFA.  Described how closely an item correlates with a factor. 
  Rotation Presents the factor loadings in a manner that makes interpretation more straightforward, resulting in a 
pattern matrix.  Only possible when more than one factor is extracted.  When done, the majority of the 
items may each show strong loading with one of the factors, a situation described as simple structure. 
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Reliability Cronbach’s 
alpha 
Internal consistency Studies the inter-relatedness between items within a scale.  However, it is dependent on the scale being 
unidimensional and reflective 
Relationship 
between DASH and 
QuickDASH 
Bland-Altman 
plots 
Agreement Studies the relationship between two variables that are expected to correlate.  In such circumstances, 
reporting correlation is common, but may not be appropriate. 
Table 7.1: Data handling and relevant statistical concepts 
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7.3.5 Relationship0between0the0DASH0and0QuickDASH0
The DASH summary score was calculated using the standard formula 
provided: 
DASH=((a/b)-1)*25 
Where “a” is the sum of the scores for the responses completed (each 
response could be scored between one and five), and “b” is the number of 
responses the patient completed. 
The QuickDASH summary score was calculated by extracting the answers to 
the relevant 11 questions.  The score was calculated using the same formula 
as for the DASH, only with these eleven items. 
As the summary scores of the DASH and the QuickDASH are virtually 
continuous scales (each scored 0-100), and the sample comprised a large 
number of independent observations, parametric analyses were used to 
compare them, in keeping with the central limit theorem (Norman, 2010).  
Pearson’s correlation coefficients were calculated between the total scores for 
the DASH and the QuickDASH for a) the total sample and b) for different time 
point subgroups.  If the relationship between the QuickDASH and the DASH 
was not absolute and did not lie on the line of equality (i.e. correlation 
coefficient was less than 1, the maximum possible correlation coefficient), 
then agreement was also studied.  Agreement was assessed by calculating 
95% limits of agreement, using Bland-Altman analysis of the difference 
between the QuickDASH and the DASH (Bland and Altman, 1986). 
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7.3.6 Handling0of0incomplete0responses0
If more than three of the 30 responses are missing (i.e. fewer than 27/30 
responses provided), then the DASH cannot be calculated (Kennedy et al., 
2011), and if more than one response of the eleven is missing (i.e. fewer than 
10/11 responses provided), then the QuickDASH cannot be calculated 
(Kennedy et al., 2011).  If either was the case, then that questionnaire was 
excluded from the whole study. 
Therefore, some of the included questionnaires still had missing data (up to 
3/30 responses missing for the DASH, or 1/11 missing for the QuickDASH).  
As the study of the relationship between the DASH and QuickDASH used 
summary scores that can still calculated despite such missing data, this was 
of no consequence for the analysis of the criterion validity of the QuickDASH.  
However, in the EFA, individual item data are required.  The questionnaires 
with some missing data were still included for analysis, but with missing 
responses excluded pairwise. 
If required (e.g. for repeated measures ANOVA), then listwise exclusion was 
used. 
Clear guidance for handling incomplete questionnaires was not available for 
the URAM.  However, as the URAM was only included in EFA, which requires 
individual item data, pairwise exclusion was used to handle missing data. 
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7.3.7 Sample0size0
Sample size estimates were based on guidance for designing EFA analyses.  
Whilst different heuristics exist for this, there is little evidence to support formal 
estimation of sample size for such analyses (Mundfrom et al., 2005).  A 
suggested sample size of 300-400 for factor loadings of 0.4 was followed, as 
summarised in a review of EFA methodology (Floyd and Widaman, 1995).  A 
target sample size of 300 was set. 
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7.4 Results0
7.4.1 Demographics0
768 DASH questionnaires were received.  These described the preoperative 
and/or postoperative assessment of 527 different procedures.  Nine cohort 
study questionnaires were incomplete to the extent that calculation of a 
summary score was not possible based on the guidance issued with the 
DASH and/or the QuickDASH, and they were excluded from all analysis.  
Thus, 759 DASH questionnaires describing 527 procedures on 523 patients 
were analysed (Figure 7.1).  The 527 procedures comprised 126 needle 
aponeurotomies, 327 fasciectomies and 74 dermofasciectomies.  The mean 
age at the time of assessment was 68 (range: 34 to 94) years and 403 of the 
523 (77%) patients were men.  TPED measurements were made at the time 
of completion of the DASH scores in 522 of the 759 occasions (109 
preoperative and 413 postoperative). 
330 URAMs were also received.  For three, the corresponding DASH was 
incomplete.  Therefore, 327 URAMs with matching DASHs were suitable for 
inclusion in the EFA of DASH and URAM items.  These described the 
outcome of 284 procedures in 284 patients.  The 284 procedures comprised 
103 needle aponeurotomies, 144 fasciectomies and 37 dermofasciectomies.  
The mean age at assessment of this group was 67.5 (range: 35 to 92) years 
and 227 of the 284 (80.0%) were male.  The mean URAM summary score 
was 7.7/45 (95% CIs: 6.7,8.6).  The mean preoperative score was 17.6, the 
University of Nottingham   Validity of PROMs 
 247 
mean 1-year postoperative score was 5.6 and the mean 5 year postoperative 
score was 6.5. 
 
 
Figure 7.1: Flow diagram demonstrating time points from which 
complete DASH questionnaires were received 
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TIME POINT MEAN DASH 
(95% CIs) 
MEAN 
QuickDASH 
(95% CIs) 
PEARSON’s r 
(95% CIs) 
Preoperative 27 
(23-31) 
28 
(24-32) 
0.98 (0.97-0.99) 
3 week 
postoperative 
37 
(33-42) 
41 
(36-46) 
0.97 (0.95-0.98) 
6 week 
postoperative 
22 
(18-26) 
24 
(20-28) 
0.98 (0.97-0.99) 
1 year postoperative 11 
(9-13) 
12 
(10-14) 
0.99 (0.98-0.99) 
5 years 
postoperative 
11 
(9-13) 
12 
(10-15) 
0.97 (0.96-0.98) 
Table 7.2: Mean DASH and QuickDASH scores and their correlations, by 
time point 
95% CIs – 95% confidence intervals 
 
7.4.2 Content0validity:0relevance0of0pain0questions0
Question 24 of the DASH (which is question 9 of the QuickDASH) requires 
participants to rate pain experienced in the arm, shoulder or hand in the 
preceding week on a scale from 1 (no pain) to 5 (severe pain).  This question 
was completed in 750 of the 759 questionnaires studied.  The median score 
for question 24 was 2/5 (“mild” pain) for the total study.  This was also the 
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case when preoperative responses were studied alone.  Sixty-eight patients 
provided answers to question 24 preoperatively, at 3 weeks and at 6 weeks.  
When these responses were compared, there was a significant difference 
between them (p=0.003, repeated measures ANOVA test).  Specifically, 
scores were lower (i.e. less pain) at 6 weeks than at 3 weeks (Tukey’s multiple 
comparison test).  Question 25 of the DASH (which is not part of the 
QuickDASH) rates pain when performing a specific activity.  It was completed 
in 745 of 759 questionnaires.  The median score overall was again 2/5, and 
this was also the case for preoperative responses.  The median score was 3/5 
for 3-week postoperative responses, falling again to 2/5 in 6 week 
postoperative responses.  Sixty-one patients provided answers to question 25 
preoperatively, at 3 weeks and at 6 weeks.  Again, when these were 
compared, there was a significant difference between them (p=0.003, 
repeated measures ANOVA test).  Scores were higher at 3 weeks than 
preoperatively and were lower at 6 weeks than at 3 weeks (Tukey’s multiple 
comparison test, Table 7.3). 
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Comparison Mean first 
time point 
(out of 5) 
Mean second 
time point (out 
of 5) 
Difference 
between means 
(95% CIs) 
Preop vs 3 week 2.12 2.41 -0.29 
(-0.59, 0.00) 
Preop vs 6 week 2.12 2.03 0.09 
(-0.17, 0.35) 
3 week vs 6 week 2.41 2.03 0.38 
(0.15, 0.62) 
Table 7.3: Tukey’s multiple comparison test of responses to question 24 
of the DASH at different time points from patients who completed 
responses at all time points (n=68) 
 
7.4.3 Construct0validity0and0reliability0of0DASH0
Across the subgroup that also had angular deformity measured, the DASH 
showed weak correlation with TPED (Pearson’s r = 0.30, 95% CIs: 0.22 to 
0.38).  The QuickDASH also correlated weakly with TPED (Pearson’s r = 0.29, 
95% CIs: 0.21 to 0.37). 
For the 759 DASH questionnaires in the analysis of the DASH’s structural 
validity, 14 of the 30 were not normally distributed based on the kurtosis 
and/or skewness of their distributions.  Therefore, logarithmic transformation 
was performed.  After logarithmic transformation, 28 of the 30 DASH items 
had normal distributions. The hypothesis that the correlation matrix of the 
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DASH items is an identity matrix, with no correlation between variables at all, 
is investigated in Bartlett’s test of sphericity (see Table 7.1).  This was highly 
statistically significant, confirming that there was correlation between 
variables.  467/471 correlation coefficients between log transformed DASH 
items were over 0.3.  Some correlation between the items is required for EFA, 
as it studies their inter-relationships.  The Kaiser-Meyer-Olkin measure of 
sampling adequacy (see Table 7.1) was 0.974, confirming the suitability of the 
data for factor analysis (Kaiser, 1974).  Two major factors were present based 
on all common tests for determining factor numbers (Figure 7.2, confirmed by 
parallel analysis) (Cattell, 1966, Horn, 1965, Patil et al., 2007); hence the 
DASH was not unidimensional. 
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Figure 7.2: Scree plot of exploratory factor analysis for log transformed 
DASH items 
In the scree plot, the line plateaus from the third point onwards, supporting the 
extraction of two factors. 
 
These factors explained 57.5% and 5.3% of variance respectively.  The 
results of the EFA are shown in Table 7.4.  The results are factor loadings, 
which are the correlation coefficients for each item in the questionnaire with 
the factor derived in the EFA.  Functional limitation items correlated well with 
Factor 1, whereas impairment and participation items generally correlated with 
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Factor 2, including pain-related items.  The EFA was also rerun using raw, 
untransformed data, and generated the same pattern of results. 
Cronbach’s alpha for the DASH was 0.975.  However its interpretation was 
limited by the finding of the DASH potentially not being unidimensional.  
Cronbach’s alpha for the QuickDASH was 0.933.  Both results were consistent 
with there being redundancy of items within the scales. 
 
  
University of Nottingham   Validity of PROMs 
 254 
Item 
number 
Item question Loading with 
factor 1 
Loading with 
factor 2 
12 Difficulty changing a light bulb overhead 0.86 -0.05 
14 Difficulty washing your back 0.84 -0.09 
7 Difficulty doing heavy household chores 0.84 0.05 
5 Difficulty pushing open a heavy door 0.82 -0.06 
13 Difficulty washing or blow drying hair 0.82 -0.03 
9 Difficulty making a bed 0.80 0.03 
16 Difficulty using a knife to cut food 0.80 0.01 
11 Difficulty carrying a heavy object (>10 lbs) 0.80 0.04 
8 Difficulty gardening 0.80 0.08 
6 Difficulty placing an object on a shelf above 
head 
0.78 -0.04 
17 Difficulty with recreational activities that require 
little effort 
0.78 -0.05 
4 Difficulty preparing a meal 0.77 0.07 
18 Difficulty with recreational activities in which 
force is taken through the limb 
0.73 0.13 
21 Difficulty with sexual activities 0.72 -0.11 
19 Difficulty with recreational activities in which 
the arm moves freely 
0.71 0.12 
3 Difficulty turning a key 0.69 0.03 
15 Difficulty putting on a pullover sweater 0.68 0.09 
20 Difficulty managing transportation needs 0.68 0.02 
10 Difficulty carrying a shopping bag/briefcase 0.67 0.15 
2 Difficulty writing 0.63 0.02 
1 Difficulty opening a tight or new jar 0.61 0.15 
22 To what extent has your problem interfered 
with normal social activities? 
0.45 0.37 
23 To what extent has your problem interfered 
with work or other daily activities? 
0.44 0.42 
University of Nottingham   Validity of PROMs 
 255 
24 Rate your arm, shoulder or hand pain -0.06 0.90 
25 Rate your arm, shoulder or hand pain when 
performing a specific activity 
-0.02 0.87 
28 Rate the stiffness in your arm, shoulder or 
hand 
0.08 0.72 
27 Rate the weakness in your arm, shoulder or 
hand 
0.17 0.69 
29 How much difficulty have you had sleeping 
because of pain in the limb? 
0.10 0.62 
26 Rate the tingling in the arm, shoulder or hand -0.04 0.59 
30 Is this true: I feel less capable, confident or 
useful because of the limb problem? 
0.29 0.51 
Table 7.4: Pattern matrix of exploratory factor analysis of log-
transformed DASH items, with two-factor solution and oblimin rotation. 
* Loadings assess the correlation between the item concerned and the latent 
factor extracted in the analysis.  They may range from -1 (perfect inverse 
correlation) through 0 (no correlation) to +1 (perfect correlation). 
N.B.  Large factor loadings (>0.3) are shown in bold. 
 
7.4.4 Relationship0between0the0DASH0and0QuickDASH0
Across the entire study, the QuickDASH was higher than the DASH indicating 
apparently worse upper limb function) (mean difference 1.6 (95%CIs: 1.3 – 
1.8), paired t test).  However the QuickDASH correlated very well with the 
DASH, Pearson’s r was 0.98 (95% CIs: 0.98 – 0.99), as shown in Figure 7.3. 
Linear regression analysis was performed with the Y-intercept constrained to 
y=0, as the QuickDASH must equal zero if the DASH equals zero.  Runs test 
confirmed that there was no significant deviation of the residuals from the 
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model in the linear regression analysis (p=0.228).  The slope for the 
relationship between the two was: 
QuickDASH = 1.054 x DASH 
Similar correlations were seen in separate preoperative, 3 week, 6 week, 1 
year and 5 year follow-up subgroup analyses (Table 7.5). 
 
 
Figure 7.3: Scatterplot of QuickDASH versus DASH (n=759). 
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TIME POINT MEAN DASH 
(95% CIs) 
MEAN 
QuickDASH 
(95% CIs) 
PEARSON’s r 
(95% CIs) 
Preoperative 27 
(23-31) 
28 
(24-32) 
0.98 (0.97-0.99) 
3 week 
postoperative 
37 
(33-42) 
41 
(36-46) 
0.97 (0.95-0.98) 
6 week 
postoperative 
22 
(18-26) 
24 
(20-28) 
0.98 (0.97-0.99) 
1 year postoperative 11 
(9-13) 
12 
(10-14) 
0.99 (0.98-0.99) 
5 years 
postoperative 
11 
(9-13) 
12 
(10-15) 
0.97 (0.96-0.98) 
Table 7.5: Mean DASH and QuickDASH scores and their correlations, by 
time point 
 
The 95% limits of agreement between the QuickDASH and the DASH were -
5.8 to +8.9 (Figure 7.4).  As relatively few differences were outside the 95% 
limits of agreement for mean scores under 30 (those with good upper limb 
function), further Bland-Altman analyses were performed for scores 
considered asymptomatic (<15/100), and scores considered symptomatic 
(>15/100) by the DASH’s creators (Kennedy et al., 2011).  When the mean of 
the DASH and QuickDASH for a patient was 15 or less (asymptomatic upper 
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limb function), the 95% limits of agreement were -3.3 to +5.5 (see Figure 7.5), 
and when the mean was over 15 (symptomatic upper limb function), they were 
-7.8 to +12.3 (see Figure 7.6). 
 
 
Figure 7.4: Bland-Altman plot of total sample, with 95% limits of 
agreement shown as dotted lines 
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Figure 7.5: Bland-Altman plot of sub group of sample for which the mean 
of the DASH and the QuickDASH was <15, with 95% limits of agreement 
shown as dotted lines 
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Figure 7.6: Bland-Altman plot of sub group of sample for which the mean 
of the DASH and the QuickDASH was >15, with 95% limits of agreement 
shown as dotted lines 
 
7.4.5 Construct0validity0of0URAM0
 
For the 327 matched DASH and URAMs, 4/9 URAM items and 17/30 DASH 
items were not normally distributed initially, based on the kurtosis or skewness 
of their distributions.  After logarithmic transformation was performed, all 
URAM items and 23/30 DASH items were normally distributed. 
Bartlett’s test of sphericity was highly statistically significant, confirming 
correlation between the 39 log-transformed URAM and DASH items.  The 
Kaiser-Meyer-Olkin measure of sampling adequacy was 0.957. 
Difference QuickDASH-DASH vs. average,
mean>15 (n=303)
20 40 60 80 100
-20
-10
0
10
20
AverageD
iff
er
en
ce
University of Nottingham   Validity of PROMs 
 261 
Overall, five factors had Eigenvalues above 1 (one of the three rules 
employed to determine the number of factors to extract).  However, on 
examination of the scree plot (Figure 7.7), the curve plateaus markedly after 
the first three of these factors.  This was confirmed by parallel analysis, in 
which the randomly generated theoretical parallel analysis Eigenvalue for 
Factor 4 was 1.52, which was larger than the actual Eigenvalue for the 
equivalent Factor 4 in the EFA (which was 1.20).  Similarly, the theoretical 
parallel analysis Eigenvalue for Factor 5 was 1.47, which was larger than the 
Factor 5 Eigenvalue in the EFA (which was 1.06).  Therefore, for Factor 4 and 
5, randomly generated Eigenvalues were larger than the actual Eigenvalues, 
supporting the conclusion that the Eigenvalues for Factors 4 and 5 being 
above 1 was due to chance.  Therefore, only three factors were extracted. 
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Figure 7.7: Scree plot of exploratory factor analysis for log transformed 
DASH items 
In the scree plot, the line plateaus from the fourth point onwards, supporting 
the extraction of three factors 
 
The extracted factors accounted for 48.7%, 5.60% and 3.36% of the total 
variance respectively.  The results of the EFA are shown in Table 7.6 
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Item Content of item Loading* 
with Factor 
1 
Loading 
with Factor 
2 
Loading 
with Factor 
3 
URAM 1 Wash self with a flannel, keeping hand 
flat 
-0.006 0.811 -0.011 
URAM 2 Wash face 0.079 0.764 0.003 
URAM 3 Hold bottle in one hand 0.305 0.473 0.137 
URAM 4 Shake someone’s hand 0.134 0.694 -0.091 
URAM 5 Stroke something or caress someone 0.072 0.833 -0.085 
URAM 6 Clap your hands -0.021 0.824 0.015 
URAM 7 Spread out your fingers -0.055 0.744 0.157 
URAM 8 Lean on hand -0.091 0.747 0.272 
URAM 9 Pick up small objects with thumb and 
index finger 
0.390 0.106 0.179 
DASH 1 Difficulty opening a tight or new jar 0.474 0.020 0.229 
DASH 2 Difficulty writing 0.551 0.046 0.055 
DASH 3 Difficulty turning a key 0.699 -0.045 0.054 
DASH 4 Difficulty preparing a meal 0.769 -0.069 0.068 
DASH 5 Difficulty pushing open a heavy door 0.765 0.076 -0.126 
DASH 6 Difficulty placing an object on a shelf 
above head 
0.759 0.012 -0.032 
DASH 7 Difficulty doing heavy household chores 0.835 0.043 -0.049 
DASH 8 Difficulty gardening 0.800 0.085 -0.032 
DASH 9 Difficulty making a bed 0.803 0.067 -0.054 
DASH 10 Difficulty carrying a shopping 
bag/briefcase 
0.712 0.040 0.079 
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DASH 11 Difficulty carrying a heavy object (>10 
lbs) 
0.769 0.034 0.030 
DASH 12 Difficulty changing a light bulb overhead 0.842 -0.037 -0.012 
DASH 13 Difficulty washing or blow drying hair 0.846 0.005 -0.088 
DASH 14 Difficulty washing your back 0.675 0.168 -0.135 
DASH 15 Difficulty putting on a pullover sweater 0.747 -0.049 0.024 
DASH 16 Difficulty using a knife to cut food 0.800 0.014 -0.014 
DASH 17 Difficulty with recreational activities that 
require little effort 
0.667 0.040 0.024 
DASH 18 Difficulty with recreational activities in 
which force is taken through the limb 
0.607 0.003 0.228 
DASH 19 Difficulty with recreational activities in 
which the arm moves freely 
0.566 0.004 0.240 
DASH 20 Difficulty managing transportation needs 0.682 -0.067 0.070 
DASH 21 Difficulty with sexual activities 0.394 -0.027 0.136 
DASH 22 To what extent has your problem 
interfered with normal social activities? 
0.375 0.145 0.301 
DASH 23 To what extent has your problem 
interfered with work or other daily 
activities? 
0.464 0.119 0.308 
DASH 24 Rate your arm, shoulder or hand pain 0.030 0.073 0.789 
DASH 25 Rate your arm, shoulder or hand pain 
when performing a specific activity 
0.022 0.135 0.776 
DASH 26 Rate the tingling in the arm, shoulder or 
hand 
0.066 0.057 0.420 
DASH 27 Rate the weakness in your arm, shoulder 
or hand 
0.213 0.000 0.642 
DASH 28 Rate the stiffness in your arm, shoulder 0.091 0.149 0.621 
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or hand 
DASH 29 How much difficulty have you had 
sleeping because of pain in the limb? 
0.323 -0.063 0.413 
DASH 30 Is this true: I feel less capable, confident 
or useful because of the limb problem? 
0.125 0.304 0.494 
Table 7.6: Pattern matrix of exploratory factor analysis of log-
transformed DASH and URAM items, with three-factor solution and 
oblimin rotation 
 
* Loadings assess the correlation between the item concerned and the latent 
factor extracted in the analysis.  They may range from -1 (perfect inverse 
correlation) through 0 (no correlation) to +1 (perfect correlation). 
N.B.  Large factor loadings (>0.3) are shown in bold. 
 
DASH items loaded on Factor 1 and Factor 3, in a similar pattern to that 
observed in the earlier EFA of DASH items alone.  Eight of the nine URAM 
items loaded on a distinct factor (Factor 2).  Item 9 within the URAM (difficulty 
picking up small objects with the thumb and index finger loaded separately 
from the other URAM items, suggesting that the URAM may not be 
unidimensional either. 
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7.5 Discussion0
7.5.1 Present0study0findings0
This study assessed the content and construct validity and reliability of the 
DASH and the URAM in Dupuytren’s disease, and the QuickDASH’s criterion 
validity against the DASH. 
PROM items covering pain have been previously criticised in Dupuytren’s 
disease, but our patients did report preoperative upper limb pain.  This may 
have been due to other comorbid upper limb conditions rather than 
Dupuytren’s disease, but even still, this would affect the overall function of 
their upper limb.  Furthermore, pain levels rose early after surgery, and then 
decreased after surgery.  This is important to capture, as postoperative pain 
may differ between treatments, and affect early recovery to different extents.  
These data support the relevance of assessing pain when treating 
Dupuytren’s disease, and therefore suggest that tools that do not measure 
pain are not comprehensive. 
The DASH was not unidimensional, with function items loading better with one 
construct, and patient perception items loading with another.  Some other 
PROMs are multidimensional; they assess distinct constructs, with the 
generation of separate subscale scores.  Examples include the Michigan 
Hand Questionnaire, which has distinct subscales for function, pain, work and 
other constructs (Chung et al., 1998).  However, the DASH is designed to 
generate a single summary score.  As a result, its items were not necessarily 
selected to measure specific distinct constructs.  As a result, the different 
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constructs identified here may not be easily interpreted.  Although the items 
loading with factor 1 appear to be related in that they are function items, 
alternatively, they may load similarly as they might also all relate to global 
upper limb, including the shoulder.  In contrast, whilst the items that load with 
factor 2 are related as patient perception items, they might also be answered 
specifically in terms of the patient’s experience of Dupuytren’s disease, rather 
than for the global upper limb, as is the case for items such as ‘doing yard 
work’.  These data suggest that the DASH’s single summary score may not be 
appropriate in Dupuytren’s disease.  Although factor 2 accounted for much 
less variance than factor 1 in this study, it was still statistically significant 
based on three separate assessments (scree plot, Eigenvalue and parallel 
analysis).  Nevertheless, as it accounts for such little variance, this finding 
does not completely preclude the use of the DASH and its summary score in 
Dupuytren’s disease.  However, its selection as an endpoint for future studies 
should be carefully considered. 
Interpreting whether agreement is adequate or not is a clinical decision (Bland 
and Altman, 1986).  Given that the minimum detectable change at the 95% 
confidence level (MDC95) for the DASH is around 13, and that the MDC95 of 
the QuickDASH is around 16 (Kennedy et al., 2011), then the 95% limits of 
agreement seen here are of similar magnitude to both tools’ abilities to detect 
true change, though these MDCs have not been specifically confirmed in 
Dupuytren’s disease.  Therefore, it is likely that the level of agreement seen 
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here would support the use of the QuickDASH as an alternative to the DASH if 
either were considered appropriate in Dupuytren’s disease. 
Our large sample size allowed meaningful subgroup analysis, which 
demonstrated that close correlation between the two tools was seen at 
preoperative, early postoperative, and late outcome time points. 
The second EFA performed demonstrates that the DASH and the URAM may 
reflect different underlying constructs.  EFA demonstrates the statistical 
relationship between different items in scales, but cannot explain what the 
factors extracted actually represent.  It is possible that the activity limitation-
based items of the DASH might reflect shoulder impairment, that the URAM 
items might reflect impairment from loss of extension, and that the symptom-
related DASH items might reflect more generalised hand function impairment.  
Even if this were the case, it is possible that the URAM is still not ideal in 
terms of face validity.  As discussed already, pain appears to be a relevant 
symptom in the early postoperative phase, and the URAM may not be 
comprehensive enough to reflect this adequately.  It may be biased towards 
loss of extension in isolation.  At gross examination, the first eight items of the 
URAM appear to reflect tasks affected by loss of finger extension.  In contrast, 
item nine (difficulty picking up small objects with the thumb and index finger) 
does not.  Instead, it appears to represent more generalised fine control of 
hand function.  In the developers’ own EFA, the URAM was reported as being 
unidimensional, though the original data is not provided (Beaudreuil et al., 
2011).  However, this might be an artefact of the analysis itself, which has 
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been clarified in the present study.  In factor analysis, it is recommended that 
items are selected such that several items load each factor that is to be 
modelled (Floyd and Widaman, 1995).  Failure to do this may weaken the 
model.  In the developers’ EFA, if only item nine loaded on a distinct factor, 
then that factor may not have been adequately modelled.  As discussed in the 
methods, several different statistical methods can be employed in ‘factor 
analysis’.  These include principal component analysis as well as the principal 
axis factoring method employed here.  Principal component analysis has 
advantages and may be mathematically simpler (Pallant, 2010).  However, if 
only few items load on a factor, as is the case here, and was even more so in 
the developers’ EFA (Beaudreuil et al., 2011), the principal component 
analysis may lead to spurious results (Floyd and Widaman, 1995).  For this 
reason, principal axis factoring was used in the present project.  The URAM’s 
developers did not specify which technique was used in their original 
validation study (Beaudreuil et al., 2011). 
However, the results of the EFA might also relate to logistical considerations.  
In particular, the DASH and URAM questionnaires were administered in their 
original forms.  The DASH’s layout was produced by the developer, and 
maintaining the original layout is a condition of its licence for use (Kennedy et 
al., 2011).  In contrast, the URAM questionnaire used was that in the original 
paper (Beaudreuil et al., 2011).  As a result, the two questionnaires had 
different styles, layouts, font types and font sizes.  These variables may have 
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influenced the patient’s completion of the different questionnaires, leading to 
them apparently loading separately. 
Even if this were the case, it may not be important when considered 
pragmatically.  Standard layouts of the two tools were used here, and it would 
be reasonable to expect the two tools to still reflect the same single construct 
in the present study.  Furthermore, the fact that the one URAM item whose 
face validity suggested that it may not reflect the same construct as the other 
items (URAM item nine appears more in keeping with DASH task items than 
with the other URAM items), did load on the same factor as DASH task items 
suggests that the loading pattern is not due to layout and style of 
questionnaires, but instead due to the performance of the items studied. 
7.5.2 Limitations0
There are limitations to this study.  The sample included some patients who 
provided more than one measurement.  In such circumstances, specific 
approaches to assessing agreement have been proposed (Bland and Altman, 
2007).  However, multiple measurements over time (preoperative, 3 weeks 
postop, 6 weeks postop and 1 year) do not constitute replicate measurements.  
They are best considered as independent assessments, as the patient’s 
functional status is expected to be different at each time point, due to 
treatment of disease and progressive recovery. 
Logarithmic transformation was used in an attempt to normalise the positive 
skew and kurtosis encountered.  Suggested methods for handling skewed 
data vary (Ferguson and Cox, 1993, Floyd and Widaman, 1995).  However, 
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similar results were obtained when the EFAs were run using raw, 
untransformed data. 
Here, as in previous studies (Gummesson et al., 2006, Niekel et al., 2009), the 
QuickDASH and DASH were calculated from a single set of responses, on the 
DASH questionnaire’s proforma.  Intra-observer reproducibility, or test-retest 
reliability, is not observed when using a single set of responses.  However, the 
methodology was the most appropriate to fulfil the specific objective of this 
study.  The objective of this aspect of the study was to determine whether the 
QuickDASH formula demonstrates acceptable criterion validity with the longer 
DASH formula for a given set of responses, in keeping with the COSMIN 
checklist (Mokkink et al., 2010).   
Test-retest reliability has been shown to be consistently high in previous 
studies, as summarised in the user manual for the DASH and the QuickDASH 
(Kennedy et al., 2011).  The present study aims to establish whether for a 
given set of responses, the QuickDASH formula delivers the same summary 
score as the DASH formula.  If patients had completed the DASH and then the 
QuickDASH, then there would have been additional error due to intra-observer 
reproducibility.  This would have affected the ability to answer the study 
question. 
7.5.3 Relationship0to0existing0literature0
Although the DASH is the most commonly used Patient Reported Outcome 
Measure (PROM) tool in Dupuytren’s research (Ball et al., 2013), Dupuytren’s-
specific outcome measures are available, for example the URAM scale 
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(Beaudreuil et al., 2011) and the Southampton Dupuytren’s score (Mohan et 
al., 2014).  Exploratory factor analysis was incorporated into the design 
process of the URAM to ensure that it was unidimensional (Beaudreuil et al., 
2011).  Preoperative Dupuytren’s disease is considered painless, and pain is 
not assessed in the URAM (Beaudreuil et al., 2011).  However, pain has been 
described as a symptom, particularly related to Dupuytren’s nodules (Hueston, 
1963, Rodrigues et al., 2014, von Campe et al., 2012).  These data 
demonstrated that pain was relevant, in that it was present preoperatively, 
increased at 3 weeks postop compared to baseline, returned to the 
preoperative level by 6 weeks postop, but did not disappear completely.  
Omitting pain from a tool for use before and after treatment for Dupuytren’s 
disease may mean that the scale is not comprehensive. 
The QuickDASH was produced from the DASH using item reduction 
methodology (Beaton et al., 2005).  The two showed good correlation in mixed 
cohorts of hand surgery patients (Gummesson et al., 2006, Niekel et al., 
2009).  However, correlation is not appropriate for studying agreement (Bland 
and Altman, 1986, Bland and Altman, 1990, Schuck, 2004).  No study 
assessing agreement between the DASH and the QuickDASH in Dupuytren’s 
disease specifically, with the technique recommended by Bland and Altman 
(Bland and Altman, 1990), could be identified.  Studying the strength of 
relationship between the two correlated measures, as has been done 
elsewhere, may conceal absolute differences in values between them.  Such 
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differences are unmasked when agreement is studied using other techniques, 
as has been done here (Bland and Altman, 1986, Bland and Altman, 1990). 
Poor correlation between angular deformity and the DASH has been 
previously reported in Dupuytren’s disease (Degreef et al., 2009, Engstrand et 
al., 2009, Jerosch-Herold et al., 2011, Zyluk and Jagielski, 2007).  This has 
led to the suggestion that the DASH may not be valid for use in Dupuytren’s 
disease (Packham, 2011), though the basis for this claim was a series of only 
seven patient interviews (Pratt and Byrne, 2009).  However, such conclusions 
are dependent on angular deformity being a ‘gold standard’ for assessing 
Dupuytren’s disease, allowing the assessment of criterion validity.  This is not 
appropriate, as no true ‘gold standard’ for hand function can exist (Mokkink et 
al., 2010). 
Concerns about the absence of the expected unidimensionality for the DASH 
have been previously reported.  A recent study investigated the structural 
validity of the DASH as the secondary analysis of a randomised controlled trial 
of splinting in Dupuytren’s disease (Forget et al., 2014).  In that article, EFA 
had been performed on preoperative and early postoperative DASH scores 
from 153 fasciectomies and dermofasciectomies randomised to receiving 
postoperative splinting or no postoperative splinting.  In contrast, the present 
study evaluated preoperative, early postoperative and late postoperative 
outcomes of over 500 procedures, including needle aponeurotomies in 
addition to fasciectomies and dermofasciectomies.  All procedures in the 
present study were performed under routine clinical conditions.  Forget and 
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colleagues demonstrated that the DASH was not unidimensional in their EFA, 
though they proceeded to then perform Rasch analysis validation, which 
requires unidimensionality.  The DASH did not perform well in Rasch analysis 
either (Forget et al., 2014).  A range of items in the DASH did not load well 
with the equivalent Factor 1 in Forget and colleagues’ EFA, which are difficult 
to interpret with clinical logic.  In contrast, there was a clear division in our 
factor analysis between task items and patient symptom items.  One other 
study reported a heterogeneous cohort comprising a range of upper limb 
conditions (mainly affecting the shoulder) and only a small minority with 
Dupuytren’s disease (Franchignoni et al., 2010).  In that study, the DASH 
items loaded on three distinct factors in EFA, and this was confirmed using 
other techniques classified as confirmatory factor analysis.  Franchignoni and 
colleagues reported similar results to the present study, with patient 
perception items 22 to 30 loading separately from the main factor.  However, 
Franchignoni and colleagues found that of the other items, those relating to 
manual function loaded distinctly from those assessing shoulder functions. 
In the present study and in both of the previous studies, the further factors 
extracted accounted for relatively small proportions of the variance.  This 
might mean that besides Factor 1 in all EFAs, the other factors are relatively 
insignificant.  Indeed, this was the explanation given for proceeding to Rasch 
analysis in one study (Forget et al., 2014).  However, the present study is now 
the third study to consistently demonstrate a lack of unidimensionality for the 
DASH.  The URAM’s apparent lack of unidimensionality when modelled along 
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with DASH items in the present study is a novel finding, and conflicts with the 
developers’ original EFA (Beaudreuil et al., 2011).  However, the present 
study findings fit with face validity examination of the URAM items.  This 
should be further investigated. 
This supports the possibility that Factor 1 in both of the EFAs in the present 
study is not a reliable indicator of hand function in relation to Dupuytren’s 
disease.  Our data further question the structural validity of the DASH in 
Dupuytren’s disease, and by association, the QuickDASH.  Due to this, it was 
not believed necessary or appropriate to subject the DASH to further analyses 
such as Rasch analysis.  Instead, other PROMs that also assess pain may be 
more appropriate, such as the MHQ or the PEM. 
 
7.5.4 Conclusions0of0study0of0validity0
This study supports the assessment of pain when studying recovery from 
Dupuytren’s surgery.  As a result, the URAM may not be comprehensive for 
use after treatment.  The QuickDASH show acceptable agreement with the full 
DASH.  However, neither the current versions of the DASH nor the URAM 
may be structurally valid for use in Dupuytren’s disease as they were both not 
unidimensional, and further study of existing PROMs for use in Dupuytren’s 
disease is needed. 
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SUMMARY 
The chapter demonstrates that the DASH is not structurally valid when used in 
Dupuytren’s disease, in keeping with other studies.  In particular, all of the 
items that comprise the DASH do not assess the same latent constructs, so it 
is not appropriate that they all contribute to a single summary score.  As 
hypothesised, the QuickDASH exhibited acceptable agreement with the DASH 
and so is also likely to be unsuitable for future use. 
The URAM’s structural validity was demonstrated as part of its development 
(Beaudreuil et al., 2011).  However, when the factor analysis model was 
expanded here, the final item in the URAM reflected a different construct from 
the others, which could be explained in terms of the URAM’s face validity.  
This illustrates one of the limitations of studying validity, but is likely to be 
relevant when the findings are considered logically. 
The URAM does not measure pain, yet here pain is identified as a relevant 
domain to consider during the early recovery from treatment for Dupuytren’s 
disease. 
As a result, in order to provide comprehensive measurement, the URAM 
needs further study and it is hypothesised from these novel findings that with 
expansion, a modified URAM might include to subscales: one that reflects 
symptoms related to the contracture, and one that reflects sequelae and 
complications of treatment like pain and stiffness. 
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Neither the DASH nor the URAM are ideal for use in their existing forms.  
However, based on the above interpretation and its more contemporary 
design, further work based using the existing URAM scale as the starting point 
is indicated. 
As well as the validity of outcome measures, their interpretability may also 
affect their suitability for use.  Assessments of interpretability for specific 
outcome measures are also necessary to interpret data from previous studies.  
Given that both the DASH and the URAM have been used previously (Ball et 
al., 2013), assessing their interpretability is a logical next step.  The following 
chapters comprise a systematic review of interpretability studies in hand 
surgery to identify existing interpretability data followed by analysis cohort 
study data for the DASH and the URAM. 
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8 Systematic Review of Interpretability of Outcome 
Measures for Use in Dupuytren’s Disease 
8.1 Preface0
An appropriate measure for future studies of treatments in Dupuytren’s 
disease should be appropriately responsive, but should also have 
demonstrated interpretability.  Not only is this an important parameter of the 
outcome measure, alongside validity and responsiveness, but also evidence 
of what constitutes a clinically meaningful change, or minimal important 
change (MIC), is necessary to design a suitably powered randomised 
controlled trial.  However, as a situational metric, it may vary for different 
diagnoses, interventions and follow up periods, and can be calculated in 
distinct ways. 
The previous chapter demonstrated that different outcome measures have 
been used in trials of the treatment of Dupuytren’s disease.  However, 
interpreting the methodological quality of these studies and their findings 
requires evidence of the interpretability of the measures used.  As a result, 
interpretability data is of importance in clinical guideline development as well. 
This chapter will review studies of interpretability for outcome measures that 
could be used to investigate treatments in Dupuytren’s disease, and identify 
targets for future research. 
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8.2 Introduction0
The change in an outcome measure after treatment can be statistically 
significant without being large enough to be considered worthwhile by 
patients.  Indeed statistical significance following treatment is influenced by 
variables like the sample size of the study (Dawson et al., 2008).  Therefore, 
the interpretation of clinical data, in either research or clinical practice, is 
critical. 
8.2.1 Terminology0
The minimum detectable change (MDC), or smallest detectable change 
(SDC), is the smallest change that can be reliably detected by an outcome 
measure.  Whilst the MDC describes the responsiveness of an outcome 
measure, it may not be a clinically important change.  Instead, what 
constitutes a change in a measure that is relevant to a patient should be 
appreciated (de Vet et al., 2006).  The smallest change in an outcome 
measure that is clinically meaningful, and not simply statistically significant, 
has been referred to as the ‘minimal clinically important difference’ (MCID) or 
‘minimal clinically important change’ (MCIC) (Copay et al., 2007).  ‘Difference’ 
is used to describe the inter-individual difference that would be important (i.e. 
the difference between a patient who has undergone successful treatment 
compared to a patient who has not experienced benefit), whereas ‘change’ 
describes an important pre-treatment to post-treatment change for an 
individual (i.e. the smallest change that one individual would perceive as 
beneficial).  As MCIDs and MCICs are patient-centred (Revicki et al., 2008), 
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the elimination of the first ‘C’ from MCIC, to ‘minimal important change, or 
MIC, has been proposed (Schunemann and Guyatt, 2005).  MICs describe a 
measure’s interpretability, which is distinct from other measures of 
responsiveness.  MICs for specific measures and for particular conditions can 
be used to inform power calculations during study design, and to ensure 
detection of clinically meaningful differences between treatments.  Thus, 
having appropriate MICs for the outcome measures being used is important 
for designing future studies of treatment of Dupuytren’s disease. 
8.2.2 MICs0may0be0contextRspecific0
MICs can be calculated for objective measures, such as angular deformity or 
grip strength, as well as for patient-reported outcome measures (PROMs) 
(Katz et al., 1994, Waljee and Chung, 2012, Witthaut et al., 2011).  However, 
as discussed, MICs may vary between conditions, patient groups, treatment 
types, outcome measures used, and length of time between treatment and 
outcome assessment (Ring, 2013).  Indeed comorbidities may even influence 
MICs, despite the same treatment and follow up for the same condition.  For 
example, MICs for carpal tunnel release have been shown to differ depending 
on whether or not a patient is diabetic (Ozer et al., 2013).  Therefore, the 
context in which an MIC was derived should be considered before it is used 
for other studies, and ideally MICs that have been calculated specifically for 
the circumstances concerned should be used.  MICs may be calculated by 
different methods; hence MICs are often reported as estimated ranges, rather 
than discrete values (Revicki et al., 2008). 
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8.2.3 Calculating0MICs0
Methods that can be used to determine MICs include anchor-based 
techniques and distributional analyses (Copay et al., 2007). 
8.2.3.1 Anchor,based2methods2
These use an external criterion, which is a separate measure, to separate 
those who are ‘meaningfully better’ from those who are not.  A common 
external criterion is the Global Rating of Change scale (GRC), which 
comprises a 15-point scale that ranges from -7 (‘worse’) to +7 (‘better’) 
(Jaeschke et al., 1989).  Patients complete the GRC in addition to the 
outcome measure being studied.  ‘Meaningful improvement’ is defined as +4 
to +7 on the GRC scale, and ‘stable’ as -3 to +3, based on its original use 
(Jaeschke et al., 1989).  As a retrospective anchor, patients complete the 
GRC after treatment, and must recall whether they have improved from 
baseline.  Prospective anchors also exist.  In such cases, the anchor is 
completed before and after treatment, and the change in the anchor is the 
external criterion. 
Once outcomes have been sub-grouped into improved, stable and 
deteriorated, MICs can be estimated in different ways.  The average change in 
the improved group is sometimes considered to represent the MIC, and may 
be compared statistically to the stable group.  Alternatively, the difference 
between the change in the improved group and the change in the stable group 
may is reported as the MIC (Copay et al., 2007).  Alternatively, the ability of 
the outcome measure to separate ‘improved’ patients from ‘stable’ patients 
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can be assessed with a receiver operating characteristic (ROC) curve.  This 
considers the outcome measure as if it were a binary diagnostic test, and 
evaluates different cut offs on the quantitative scale for their ability to separate 
improved from stable outcomes.  Using a ROC curve analysis, the MIC is the 
change in the outcome measure that is most sensitive and specific for 
identifying meaningful improvement (defined using the anchor measure) 
(Deyo and Centor, 1986). 
The area under the curve (AUC) in ROC curve analysis varies from 0.5 to 1.0.  
When the AUC is 0.5, then measure being assessed has 50% sensitivity and 
50% specificity at all cut offs, i.e. it is no better at determining whether a 
patient has had a meaningful improvement than a random guess.  In contrast, 
when the AUC is 1.0, then the measure has 100% sensitivity and specificity at 
all cut-offs.  The generation of such AUC data as part of ROC curve analysis 
provides further meaningful information to guide the selection of outcome 
measures for future studies. 
An example of the anchor-based method is the calculation of the MIC for the 
treatment of shoulder pain with physiotherapy, as assessed by the shortened 
Disabilities of the Arm, Shoulder and Hand (QuickDASH) PROM (Mintken et 
al., 2009).  Patients completed the QuickDASH before and 2-4 weeks after 
treatment.  They also completed the GRC at follow up.  Patients were grouped 
according to their GRC score into those who were ‘stable’ (GRC of -3 to +3) 
and those who were ‘better’ (GRC of +4 or more).  None rated the GRC worse 
than -3.  A ROC curve was generated to study the ability of the QuickDASH to 
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separate ‘stable’ outcomes from ‘better’ outcomes, and the MIC was 
estimated to correspond to an improvement of 8 points (out of the 100 points 
in the QuickDASH summary score scale), as this corresponded to point at the 
upper left hand corner of the curve, which represents the best combination of 
sensitivity and specificity at identifying meaningful change. 
8.2.3.2 Distributional2analysis2methods2
Distributional analyses relate the change in the score of an outcome measure 
to a parameter of its variability, to generate assessments that are used as the 
MIC, for example, the effect size (ES), standard error of the mean (SEM), or 
half of its standard deviation (SD) (Copay et al., 2007).  As a result, they use 
properties derived from the outcome measure’s distribution to estimate the 
MIC.  Each of the above metrics has been considered to represent the MIC 
(Copay et al., 2007).  To do so, patients only complete the study outcome 
measure, and these ‘MIC’ variables are then calculated without the need for 
any other data. 
An example of the use of distributional analyses is the estimation of the MIC 
for physiotherapy as a treatment for soft tissue shoulder disorders, assessed 
with the DASH PROM, at 12 weeks or at the time of discharge from therapy 
(Beaton et al., 2011).  Several distributional analyses were used in this 
estimation, including 0.2 SD, 0.5 SD and the SEM for their dataset.  The use 
of several different analyses resulted in an estimated range for the MIC DASH 
of between 3.9 and 15 points (the DASH summary score range is between 0 
and 100).  This approach may have limitations.  Different treatments for 
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different conditions will have different failure rates, and this rigid approach 
does not account for this. 
8.3 Aims0and0objectives0of0the0present0review0
This aim of this chapter was to identify relevant MIC values for the treatment 
of Dupuytren’s disease.  The objectives were to identify MICs for surgery for 
Dupuytren’s disease (or for other elective hand surgery applications that could 
be extrapolated to Dupuytren’s disease) for commonly used outcome 
measures, in particular the Disabilities of the Arm, Shoulder and Hand (DASH) 
(which is the most popular PROM in Dupuytren’s disease research (Ball et al., 
2013)), the Unité Rhumatologique des Affections de la Main (URAM), which is 
the first Dupuytren’s disease-specific PROM to have been developed 
(Beaudreuil et al., 2011), and loss of extension.  The methodologies used to 
calculate such MICs would also be appraised. 
8.4 Methods0
The methodological design was based on the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement (Moher et al., 
2009). 
8.4.1 Search0strategy0
A search strategy was developed to identify articles describing the calculation 
of the MIC in Dupuytren’s disease, or in other aspects of elective hand or wrist 
surgery.  As some measures (for example DASH PROM (Hudak et al., 1996)) 
can be used throughout the upper limb, the search strategy also included 
upper limb studies.  The AMED (Allied and Complementary Medicine) (1985 
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to January 2014), Ovid MEDLINE (1946 to January Week 3 2014), and 
Embase Classic + Embase (1947 to 2014 Week 04) databases were searched 
in parallel on 29th January 2014.  No search limitations were used.  The 
search strategy identified studies with any of the following in their titles or 
abstracts: ‘minimal important change’, ‘clinically important difference’, 
‘clinically important change’, ‘minimal important difference’, or ‘mcid’.  The 
results were then combined using the AND Boolean operator so that the 
results only included articles that had one or more of the following terms in 
their titles or abstracts: ‘hand’, ‘finger’, ‘wrist’, or ‘upper limb’. 
The Online First section of the Journal of Hand Surgery (European Volume) 
website was also manually searched for the period of November 2013 – May 
2014.  All clinical articles were reviewed and their reference lists and citing 
articles screened to identify further studies reporting relevant MICs. 
8.4.2 Article0Selection0
After de-duplication of the electronic search results, the candidate applied a 
stepwise selection strategy.  Only articles describing MICs of relevance to the 
elective treatment of Dupuytren’s disease or of outcome measures that could 
be used in Dupuytren’s disease were included.  For example, a study of the 
MIC for the DASH would be included even if the patient population involved 
had shoulder pathology, as this MIC might be extrapolated to the use of the 
DASH in Dupuytren’s disease.  In contrast, a study of a shoulder-specific 
measure, such as the Shoulder Pain and Disability Index (SPADI), would be 
excluded, as this outcome measure cannot be used in Dupuytren’s disease.  
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Similarly, studies of acute trauma were excluded, as preoperative state cannot 
be measured as the baseline for describing change, unlike chronic conditions 
that are treated electively, such as Dupuytren’s disease.  Studies assessing 
multiple anatomical sites in addition to the upper limb were excluded, for 
example cerebrovascular accident rehabilitation studies, as they tended to 
employ outcome measures pertinent to neurology rather than hand surgery 
(Bindra et al., 2003).  The latter selection stages involved screening full text 
articles.  Reference lists from the full text papers that were screened, and 
articles citing them, were screened to identify further studies for inclusion.  A 
second author verified the classification of search results. 
8.4.3 Data0Extraction0
Data describing the conditions and treatments, outcome measures, follow up 
time point(s) studied, MICs obtained, and the methodologies used to generate 
the MIC were extracted for analysis. 
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8.5 Results0
 
Figure 8.1: PRISMA-style flow diagram of article selection 
Figure 1: PRISMA-style Flowchart 
 
 
301 records 137 duplicates excluded 
164 records proceeded to 
abstract screening 
106 excluded for not reporting management 
of upper limb conditions 
58 records 9 excluded for not describing original data 
relevant to the MID or equivalent 
20 excluded as did not calculate MID (e.g. 
used MID calculated elsewhere), or 
described outcome measures that cannot be 
used in hand/wrist surgery (e.g. shoulder-
specific PROMs), or trauma 
49 full text articles screened 
29 full text articles  
References from articles reviewed to identify 
other sources of MID estimations  
29 articles included 
283 records from electronic 
search 
18 further articles identified from reference 
and hand searching 
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8.5.1 Search0results0
The electronic search retrieved 283 records.  A further 18 articles were later 
identified by the searches of reference lists.  The selection process retained 
29 articles that were analysed (Figure 8.1) (Adams et al., 2012, Amirfeyz et 
al., 2009, Atroshi et al., 2011, Beaton et al., 2001, Beaton et al., 2011, 
Beaudreuil et al., 2011, Bessette et al., 1998, Dawson et al., 2008, 
Franchignoni et al., 2014, Gummesson et al., 2003, Katz et al., 1994, Kim and 
Jeon, 2013, Kim and Park, 2013, Levine et al., 1993, London et al., 2014, 
Malay and Chung, 2013, Mintken et al., 2009, Ozer et al., 2013, Ozyurekoglu 
et al., 2006, Polson et al., 2010, Poltawski and Watson, 2011, Schmitt and Di 
Fabio, 2004, Shauver and Chung, 2009, Sorensen et al., 2013, Spies-Dorgelo 
et al., 2006, Tashjian et al., 2009, van der Giesen et al., 2008, Waljee and 
Chung, 2012, Witthaut et al., 2011).  During the manual search, one other MIC 
was identified in a reference from a review article (Carswell et al., 2004).  This 
was an MIC of 2 points for The Canadian Occupational Performance Measure 
(COPM), but was in a textbook rather than a peer-reviewed journal, therefore 
it was not included in the analysis. 
8.5.2 Article0characteristics0
Twenty-eight of the 29 were full-length articles, and the other was a published 
conference proceeding abstract.  Twenty-six were prospective cohort studies, 
two were secondary analyses from prospective randomised controlled trials, 
and the remaining article was a retrospective study.  Most were published 
after 2000, with the majority published in the last 5 years (2009-2014). 
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Terminology varied, with 17 of 29 articles using the term ‘MCID’, and two 
using ‘MIC’.  Two more used ‘minimal important change’, and two used 
‘clinically important difference’.  The remaining six used no specific 
terminology to describe their reporting of an analysis consistent with an MIC.  
These articles were typically only identified from screening lists of references 
from other papers and from full article screening by the review group, and 
provided narrative descriptions, for example: “We analyzed all measures of 
objective hand function variables as continuous variables to determine the cut-
off point that corresponds with the presence or absence of patient satisfaction, 
and created ROC curves for each variable against patient satisfaction scores” 
(Waljee and Chung, 2012). 
Several articles reported more than one MIC.  Articles with multiple MICs 
either studied several conditions, outcome measures, comorbidities, or follow 
up time points.  In total, there were 99 MICs in the 29 included articles (Table 
8.1). 
 
University of Nottingham    Systematic Review of Interpretability 
 290 
  
Condition Source Treatment(s) Outcome Measure Measure Score 
Scale 
Min         Max 
Assessment 
Time point (days) 
MIC Method 
used 
Carpal Tunnel Syndrome        
 Amirfeyz 2009 CTD CTQ (Kamath modification) 0 12 42 1.97 B 
 Kim & Jeon 2013 CTD CTQ (total) 1 5 90 0.92 A, B 
 Bessette 1998 CTD CTQ (unweighted modified) 1 5 180 0.74 A 
 Bessette 1998 CTD CTQ (weighted modified) 1 5 180 0.79 A 
         
 Amirfeyz 2009 CTD CTQ FSS 1 5 42 0.47 B 
 Kim & Jeon 2013 CTD CTQ FSS 1 5 90 0.74 A, B 
 Levine 1993 CTD CTQ FSS 1 5 425 1.16 C 
 Ozer 2013 CTD (in diabetics) CTQ FSS 1 5 90 1.95 B 
 Ozer 2013 CTD (in diabetics) CTQ FSS 1 5 180 2.05 B 
 Ozer 2013 CTD (in non-diabetics) CTQ FSS 1 5 90 1.25 B 
 Ozer 2013 CTD (in non-diabetics) CTQ FSS 1 5 180 1.45 B 
         
 Amirfeyz 2009 CTD CTQ SSS 1 5 42 0.16 B 
 Kim & Jeon 2013 CTD CTQ SSS 1 5 90 1.14 A, B 
 Levine 1993 CTD CTQ SSS 1 5 425 1.84 C 
 Ozer 2013 CTD (in diabetics) CTQ SSS 1 5 90 1.45 B 
 Ozer 2013 CTD (in diabetics) CTQ SSS 1 5 180 1.55 B 
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 Ozer 2013 CTD (in non diabetics) CTQ SSS 1 5 90 0.8 B 
 Ozer 2013 CTD (in non-diabetics) CTQ SSS 1 5 180 1.6 B 
         
 Amirfeyz 2009 CTD DASH 0 100 42 20.9 B 
 Bessette 1998 CTD PCS-12 0 100 180 4.76 A 
 Bessette 1998 CTD PCS-36 0 100 180 2.01 A 
 Bessette 1998 CTD quality of life rating 0 100 180 7.88 A 
 Bessette 1998 CTD SF-36 body pain subscale 0 100 180 8.73 A 
 Bessette 1998 CTD SF-36 physical functioning subscale 0 100 180 21.34 A 
         
 Shauver 2009 Limited Incision CTD MHQ function 0 100 270 13 B 
 Shauver 2009 Limited Incision CTD MHQ pain 0 100 270 23 B 
 Shauver 2009 Limited Incision CTD MHQ work 0 100 270 8 B 
         
 Atroshi 2011 Open CTD 6-item CTS symptom scale 1 5 105 0.9 A 
         
 Katz 1994 Open Vs Endoscopic CTD 2 point discrimination sensation n/a n/a 90 1.6mm C 
 Katz 1994 Open Vs Endoscopic CTD ADL score 0 20 90 3.8 C 
 Katz 1994 Open Vs Endoscopic CTD APB strength (MRC) 0 5 90 0.23 C 
 Katz 1994 Open Vs Endoscopic CTD CTQ FSS (modified) 0 24 90 4 C 
 Katz 1994 Open Vs Endoscopic CTD CTQ SSS (modified) 0 44 90 8.14 C 
 Katz 1994 Open Vs Endoscopic CTD grip strength n/a n/a 90 5.47 C 
 Katz 1994 Open Vs Endoscopic CTD pinch strength n/a n/a 90 1.66 C 
 Katz 1994 Open Vs Endoscopic CTD Semmes Weinstein sensation n/a n/a 90 0.3 C 
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 Ozyurekoglu 2006 Steroid Injection CTQ SSS 0 5 21 1.04 B, C 
         
Dupuytren's Disease        
 Witthaut 2011 Collagenase Vs Placebo range of motion n/a n/a 30 13.5o F 
 Beaudreuil 2011 Needle Aponeurotomy URAM 0 45 30 2.9 C 
         
         
Elbow Surgery        
 Dawson 2008 Unclear DASH 0 100 180 ≈10 B, C 
         
Idiopathic Ulnar Impaction         
 Kim & Park 2013 Ulnar Shortening Osteotomy DASH 0 100 365 13.8 B 
 Kim & Park 2013 Ulnar Shortening Osteotomy PRWE 0 100 365 17.3 B 
         
Lateral Epicondyle Tendinopathy       
 Poltawski 2011 Novel Adjunct To 
Physiotherapy 
Patient-rated tennis elbow evaluation 0 100 21 7 B 
 Poltawski 2011 Novel Adjunct To 
Physiotherapy 
Patient-rated tennis elbow evaluation 0 100 21 21 B 
         
Mixed          
 Schmitt 2004 Physiotherapy DASH 0 100 90 17.1 A 
 Schmitt 2004 Physiotherapy PCS-12 0 100 90 7.3 A 
 Schmitt 2004 Physiotherapy PRWE 0 100 90 24 A 
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 Adams 2012 Unclear DASH 0 100 14, 28 11 A 
 Beaton 2001 Unclear DASH 0 100 84 15-20 B 
 Adams 2012 Unclear PRWE 0 100 14, 28 14 A 
 Adams 2012 Unclear quickDASH 0 100 14, 28 16 A 
         
 Sorensen 2013 Various DASH 0 100 14 or 28 10 A 
 London 2014 Various MHQ ADL 0 100 28 or 84 10.1 A, B, D 
 London 2014 Various MHQ aesthetic 0 100 28 or 84 * N/A 
 London 2014 Various MHQ function 0 100 28 or 84 10.3 A, B, D 
 London 2014 Various MHQ overall 0 100 28 or 84 8.7 A, B, D 
 London 2014 Various MHQ pain 0 100 28 or 84 18.4 A, B, D 
 London 2014 Various MHQ satisfaction 0 100 28 or 84 33.0 A, B, D 
 London 2014 Various MHQ work 0 100 28 or 84 10.0 A, B, D 
 Sorensen 2013 Various PRWE 0 100 14 or 28 14 A 
 Sorensen 2013 Various quickDASH 0 100 14 or 28 14 A 
         
Mixed Hand And Wrist Problems        
 Spies-Dorgelo 2006 Unclear CTQ SSS 1 5 90 0.23 B 
 Spies-Dorgelo 2006 Unclear Dutch-AIMS2-HFF 0 10 90 0.31 B 
         
Orthopaedic Surgical        
 Gummesson 2003 Unclear DASH 0 100 180 10 A 
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Rheumatoid Arthritis Of Hand        
 Van Der Giesen 2008 Operative, Non Op, Both MHQ total 0 100 90 11.3 A 
         
 Waljee 2012 Silicone MCPJ Arthroplasty extension  lag n/a n/a 730 30o B 
 Waljee 2012 Silicone MCPJ Arthroplasty MCPJ arc of motion n/a n/a 730 31o B 
 Shauver 2009 (193) Silicone MCPJ Arthroplasty MHQ ADL 0 100 365 11 B 
 Shauver 2009 (193) Silicone MCPJ Arthroplasty MHQ function 0 100 365 13 B 
 Shauver 2009 (193) Silicone MCPJ Arthroplasty MHQ pain 0 100 365 3 B 
 Waljee 2012 Silicone MCPJ Arthroplasty ulnar drift n/a n/a 730 9o B 
         
Rotator Cuff Disease        
 Tashjian 2009 Various pain VAS 0 10 108 1.37 E 
         
Shoulder Disorder         
 Schmitt 2004 Physiotherapy DASH 0 100 90 10.2 A 
 Schmitt 2004 Physiotherapy PCS-12 0 100 90 6.5 A 
         
Shoulder Pain        
 Mintken 2009 Physiotherapy NPRS 0 10 14-28 1.1 B 
 Mintken 2009 Physiotherapy quickDASH 0 100 14-28 8 B 
         
Soft Tissue Shoulder Disorder        
 Beaton 2011 Physiotherapy DASH 0 100 84 3.9 - 15 C, D 
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Ulnar Nerve Entrapment        
 Malay 2013 Simple Decompression CTQ FSS 1 5 90 0.3 B 
 Malay 2013 Simple Decompression CTQ FSS 1 5 180 0.3 B 
 Malay 2013 Simple Decompression CTQ FSS 1 5 365 0.4 B 
         
 Malay 2013 Simple Decompression CTQ SSS 1 5 90 0.4 B 
 Malay 2013 Simple Decompression CTQ SSS 1 5 180 0.7 B 
 Malay 2013 Simple Decompression CTQ SSS 1 5 365 0.7 B 
         
 Malay 2013 Simple Decompression DASH 0 100 90 8 B 
 Malay 2013 Simple Decompression DASH 0 100 180 7 B 
 Malay 2013 Simple Decompression DASH 0 100 365 7 B 
         
 Malay 2013 Simple Decompression MHQ ADL 0 100 90 6 B 
 Malay 2013 Simple Decompression MHQ ADL 0 100 180 8 B 
 Malay 2013 Simple Decompression MHQ ADL 0 100 365 6 B 
         
 Malay 2013 Simple Decompression MHQ function 0 100 90 11 B 
 Malay 2013 Simple Decompression MHQ function 0 100 180 11 B 
 Malay 2013 Simple Decompression MHQ function 0 100 365 13 B 
         
 Malay 2013 Simple Decompression MHQ pain 0 100 90 9 B 
 Malay 2013 Simple Decompression MHQ pain 0 100 180 8 B 
 Malay 2013 Simple Decompression MHQ pain 0 100 365 13 B 
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Upper Limb MSK Disorder         
 Franchignoni 2014 Physiotherapy DASH 0 100 14-35 10.83 B, C, D 
 Schmitt 2004 Physiotherapy DASH 0 100 90 12.6 A 
 Franchignoni 2014 Physiotherapy quickDASH 0 100 14-35 15.91 B, C, D 
 Polson 2010 Physiotherapy quickDASH 0 100 42 or discharge 19 A 
         
Upper Limb MSK Disorder Requiring Physiotherapy       
 Schmitt 2004 physiotherapy PCS-12 0 100 90 6.8 A 
Table 8.1: MICs grouped by condition, sub-grouped by treatment, and ordered by outcome measure and length of follow 
up 
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Key to abbreviations: 
CTD – carpal tunnel decompression, CTS – carpal tunnel syndrome, ADL – activities of daily living, APB – abductor pollicis brevis, 
MRC – Medical Research Council, CTQ – carpal tunnel questionnaire, FSS – functional status scale, SSS – symptom severity 
scale, Dutch-AIMS2-HFF – hand and finger function subscale of the Dutch arthritis impact measurement scales, OA - osteoarthritis, 
MSK - musculoskeletal, MCPJ – metacarpophalangeal joint, MHQ – Michigan Hand Questionnaire, NPRS – numerical pain rating 
scale, VAS – visual analogue scale, PCS – physical component summary, PRWE – patient rated wrist evaluation, SF-36 – short 
form 36, URAM – Unité Rhumatologique des Affections de la Main scale. 
* – MIC could not be calculated 
Key to methods used: 
A – Change in ‘minimally improved group’, with comparison to other subgroups presented (anchor-based) 
B – ROC curve (anchor-based) 
C – Change in ‘minimally improved group’, without comparison to other subgroups (anchor-based) 
D – Distributional data 
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E – Difference between ‘minimally improved’ and ‘stable’ groups (anchor-based) 
F – Regression against anchor (anchor-based) 
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8.5.3 Outcome,measures,,conditions,and,time4points,studied,
There were only two MICs for Dupuytren’s disease specifically, and both were 
calculated at 30 days’ follow up. 
One was for range of motion in a randomised controlled trial of collagenase 
versus placebo.  Sub-groups for each treatment arm were not studied 
individually (Witthaut et al., 2011).  The other estimated an MIC for the URAM 
scale following needle aponeurotomy, and used an unconventional method 
involving regression of the URAM score against an uncited anchor.  No MICs 
were identified for the most common measure used (the DASH) in 
Dupuytren’s disease, and none were identified for surgical treatments such as 
fasciectomy or dermofasciectomy. 
MIC estimates for the DASH varied widely.  The lowest DASH MIC was 
3.9/100 for physiotherapy of soft tissue shoulder conditions (Beaton et al., 
2011) whereas the highest was 20/100, for a study of mixed treatments of 
upper limb disorders (Beaton et al., 2001).  Both extremes of DASH MIC came 
from studies with equivalent follow up periods (84 days).  Even within a single 
study, a broad range of estimates for the MIC of the DASH were reported, 
varying from 3.9 to 15, depending on the method used (Beaton et al., 2011). 
Thirty-two of the 99 MICs were calculated in heterogeneous cohorts of 
patients with different conditions.  Heterogeneity was sometimes also seen in 
studies describing one condition.  For example, rotator cuff disease was 
classified as one condition in the studies in the present review, though may 
involve different pathologies affecting the rotator cuff (i.e. rotator cuff tear, 
University of Nottingham  Systematic Review of Interpretability 
 300 
subacromial bursitis and adhesive capsulitis (frozen shoulder)).  Eighty MICs 
involved conditions affecting the elbow, forearm, wrist and hand, six described 
conditions proximal to the elbow, and the other 13 described outcomes for 
conditions both proximal and distal to the elbow.  Sixty-five MICs were based 
on surgical treatments, 24 on non-operative treatment (most commonly 
physiotherapy), and eight involved a mixture of operative and non-operative 
treatments.  Treatment modalities were unclear in the others.  Twenty MICs 
were estimated in heterogeneous cohorts that underwent more than one type 
of treatment.  All MICs involved the study of improvement following treatment, 
with none considering the MIC of later clinical deterioration in chronic 
conditions, such as recurrence after surgery for Dupuytren’s disease. 
Overall, MICs had been calculated for 40 different measures (Figure 8.2).  Of 
these the DASH had the most MICs, with 15 different estimations.  Eight of the 
40 measures were variants of the Boston carpal tunnel questionnaire (Levine 
et al., 1993). 
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Figure 8.2: Numbers of MICs for different outcome measures 
Only measures with more than one MIC are shown in this chart.  A further 29 
measures had one MIC each, and are shown in Table 8.1. 
Key: CTQ – carpal tunnel questionnaire, FSS – functional status scale, SSS – 
symptom severity scale, MHQ – Michigan Hand Questionnaire, PRTEE – 
Patient-rated tennis elbow evaluation, PCS – physical component summary, 
ADL – activities of daily living, DASH – Disabilities of the Arm, Shoulder and 
Hand. 
 
Amongst other hand surgery treatments, MICs were identified for open carpal 
tunnel decompression, limited incision carpal tunnel decompression, 
endoscopic carpal tunnel decompression, steroid injection for carpal tunnel 
syndrome, ulna-shortening osteotomy for idiopathic ulnar impaction, simple 
0" 2" 4" 6" 8" 10" 12" 14" 16"DASH"
CTQ"SSS"CTQ"FSS"
MHQ"pain"MHQ"function"
MHQ"ADL"QuickDASH"
PRWE"PCS@12"
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decompression of ulnar nerve entrapment at the elbow (cubital tunnel 
syndrome) and silicone metacarpophalangeal joint arthroplasty. 
Length of time between treatment and follow up assessment varied from 14 to 
730 days, and several MICs were derived from studies involving assessments 
performed at inconsistent follow up time points. 
One study investigated the MIC for the Jebsen Hand Function Test in a 
heterogeneous cohort (Sears and Chung, 2010).  The area under the curve in 
ROC curve analysis was low (close to 0.5), indicating that the Jebsen Hand 
Function Test had failed to identify meaningful improvement.  As a result, an 
MIC estimation could not be made. 
8.5.4 Methodologies,used,
All 99 MICs were estimated using at least one anchor.  For 41 of them, this 
involved a prospectively assessed anchor (e.g. several used the change in the 
satisfaction domain of the Michigan Hand Questionnaire as the anchor), and 
in the remainder it was a retrospective anchor (i.e. an assessment of 
improvement obtained during follow-up, after treatment had occurred).  The 
anchors varied, and their origin was often unclear and not referenced. 
Fifty-two of 99 MICs were in articles that also presented distributional 
analyses.  For example, the MDC was frequently presented in articles in 
addition to the MIC.  Nine MICs were based on both distributional and anchor-
derived estimations. 
Sixty-one MICs involved ROC curve analyses, and 49 presented the average 
changes in subgroups of patients classified as ‘minimally improved’.  One MIC 
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was calculated from a regression of the measure (angular deformity) against 
the anchor (Witthaut et al., 2011).  To do so, patient rated change that had 
been scored between 0% and 100% was split into four groups, and then this 
was used as the external criterion against which the change in angle was 
studied. 
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8.6 Discussion,
8.6.1 Present,study,findings,
This review identified only two MICs specifically for Dupuytren’s disease 
treatment, and none for open surgery (fasciectomy and dermofasciectomy).  
The two identified may be of limited value.  One studied the MIC of range of 
motion (Witthaut et al., 2011), which is a relatively uncommon objective 
outcome (Ball et al., 2013).  The other used an unusual methodology, which 
was not used in any other study (Beaudreuil et al., 2011).  Both MICs were 
calculated after 30 days of follow up.  It is not clear whether this is the optimal 
time point to study recovery following collagenase or needle aponeurotomy.  It 
is less likely that recovery from more invasive surgery such as fasciectomy or 
dermofasciectomy would be complete by this time.  If these patients were 
assessed whilst still recovering, they may be less satisfied with their ‘result’ 
than if they were assessed once fully rehabilitated. 
Other MICs for a range of clinical scenarios were identified.  As the MIC is 
likely to vary between patient groups, conditions, treatments and time points, 
these MICs may be best interpreted as an approximation of meaningful 
improvement after treatment of Dupuytren’s disease (Ring, 2013).  However 
extrapolating them in such a fashion is not ideal. 
The heterogeneity between the studies included here prevented comparison 
between MICs from different articles.  However, considerable variability in the 
MIC for a particular measure was seen.  For example, MIC estimates for the 
DASH varied widely.  The lowest DASH MIC was 3.9/100 for physiotherapy of 
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soft tissue shoulder conditions (Beaton et al., 2011) whereas the highest was 
20/100, for a study of mixed treatments of upper limb disorders (Beaton et al., 
2001).  Both extremes of DASH MIC came from studies with equivalent follow 
up periods (84 days).  Even within a single study, a broad range of estimates 
for the MIC of the DASH were reported, varying from 3.9 to 15, depending on 
the method used (Beaton et al., 2011).  The MICs for the DASH at different 
time points after decompression of ulnar nerve entrapment were presented in 
one study, and were similar when assessed using a prospective anchor (8 at 
90 days, 7 at 180 days, and 7 at 1 year) (Malay and Chung, 2013).  However, 
such stability may not be seen for all time points in all conditions.  This 
variability emphasises the need for careful selection of an MIC when 
designing a study, or interpreting clinical outcome data. 
We did not identify any studies aiming to define what constitutes a meaningful 
late deterioration after initially successful treatment (such as recurrence of 
Dupuytren’s disease).  Instead, all MICs identified described improvement 
after treatment, and are not applicable in defining a meaningful deterioration of 
on-going conditions (de Vet et al., 2006). 
There is no consensus on which method should be used to calculate MICs 
(Bago et al., 2009).  It has been suggested that several techniques be 
employed, and the MIC described as a range of values from these different 
techniques (Revicki et al., 2008).  However, it is unlikely that all methodologies 
are equally robust.  Anchor-based measures are dependent on the external 
criterion being valid and reliable itself.  Whilst there has been support for the 
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use of retrospective anchors (Guyatt et al., 2002), concerns have been raised 
about their robustness (Norman et al., 1997), and the decision as to what 
indicates an “improved” score on scales such as the 15 point GRC is arbitrary 
(scores of +4 or more are improved) (Jaeschke et al., 1989).  Retrospective 
anchors may reflect the status at the time of assessment, rather than the 
change in state over time that they are supposed to measure (Garrison and 
Cook, 2012, Schmitt and Di Fabio, 2005).  Most MICs identified in this review 
were calculated using retrospective anchors, and further studies using 
prospective anchors may be warranted to confirm them.  There may be other 
problems from some anchor-based methodologies.  Although calculating the 
mean change in the ‘minimal improved’ group is an accepted technique for 
deriving the MIC, and was used in several of the articles included in this 
paper, there may be issues with the value obtained by this technique.  If used 
without further analysis, it does not confirm whether the change in the 
‘minimally improved’ group actually differs from the ‘no change’ group, and so 
whether this MIC is able to discriminate meaningful change from other 
outcomes.  To tackle this, several of the studies did test for a statistically 
significant difference between the ‘minimal improved’ group and others.  
Alternatively, the difference between the ‘minimally improved’ group and the 
‘no change’ group has been considered as the MIC. 
Distributional analyses also have problems.  They are affected by the variation 
amongst the subjects in a study, and it has been suggested that due to their 
nature, they may fail to describe ‘meaningful’ change at all (Copay et al., 
University of Nottingham  Systematic Review of Interpretability 
 307 
2007).  Few of the MICs in this review involved the use of distributional data.  
This might reflect the input of clinicians in the design to the studies.  However, 
given that the MIC might be best considered from a series of calculations 
using different methods (Revicki et al., 2008), perhaps more use of these 
analyses alongside anchor-based methods should be considered in future. 
Besides such issues that are intrinsic to particular methodologies, there were 
other potential weaknesses in the study designs used to calculate several 
MICs reviewed here.  Some did not have a fixed length of follow up amongst 
the study cohort, which is unsatisfactory as the MIC may depend on the length 
of time between the treatment and assessment; patients still recovering may 
be less satisfied than those who are fully rehabilitated.  Also the risks 
associated with a retrospective anchor, which have already been discussed, 
might increase with longer follow up.  This raises concerns about the 
robustness of some MICs, and further study to support the estimates of these 
MICs at specific time points may be required.  Additionally, some MICs were 
calculated for mixed cohorts, comprising patients with different conditions, or 
patients who had received different treatments for the same condition.  MICs 
generated in this way may be of less value when applied to changes in 
specific conditions or following particular treatments.  They will be influenced 
by the case-mix of the cohort study, and the resulting ‘average’ MIC will not be 
applicable to any particular individual patient, condition or treatment.  Some 
groups that studied multiple conditions or time points reported separate MICs 
for each clinical situation (Malay et al., 2013), which provides more applicable 
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data.  This illustrates some of the issues already discussed: the MIC for the 
Carpal Tunnel Questionnaire Symptom Severity Scale (CTQ SSS) 
Some articles screened did not present MICs, but instead reported other 
assessments of responsiveness.  Others avoided calculating MICs (Chatterjee 
and Price, 2009).  In one case, ROC curve analysis demonstrated that the 
Jebsen Hand Function Test was too poor at identifying improvement to allow 
the estimation of an MIC (Sears and Chung, 2010).  This conclusion was 
based on the Area Under the Curve (AUC) of the ROC curve being lower than 
the typically acceptable cut-off of 0.75 (Fan et al., 2006).  
8.6.2 Limitations,
There are some limitations to this review.  Steps were taken to ensure that the 
search strategy was comprehensive, but studies containing relevant data may 
have been missed.  This is a particular risk due to the variation in terminology 
used between studies.  By extending the search to include the screening of 
reference lists, it is believed that all articles of relevance to Dupuytren’s 
disease have been included. 
8.7 Conclusions,of,Systematic,Review,of,Interpretability,
No studies of interpretability of outcome after open surgery for Dupuytren’s 
disease specifically could be identified.  Two MICs had been derived in 
patients with Dupuytren’s disease, one for the URAM 30 days after needle 
aponeurotomy and the other for range of motion in a trial comparing 
collagenase to placebo.  Several MICs did exist for the DASH, but were 
derived for different conditions and treatments, and showed considerable 
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variation.  Given the nature of MICs, extrapolating them from other 
circumstances to open surgery for Dupuytren’s disease is not appropriate.  
Further study of interpretability of outcome measures in Dupuytren’s disease 
would inform future study design and guide interpretation of data. 
The Consensus-based Standards for the Selection of Health Status 
Measurement Instruments (COSMIN) collaboration separates validity of single 
time point measurements, from responsiveness and from interpretability 
(Mokkink et al., 2010), and the following chapters will consider aspects of the 
validity and reliability of different candidate outcome measures that might be 
used in future research.  As they have been used in a range of existing 
studies, the investigations in the following chapters will also inform appraisal 
of the evidence base, as is required in the development of clinical guidance. 
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SUMMARY 
This chapter demonstrates that whilst MICs have been estimated for use in a 
range of hand surgery clinical scenarios, few are applicable to surgery for 
Dupuytren’s disease, and even those that are relevant to hand surgery are not 
suitable for use following open surgery, or at a follow up time point at which 
recovery after surgery is complete.  As a result, there is not currently enough 
interpretability information available to be able to design an appropriately 
powered study of different treatment options for Dupuytren’s disease.  
Furthermore, interpretation of findings of existing studies, which have been 
summarised in the previous systematic review chapter, is also limited by this 
paucity of evidence.  Further examination of what constitutes an important 
change in outcome measures following treatment of Dupuytren’s disease is 
still required.  The next chapter will present cohort study data to investigate 
the interpretability of the DASH and the URAM. 
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9 Recovery,,Responsiveness,And, Interpretability,Of, Patient4
Reported, Outcome, Measures, After, Surgery, For,
Dupuytren’s,Disease,
9.1 Preface,
The preceding chapters have studied aspects of the reliability and validity of 
three candidate outcome measures for future studies of Dupuytren’s disease, 
namely angular passive extension deficit, the Disabilities of the Arm, Shoulder 
and Hand (DASH) patient-reported outcome measure (PROM), and the Unité 
Rhumatologique des Affections de la Main scale (URAM).  The results 
obtained thus far demonstrate issues with the performance of each of these 
measures.  However, they have all been used to study Dupuytren’s disease to 
date, and further investigation of them is warranted to guide appropriate 
interpretation of papers that have used them. 
Responsiveness and interpretability are other parameters of relevance to the 
performance of outcome measures, besides validity and reliability.  
Interpretability can also determine meaningful change, but there are few 
applicable data available for the measures concerned, as discussed in the 
Systematic Review of Interpretability of Outcome Measures for Use in 
Dupuytrens’ Disease.  Furthermore, such analyses are dependent of 
appropriate timing of follow up assessment, such that recovery is complete.  
Knowledge of what constitutes a clinically meaningful change is required when 
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interpreting data for clinical practice, and for guideline development.  These 
parameters will be investigated in this chapter. 
9.2 Introduction,
Evaluating the outcome of Dupuytren’s disease treatment requires an 
appreciation of what constitutes a clinically important change following 
treatment and consideration of the timing of assessment in relation to 
recovery, assuming that the outcome measure being used is appropriate. 
The Consensus-based standards for the selection of health status 
measurement instruments (COSMIN) study defined validity in terms of the 
appropriateness of a single time point measurement (Mokkink et al., 2010), for 
example, whether the score achieved on a preoperative hand function 
questionnaire reflects hand function at that time.  The responsiveness is the 
validity of a change in score based on a change in the construct being 
measured, which in the case of Dupuytren’s disease is often hand function.  In 
contrast, interpretability is concerned with interpreting a change score, often 
via the minimal important change (MIC) (Mokkink et al., 2010).  The MIC is 
that smallest change in a score following treatment that is considered clinically 
important by patients.  This can be calculated in different ways and is likely to 
be context-specific, so it may vary between different conditions and treatments 
(Revicki et al., 2008).  A range of MIC estimations exists for hand surgery, and 
include values for PROMs, but also for objective measures, such as angular 
deformity or grip strength (Rodrigues et al., 2014).  However, in the cited 
review, the only estimation of an MIC for a PROM in Dupuytren’s disease was 
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for the URAM Dupuytren’s disease-specific scale, and was calculated for 
needle aponeurotomy (Beaudreuil et al., 2011).  It is possible that the MIC 
after open surgery (fasciectomy or dermofasciectomy) may differ from this.  
The DASH PROM had the most MIC estimations across all hand surgery 
conditions (Rodrigues et al., 2014), and has been the most widely used 
PROM in Dupuytren’s disease (Ball et al., 2013).  However, its MIC in 
Dupuytren’s disease has not been estimated. 
Six weeks following treatment has been used as the time point when early 
outcome of surgery for Dupuytren’s disease is measured (van Rijssen et al., 
2006).  However, other studies suggest that recovery, at least from open 
surgery such as fasciectomy and dermofasciectomy, may continue for longer 
than this (Ullah et al., 2009).  Measuring outcome too early might 
underestimate the benefit of treatment in general, or may bias comparisons 
towards less invasive treatments that might have quicker recovery, such as 
aponeurotomy. 
A range of outcome measures has been used to study Dupuytren’s disease 
(Ball et al., 2013), and can be broadly grouped into generic, domain-specific 
and disease-specific measures (Szabo, 2001).  Recently, Dupuytren’s 
disease-specific measures have been developed (Beaudreuil et al., 2011, 
Mohan et al., 2014), and the suitability of the most popular outcome measure, 
the upper limb domain-specific DASH, has been questioned (Packham, 2011). 
This present chapter describes a prospective cohort study that investigated 
recovery time from open surgery for Dupuytren’s disease, and the 
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responsiveness and interpretability of the DASH and URAM PROMs following 
fasciectomy and dermofasciectomy, and potential explanations for differences 
in their performance. 
9.3 Methods,
The data presented in this study were gathered as part of a larger service 
evaluation comprising a cohort study and a cross sectional study. 
Data from the two studies were used for distinct purposes.  Data from the 
cohort study were used in analyses of recovery, responsiveness and 
interpretability.  Data from the cross sectional study were used in addition to 
data from the cohort study in analysis of construct validity, which in this study 
was the exploratory factor analysis. 
9.3.1 Patient,recruitment,and,data,collection,
Patient recruitment took place between September 2011 and April 2013.  The 
inclusion criteria were primary or recurrent Dupuytren’s disease and either: 
• Patients awaiting fasciectomy or dermofasciectomy at one UK hand 
surgery centre (for the cohort study) 
• Patients available for assessment at five UK hand surgery centres 1 
year or 5 years (+/- 2 months) after their surgery when the candidate 
was available (for the cross sectional study). 
 
Exclusion criteria were: 
• Cognitive impairment preventing informed consent 
• Refusal of invitation to participate 
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In the cohort study, preoperative patients were recruited at the routine 
preadmission clinic visit prior to surgery.  Those who were eligible and 
consented to participate completed the DASH prior to surgery.  These patients 
were also sent questionnaires for completion by post at 3 weeks, 6 weeks and 
1 year after surgery.  Patients who were scheduled for surgery to the left and 
right hand at different times during the study recruitment period were eligible 
for recruitment twice.  This happened on four occasions.  The URAM scale 
was published during the study period.  Patients recruited later in the cohort 
(August 2012 onwards) also completed the URAM at preoperative, and postal 
questionnaires at 6 week and 1 year postoperative time points. 
After completion of the 1-year follow up period, all patients were posted the 
Global Rating of Change questionnaire (GRC) (Jaeschke et al., 1989), either 
with their 1-year hand function questionnaires or separately. 
In the cross-sectional study, patients were invited to participate on a voluntary 
basis with a letter explaining the project and a fixed stipend offered to cover 
travel expenses.  The candidate assessed those who consented to participate.  
The assessment included collection of demographic data and completion of 
the DASH and, from August 2012 onwards, the URAM. 
9.3.2 Handling,of,incomplete,questionnaires,
The DASH remains reliable as long as at least 27/30 items are complete 
(Kennedy et al., 2011).  Therefore, all returned questionnaires meeting this 
criterion were included. 
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Two options were considered for handling missing data (when questionnaires 
were not returned or were returned with more than 3/30 items incomplete).  In 
pairwise exclusion, incomplete data are omitted from specific analyses, but 
where possible, are included in other analyses.  In listwise exclusion, that 
patient is excluded from all analysis.  Pairwise exclusion was the preferred 
method for handling unreturned or more incomplete questionnaires.  If 
required (e.g. for repeated measures ANOVA), then listwise exclusion was 
used.  For example, if a patient submitted DASH questionnaires for 
preoperative assessment and 1-year postop state, but did not return the 3-
week and 6-week questionnaires, then that patient was still included in 
interpretability analyses that only required preoperative and 1-year 
postoperative assessments. However, that patient would be excluded from the 
study of recovery, as this looks at patients’ changes over all time points. 
As clear guidance for handling incomplete questionnaires was not available 
for the URAM, all URAMs with any missing entries were excluded in the same 
fashion. 
9.3.3 Data,handling,
The DASH summary score was calculated using the standard formula 
provided: 
DASH=[(a/b)-1]*25 
Where “a” is the sum of the scores for the responses completed (each 
response could be scored between one and five), and “b” is the number of 
responses the patient completed. 
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The URAM summary score was calculated by adding the responses to all 
items. 
As the PROM summary scores are virtually continuous scales (the DASH is 
scored 0-100; the URAM 0-45), and the sample comprised a large number of 
independent observations, parametric analyses were used to compare them, 
in keeping with the central limit theorem.  The central limit theorem 
demonstrates that datasets of ‘large’ sample sizes (typically over n=30) 
comprising independent observations of a continuous behave acceptably 
when subjected to parametric statistics, even in the absence of a normal 
distribution (Norman, 2010).  An advantage of this approach is that parametric 
analyses typically retain more power and so pose less risk of a type II error. 
9.3.4 Analysis,of,recovery,
Recovery time was analysed by comparing DASH scores at different time 
points using repeated measures analysis of variance (ANOVA) with Tukey’s 
multiple comparison test. 
9.3.5 Analysis,of,responsiveness,and,interpretability,
Responsiveness was studied by calculating the effect size, defined as the 
change in score divided by the standard deviation of the baseline 
(preoperative) scores across the cohort (Kazis et al., 1989).  When 
interpreting the effect sizes, 0.2 was considered small, 0.6 moderate and 1.0 
large (Testa, 1987). 
Interpretability was studied using receiver operating characteristic (ROC) 
curves, as this has been the most common method used in hand surgery 
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(Rodrigues et al., 2014).  ROC curves treat an outcome measure (such as the 
preoperative-postoperative change in DASH or URAM) as a diagnostic test, 
with the aim of reliably diagnosing clinical improvement from stable results 
(Deyo and Centor, 1986).  To do this, those patients who are ‘improved’ are 
separated from those who are ‘stable’, using an external criterion, or anchor 
(Revicki et al., 2008).  ROC curves then trial different possible cut values (e.g. 
improvement in DASH of 20/100 compared to 30/100 or 40/100).  Each trial 
cut value will have its own combination of sensitivity and specificity for 
diagnosing improvement.  The MIC can be considered to be Youden’s index, 
which is the point with the highest combination of sensitivity and specificity for 
identifying improvement (Youden, 1950).  To do this, outcomes were sub 
grouped based on the response to the GRC into those who were ‘improved’ 
(GRC+4 to +7), those who were ‘stable’ (GRC -3 to +3), and those who were 
‘worse’ (GRC -7 to -4), as previously described (Mintken et al., 2009).  ROC 
curves were generated using Prism 6.0 for Mac OS X (GraphPad® Software, 
La Jolla, USA, 2012). 
 ,
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9.4 Results,
9.4.1 Patients,and,procedures,
In the cohort study, 101 patients were recruited in total, of which 44 were sent 
URAM questionnaires in addition to DASH questionnaires.  The demographics 
of the cohort are shown in Table 9.1.  Sixty eight per cent completed all follow 
up function PROMs. 
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Detail DASH URAM 
Age at recruitment 
(mean years, range) 
 
67, 34-90 66, 38-90 
Gender 
 
83/101 male (82.2%) 38/44 male (86.4%) 
GRC, preop, 6 week, 1 
year PROMs 
completed* 
 
68/101 (67.3%) 29/44 (65.9%) 
Procedures 73 fasciectomies 
28 dermofasciectomies 
29 fasciectomies 
15 dermofasciectomies 
Hand treated 
 
61/101 right (60.4%) 25/44 right (56.8%) 
Multiple digits treated 
 
27/101 (26.7%) 12/44 (27.3%) 
Digits treated 135 digits in 101 cases 
80/135 little (59.3%) 
39/135 ring (28.9%) 
10/135 middle (7.4%) 
4/135 index (3.0%) 
2/135 thumb (1.5%) 
59 digits in 44 cases 
34/59 little (57.6%) 
15/59 ring (25.4%) 
7/59 middle (11.9%) 
2/59 index (3.4%) 
1/59 thumb (1.7%) 
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Table 9.1: Patient demographics and procedure details in study 
DASH- Disabilities of the Arm, Shoulder and Hand, URAM – Unité 
Rhumatologique des Affections de la Main, PROM – Patient-reported outcome 
measure, GRC – Global Rating of Change 
* “Complete” DASH questionnaires defined as at least 27/30 items complete, 
such that a summary score can be calculated.  Complete URAM 
questionnaires defined as all items completed. 
 
9.4.2 Recovery,
Sixty-five patients completed preoperative, 3-week, 6-week and 1-year 
postoperative DASHs.  The scores at different time points are shown in Figure 
9.1.  The mean DASH summary score was significantly different between time 
points (p<0.0001, repeated measures ANOVA).  Tukey’s multiple comparisons 
test demonstrated significant differences between all time points, with the 
exception of comparing preoperative to 6-week postoperative scores.  
Function deteriorated between preoperative and 3-week postoperative 
assessments.  Notably, the difference between 6 weeks and 1 year was 
significant (p=0.0006).  The developers of the DASH advise that a DASH 
summary score above 15/100 is consistent with a symptomatic upper limb, 
and the mean DASH summary score only fell below 15/100 at 1 year.  Of 
note, there was no difference between scores for fasciectomies and scores for 
dermofasciectomies at any time point, hence results from both procedures 
were combined for all further analyses. 
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Figure 9.1: Line chart of DASH summary scores from patients who 
completed all time points (n=65) 
95% CI – 95% confidence intervals 
 
9.4.3 Responsiveness,and,interpretability,
As functional state was significantly better at 1 year compared to 6 weeks, 
responsiveness and interpretability analyses were performed using change 
between preoperative and 1 year PROMs. 
Responses from patients who adequately completed preoperative and 1-year 
postoperative questionnaires were included in responsiveness analysis.  Both 
the DASH and URAM had significant changes in scores from preoperative 
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assessment to 1-year postoperative assessment, though the URAM had a 
larger effect size than the DASH (Table 9.2). 
 
 DASH (n=71) URAM (n=30) 
Preoperative 
[mean (95% CIs)] 
24.5/100 (19.9, 29.0) 17.8/45 (14.5, 21.1) 
1-year 
postoperative 
[mean (95% CIs)] 
12.4/100 (8.9, 16.0) 10.1/45 (6.1, 14.1) 
Difference post-
preop 
[mean (95% CIs)], 
paired t test 
12.0/100 (8.2, 15.9) 
p<0.0001 
7.7/45 (3.7, 11.7) 
p=0.0005 
Effect size 
(mean/SD preop) 
0.58 0.87 
Table 9.2: Responsiveness of DASH and URAM at 1-year postoperative 
assessment 
 
The mean GRC in the DASH cohort was +4.3 (95% confidence intervals [95% 
CIs]: +3.4, +5.2).  When sub grouping of DASH outcomes using the GRC was 
performed, five patients were worse, eleven were stable and 52 were 
improved.  The mean DASH change in the improved subgroup was 13.0/100, 
and the mean DASH change in the stable subgroup was 10.8/100.  The 
difference between them (2.2/100 [95% CIs: -13.3, 8.9]) was not statistically 
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significant (p=0.69, unpaired t test).  The ROC curve for the DASH is shown in 
Figure 9.2.  The area under the curve (AUC) was 0.51 (95% CIs: 0.33, 0.69), 
indicating that the DASH could not identify meaningful change defined by the 
GRC.  Consequently, an MIC could not be estimated for the DASH at 1 year 
after fasciectomy or dermofasciectomy. 
 
Figure 9.2: ROC curve of DASH’s ability to separate ‘improved’ from 
‘stable’ outcomes, based on the GRC 
The red line indicates the line of identity, where sensitivity and specificity are 
both 50%, and corresponds to an area under the curve of 0.5.  The blue points 
represent trial cut offs for change in DASH that could be used to attempt to 
separate ‘improved’ from ‘stable’ outcomes. 
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For the cohort that completed the URAM, the mean GRC was +2.9 (95% CIs: 
+1.2, +4.6).  When GRC-based sub grouping was performed, 18 were 
improved, eight were stable and four were worse.  The mean URAM change 
in the improved subgroup was 11.9/45 (95% CIs: 6.7, 17.0), and the mean 
URAM change in the stable subgroup was 3.6 (9.3, -2.0).  The difference 
between them (8.3/45, 95% CIs: 0.04, 16.5) was significant (p=0.049, 
unpaired t test).  A change of 8.3/45 on the URAM constitutes an MID (as 
opposed to an MIC), as it describes the difference between individuals 
considered clinically important. 
The ROC curve determines the MIC, as the change that an individual patient 
considers significant.  For the URAM, it is shown in Figure 9.3.  The AUC was 
0.74 (95% CIs: 0.55, 0.93).  The MIC for the URAM for 
fasciectomy/dermofasciectomy at one year (defined as Youden’s j index) 
corresponded to an improvement in the URAM of greater than 10.5, which had 
a sensitivity of 55.6% and a specificity of 87.5%.  The likelihood ratio for an 
improvement in the URAM of 10.5 was 4.4; that is, a patient with a URAM 
improvement over 10.5 was 4.4 times more likely to be ‘improved’ than a 
patient whose URAM had improved by less than 10.5. 
Across the cohort studied, the GRC correlated significantly with the 1-year 
DASH (Pearson’s r: -0.48, p<0.0001), but did not correlate with the change is 
DASH (Pearson’s r: -0.22, p=0.07).  It also did not correlate with the 
preoperative DASH (Pearson’s r: -0.18, p=0.15).  For the URAM, the GRC 
correlated more closely with the 1-year assessment (Pearson’s r: -0.68, 
University of Nottingham   Recovery & Interpretability 
 326 
p<0.0001), than with the change in the URAM (Pearson’s r: -0.56, p=0.001).  It 
did not correlate with the preoperative URAM (Pearson’s r: -0.15, p=0.44). 
 
 
Figure 9.3: ROC curve of URAM’s ability to separate ‘improved’ from 
‘stable’ outcomes, based on the GRC 
The red point on the blue line corresponds to the MIC described above.  This 
corresponds to a cut point of an improvement of >10.5 in the URAM. 
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9.5 Discussion,
9.5.1 Present,study,findings,
The timing of early outcome assessment is likely to influence differences 
between treatment types in Dupuytren’s disease.  In this study, recovery 
following fasciectomy or dermofasciectomy took longer than 6 weeks.  In 
contrast, less invasive procedures such as needle aponeurotomy and 
collagenase, which were not included in this cohort, are likely to recover 
quicker.  In such a situation, functional outcome for more invasive procedures 
may appear poor, as patients are yet to realise the full benefit of the treatment.  
To minimise patient burden in the present study, only one further assessment 
was made, at 1 year after surgery.  The statistically significant difference 
between 6-week outcome and 1 year outcome may also be clinically 
significant, as the 1-year time point was the only one with a mean summary 
score below 15/100, the threshold above which a patient’s upper limb is 
considered symptomatic (Chart 1) (Kennedy et al., 2011).  This is likely to 
affect the interpretability of outcome measures as well.  Although it might be 
expected that incomplete recovery at 6 weeks would be accounted for in 
patients’ responses to the anchor item, determining perceived change or 
satisfaction when patients are still recovering from treatment may not be as 
meaningful as assessing interpretability once patients have fully recovered. 
However, it is unclear from these data whether recovery is complete earlier 
than 1-year, or if it continues after this time point.  Given the improvement 
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between 6 weeks and 1 year, subsequent analyses performed in this study 
used the 1-year assessment as the follow up time point. 
Using 1-year follow up data, the DASH exhibited moderate responsiveness.  
The URAM’s responsiveness was better, albeit in a slightly different and 
smaller cohort.  However, commonly used responsiveness analyses, such as 
the effect size used here, are only appropriate if all patients studied have 
undergone a clinically meaningful improvement.  If patients underwent a sham 
procedure, and received no benefit at all (including placebo), then it would be 
reasonable to expect that an appropriate outcome measure would exhibit no 
change from before to after the sham treatment, i.e. the effect size would be 
negligible. 
The aim of the interpretability analyses was to separate those who had 
experienced meaningful improvement from those who had not, and then to 
calculate the MIC using this dichotomy.  Indeed, a notable (16/68) proportion 
of patients did not experience benefit, or even experienced worsening, as 
defined by the GRC.  The DASH could not identify this meaningful change, 
and an MIC could not be calculated.  In contrast, the URAM showed 
acceptable interpretability, with an MIC for open surgery of 10.5. 
The difference in performance between the DASH and the URAM may relate 
to the fact that they measure different underlying constructs, as demonstrated 
in the exploratory factor analysis in the previous chapter.  EFA demonstrates 
the statistical relationship between different items in scales, but cannot 
describe the nature of the latent factors extracted.  It is possible that the 
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activity limitation-based items of the DASH might reflect shoulder impairment, 
that most of the URAM items might reflect impairment from loss of extension, 
and that the symptom-related DASH items might reflect more generalised 
hand impairment.  Thus, the analyses in the present chapter (responsiveness 
assessed by effect size, and interpretability described by the MIC and MID) in 
isolation cannot be claimed to demonstrate that the URAM is more 
appropriate than the DASH for the assessment of hand function in patients 
with Dupuytren’s contractures.  However, in conjunction with the studies of 
validity in the previous chapter, they further question the role of the DASH in 
future studies of Dupuytren’s disease, despite the DASH’s previous popularity. 
9.5.2 Limitations,
As 6 weeks and 1 year were the only time points studied, it is not possible to 
accurately determine an accurate recovery plateau time from the data here.  
Indeed, based on studies of other outcome measures (Ullah et al., 2009), it is 
possible that recovery may plateau close to 3 months after surgery, but the 
quality of their data is uncertain as it was only presented in graphical form, 
with no information provided about attrition. 
The methodology used to study interpretability has limitations, which may be 
affected by the long follow up for assessing recovery.  Although the GRC was 
developed for the purpose of anchoring outcomes, it is retrospectively 
administered, and the use of such retrospective anchors has been criticised 
(Norman et al., 1997).  In particular, the GRC may reflect the status of the 
hand at the time of assessment, rather than reflecting the change that has 
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occurred from the preoperative state (Garrison and Cook, 2012, Schmitt and 
Di Fabio, 2005).  In this study, the GRC correlated more closely with the 1-
year postoperative state than it did with the change in score.  The GRC was 
chosen here, as most studies of MICs in hand surgery have used 
retrospective anchors to date (Rodrigues et al., 2014).  It is possible that the 
interpretability of the PROMs studied would be different if a prospective 
anchor were used.  Prospective anchors capture data at baseline and again at 
follow up, rather than relying on patient recall of the baseline state, which is 
the case for retrospective anchors like the GRC.  Some prospective anchors 
have been used in hand surgery.  In particular, the satisfaction domain of the 
Michigan Hand Questionnaire has been used as a prospective anchor 
(Rodrigues et al., 2014).  Whether satisfaction is the most appropriate domain 
to assess as an anchor is not clear, as it may be influenced by patient 
experience of health care system, rather than the treatment itself, and so 
results based on satisfaction may not be generalisable to other health care 
services, even if the treatment itself is similar.  Further study of anchors is 
required.  The present study findings should then be confirmed using such 
methodology. 
The methodology for sub-grouping outcomes to construct the ROC charts was 
based on commonly used methodology from previous studies, with exclusion 
of patients who experienced deterioration.  However, more recent work has 
led to the suggestion including the entire cohort may improve precision in MIC 
analyses (Turner et al., 2009).  This might be considered in the future work 
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proposed above, in which interpretability would be studied with a prospective 
anchor. 
The cohort studied may be heterogeneous, as it included both fasciectomies 
and dermofasciectomies.  These data were collected as service evaluation of 
standard clinical practice, and on several instances, the type of procedure was 
changed from the preadmission clinic, based on surgeon preference, or for 
technical reasons during the surgery itself.  It is possible that the 
interpretability of the DASH and the URAM may differ between fasciectomies 
and dermofasciectomies.  However, given that the recovery was not different 
between procedure types, and that MICs are considered estimates rather than 
exact values, this is unlikely to be of significance. 
9.5.3 Relationship,to,existing,literature,
Whilst early recovery from surgery for Dupuytren’s disease has been 
assessed at 6 weeks (van Rijssen et al., 2006), and studies of other 
treatments have assessed outcome at 30 days (Hurst et al., 2009), the current 
data support the limited existing data demonstrating that recovery from open 
surgery takes longer than this (Ullah et al., 2009).  Confirmation of the most 
appropriate time point for studying recovery is required. 
Interpretability had been studied in Dupuytren’s disease (Beaudreuil et al., 
2011, Witthaut et al., 2011).  Neither of these studies considered open 
surgery, though one did generate an MIC estimate of 2.7 for the URAM for 
needle aponeurotomy (Beaudreuil et al., 2011).  The present study generated 
a considerably larger MIC, which may be due to the different methods used (a 
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ROC curve of dichotomised outcomes was used here, compared to regression 
against satisfaction in other studies).  However, it is more likely to reflect the 
differences in recovery between open surgery and aponeurotomy.  As open 
surgery involves a rise in postoperative as demonstrated in previous chapters 
and a prolonged recovery period, probably with more visits to hospital, it is 
likely that patients might expect to see greater improvement in their before 
they begin to consider this more invasive and inconvenient treatment to have 
been worthwhile. 
This is a reasonable suggestion as it is already thought that MICs may vary 
between treatments (for the same condition) in general (Revicki et al., 2008), 
Interpretability of outcome in hand surgery has been studied using a range of 
methods (Rodrigues et al., 2014).  Most MICs in this field have used 
retrospective anchor-based methods, though hand-specific prospective 
anchoring using the satisfaction domain of the Michigan Hand Questionnaire 
(MHQ) is also possible, as already discussed (Malay et al., 2013, Shauver and 
Chung, 2009, Waljee and Chung, 2012).  Many of these studies involved 
assessing the interpretability of different subscales of the MHQ.  Whether it is 
appropriate to use the satisfaction domain of the MHQ, another component of 
the same tool, as the prospective anchor is not clear. 
9.6 Conclusions,of,study,of,recovery,,responsiveness,and,interpretability,
This study raises further questions regarding the DASH’s suitability for use in 
Dupuytren’s disease, in terms of interpretability.  However, given the potential 
issues associated with retrospective anchors, the poor interpretability of the 
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DASH should be confirmed using a prospective anchor.  Measurement of the 
interpretability of other PROMs for use in Dupuytren’s disease is also required 
to be able to interpret existing research and ensure appropriate outcome 
measures are used in future studies. 
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SUMMARY 
This chapter demonstrates that recovery from fasciectomy and 
dermofasciectomy takes longer than the 6 weeks often studied, and 
measuring outcome at 6 weeks will underestimate the benefit from these 
procedures. 
The DASH shows moderate responsiveness to surgery for Dupuytren’s 
disease, and the URAM shows good responsiveness.  However, the DASH 
was not interpretable in this study.  As seen in the earlier Validity chapter, the 
DASH reflects different underlying constructs to the URAM, which may explain 
the DASH’s poorer performance.  Given the earlier chapter’s findings of the 
DASH’s validity and this chapter’s findings regarding interpretability, the DASH 
should not be used in future trials in Dupuytren’s disease. 
The MIC for the URAM after open surgery (10.5/45) was greater than that 
previously reported for aponeurotomy (2.7/45) (Beaudreuil et al., 2011). 
Future work should involve prospective anchors, given that the GRC 
correlated more closely with final functional state than with change in 
functional following treatment, and further study of timing of assessment after 
treatment is required. 
Alongside examination of hand function outcome measures themselves as 
described in the earlier chapters in the thesis, understanding the variables 
associated with poor functional outcome has been neglected in previous 
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research, yet understanding which variables are relevant to functional 
outcome will inform future research design. 
The next chapter will investigate the factors associated with poor functional 
outcome through a cross sectional design. 
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10 Functional,Outcome,,Complications,and,Associated,Factors,
Following,Surgery,For,Dupuytren’s,Disease,,
10.1 Preface,
The previous chapters have investigated aspects of the performance of 
outcome measures in Dupuytren’s disease.  Further work will be required to 
ensure that the optimal outcome is chosen for the purpose required in future 
studies, though aspects of poor performance have been demonstrated for the 
commonly used measures of the DASH, the URAM and passive extension 
deficit.  In addition to the selection of an appropriate measure, study design 
may need to account for factors that independently influence outcome besides 
the type of treatment received.  Factors associated with recurrence have been 
studied previously, and collectively have been termed the Dupuytren’s 
‘diathesis’.  However, the factors associated with functional outcome are not 
well described.  Identifying and controlling differences in such factors would be 
important in designing non-randomised comparative studies, to ensure that 
groups are matched.  Confirmation that randomised trial groups are 
appropriately matched for such factors would also be important.  This chapter 
investigates late outcome of treatment and the factors associated with poor 
functional state after treatment. 
 !
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10.2 Introduction,
The factors associated with the ‘Dupuytren’s diathesis’ have been studied 
(Abe et al., 2004, Dias et al., 2013, Gelberman et al., 1980, Hindocha et al., 
2006, van Rijssen et al., 2012).  However the objective outcomes studied, 
such as recurrence, provide an incomplete representation of the diverse 
disability and functional impairment experienced by patients with Dupuytren’s 
disease (Rodrigues et al., 2014).  Recurrence and extension are not the only 
causes of poor outcome after surgery for Dupuytren’s disease.  For example, 
complications causing loss of finger flexion may also have serious functional 
consequences.  A recent review has considered the rates of complications 
reported in the literature following treatment of Dupuytren’s disease (Crean et 
al., 2011).  However, factors associated with poor functional outcome and 
complications of surgery have not been investigated. 
The Disabilities of the Arm, Shoulder and Hand (DASH) patient-reported 
outcome measure (PROM) correlates poorly with angular deformity (Degreef 
et al., 2009, Engstrand et al., 2009, Jerosch-Herold et al., 2011, Zyluk and 
Jagielski, 2007), which has led to the conclusion that such PROMs may not be 
valid in Dupuytren’s disease (Packham, 2011).  Other measures, such as the 
Sollerman hand score show a statistically significant, though weak, correlation 
with angular deformity (Sinha et al., 2002).  A new Dupuytren’s disease-
specific PROM, the Unité Rhumatologique des Affections de la Main (URAM) 
scale correlates with angular deformity (Beaudreuil et al., 2011),  but may not 
describe other domains of outcome, such as pain (Beaudreuil et al., 2014). 
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In this study, functional outcome and complications of surgery for Dupuytren’s 
disease were assessed, along with the factors associated with these 
parameters rather than those associated with recurrence or extension alone. 
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10.3 Methods,
10.3.1 Patient,recruitment,and,data,collection,
This project was independently approved as a service evaluation at each 
participating centre prior to commencing data collection at that centre.  
Information governance, and where required Caldicott Guardian, approval was 
also obtained locally prior to commencing recruitment.  Clinical coding 
departments at five UK NHS hand surgery centres (Derby, Livingston, 
Nottingham, Plymouth, Rotherham) identified patients who had undergone 
aponeurotomy, fasciectomy or dermofasciectomy either 1 year or 5 years 
earlier.  Codes for amputation were not included.  Patients living within 20 
miles of the centre were invited to attend a locally approved service 
evaluation.  A single surgeon assessed all who consented who could be 
assessed 1 or 5 years (+/- 2 months) after their surgery.  The candidate 
performed a standardised examination on all patients. 
Data captured included patient demographics, known and suggested risk 
factors for the progression of Dupuytren’s disease, complications of surgery, 
reoperation to the digit since the index procedure, angular deformity, and the 
DASH PROM. 
If more than one digit on a hand had been treated with the same procedure 
(e.g. fasciectomy to little and ring fingers in a single procedure), then only one 
digit was assessed.  The digit selected in such cases was the one that 
currently had the worst total active extension deficit. 
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If different procedures were performed in one operation (e.g. fasciectomy to 
ring finger and dermofasciectomy to little finger), then both procedures were 
analysed as separate events for the study of objective outcomes, but the 
patient was not included in the functional outcome analyses. 
If both hands were treated with the same procedure in one operation (which 
only occurred with aponeurotomy), then only the treated digit on the dominant 
hand was assessed, and was included in objective and functional outcome 
analyses.  This avoided any patient being recruited to the same subgroup 
more than once (Sauerland et al., 2003). 
Analyses were performed using Prism 6.0 for Mac OS X (GraphPad® 
Software, La Jolla, USA, 2012) and SPSS® Statistics version 21 (IBM® 
Software, Redmond, USA, 2012).  DASH scores were dichotomised into those 
above 15 (symptomatic scores) and those below 15 (asymptomatic scores), 
based on guidance from the developer of the tool (Kennedy et al., 2011). 
10.3.2 Objective,outcomes,
Reoperation (defined as further surgery for recurrence or extension of 
Dupuytren’s disease in the same digit) was assessed by patient recall, and 
confirmed via hospital records if unclear.  The candidate assessed passive 
extension deficit at MCPJs and PIPJs for all cases.  During all measurements, 
the other joints in the ray being assessed were held in maximum passive 
flexion, to standardise the effect of dynamism (Rodrigues et al., 2014). 
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10.3.3 Functional,outcome,
Proportions of patients with poor functional outcome 1 and 5 years after 
different types of procedure were compared using Chi square tests. 
Binary logistic regression analysis was performed to identify and control for 
factors associated with poor functional outcome (defined as DASH>15 at 1 
year after treatment).  The independent variables studied were further 
ipsilateral Dupuytren’s disease surgery since the index procedure (“surgery 
since”), length of follow up (1 year or 5 years) and eight factors, some of which 
are part of the traditional Dupuytren’s diathesis, and others putative novel 
factors that might be expected to influence functional outcome: 
• Self reported alcohol consumption >28 United Kingdom units per week 
(1 unit is equivalent to 10 milligrams of ethanol) 
• Active smoker 
• Self reported positive family history of Dupuytren’s disease 
• Surgery to the little finger 
• Presence of knuckle pads on examination 
• Index procedure being revision of previous surgery (defined as 
previous surgery to the same digit) 
• Diabetes mellitus 
• Gender 
Operation type was entered with aponeurotomy as the constant, so that 
fasciectomy and dermofasciectomy were compared to it. 
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The suitability of the data for logistic regression was verified prior to analysis.  
In particular, the data were examined for the absence of multicollinearity, 
which occurs when two or more of the independent variables studied correlate 
with each very strongly.  This can affect regression, and in particular can 
influence the results obtained regarding the independent variables concerned 
(Pallant, 2010).  To do this, tolerance, the amount of variance that cannot be 
accounted by other variables, was calculated for each variable.  If it is low, 
then the variable may show collinearity with another variable, or 
multicollinearity with several variables (Pallant, 2010).  In keeping with 
convention, an unacceptable level of tolerance was defined as <0.1. 
To control for false discoveries (false positives), the p value threshold 
considered significant was adjusted using a described method (Benjamini and 
Hochberg, 1995).  As the variables associated with poor functional outcome 
have not been studied widely, a false discovery rate (Q) of 20% was 
considered reasonable to minimise type 2 error risk.  The variables in the 
model were ordered by p value and ranked, and the threshold for each 
variable calculated using the formula (i/m)*Q, where ‘i’ was the rank of the 
variable and ‘m’ was the total number of tests (13 in the analysis of functional 
outcome).  If the p value obtained was smaller than 0.05 and lower than its 
calculated threshold, then the significant result was considered true. 
 
10.3.4 Adverse,outcomes,
The adverse outcomes assessed were: 
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• Cold intolerance (described using an existing scale (Campbell and Kay, 
1998)) 
• Loss of flexion (defined as a fingertip pulp to distal palmar crease 
distance of over 10mm on active flexion) 
• Infection (defined as patient recall of the need for at least one 
postoperative course of antibiotics that was not prescribed as 
prophylaxis) 
• Complex regional pain syndrome (CRPS) (defined using the modified 
International Association for the Study of Pain (IASP) criteria (Harden 
et al., 2007)) 
• Altered sensation (defined as failure to identify 2/3 tests of two point 
discrimination at 6 millimetres at distal phalanx level in one or both 
digital nerve territories on the operated digit) 
Proportions of patients with each complication were compared between 
procedures with Chi square tests.  Hierarchical binary logistic regression 
analyses were performed for each complication in a similar manner as for 
functional outcome.  The independent variables selected for study were ones 
that might influence the risk of complications.  In addition to further ipsilateral 
surgery for Dupuytren’s disease, they were: 
• Multiple digit surgery during index procedure 
• Gender 
• Diabetes mellitus 
• Smoking status 
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• Index procedure being revision of previous surgery (defined as 
previous surgery to the same digit) 
For complications expected to change between 1 and 5 years postoperatively, 
the time point (1 year versus 5 years) was also studied.  These were loss of 
flexion and cold intolerance (which might improve in the intervening period).  
For other complications, all assessments were studied together. 
10.3.5 Sample,size,
A sample size with ten outcome events per predictor variable is often quoted 
for logistic regression analyses.  As twelve predictor variables were used here, 
this would require 120 poor functional outcomes (DASH>15) in our study.  
However, more recent examination of this rule has suggested that five to nine 
outcome events per predictor variable may be acceptable (Vittinghoff and 
McCulloch, 2007).  Furthermore, the proportion of patients with poor functional 
outcome following Dupuytren’s disease surgery is not well described.  A target 
of 100 poor functional outcomes was set, and a total target sample size of 
400, based on an assumption that approximately 25% would have poor 
function. 
 
10.4 Results,
10.4.1 Patients,and,procedures,
Four hundred and fourteen patients were recruited and assessed between 
September 2011 and June 2013 across all sites.  These 414 patients had 
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undergone 433 procedures.  One had undergone an amputation after the 
index procedure, and was excluded from the analysis. 
All remaining 432 procedures in 413 patients were included in analyses of 
reoperation and complications, as these were recorded at digit level (Table 
10.1).  However, function was assessed at patient level.  Ten of the 413 
patients had undergone aponeurotomy to both hands in a single procedure, 
and only their dominant hand procedures were assessed.  A further nine 
patients had undergone different procedures to different digits, and so were 
excluded from analyses of function.  Thus, 404 patients were included in 
analyses of function (Table 10.1). 
Nine patients (2%) had different procedures assessed separately at different 
times in the study period.  This comprised seven patients who had undergone 
fasciectomy and dermofasciectomy to different digits of the same hand 1 year 
earlier and one patient who had undergone fasciectomy and 
dermofasciectomy to different digits of the same hand 5 years earlier.  The 
other patient had undergone fasciectomy to one hand and aponeurotomy to 
the other hand in the same procedure. 
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 1 YEAR FOLLOW UP 5 YEAR FOLLOW UP 
 Number of procedures in 
objective analyses 
Number of patients in 
function analyses 
Number of procedures in 
objective analyses 
Number of patients in 
function analyses 
Total 
 
270 245 162 159 
Aponeurotomy 114 104 20 19 
Fasciectomy 126 118 125 124 
Dermofasciectomy 30 23 17 16 
Table 10.1: Sample sizes studied 
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The demographics of the 413 patients are shown in Table 10.2.  In terms of 
reoperation choice, 4/11 reoperations after aponeurotomy were further 
aponeurotomies, and the remaining 7/11 were fasciectomies.  After 
fasciectomy, 1/11 was an aponeurotomy, 5/11 were fasciectomies and the 
remaining 5/11 were dermofasciectomies.  These proportions were 
significantly different (p=0.028, Chi square test).  It was not clear whether 
these choices were due to patient preference, surgeon preference, or other 
reasons. 
 
10.4.2 Objective.outcomes.
The percentage of procedures that that resulted in reoperation was not 
different between the three procedures in the 1-year postoperative group 
(p=0.393, Chi square test, see Table 10.3).  However, the reoperation rate 
was significantly greater after aponeurotomy in the 5-year group (p=0.000, Chi 
square test, see Table 10.3).  The reoperation rate after aponeurotomy was 
significantly higher at 5 years than at 1 year after treatment (p=0.002, Fisher’s 
Exact test, see Table 10.3).  There was no significant difference between 1 
and 5-year subgroups for fasciectomy or dermofasciectomy (see Table 10.3). 
‘Poor objective outcome’ was estimated to account for patients who may have 
declined revision surgery or been considered unsuitable for further surgery.  
This was done by combining those who had undergone reoperation with those 
who had considerable loss of extension but had not undergone further 
surgery.  The proportion of ‘poor objective outcome’ cases was significantly 
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greater 1 year after more invasive procedures (Table 10.3).  However, there 
was no difference between procedures in the 5-year groups. 
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Demographic or candidate risk factor  
Age Mean 66, Range 33-89 
Male : Female 318 : 95 (77% male) 
Hand dominance 371/413 right handed 
(90%) 
Diabetic 61/413 (15%) 
Smoker 60/413 (15%) 
Self reported weekly alcohol intake (UK units) Mean 14.7  
Previous ipsilateral surgery prior to index 
operation 
103/413 (25%) 
Index operation was revision of previously 
treated digit 
85/413 (21%) 
Self reported positive family history of 
Dupuytren’s disease 
180/413 (44%) 
Knuckle pads present 122/413 (30%) 
Hand treated 212/413 right (51%) 
Digit studied 248 little (60%) 
129 ring (31%) 
25 middle (6%) 
9 index (2%) 
2 thumb (0.5%) 
Table 10.2: Patient demographics and prevalence of candidate risk 
factors 
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Outcome  Aponeurotomy Fasciectomy Dermofasciectomy Chi square test  
Reoperation 1 year 
5 years 
5/114 (4.4%) 
6/20 (30.0%) 
3/126 (2.4%) 
8/125 (6.4%) 
0/30 (0%) 
0/17 (0%) 
p=0.393 
p=0.000 
‘Poor objective outcome’ 
(Reoperation or either MCPJ 
or PIPJ>25o) 
1 year 
5 years 
25/114 (21.9%) 
8/20 (40.0%) 
48/126 (38.1%) 
61/125 (48.8%) 
14/30 (46.7%) 
10/17 (58.8%) 
p=0.006 
p=0.521 
Table 10.3: Objective outcomes 
MCPJ – metacarpophalangeal joint, PIPJ – proximal interphalangeal joint 
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10.4.3 &Functional&outcome&&
The proportion of patients with symptomatic DASH scores was not 
significantly different between the three procedures for either 1-year or 5-year 
postoperative patients (Table 10.4).  However different proportions of these 
patients had undergone further surgery in the 1 or 5 years since, with a 
significantly higher reoperation rate 5 years after aponeurotomy than after 
dermofasciectomy. 
As the prerequisites were met in terms of tolerance of the variables studied, 
logistic regression analysis was performed.  The omnibus test demonstrates 
whether the model built by the analysis performs well in terms of ‘goodness of 
fit’, i.e. whether the included variables do actually contribute to predicting poor 
functional outcome.  Here, it was statistically significant (p=0.000), 
demonstrating that this was the case.  The results of the logistic regression 
analysis are shown in Table 10.5.  Controlling for confounding variables such 
as the effect of further surgery since, and of length of follow up, the only other 
variables studied that showed significant associations with poor function were 
female gender, diabetes mellitus and previous ipsilateral surgery for 
Dupuytren’s disease.  In general, the variables considered part of the 
Dupuytren’s diathesis were not associated with poor functional outcome.!
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Outcome Time 
point 
Aponeurotomy Fasciectomy Dermofasciectomy p value 
DASH summary score 
(mean (95%CIs)) 
1 year 
5 years 
9.5 (6.8, 12.2) 
9.1 (4.7, 13.5) 
10.7 (7.6, 13.8) 
10.9 (8.3, 13.5) 
14.3 (6.2, 22.5) 
15.1 (5.5, 24.8) 
0.421* 
0.448* 
Proportion DASH>15 1 year 
5 years 
19/104 (18.3%) 
5/19 (26.3%) 
26/118 (22.0%) 
34/124 (27.4%) 
7/23 (30.4%) 
5/16 (31.3%) 
0.416† 
0.940† 
Table 10.4: Functional outcomes 
*One way ANOVA 
†Chi square test 
DASH – Disabilities of the Arm, Shoulder and Hand, 95%CIs – 95% confidence intervals 
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Independent variable Adjusted 
Odds 
Ratio 
(OR) 
95% confidence 
intervals of 
adjusted OR 
Rank 
by p 
value (i) 
† 
(i/m)*Q 
p value 
threshold 
† 
Significance 
of 
association 
(p value) 
Gender      
 Female 3.85 2.13-7.14 1 0.02 0.00 
 Male 1     
Previous ipsilateral Dupuytren’s 
surgery 
    
 Yes 2.13 1.18-3.85 2 0.03 0.01 
 No 1     
Diabetic      
 Yes 2.07 1.10-3.91 3 0.05 0.03 
 No 1     
Smoker      
 Yes 1.67 0.83-3.37 4 0.06 0.15 
 No 1     
Little finger surgery      
 No 1.35 0.79-2.27 5 0.08 0.27 
 Yes 1     
Follow up length      
 5 years  1.33 0.79-2.27 6 0.09 0.28 
 1 year 1     
Knuckle pads      
 Present 1.31 0.76-2.28 7 0.11 0.33 
 Absent 1     
Further surgery since      
 Yes 1.60 0.58-4.43 8 0.12 0.36 
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 No 1     
Age at surgery      
 Under 50 1.52 0.56-4.16 9 0.14 0.41 
 50 or over 1     
Procedure was fasciectomy     
 Fasciectomy 1.25 0.68-2.28 10 0.16 0.48 
 Aponeurotomy 1     
Procedure was dermofasciectomy     
 Dermofasciectomy 1.21 0.45-3.27 11 0.17 0.70 
 Aponeurotomy 1     
Family history of Dupuytren’s disease     
 Yes 1.05 0.64-1.74 12 0.34 0.84 
 No 1     
Weekly alcohol intake      
 <=28 units 1.01 0.49-2.08 13  0.98 
 >28 units 1     
Table 10.5: Logistic regression of function 
 
 !
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10.4.4 Complications!
The rates of different complications are shown in Table 10.6, grouped by 
procedure (and length of follow up where relevant).  Complications that were 
hypothesised to improve over time (cold intolerance and loss of flexion) were 
more common at 1-year follow up compared to 5-year follow up.  Infection and 
altered sensation were observed more frequently after more invasive 
procedures than after aponeurotomy.  At 1-year follow up cold intolerance and 
loss of flexion were more common after more invasive procedures.  There was 
no difference between procedures at 5-year follow up, though significantly 
more of the aponeurotomy group had undergone further surgery. 
Tolerances for all variables studied in relation to complications were 
acceptable, and logistic regression analyses were performed for all 
complications except CRPS, as this was found infrequently.  Each of the 
models for cold intolerance, loss of flexion, altered sensation and infection 
was significant on omnibus testing.  All statistically significant results from the 
analyses are shown in Table 10.7. 
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Complication Time point Aponeurotomy 
(total n=134) 
Fasciectomy 
(total n=251) 
Dermofasciectomy 
(total n=47) 
p value (Chi square 
tests) 
Reoperation 1 year 5/114 (4%) 3/126 (2%) 0/30 (0%) 0.39 
5 years 6/20 (30%) 8/125 (6%) 0/17 (0%) 0.002 
Cold intolerance 1 year 11/114 (10%) 39/126 (31%) 19/30 (63%) <0.0001 
5 years 1/20 (5%) 20/126 (16%) 5/17 (29%) 0.13 
Flexion loss>10mm 1 year 20/114 (18%) 42/126 (33%) 13/30 (43%) 0.002 
5 years 3/20 (15%) 30/125 (24%) 3/17 (18%) 0.60 
Altered sensation* 6/134 (4%) 38/251 (15%) 9/47 (19%) 0.003 
Infection 2/134 (1%) 22/251 (9%) 7/47 (15%) 0.003 
CRPS 1/134 (1%) 5/251 (2%) 0/47 (0%) 0.42 
Table 10.6: Complications 
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*Defined as absent 2 point discrimination at 6 millimetres in either radial or ulnar digital nerve territories over the pulp of the distal 
phalanx 
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Adverse 
outcome 
 
Independent 
variable 
Adjusted 
Odds 
Ratio 
(OR) 
95% 
confidence 
intervals of 
adjusted OR 
Rank 
by p 
value 
(i) 
† 
(i/m)*Q 
p value 
threshold 
† 
Significance 
of 
association 
(p value)  
Cold intolerance      
 Dermofasciectomy 14.77 5.78-37.74 1 0.02 0.000 
 Aponeurotomy 1     
      
 Fasciectomy 4.00 1.97-8.12 2 0.04 0.000 
 Aponeurotomy 1     
      
 Dermofasciectomy 3.69 1.75-7.80 3 0.06 0.001 
 Fasciectomy 1     
       
 1-year follow up 2.68 1.54-4.67 4 0.08 0.001 
 5-year follow up 1     
       
 Smoker 2.66 1.44-4.94 5 0.1 0.002 
 Non-smoker 1     
       
Loss of flexion>10mm      
 Dermofasciectomy 5.34 2.16-13.21 1 0.02 0.000 
 Aponeurotomy 1     
      
 Fasciectomy 3.66 1.86-7.17 2 0.04 0.000 
 Aponeurotomy 1     
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Altered sensation      
 Fasciectomy 3.09 1.21-7.85 1 0.02 0.018 
 Aponeurotomy 1     
     
 Dermofasciectomy 3.91 1.19-12.80 2 0.04 0.024 
 Aponeurotomy 1     
     
 Female 2.11 1.10-4.03 3 0.06 0.024 
 Male 1     
     
Infection     
 Dermofasciectomy 7.59 1.42-43.42 1 0.02 0.018 
 Aponeurotomy 1     
      
 Fasciectomy 6.07 1.33-27.60 2 0.04 0.020 
 Aponeurotomy 1     
      
 Revision 
procedure 
2.36 1.03-5.38 3 0.06 0.041 
 Primary procedure 1     
 
Table 10.7: Significant independent variables in logistic regression 
analyses of complications  
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10.5 Discussion,
10.5.1 Present,study,findings,
This study confirms that aponeurotomy is associated with a higher reoperation 
rate than fasciectomy or dermofasciectomy.  However, after controlling for 
some independent variables that might differ between the groups, functional 
outcome was not significantly different between these three procedures at 1 
year and 5 year follow-up.  This finding requires confirmation in a study with a 
larger number of dermofasciectomy and aponeurotomy cases with 5-year 
follow-up but is important and may be valid.  This is as complications that limit 
function, such as loss of flexion, cold intolerance and altered sensation, may 
be more frequent following more invasive procedures, which typically had 
higher complication rates in this study. 
The cross-sectional design of our study means that patients’ immediate 
postoperative outcome is not known and limits the interpretation of our data in 
Table 3.  However, other studies have demonstrated reliable rates of initial 
correction, including for aponeurotomy (Pess et al., 2012). 
The choice of recurrence as the primary endpoint for studying treatment in 
Dupuytren’s disease is challenged by the data presented here, which 
demonstrates the different rates of complications after different treatments.  
As many of these complications are not associated with recurrence, they will 
not be captured if recurrence is used as the primary outcome measure.  
Consequently, recurrence may be a surgeon-centred outcome, but is unlikely 
to be patient-centred, and it may be of limited value in cost utility analyses. 
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The variables associated with poorer outcome in this study differ from those 
identified as contributing to the Dupuytren’s diathesis in other studies (Abe et 
al., 2004, Hindocha et al., 2006, Hueston, 1963).  This suggests that those 
patients whose hand function is worse following surgery may not always be 
the patients who experience recurrence. 
Several variables were associated with poor function here.  Patients 
undergoing revision treatment may not achieve the same degree of improved 
hand function as those undergoing primary surgery due to an accumulation of 
iatrogenic insults to the hand, or perhaps due to disease severity.  Women 
reported worse hand function than men, though it is not clear why this is the 
case.  It may be intrinsic to the DASH itself, as similar patterns have been 
reported with DASH-related measures in other hand conditions (the 
QuickDASH in carpal tunnel release) (Jenkins et al., 2012).  Diabetics might 
be expected to have greater risk of complications, such as infection and poor 
healing, and worse rehabilitation as a result.  Alternatively, their higher DASH 
scores may reflect a higher prevalence of comorbid upper limb conditions, 
such as cheirarthropathy, trigger fingers, and carpal tunnel syndrome (Larkin 
et al., 2014, Pandey et al., 2013), which may be confounding factors.  Newer 
developments have included the launch of at least two Dupuytren’s-specific 
measures (Beaudreuil et al., 2011, Mohan et al., 2014).  However, the DASH 
has been the most commonly employed measure to date (Ball et al., 2013).  
Therefore, the data presented here are important to consider when 
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interpreting the findings of studies regarding functional outcome in 
Dupuytren’s disease. 
When the independent variables studied were controlled for, there was no 
difference in the odds of having poor hand function 5 years after 
aponeurotomy compared to fasciectomy or dermofasciectomy.  This may 
reflect a balance between a greater risk of recurrence after aponeurotomy 
(being offset by the less invasive nature of the procedure and perhaps less 
frequent or less severe complications.  However, given the limitations of this 
study apparent from the different interpretations of the individual findings, a 
randomised controlled trial with hand function as the primary endpoint is 
required to confirm this and to facilitate comparison of the relative cost 
effectiveness of different treatments for Dupuytren’s disease. 
10.5.2 Limitations,
The most important limitation to this study relates to its cross-sectional design.  
As a result, the preoperative and immediate postoperative states of patients 
were not known, and may not have been matched.  However, steps were 
taken to improve the reliability of the data presented.  The centres that 
contributed had different preferences for treatment, with some favouring 
aponeurotomy and others fasciectomy.  Those centres that preferred 
aponeurotomy have considerable experience with it, and so use it as their first 
line treatment for most cases of Dupuytren’s disease.  Therefore, it is 
expected that a large proportion of patients who underwent aponeurotomy at 
these centres would have received fasciectomy at the others in the study.  
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However, this cannot be confirmed.  Furthermore the logistic regression 
analyses were performed with the aim of adjusting for differences between 
groups.  Despite this, the comparison between procedure types may not be as 
robust as would be achieved in a prospective comparative study.  
Nevertheless, the examination of the factors associated with poor functional 
outcome is important in its own right.  The findings of this study certainly need 
verification with a prospective study, preferably incorporating randomisation. 
Some of the variables studied were self-reported and may not have been 
accurate: for example, smoking status may have changed since the patient 
underwent surgery, there may have been recall bias, and there may have 
been social desirability responses with patients denying or underestimating 
factors such as excessive alcohol intake or smoking.  Studying such variables 
prospectively would be more reliable and thus allow for more accurate 
statistical modelling. 
Some sub groups within our study were relatively small.  However, the rates of 
complications identified are largely comparable to those reported elsewhere in 
the literature (Crean et al., 2011).  Our findings need to be validated with 
further large size studies, or even registry-level data. 
There are other limitations to our data that might contribute to the findings 
differing from those in other studies.  There may have been selection bias in 
studies in which patients were invited to participate retrospectively.  Also there 
may be differences in the pre-operative states of the digits treated in different 
studies, or in patient or surgeon attitudes, either relating to different 
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international cultural norms or perhaps related to involvement in a trial 
compared to routine clinical practice.  However, given the paucity of literature 
focussing primarily on functional outcome in Dupuytren’s disease, rather than 
recurrence, it is envisaged that this area merits attention adds value and 
should influence the design of future research studies. 
10.5.3 Relationship,to,existing,literature,
Reoperation may be an important clinical and economic endpoint to study, but 
is a complex variable.  In order to undergo further treatment, a patient would 
have to have recurrent or extended disease that is amenable to further 
surgery, be offered surgery by a clinician, and consent to the further 
treatment.  Indeed, it was noted during the assessments that some patients 
described progressive recurrence but had not sought further intervention.  
This pattern has been previously reported, with ‘reoperation rates’ lower than 
‘treatment failure’ rates, where reoperation or recurrent contracture is studied 
(van Rijssen et al., 2012).  As a result, reoperation is not a valid surrogate for 
recurrence.  In this study, the proportions of patients undergoing reoperation 
within 5 years of treatment were higher after aponeurotomy, as might be 
expected, but were still lower than reported by others (Foucher et al., 2003, 
van Rijssen et al., 2012).  In a randomised controlled trial that compared 
aponeurotomy to fasciectomy, proportions of patients undergoing reoperation 
within 5 years were higher, with reoperations rates of 33/52 (63%) and 4/41 
(9%) for fasciectomy (van Rijssen et al., 2012). 
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Abe and colleagues investigated the factors associated with reoperation at a 
mean follow-up length of 5 years in a small Japanese population (Abe et al., 
2004).  However, the applicability of findings in this population to other 
populations is not clear.  Additionally, the length of follow-up ranged from 3 to 
12 years.  As Dupuytren’s disease is a slowly progressive condition, patients 3 
years following Dupuytren’s disease surgery are not comparable to those 12 
years after treatment. 
Hindocha and colleagues studied the factors associated with recurrence of 
palpable disease in the operated field (Hindocha et al., 2006).  Whilst this is a 
common definition of recurrence (Becker and Davis, 2010), one may argue 
that it is less clinically relevant than other endpoints.  The reappearance of 
palpable disease alone does not require treatment, does not necessarily 
impair function, and has not been shown to predict subsequent deterioration, 
and as such, does not in itself mandate treatment. 
van Rijssen and colleagues studied factors associated with recurrence defined 
as a progressive angular deformity (van Rijssen et al., 2012).  As further 
treatment might become advisable with deterioration in angular deformity, this 
may be a more clinically applicable and reliable endpoint than those used in 
either of the earlier studies.  However, it does not describe the patient’s hand 
function or health-related quality of life, which is probably also influenced by 
factors such as complications. 
Most recently, Dias and colleagues investigated factors associated with 
progressive contracture recurrence in a randomised controlled trial of firebreak 
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dermofasciectomy versus z-plasty closure of fasciectomy wounds (Dias et al., 
2013).  The degree of progression that constituted recurrence was not 
formally defined. 
However, not all studies of recurrence support the predictive value of diathesis 
factors (Gelberman et al., 1980). 
Others have investigated the factors associated with poor outcome in the 
absence of recurrence of disease (Misra et al., 2007), highlighting that ‘poor 
outcome’ in Dupuytren’s disease is not entirely due to recurrence. 
Recurrence has been the focus of much research in Dupuytren’s disease 
(Becker and Davis, 2010).  Whilst treating recurrent disease may be 
challenging, doing so following an aponeurotomy may be more straightforward 
than after more invasive surgery (van Rijssen and Werker, 2012).  
Furthermore, it is important to appreciate variables that might be associated 
with a tendency for Dupuytren’s disease to recur following treatment; 
recurrence alone cannot be used as a surrogate for functional outcome.  This 
is important given that the correlation between angular deformity and loss of 
function is weak (Engstrand et al., 2009, Jerosch-Herold et al., 2011, Zyluk 
and Jagielski, 2007).  Also an assessment of health-related quality of life 
should be made to allow cost effectiveness analysis (NICE, 2008).  
Additionally, these factors might provide a more patient-centred and relevant 
evaluation of treatment outcome; avoiding recurrence at the expense of an 
increased risk of complications of surgery may not be desirable.  Instead, 
University of Nottingham   Functional outcome 
 367 
considering the impact of both recurrence and complications in affecting 
function may be more appropriate. 
10.6 Conclusions,of,study,of,late,outcome,and,complications,
Functional state following treatment for Dupuytren’s disease remained 
matched between procedures in this study, after controlling for confounding 
factors.  However, due to the limitations arising from its cross sectional nature, 
this finding needs verification in a prospective study.  However, the factors 
associated with poor functional outcome were not the same factors associated 
with recurrence, or the Dupuytren’s diathesis.  As with previous studies, 
complications were relatively common, particularly after more invasive 
surgery.  The functional outcome of surgery for Dupuytren’s disease may 
reflect both correction and recurrence of contractures, but also complications. 
 
SUMMARY 
The comparison of different procedures in this chapter demonstrates that 
despite very different recurrence rates, the final functional state that patients 
achieve after treatment was not different between them.  There are limitations 
to this finding, for example preoperative state was not known and so the 
groups may not be matched, but further investigation of functional outcome is 
indicated. 
The differences between treatments in terms of complications are 
considerable, and a logical interpretation is that functional outcome represents 
the balance of achieving and maintaining correction versus avoiding treatment 
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sequelae.  This might explain the poor correlation between hand function and 
angular deformity reported earlier in this project, and in previous studies 
(Engstrand et al., 2009, Jerosch-Herold et al., 2011, Zyluk and Jagielski, 
2007). 
The factors associated with poor functional state differed from diathesis 
factors, and hand surgeons need to reassess which patients are at risk of 
completing rehabilitation with a worse functional outcome in light of this 
finding.  More aggressive hand therapy may be warranted for this subgroup. 
The results of this study may inform interpretation of papers in which the 
DASH was used; the findings should be confirmed for other existing outcome 
measures and ideally after development of an optimal measure of hand 
function. 
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11 Project,discussion,
11.1 Findings,of,the,chapters,in,the,project,
11.1.1 Existing,literature,
The systematic review of trials in Dupuytren’s disease has confirmed that 
there are very few high quality comparative studies of the treatment of 
Dupuytren’s disease.  Even relatively modern studies have significant risks of 
bias.  In the case of those that reported angular deformity as the primary 
outcome (van Rijssen et al., 2006, van Rijssen et al., 2012), poor blinding of 
observers posed a significant risk.  This potential severity of this risk has been 
further explored in the present project by assessing the extent of dynamism 
that might be present.  Dynamism is a significant issue that may have been 
previously underestimated, as it had not been quantified.  As has been 
identified in other reviews (Ball et al., 2013, Becker and Davis, 2010), the 
outcomes reported have been inconsistent and are not standardised. 
A patient-reported outcome measure (PROM) may be a more suitable option.  
Whilst a range have been used in Dupuytren’s disease (Ball et al., 2013), 
aspects of their validity have not been fully investigated in Dupuytren’s 
disease, and the review of interpretability performed here identified limited 
data describing their interpretability.  There is an urgent need for investigation 
of candidate outcome measures for future research and for use in clinical 
practice, some of which has been performed in the present project. 
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At the same time, the meta-analysis of trials of splinting demonstrated that 
postoperative splinting, a commonly used component of treatment, may 
actually impair outcome.  This finding was not apparent in any of the meta-
analysed trials in isolation; it only became apparent when results were pooled 
here.  It is apparent that further research is required in this area 
11.1.2 Methods,employed,to,develop,and,appraise,outcome,measures,
This project has employed a range of techniques to appraise candidate 
outcome measures for future use in Dupuytren’s disease.  Frameworks exist 
to guide development of PROMs and their validation (Mokkink et al., 2010).  
However, this project has identified some limitations of contemporary PROM 
development methodology.  In particular, the preoperative impairments 
experienced in Dupuytren’s disease are diverse, and they also differ from the 
impairments present in the postoperative phase from treatment sequelae.  As 
a result, developing a PROM based on the preoperative experience of 
Dupuytren’s disease may result in a tool that is not comprehensive for use.  
These issues should be considered in future research design, and are 
relevant to a range of conditions, not just hand surgery or Dupuytren’s 
disease. 
11.1.2.1 Tool'Development'
Many of the outcome measures used to date in Dupuytren’s disease are best 
considered to be ‘legacy measures’, which were developed using out-dated 
methods.  For example, surgeons developed the PEM without any clear 
patient involvement (Macey et al., 1995).  More modern tools such as the 
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URAM involved physician input in the item generation process (Beaudreuil et 
al., 2011), which it could be argued prevents them from being truly ‘patient 
centred’.  This deviation from a truly patient-centred approach may also have 
occurred in the item reduction stages of development.  Modern approaches to 
item selection include removal of candidate items based on mathematical 
properties such as a limited spread of responses provided in a pilot study.  
However, this may render the tool further removed from the ‘real world’ patient 
experience of the condition.  Certainly, our patients’ goals were very diverse 
(almost unique at the individual level) and difficult to capture with a tool 
comprising task-based items, as is the case for the URAM.  Additionally, the 
data in the cohort study described here supports the conclusion that the 
URAM may not be comprehensive in terms of content validity, particularly in 
relation to postoperative pain. 
 
The developers of the URAM argue that it provides an assessment of the 
limitation arising from loss of extension (Beaudreuil et al., 2014).  However, if 
loss of extension is not a surrogate for global hand function or patient 
perception of improvement, then it is of limited practical value, particularly at a 
healthcare architecture level, where cost utility needs to be assessed to justify 
investment in treatment.  Assessing cost utility in the UK at present typically 
involves assessment of health-related quality of life (NICE, 2008), though may 
be performed using global hand function, which might be better assessed with 
University of Nottingham  Discussion 
 372 
domain-specific PROMs such as the Patient Evaluation Measure or the 
Michigan Hand Questionnaire. 
 
Future tool development must adopt a more patient-centred approach, to 
ensure that they appropriately reflect the lived experience and functional 
limitation in Dupuytren’s disease.  To achieve this, the scope of future 
outcome measures must be clearly defined and should be appropriate.  If cost 
utility of treatment and meaningful clinical improvement is to be achieved, then 
the items incorporated should describe one or more of global hand function, 
activity restriction, patient perception or health-related quality of life.  To do 
this, item generation should be based on patient input, and should include the 
experiences of patients in the early and late postoperative periods, so that the 
impact of treatment sequelae and complications are incorporated into the 
measure.  Given that domains such as functional impairment from loss of 
extension are likely to improve following treatment, but that complications 
such as cold intolerance and stiffness are likely to increase after surgery, it is 
reasonable to hypothesise that they will load on different constructs.  If this is 
found to be the case, then it is likely that a comprehensive outcome measure 
for use in Dupuytren’s disease will comprise at least two sub scales: one to 
assess the impact of preoperative symptoms that generally improve after 
treatment, and one to assess sequelae that arise from treatment. 
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This approach to tool development may be very apparent from a project such 
as this.  As has been demonstrated in the study of surgical complications in 
this project, the sequelae of the treatment of Dupuytren’s disease are very 
different to preoperative symptoms.  This may not be the case in other 
conditions where postoperative complications lead to similar functional 
impairments as the original preoperative symptoms.  However, adopting the 
approach suggested here may provide a more robust model for developing 
PROMs. 
 
11.1.2.2 Validity'and'Reliability'
Robust evidence for validation processes does not exist.  However, 
international consensus has been achieved through the Delphi process that 
generated the COnsensus-based Standards for the selection of health status 
Measurement INstruments (COSMIN) (Mokkink et al., 2010).  This venture 
resulted in a series of ‘checklists’ against which studies may be benchmarked.  
It also documented leading international opinion around choice of analyses.  
Given that most of the PROMs that have been used to study Dupuytren’s 
disease to date were developed prior to COSMIN, it is not surprising that 
these standards have not always been applied.  This project has applied some 
of these validation techniques to existing legacy measures, such as the 
DASH, to establish whether they display acceptable validity in spite of having 
been produced using parochial approaches to PROM development.  Typical 
deviations from COSMIN include inappropriate assessment of criterion 
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validity, failure to appropriately assess structural validity in relation to 
reliability, and issues relating to other parameters such as responsiveness and 
interpretability.  For example, COSMIN identifies a range of analyses that are 
not recommended for studying responsiveness, including all commonly used 
metrics, such as standardised response mean and effect size.  However, 
COSMIN was not able to establish which alternatives to these analyses are 
appropriate. 
 
Criterion validity has been studied for a range of PROMs in Dupuytren’s 
disease, with objective angular loss of extension used as the ‘gold standard’ 
against which the PROM’s performance is benchmarked.  Poor correlation 
with this gold standard has led to criticism of particular outcome measures.  
However, COSMIN establishes that surrogates such as loss of extension 
cannot be used as ‘gold standards’.  The only scenario in which a gold 
standard can be used is when an abridged version of a PROM is being 
compared to the original full length PROM, such as when establishing whether 
the QuickDASH behaves similarly to the full DASH, as studied here. 
 
Using angular deformity as the ‘gold standard’ against which a PROM’s 
criterion validity is assessed is illogical.  If angular deformity is the optimal 
measurement, then it ought to be used as the outcome measure, and the 
PROM is redundant.  The range and breadth of patient goals identified in this 
project demonstrates that preoperative functional limitation in Dupuytren’s 
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disease cannot be attributed to loss of extension alone.  Furthermore, angular 
deformity is subject to potential bias in the form of dynamism, which has also 
been quantified here.  Finally, postoperative complications studied in this 
project demonstrate that postoperative functional impairment is likely to relate 
to domains other than loss of extension.  This is why a suitable alternative to 
measuring angular deformity is required.  To then benchmark candidate 
outcome measures against the existing flawed measure of angles is not 
informative. 
 
COSMIN does consider assessing the relationship between a candidate 
outcome measure and other outcome measures under the umbrella of 
construct validity.  However, this ‘hypothesis testing’ involves examining 
specified hypotheses about how a PROM should behave in relation to other 
outcome measures.  As discussed, simply expecting a PROM to correlate well 
with angular deformity is not a sensible hypothesis to examine.  Indeed, if a 
PROM did correlate strongly with angular deformity, then two alternative 
conclusions are possible.  Firstly, the PROM is of no additional value 
compared to measuring angles.  Secondly, the PROM may be invalid, given 
that angular deformity is itself a flawed measure.  A better outcome measure 
might not necessarily correlate well with an existing flawed outcome measure.  
Although a single ‘gold standard’ is not available to resolve this issue, as 
already discussed.  However, convergent and divergent validity against a 
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battery of other outcome measures, and careful consideration of the face 
validity of what matters to patients are central to clarifying this situation. 
 
Another aspect of construct validity is to assess the internal relationships of 
items that comprise a PROM.  Cronbach’s alpha is commonly used to 
summarise the internal consistency of items.  However, this assumes that the 
items contributing to a summary score reflect the same underlying construct.  
Theoretically, a factor analysis ought to be performed to confirm this prior to 
measuring Cronbach’s alpha.  This was done as part of the original validation 
of the URAM (Beaudreuil et al., 2011), and has been considered for the DASH 
previously (Forget et al., 2014, Franchignoni et al., 2010), but had not been 
considered for the DASH when treating Dupuytren’s disease in pragmatic 
clinical practice.  The present project identified factor loadings that suggest 
that the DASH is not unidimensional, nor is the URAM.  Furthermore, they 
appear to reflect different constructs.  As already discussed above in outcome 
measure development, it may be that more than one sub scale is required to 
assess both the correction of preoperative symptoms and the occurrence of 
postoperative complications.  Two broad approaches to factor analysis may 
be employed: exploratory factor analysis and confirmatory factor analysis.  
Given the parochial development of a legacy PROM such as the DASH, its 
factor structure may not be easily predicted, hence exploratory factor analysis 
was used in this project.  The relevant constructs for assessing outcome in 
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hand surgery in general, and in Dupuytren’s disease may need further 
exploration before confirmatory factor analyses can be used for validation. 
 
11.1.2.3 Responsiveness'and'Interpretability'
Unlike responsiveness, interpretability is not considered as a measurement 
property of a PROM by COSMIN, but is acknowledged as an important 
characteristic (Mokkink et al., 2010).  Both the DASH and the URAM 
demonstrated acceptable responsiveness in this project, as defined by effect 
size from before to after treatment.  However when an external criterion, or 
anchor, was used to stratify outcomes and separate those that showed 
improvement from those that did not, the DASH was not interpretable, and an 
MIC could not be calculated.  Although the retrospective anchoring used may 
not be ideal methodology for studying interpretability compared to prospective 
anchoring, it is the most widely used anchor found in the review of the 
literature conducted as part of this project.  Besides the DASH in the present 
project, the systematic review of interpretability found only one other measure 
is uninterpretable: the Jebsen hand function test.  Although assessing 
interpretability this way has limitations, it may be a more clinically relevant 
parameter than responsiveness, and an appreciation of relevant MICs is 
important in trial design and data interpretation as part of guideline 
development.  However, the fact that the retrospective GRC anchor correlated 
better with postoperative state rather than with change in function, further 
supports the use of prospective anchors in future studies of interpretability.  
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According to the systematic review of interpretability, the most commonly used 
prospective anchor in hand surgery is the satisfaction domain of the Michigan 
Hand Questionnaire (MHQ), though there are issues with this.  It has been 
used by the MHQ’s developer, is frequently used to study the interpretability of 
other domains of the same tool (other parts of the MHQ), and it is unclear 
whether satisfaction is an appropriate construct to use as an anchor when 
assessing hand function.  Further investigation of anchors is required. 
 
Studying responsiveness may seem theoretically sound, as the complexity of 
appraising the performance of an anchor is avoided.  However, given that 
treatment of Dupuytren’s disease is not always successful in achieving 
correction of deformity, and that function might deteriorate from complications, 
the practicality of assessing responsiveness is a major challenge compared to 
studying interpretability.  Furthermore, PROMs that are not comprehensive, as 
may be the case with the URAM, may still show desirable responsiveness.  
Studying interpretability, even given its limitations, may identify poor 
performance of PROMs that are not comprehensive in a way that is missed by 
looking at responsiveness alone. 
 
Greater issues regarding interpretability also exist.  This project has 
considered clinically meaningful change following treatment at an individual 
level.  However, whether such a value can be applied to represent the clinical 
important difference between a bad average outcome from one treatment 
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compared to a good average outcome from a superior treatment, is not clear.  
It may be that the MIC is the best of a bad bunch of options, not just for 
determining meaningful change for an individual, but also for estimating a 
clinically important difference between individuals as is required for a power 
calculation for clinical trial comparing these options. 
 
One other issue regarding interpretability was identified in the systematic 
review of MICs conducted as part of this project.  To date, no data exists to 
describe the MIC for deterioration after treatment.  This is particularly 
important in the context of a progressive condition such as Dupuytren’s 
disease, where recurrence occurs frequently, and may adversely impact on 
function.  Indeed, undergoing multiple procedures was associated with worse 
functional outcome at five years in this project.  These patients may 
experience a combined effect, with functional impairment arising from both the 
complications of previous surgery as well as from recurrence of disease.  MIC 
for deterioration could be studied through a cohort study with the use of an 
appropriate anchor.  Given the issue with recall bias that limits the value of 
retrospective anchors that were confirmed in this project, studies of 
interpretability of deterioration over the years following treatment should use 
prospective anchors.  This would be achieved by the patient completing the 
anchor at baseline or preoperative assessment and again at follow up, and the 
change in  the anchor item would then be used to subgroup the outcomes. 
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11.1.3 Validity,, reliability,, responsiveness,and, interpretability,of,specific,outcome,
measures,studied,
Investigations of the performance of outcome measures in this thesis have 
revealed several findings, including limitations of validity of the two PROMs 
that might be candidates for use in future studies. 
 
11.1.3.1 The'Unité'Rhumatologique'des'Affections'de'la'Main'scale'
As the first Dupuytren’s disease-specific PROM to be developed, the URAM 
has been an important tool to assess in this project.  It may not be cross-
culturally sensitive for use in the UK, or may not be comprehensive in terms of 
content validity, as it did not describe some common important goals for 
patients in this project.  The state of validation of the URAM scale is 
summarised in Table 11.1.  Its interpretability was at the threshold of 
acceptability in this project, based on the area under the receiver operating 
characteristic (ROC) curve being 0.74, virtually at the lower limit of 
acceptability of 0.75 (Fan et al., 2006). 
 
In contrast to the more parochial legacy measures used in Dupuytren’s 
disease, modern tools such as the URAM were developed using 
contemporary methodology (Beaudreuil et al., 2011).  Consequently, the 
URAM would be expected to perform better than other measures in 
assessments of its performance.  Despite this, limitations in its performance 
have been identified in this project.  The methodology used to develop the 
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URAM (Beaudreuil et al., 2011) may have contributed to the problems with the 
scale’s performance.  In the development process, a long list of candidate 
items was generated to describe the symptoms that patients might experience 
from Dupuytren’s disease, but not necessarily what they might experience 
from complications of treatment.  As discussed, this may limit the 
comprehensiveness of the URAM for assessing function after treatment, when 
complications may be relevant to assess. 
 
The candidate item list was narrowed down based on defined criteria, such as 
eliminating candidate items that were never performed by more than 5% of the 
study population, or eliminating items if the range of responses provided by 
the study group were not spread across five or more of the six options 
provided in the scale (0-5) (Beaudreuil et al., 2011).  The overall long list was 
not provided, nor was a breakdown of which items were excluded on the basis 
of which criterion so it is only possible to speculate on how this methodology 
may have affected the final scale.  However, there are learning points for the 
future.  While the criteria for excluding candidate items seem sensible, they 
have reduced its comprehensiveness.  If a task was never performed by 5% of 
the French URAM design cohort, then it will have been eliminated from the 
scale.  Improving pain was cited as a goal by 15% of patients in the current 
project, and if a similar proportion experienced pain preoperatively in the 
URAM design group, then it may have been eliminated on the basis of this, or 
may not have been included given the task-based nature of the items in the 
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URAM.  However, pain was not only seen as a preoperative symptom, but 
also increased after surgery in our prospective cohort, and so may be 
important to study.  In other clinical conditions, the symptoms and functional 
limitations of the disease may closely resemble the symptoms and limitations 
experienced following complications of treatment.  For example large joint 
osteoarthritis may present with pain, and pain might occur after a complicated 
arthroplasty.  In contrast, the treatment of Dupuytren’s disease is different.  
The complications of treatment identified in this project, and in previous work 
(Crean et al., 2011), may manifest with different symptoms and limitations 
from the preoperative symptoms.  The resulting URAM scale was 
unidimensional in an exploratory factor analysis conducted by the developers 
(Beaudreuil et al., 2011).  However, in the current project, an exploratory 
factor analysis was performed using the URAM items and the DASH items.  In 
the current analysis, the URAM was not unidimensional.  Instead, the final 
item in the URAM scale (“difficulty picking up objects with the thumb and index 
finger”), loaded on a different construct from the other items.  It is notable that 
this item may not directly relate to loss of extension in the same way as the 
other eight items in the URAM.  Furthermore, the thumb and index fingers are 
typically least affected by Dupuytren’s disease.  Instead, it loaded with task-
based items in the DASH. 
 
The disparity between this result and that obtained by the URAM developers 
may relate to entering all the DASH and URAM items in the same factor 
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analysis.  Typically each factor or construct generated extracted in a factor 
analysis should be reflected by several items for the analysis to be reliable 
(Floyd and Widaman, 1995).  Given that only item nine of the URAM loaded 
on a different factor to items one through eight, this may not have been 
detected in the factor analysis run by the developers, and only became 
apparent in this thesis as here constructs may have been better modelled by 
the incorporation of DASH items that behave similar to item nine of the URAM.  
Whether this lack of unidimensionality is large enough to be of clinical 
significance is not clear.  The disparity does demonstrate that even 
contemporary techniques of validation have limitations, and require cautious 
interpretation. 
 
The exploratory factor analyses extract underlying mathematical constructs 
that account for proportions of variance seen across the study cohort.  
However, the analyses cannot explain what exactly the underlying constructs 
are.  Instead, these require logical interpretation.  Understanding the 
constructs reflected by the URAM is potentially straightforward.  All nine items 
in the URAM are activity/participation restriction items, and all were generated 
from patients and clinicians aiming to capture the preoperative experience of 
Dupuytren’s disease (Beaudreuil et al., 2011).  The URAM correlates most 
closely with loss of extension (Beaudreuil et al., 2011), and items such as 
difficulty stroking or caressing are more likely to be impaired by loss of 
extension in the preoperative state, than loss of flexion as a postoperative 
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complication.  Preoperative symptom items should improve with successful 
treatment, but treatment complication items would deteriorate in cases in 
which adverse effects occur.  As a result, they may load onto different 
constructs that together provide a more complete reflection of hand function.  
If they do load differently, then disability or hand function might be better 
assessed as two separate summary scores.  If this is the case, then although 
the URAM may not be comprehensive as an assessment of disability or hand 
function in isolation, it might provide a sub scale summary score that 
describes the former, but a separate sub scale needs to be developed to 
assess postoperative sequelae as the latter.  Indeed, as URAM item nine 
(which assesses fine pinch grip) loaded separately from the other URAM 
items when a model was built using DASH and URAM items together, it may 
constitute the first item for such a sequelae subscale. 
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ASPECT OF 
VALIDITY 
SUBTYPE DATA IN PREVIOUS 
LITERATURE 
DATA IN CURRENT 
PROJECT 
COMMENTS 
Criterion validity  No No Not appropriate 
Construct validity Structural validity Yes 
(Beaudreuil et al., 
2011) 
Yes Exploratory factor analyses used 
in both.  Unidimensional in 
developers’ study, but not 
unidimensional in current project 
when model incorporated DASH 
items. 
 Hypothesis testing Yes 
(Beaudreuil et al., 
2011) 
No Compared to angular deformity 
and other PROMs with defined 
hypotheses 
 Cross-cultural 
sensitivity 
No Yes Cross-cultural sensitivity to UK 
patients studied.  May not be 
cross culturally sensitive 
University of Nottingham      Discussion 
 386 
Content validity Comprehensiveness No Yes URAM may not be 
comprehensive for use based on 
UK patients’ goals.  May not be 
appropriate for comprehensive 
assessment of postoperative 
state 
 Relevance No Yes All URAM items matched goals 
provided in this project, 
therefore, they are likely to be 
relevant, even if there were not 
enough items to  
comprehensively cover goals. 
 
Table 11.1: State of validation of URAM scale 
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Despite these concerns, the interpretability of the URAM was reasonable in 
this project.  The area under the ROC curve achieved was at the threshold of 
acceptability.  This is despite the study being conducted with an anchor that 
may be less appropriate than prospective anchors.  The interpretability of the 
URAM should be confirmed with a prospective anchor.  The MIC and MID 
obtained for open surgery in the form of fasciectomy and dermofasciectomy 
was considerably higher than the MID reported for needle aponeurotomy 
(Beaudreuil et al., 2011).  This may be influenced by the different methods 
used to estimate the MID.  In the current project, the difference between the 
mean change in the improved group and the mean change in the stable group 
was considered to be the MID, whereas regression analysis against 
satisfaction was used in previous literature (Beaudreuil et al., 2011).  
However, it is more likely to reflect the differences in rehabilitation between 
the less invasive aponeurotomy procedures and open surgery (fasciectomy or 
dermofasciectomy).  It is likely that a greater improvement in function is 
needed after open surgery before patients consider the prolonged recovery 
worthwhile. 
 
Although the MIC and MID of the URAM still requires further investigation, the 
marked difference between the MID for surgery and that for aponeurotomy 
may pose an issue in the design of future randomised trials.  Even if the 
URAM is not considered to be the optimal primary outcome measure for such 
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a trial, similar differences between MICs for aponeurotomy and open surgery 
are likely to be obtained for other outcome measures, for the reasons 
discussed.  What data would then be used in power calculations for such trials 
is not clear and will require further consideration. 
 
11.1.3.2 The(Disabilities(of(the(Arm,(Shoulder(and(Hand(tool(
The DASH is the most commonly used PROM in studies of Dupuytren’s 
disease (Ball et al., 2013).  It was produced in the 1990s (Hudak et al., 1996), 
and thus its development and validation were mainly performed prior to 
current standards such as those specified by COSMIN.  The DASH was 
developed specifically to assess the entire upper limb as a single domain.  
Item generation for the development of the DASH was based on a literature 
review, without any direct patient input.  Item reduction was then performed in 
two stages, the first of which involved expert opinion (Hudak et al., 1996).  
Consequently, it may be argued that it is not patient-centred.  Furthermore, it 
is unclear whether the entire upper limb constitutes a single domain, 
particularly when using the DASH to study a hand-specific condition such as 
Dupuytren’s disease. 
 
The assumption that the entire upper limb functions as a single domain may 
not be appropriate: items such as ‘difficulty placing an object on a high shelf’ 
would be impaired by shoulder disease, but not necessarily by Dupuytren’s 
disease or other hand conditions.  The DASH’s user manual includes a review 
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of papers investigating its construct validity (Kennedy et al., 2011).  The 
methods used in the papers summarised in the DASH’s user manual mainly 
comprised hypothesis testing of the DASH’s relationship to other outcome 
measures using correlation coefficients.  They conclude that as hypothesised, 
the majority of such papers demonstrate that the DASH correlates well with 
similar measures, and poorly with measures measuring different entities.  
However, one paper that is not well discussed found the DASH to be so broad 
that it is responsive to lower limb injuries as well as upper limb conditions 
(Dowrick et al., 2006). 
 
These issues can be explored further from the findings of the current project.  
Whilst the project supports the theory that the URAM scale may be too narrow 
to provide a comprehensive reflection of hand function in Dupuytren’s disease, 
data have been generated that suggest that the DASH may be too broad. 
 
In the exploratory factor analyses in the present project, DASH items loaded 
on more than one construct, suggesting that the DASH is not unidimensional 
when used in Dupuytren’s disease.  Given that the DASH was developed to 
reflect a single construct, this finding would not be expected, but is in keeping 
with previous studies (Forget et al., 2014, Franchignoni et al., 2010). 
 
The variance explained by the first extracted construct was much greater than 
that explained by other factors in both the DASH item model and DASH and 
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URAM item model.  This may mean that the second and third constructs are 
not particularly clinically relevant.  Alternatively, the limited amount of shared 
variance explained by the second and third constructs here may be because 
the majority of items (DASH items one through 21 and URAM item nine) 
loaded on the first construct, so the model is better able to extract the first 
construct as a result.  Assuming that the DASH does reflect two distinct 
constructs, it may be more appropriate to generate two separate summary 
scores for subscales based on these different groups of items.  However, 
understanding what these summary scores represent may not be 
straightforward, as this is dependent on confidently interpreting the factors 
extracted in the EFA models.  For the DASH, this may be more complex than 
for the URAM.  In the EFA of DASH items, the activity-limitation items in the 
DASH loaded on a distinct factor from the impairment perception-based items.  
Within the World Health Organisation’s International Classification of 
Functioning, structural impairment, functional limitation and participation 
restriction are separate tiers (World Health Organisation, 2014).  It may be 
that these three tiers are different domains, and that that the DASH items 
reflect two of them that both are relevant to the performance of the upper limb, 
but are separate from each other. 
 
However, this theorem is not supported by the later exploratory factor 
analysis, in which both DASH and URAM items were studied in a single EFA 
model.  In this later model, the URAM items expected to relate most closely to 
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loss of extension generally loaded with a third latent factor, distinct from the 
factors that DASH items loaded onto.  The exception was URAM item nine, 
which loaded alongside DASH activity-limitation items.  This suggests that the 
DASH items may not reflect that functional impairment resulting from loss of 
finger extension in Dupuytren’s disease. 
 
The most appropriate interpretation might be a combination of both of the 
above.  The URAM correlated most closely with loss of extension when it was 
validated by the developers (Beaudreuil et al., 2011), and previous studies 
that explored the correlation between the DASH and angular loss of 
extension, all of which found weak or no correlation (Degreef et al., 2009, 
Engstrand et al., 2009, Jerosch-Herold et al., 2011, Zyluk and Jagielski, 
2007).  Given that URAM items one through eight load with one factor and are 
expected to reflect loss of extension rather than overall hand function, it is 
possible that DASH items assess the remainder of hand function, along with 
URAM item nine.  When considered together, items 22 through 30 of the 
DASH resemble the second part of the Patient Evaluation Measure (PEM) tool 
(Macey et al., 1995), another common hand function legacy PROM.  However, 
URAM item nine loaded alongside the activity and participation items of the 
DASH (items one through 21), rather than the impairment perception items.  
This may be due to differences between these groups of items, in keeping 
with their relative positions within the World Health Organisation’s 
International Classification of Functioning, as already discussed. 
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ASPECT OF 
VALIDITY 
SUBTYPE DATA IN PREVIOUS 
LITERATURE 
DATA IN CURRENT 
PROJECT 
COMMENTS 
Criterion validity  Yes 
(Degreef et al., 2009, 
Engstrand et al., 
2009, Jerosch-
Herold et al., 2011, 
Zyluk and Jagielski, 
2007) 
No Not appropriate, as no gold 
standard against which the 
DASH can be benchmarked 
Construct validity Structural validity Yes 
(Franchignoni et al., 
2010) 
Yes Exploratory factor analyses used 
in both.  Not unidimensional in 
either. 
 Hypothesis testing Yes 
(Kennedy et al., 
2011) 
No Compared to angular deformity 
and other PROMs with defined 
hypotheses 
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 Cross-cultural 
sensitivity 
Yes 
(Kennedy et al., 
2011) 
No Developed in English.  Cross-
cultural sensitivity studied in a 
variety of settings and 
languages.  Not specifically in 
Dupuytren’s disease, or for UK 
use. 
Content validity Comprehensiveness No No  
 Relevance No No  
Table 11.2: State of validation of DASH in Dupuytren's disease 
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The DASH was not interpretable in this project.  This was due to there being a 
low area under the ROC curve used to estimate the MIC, and there being no 
significant difference between the mean changes in the ‘improved’ subgroup 
and the ‘stable’ subgroup.  There are limitations to all methods of assessing 
interpretability, which have been discussed already.  In particular the use of 
the GRC retrospective anchor may be problematic.  Even still, this 
methodology has been widely used and the systematic review of MICs 
conducted only found one scenario in which a recognised outcome 
measurement was not interpretable, for the Jebsen hand function test.  Most 
other studies of interpretability of relevance to Dupuytren’s disease had used 
the same potentially flawed methodology, and the outcome measures studied 
had exhibited adequate interpretability to allow the estimation of an MIC or 
MID.  Therefore, the inability of the DASH to identify clinically meaningful 
change here raises concerns about its on-going use in Dupuytren’s disease.  
Given the close agreement between the DASH and the QuickDASH in this 
project, the QuickDASH may also not be suitable for use in Dupuytren’s 
disease either. 
 
In contrast to the interpretability results, the DASH exhibited moderate 
responsiveness.  However, when responsiveness is classified in this way, it is 
not easy to appraise the performance of the measure, and very poor 
interpretability may exist in the presence of ‘good’ responsiveness when 
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studying a cohort of patients in which a significant proportion did not 
experience clinically meaningful change.  The interpretability data from this 
project reinforce these points. 
 
11.1.3.3 Passive*extension*deficit*
Although the use of ‘gold standards’ to study the criterion validity of an 
outcome measure is considered inappropriate in most settings (Mokkink et al., 
2010), correlation of PROM scores with angular deformity is widely used to 
determine the validity in Dupuytren’s disease (Beaudreuil et al., 2011, Degreef 
et al., 2009, Engstrand et al., 2009, Jerosch-Herold et al., 2011, Zyluk and 
Jagielski, 2007).  However, assessing the correlation of a candidate outcome 
measure with other outcome measures can be considered as a hypothesis 
test, under the umbrella of construct validity in the framework established by 
COSMIN.  The validation of the URAM involved comparison to a range of 
other outcomes, including some with which the URAM was expected to show 
poor correlation (Beaudreuil et al., 2011).  The distinction might be best 
considered by examining the hypotheses made.  Even though the URAM’s 
developers made a range of distinct hypotheses for different comparisons, the 
URAM was still expected to correlate best with angular deformity, and when 
this pattern was observed, this was considered to represent success.  This 
approach towards extension deficit as a gold standard contradicts the 
consensus established by COSMIN, and might be considered illogical; if 
angular deformity is the gold standard, then a PROM that simply correlates 
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very strongly with angular deformity may not provide any advantage over just 
measuring joint angles directly.  Indeed, this may also be inconsistent with the 
PROM being truly patient-centred, as direct measurement of angular deformity 
is a surgeon-centred outcome. 
 
Putting aside the issues of using angular deformity as a gold standard for 
validating PROMs in Dupuytren’s disease, the validity of loss of extension as 
an outcome in its own right should still be subjected to the same analyses as 
other outcome measures.  The broad range of patient goals identified in the 
present project suggests that loss of extension alone may not adequately 
describe the goals and expectations of patients for their planned treatment.  
Based on the terminology established by COSMIN, loss of extension may not 
be comprehensive as an outcome measure.  It might not even be relevant.  
The latter may apply when considering specific cut offs for angular deformity 
to define good and bad outcome or recurrence versus no recurrence.  A range 
of different angular measurements has been studied in the Dupuytren’s 
disease literature (Ball et al., 2013).  Study endpoints include correction of 
angular deformity to 0o to 5o of loss of extension per joint and recurrence 
defined as increase in the postop contracture by 20o per joint (Hurst et al., 
2009).  However, the review of interpretability conducted as part of this project 
failed to identify any evidence to support these cut offs.  Not only may they not 
be evidence-based, they may also be illogical; it is unlikely that correction of a 
15o joint contracture to 5o would be considered success, yet correcting a 90o 
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contracture to 10o would be considered as a failure.  Similar logic may be 
applied to assessing fixed cut offs for recurrence.  These particular end points 
may not be clinically meaningful, and if other possible cut off options also fail 
to separate meaningful changes and differences, it might be argued that 
angles are not relevant at all in terms of patient-centred content validity.  
However, change in angle might be more meaningful.  Rather than requiring 
all joints to achieve correction to zero to five degrees, improving total 
extension deficit across all joints in a ray by 20 or 30 degrees might describe a 
meaningful improvement for many patients.  This may capture meaningful 
change for patients with different goals.  For example, achieving full correction 
for a patient who has presented with a mild contracture, but who needs to be 
able to place the palm flat for work tasks, is as meaningful as allowing the 
fingers to extend out of the palm to facilitate hand hygiene for a patient who 
has presented much later with severe contractures and the fingertips close to 
the palmar skin.  This may explain the diverse range of patient goals identified 
in the present project. 
 
Measurements such as loss of extension are often categorised as ‘objective’, 
in contrast to ‘subjective’ PROMs.  However, there are potential sources of 
bias that might arise from measuring angles, such that they may not be quite 
so objective.  The effect of dynamism on passive extension deficit angular 
measurements was considerable in this project, and as it had not been 
quantified, it may have been underestimated previously.  Dynamism was 
University of Nottingham   Discussion 
 398 
extremely common in cords crossing the PIPJ, and could influence the 
classification of treatment success versus failure, or recurrence versus no 
recurrence in studies.  However, the methodology used to study dynamism in 
the present project aimed to identify the maximum amount of dynamism that 
could be achieved.  This extent is unlikely to be encountered in a trial in which 
observers are trained to perform measurements.  A recent study of 
Dupuytren’s disease assessment found that inter observer reproducibility of 
angular measurements were better than the dynamism data in the present 
study would suggest (Broekstra et al., 2015).  However, there are numerous 
limitations to Broekstra and colleagues’ study.  As an agreement study, bias 
that might lead to an observer consciously or subconsciously influencing the 
measurements based on the treatment that a patient had received would not 
be present.  The systematic review of trials conducted in the present project 
suggests that this assumption is unlikely to be the case in future studies.  
Unblinded assessment of outcome posed a risk of performance bias in nearly 
all trials to date.  Furthermore, the inter- and intra-observer reproducibility 
were evaluated using intra-class correlations.  This method is flawed (Bland 
and Altman, 1986), as has been discussed in the present project’s discussion 
on the relationship between the DASH and QuickDASH. 
 
There are strategies that might be adopted to minimise the influence of 
dynamism on outcome measurement.  Assessing active extension deficit may 
avoid this risk of bias, and is likely to be more clinically relevant than passive 
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extension deficit, as the active extension deficit measures the angles that the 
patient achieves himself or herself.  Assessment of angles in studies of 
Dupuytren’s disease remains important, particularly in explanatory studies of 
treatments, and given the complicating effect of differences in finger joint 
anatomy between the MCPJ and the PIPJ discussed in the introduction.  
However, it may be more appropriate to use such objective measures as 
secondary, rather than primary, endpoints in pragmatic trials and assessments 
of cost effectiveness.  The interpretability of angular measurements, and the 
cut offs used, needs to be studied in more detail. 
 
11.1.4 Choice*of*outcome*measure*
The findings of the present project, including the review of interpretability 
studies applicable to Dupuytren’s disease, demonstrate that the existing 
evidence base is not adequate to make firm recommendations regarding 
which outcome measures to use for the study of Dupuytren’s disease in 
clinical practice, research or guideline development.  Further work is required 
to determine whether other existing legacy measures perform well in 
Dupuytren’s disease, according to current standards of validity, interpretability 
and responsiveness. 
 
The results of the present project suggest that there may be different 
constructs of relevance to Dupuytren’s disease, and different outcome 
measures may reflect distinct underlying constructs.  As discussed, the DASH 
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may not be unidimensional, and face validity examination of the task-based 
items in it suggest that the main construct that it reflects may not be of 
relevance to hand function in Dupuytren’s disease.  In keeping with this, the 
DASH was not interpretable in the present project.  Most of the URAM items 
may reflect disability related to loss of extension, but the scale does not 
necessarily assess global hand function. 
 
As a result, even once further validity data have been generated and 
appraised, the most appropriate choice of primary outcome measure in 
Dupuytren’s disease is likely to depend on intended purpose.  In early phase 
and explanatory studies, such as a study of correcting PIPJ contractures with 
a novel untested technique, then active extension deficit angles may still be 
the most appropriate assessment.  If this is the case, more careful 
consideration of meaningful cut offs for endpoints will need to be considered 
than has been done to date.  However, for most applications involving 
pragmatic studies of clinical outcome and cost utility, it is likely to be more 
meaningful to assess global hand function than to measure angular deformity, 
or to assess just the disability associated with loss of extension in isolation.  
As discussed, this may involve a modification of the URAM scale, with a 
separate subscale to capture complications, or a completely novel outcome 
measure. 
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Further examination of candidate outcome measures for the assessment of 
hand function in Dupuytren’s disease is needed, as the results of the present 
project do not support the on-going use of the DASH in its current form in 
Dupuytren’s disease.  Although there have been learning points derived from 
this project, such as the potential limitation of studying interpretability using a 
retrospective anchor, the interpretability of the DASH is so poor that it is 
improbable that it would exhibit a high level of interpretability even with a 
prospective anchor.  The present project findings suggest that the URAM is a 
more suitable, though still flawed, outcome measure that could be used. 
 
11.1.5 Outcome*and*associated*factors*
In the same manner that continuing to assess passive extension deficit is 
likely to be inadequate as the primary outcome measure in pragmatic trials, 
using recurrence as the primary endpoint of similar Dupuytren’s disease 
research is probably not appropriate, given that in the present project, it was 
not comprehensive in relation to patients’ preoperative goals, or to 
postoperative treatment complications.  The latter were common after 
treatment in this project.  As a result, inappropriate prioritisation of recurrence 
over global hand function might promote the use of more invasive treatments, 
such as dermofasciectomy, that achieve greater deformity correction and less 
recurrence, but place patients at risk of poor global hand function outcome 
due to their relatively greater iatrogenic insult and greater potential for 
complications that affect hand function. 
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Factors that are independently associated with poor outcome should be 
appreciated.  This may foster improved clinical care by identifying those at risk 
of poor outcome at the outset, and would promote high quality research 
design, conduct, and interpretation in clinical guideline development.  This 
project has demonstrated that the factors associated with a symptomatic 
upper limb following treatment for Dupuytren’s disease are not the same as 
the factors that comprise the Dupuytren’s diathesis.  Female gender, previous 
ipsilateral surgery and diabetes mellitus were associated with poor function 
(defined here as a DASH score of 15 or more, the cut off considered by the 
developers’ review of the literature to represent the threshold at which the 
upper limb becomes symptomatically limited (Kennedy et al., 2011)).  In 
contrast, the traditional diathesis factors considered to be associated with 
disease recurrence include male gender and early age of onset.  Some of the 
present study findings make sense.  Repeated operations on the same hand 
will lead to accumulation of iatrogenic insult, with more scar tissue, and 
greater risk of complications such as stiffness and altered sensation.  
Furthermore, diabetics may experience delayed wound healing and a greater 
risk of infection, which might be expected to affect their functional outcome 
after surgery. 
 
However, this study investigated associations with poor function, and causality 
in the relationship could not be studied using this cross sectional study design.  
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The relationship between some factors and poor functional outcome is not 
immediately clear: why there was a strong association between female gender 
and poor functional outcome following surgery for Dupuytren’s disease is not 
immediately apparent.  There are other limitations to this aspect of the project.  
The definition of poor functional outcome was a cut off of 15/100 on the DASH 
score.  As discussed already, the DASH’s performance in Dupuytren’s 
disease in the present project was poor, and the interpretability of specific cut 
offs such as this may not be evidence based.  The latent constructs reflected 
by the DASH differed from the URAM, and may not relate to Dupuytren’s 
disease.  As a result, the factors identified in this cross sectional study may be 
associated with confounding comorbid upper limb conditions.  For example, 
diabetics also have a higher incidence of other upper conditions, such as 
trigger finger and carpal tunnel syndrome in the hand and adhesive capsulitis 
in the shoulder.  The poor functional outcome seen might be a result of this.  
One step towards explaining this would be to study a cohort of preoperative 
Dupuytren’s disease patients.  Preoperative function and the prevalence of 
upper limb comorbidities would need to be considered. 
 
Whilst the results of the present project probably do not provide robust 
evidence of the factors associated with poor functional outcome, they do 
demonstrate that the traditional diathesis factors cannot be assumed to be the 
only important predictors of poor outcome in Dupuytren’s disease.  This is an 
important finding in its own right, and further work to study the causes of poor 
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outcome using a more responsive and interpretable measure than the DASH 
is required.  However, in the interim, Dupuytren’s diathesis factors cannot be 
extrapolated to predicting poor treatment outcome beyond recurrence. 
 
11.1.6 Comparing*treatment*options*
The systematic review conducted in the present project confirmed that few 
randomised studies of surgery for Dupuytren’s disease exist, and that 
methodological weaknesses were encountered in all of them.  No randomised 
trial data exist to describe the investigation of some areas of equipoise in 
current clinical practice.  For example, no randomised trial data were identified 
that compared surgery to collagenase, or that compared fasciectomy to 
conventional dermofasciectomy, rather than firebreak skin grafting.  The 
current state of the evidence base limits the establishment of optimal clinical 
practice, and the development of clinical guidelines.  Further comparative data 
is needed to determine optimal practice for the treatment of Dupuytren’s 
disease. 
 
As already discussed, further investigation of outcome measures is still 
required before optimal randomised controlled trials could be designed in 
Dupuytren’s disease, both in terms of outcome selection, but also in terms of 
powering a study to identify an clinically meaningful difference between 
treatments.  However, some learning points can be established based on the 
systematic review of trials.  Greater efforts must be made to ensure that risks 
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of bias in trials in Dupuytren’s disease are minimised.  Some risks of bias that 
were encountered are readily avoidable.  For example, adequate 
randomisation processes and allocation concealment measures should be 
employed.  As blinding may prove difficult in this context, blocked 
randomisation is best avoided.  Patient involvement in study design is 
important, and may further support the adoption of patient-reported hand 
function or quality of life as the outcome constructs of greatest importance.  
Good methodological practice was also identified in the review: where 
appropriate intraoperative randomisation used (Ullah et al., 2009) that may 
minimise the risk of performance bias that is otherwise difficult to address in 
trials of surgery. 
 
The observational study of outcome performed as part of the present project 
constitutes low quality evidence using the GRADE criteria applied in the 
systematic review of trials.  However, as with the study of factors associated 
with poor outcome, it does question conventional dogma regarding 
Dupuytren’s disease treatment.  Although there are limitations to the data 
presented, the logistic regression analysis identified no difference in functional 
outcome at five years between needle aponeurotomy and excisional surgery.  
This might not be expected from previous studies, such as the trial comparing 
needle aponeurotomy and fasciectomy included in the systematic review 
conducted here (van Rijssen et al., 2006, van Rijssen et al., 2012), where a 
very large difference in recurrence rates was observed between the different 
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procedures.  However, the functional outcome findings can be potentially 
explained and supported by much of the data in the present project.  Given 
that patient goals did not solely reflect loss of extension, and that 
complications were much more common after more invasive treatment, the 
late functional outcome of treatment might be expected to reflect the balance 
of maintained correction of angular deformity offset against the risk of 
complications.  Although the DASH may not be the optimal outcome measure 
for studying Dupuytren’s disease, the URAM might not be more suitable for 
this analysis.  Given that the URAM correlates closely with angular deformity 
and may mainly reflect loss of extension, it might fail to identify the impact on 
global hand function that the present study has alluded to, in the same way 
that previous studies using recurrence of angular deformity may also have 
missed the impact of complications.  This merits further investigation. 
 
11.2 Qualitative*findings*from*patient*interactions*
In addition to the data presented in the chapters of this thesis, the candidate 
identified recurring themes from performing the patient evaluations.  The 
assessments for the cross sectional typically took 20 to 30 minutes per 
patient, and the cohort study preoperative assessment typically lasted 15 
minutes.  Both assessments are longer than the typical 10 minutes assigned 
for an NHS patient assessment in clinical practice. 
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Formal structuring of the interactions had not been performed, and so detailed 
analysis was not attempted.  However, aspects of relevance to the 
interpretation of the present project, other literature, and to future study design 
were considered. 
 
One pattern that was noted was that patients at a centre tended to favour the 
treatment modality preferred by that centre.  For example, at a centre that 
performed aponeurotomies, the patients often discussed their perceived 
superiority of that treatment.  The advantages cited during informal 
conversation included rapid recovery, minimum inconvenience and 
rehabilitation, and a willingness to undergo serial treatments for recurrence.  
This was particularly noticeable for self-employed individuals who were keen 
to minimise time off work.  In contrast, patients at centres that preferred 
fasciectomy often identified the high recurrence rate of aponeurotomy as 
being undesirable. 
 
The above pattern is complex to interpret, and there are several potential 
explanations, which are not mutually exclusive.  Patients who preferred a 
particular treatment option may have specifically sought referral to a centre 
with a reputation for that procedure.  At least one centre in this study did 
receive a significant minority of its referrals from outwith its local catchment 
area, probably for this reason.  However, in the cross sectional, patients who 
resided over 20 miles away from the centre were excluded.  This clause was 
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introduced with the aim of reducing patient inconvenience and fatigue, as 
some patients were already contributing to other research projects.  However, 
it did mean that patients who had travelled a long distance to receive a 
particular treatment modality were excluded from this project and so this 
should not have influenced the findings.  This may be an important point to 
consider in future trial design to ensure that trial groups are comparable.  
Furthermore, it demonstrates that patients may choose a treatment ‘strategy’ 
incorporating the possibility of multiple treatments over a period, rather than 
choosing a single procedure.  This is of relevance to study design and to 
guideline development, as straightforward head-to-head comparison of 
treatments may not be appropriate in a pragmatic trial.  Given the wide 
disparity in recurrence and reoperation rates between needle aponeurotomy 
and fasciectomy observed both in the present project and in previous studies 
(van Rijssen et al., 2012), it may be more appropriate to study randomise 
patients to undergoing a series of aponeurotomies over a several year period 
versus a single more invasive procedure such as fasciectomy. 
 
Alternatively, a form of social desirability response may have been 
encountered, with the patients influenced by their surgeons and other clinical 
staff.  All cross sectional study patients had undergone treatment at the time 
of recruitment.  Several had been unaware of the nature of Dupuytren’s 
disease, or of its treatment options prior to clinical assessment.  Having 
discussed the diagnosis and options with the clinician at the treating centre, 
University of Nottingham   Discussion 
 409 
they may have been influenced by the surgeon’s opinions and preferences.  
This may also apply to the study of patient goals.  Although recruitment for 
that study was performed at the preoperative stage, a proportion of patients 
had already undergone treatment for Dupuytren’s disease previously, and so 
may have been influenced by their previous clinical counselling and 
experience.  Minimising the potential effect of this in future studies might be 
achieved by only including patients undergoing primary treatment, and by 
standardising the clinical counselling provided to study participants. 
 
Given the importance of aspects such as those discussed in this section to 
study design, a formal semi-structured interview study with patients at 
preoperative and early and late postoperative stages of treatment may be 
required to ensure that the data generated are truly patient-centred where 
appropriate. 
 
11.3 Future*work*
11.3.1 Outcome*measure*appraisal*
11.3.1.1 Validity*of*outcome*measures*
In the present project, aspects of the DASH’s validity and interpretability in 
Dupuytren’s disease that had not been previously examined were studied.  
Overall, it performed poorly.  There are further analyses of validity that could 
also be performed.  For example, COSMIN’s standards also suggest the use 
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of confirmatory factor analysis to examine structural validity.  However, this 
was not deemed appropriate for the DASH, given that failings relating to its 
structural validity and interpretability had already been identified.  
Confirmatory factor analysis could be applied to the URAM to confirm the 
factor structure identified in the present project, which differed from that 
obtained by the developers (Beaudreuil et al., 2011). 
 
Additionally, Rasch analysis has also be used to study validity (Franchignoni 
et al., 2010).  This would constitute a shift to the use of item response theory 
analyses rather than classical theory analyses such as EFA.  Although Rasch 
analysis is not discussed by COSMIN, the current COSMIN checklist is now at 
least five years old.  Rasch analysis-validated outcome measures have been 
included in recently-developed standardised outcome sets established by The 
International Consortium for Health Outcome Measurement (ICHOM) for other 
health conditions (International Consortium for Health Outcome Measurement, 
2014).  Whilst the present project was conducted using the criteria set by 
COSMIN, it is quite possible that the use of Rasch analysis for validating 
outcome measures will become standard practice in future.  As a result, 
further validation of legacy and novel PROMs should consider employing such 
methods. 
 
It is likely that the validity data available will be inadequate for other legacy 
PROMs tha
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Evaluation Measure (PEM) (Macey et al., 1995), or the Michigan Hand 
Questionnaire (MHQ) (Chung et al., 1998).  These PROMs should also be 
subjected to modern validity analyses in Dupuytren’s disease.  Based on the 
findings of the present project, it is reasonable to hypothesise that they will 
perform better than the DASH and even the URAM.  The second part of the 
PEM comprises items that assess the patient’s perceptions of impairment 
such as pain.  As a result it is more likely to be unidimensional than the DASH.  
The MHQ comprises several subscales to assess distinct constructs 
separately.  As a result, the factor structure of its items is hypothesised to be 
more appropriate than the DASH or even the URAM, and it may perform more 
reliably.  However, the MHQ is lengthier and harder for patients to understand 
and to complete (Dias et al., 2008). 
 
11.3.1.2 Responsiveness*and*Interpretability*of*outcome*measures*
Further work is also required to be able to interpret the outcome measures 
used in Dupuytren’s disease.  The present project provided new data 
regarding the interpretability of the DASH and URAM, using a retrospective 
anchor.  Given that the GRC anchor correlated better with postoperative state 
than with change in score, further studies might include the use of prospective 
anchors to compare their performance.  The systematic review of 
interpretability performed in the present project identified that a number of 
studies had been conducted using the satisfaction subscale of the MHQ as 
the anchor.  However, the developer of the MHQ led all these.  Not only 
University of Nottingham   Discussion 
 412 
should consideration be afforded to the prospective versus retrospective 
nature of anchors, but also their face validity should be considered.  The GRC 
provides a very general patient perception of improvement.  Both this and the 
change in the satisfaction domain of the MHQ may instead reflect a different 
construct from using a prospectively assessed measure of health-related 
quality of life.  Furthermore, it is important that future studies clearly 
distinguish between minimal important differences (MIDs, between individuals) 
and minimal important changes (MICs, for individual patients).  The previous 
estimate of the MID for the URAM, based on regression against a satisfaction 
score, constitutes an MIC, but not an MID. 
 
As well as these conventional studies of interpretability, there are other uses 
of outcome measures that require investigation of their interpretability.  As 
long-term outcome is affected by complications, as studied in the present 
project, and also by gradual recurrence, the interpretability of late progressive 
deterioration needs to be studied as well.  According to the systematic review 
of interpretability in the present project, the few MICs and MIDs calculated for 
Dupuytren’s disease so far all relate to the interpretability of improvement 
early after treatment, and none to the later deterioration.  Outcome measures 
could also be used for other purposes in Dupuytren’s disease.  In theory, an 
appropriate PROM could be used to screen patients in primary care to select 
those at an appropriate stage for treatment in secondary care.  This would 
also require studies of the interpretability of an appropriately validated PROM. 
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11.3.1.3 Design*of*novel*PROMs*
If the above future work is conducted, it may be the case that none of the 
current legacy PROMs is ideal for use in Dupuytren’s disease.  In this 
scenario, it may be necessary to design a novel PROM.  The URAM scale 
was developed relatively recently, and using more modern methodology than 
other legacy measures such as the DASH and the PEM.  However, item 
generation involved identification of limitations reported by patients with 
Dupuytren’s disease and clinicians who treat Dupuytren’s disease.  As already 
discussed in the study of British patients’ goals, this may not necessarily 
generate a long list of items that are relevant or cross culturally sensitive.  
Additionally, given the factor structure that emerged in the present project 
when URAM items were combined with DASH items, only item nine within the 
URAM may assess complications or global hand function.  In Dupuytren’s 
disease preoperative impairments, as described in the study of patient goals, 
differ considerably from the impairments due to complications of treatment, 
which were also studied in this project.  In order to design a PROM that is 
suitable for use before and again after treatment, its development should 
incorporate the postoperative experience of treatment in addition to the 
preoperative symptoms.  As already discussed, this may result in two distinct 
constructs being assessed, resulting in separate subscale scores. 
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11.3.2 Comparative*study*design*
11.3.2.1 Considerations*for*future*comparative*study*design*
As has been discussed, more work is necessary to identify the best outcome 
measure for use in studies of Dupuytren’s disease.  Consequently, discussing 
the design of comparative studies may be premature.  However, there are 
some points that have arisen from the present project, both directly in 
experiments and indirectly through the qualitative element of patient 
interactions by the candidate, which might improve the subsequent design of 
comparative studies. 
 
As a range of treatments are currently employed, and as clinical equipoise 
may be encountered between treatment strategies, it is likely that pragmatic 
trials of treatments would be most informative.  However, given the marked 
differences between treatment modalities such as aponeurotomy and 
fasciectomy, head-to-head comparison of single treatments may not be 
appropriate.  Indeed, many of the patients assessed following aponeurotomy 
in the present project accepted that there was greater risk of recurrence, but 
they accepted this as they prioritised a more rapid recovery from the initial 
treatment.  Therefore, it might be argued that a single fasciectomy ought to be 
compared to a series of aponeurotomies performed over a period of say five 
years.  This might be akin to comparing a series of steroid injections to control 
knee osteoarthritis pain versus a single knee replacement operation. 
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While the above suggestion may more accurately reflect the pragmatic clinical 
approaches to managing Dupuytren’s disease, it might pose methodological 
challenges for study design.  In the present project, the URAM’s MIC for 
surgery was considerably larger than the developers’ previously published 
MIC for needle aponeurotomy.  As interpretability metrics are influenced by 
the context, including treatment type, it is likely that the MIC for aponeurotomy 
will be significantly lower than the MIC for surgery calculated in the present 
project.  In such circumstances, selecting the correct difference when 
powering and interpreting comparative studies will be challenging. 
 
In addition to the information regarding outcome measure selection and 
optimisation for a future comparative study, this thesis has also identified other 
areas of trial design that will require consideration.  Efforts will need to be 
made to minimise performance bias in a comparative trial.  The systematic 
review of existing trials demonstrated that all previous randomised studies 
have been risk of bias.  In particular, innovative and carefully considered 
solutions to minimise performance bias are required.  This was only rarely 
achieved in previous studies, where one of the better examples involved 
intraoperative randomisation (Ullah et al., 2009). 
 
The findings of this thesis demonstrate that considerable work is still required 
to be able to design and conduct optimal high quality randomised controlled 
trials in the treatment of Dupuytren’s disease.  However, it reaffirms the extent 
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and breadth of the impact of this condition on patients, and the value of 
investing in further improving treatment for patients with Dupuytren’s disease.  
The particular challenges identified here are also applicable to other aspects 
of hand surgery, and to other non-terminal conditions.  As a result, resolving 
the issues in Dupuytren’s disease discussed in this thesis has the potential to 
modify practices and raise the standard of clinical research in a range of 
clinical areas.  However, a proposal for a trial that incorporates the novel 
findings from this thesis will be presented, to summarise the current state of 
research in this area. 
 
11.3.2.2 Proposed*clinical*trial*protocol*
Based on the previous research of the treatment of Dupuytren’s disease and 
the findings of the experiments in this thesis, a trial outline proposal is 
presented.  Based on the findings of the first systematic review presented in 
this thesis, there are several unresolved uncertainties in Dupuytren’s disease 
treatment.  In particular, the age-old issue of disease excision versus disease 
division remains inadequately investigated.  However, in the first instance the 
differences between different excisional procedures needs to be established, 
and likewise the differences between different divisional procedures.  Once 
the superior treatment option within each strategy is identified, then 
comparison of the two strategies could be conducted. 
University of Nottingham   Discussion 
 417 
Given that the data presented in this thesis focus largely on excisional 
strategies, a trial comparing the two main excisional strategies (fasciectomy 
and dermofasciectomy) will be introduced. 
 
11.3.2.2.1 Objectives of trial 
The compare the effectiveness and safety of conventional dermofasciectomy 
to fasciectomy in terms of hand function, complications and cost utility. 
 
11.3.2.2.2 Design 
A patient-centred, pragmatic, multi-centre, randomised controlled trial with 
attention to minimising risks of bias incorporated into the design.  Patient and 
public involvement will be critical.  Given the variation in patient experience of 
Dupuytren’s disease (see Chapter 6, Patients’ Goals), more than one patient 
representative will be involved in the core trial team and named as a co-
applicant on funding applications.  The core team will also comprise 
stakeholder representatives including hand therapists, general practitioners 
and commissioners, a statistician, and a health economist.  Given the 
identification of aesthetic appearance of the hand as a patient goal for 
treatment, the involvement of a clinical psychologist may be considered.  This 
latter point represents a significant shift in approach to this condition 
compared to previous research. 
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11.3.2.2.3 Setting 
Recruitment will take place at a minimum of five NHS hand surgery services.  
These must include orthopaedic hand surgery services, plastic hand surgery 
services, and fully integrated services (such as Derby, where the Hand Unit 
comprises both).  The surgeons and hand therapists participating will all 
receive formal training in trial recruitment.  The participating centres will 
include large volume centres and smaller centres, to pragmatically reflect the 
breadth of current practice in the NHS and to ensure that the external validity 
of the trial is optimised.  All centres will include their routine postoperative 
management and hand therapy care pathways, and it is noted that this may 
involve “Any Qualified Provider” arrangements, in keeping with current NHS 
policy. 
 
11.3.2.2.4 Recruitment 
Patients attending elective hand surgery clinics with Dupuytren’s disease as 
the primary indication for referral will be screened for eligibility in the clinic, 
provided with written information about the trial and invited to participate.  
After a minimum two-week interval from initial consultation, patients will be 
recruited when attending preoperative assessment prior (but close) to their 
surgery episode.  Signed informed consent will be taken at preoperative 
assessment attendance and baseline measurements performed. 
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11.3.2.2.5 Inclusion and exclusion criteria 
Pragmatic inclusion criteria will be adopted.  The target study population are 
patients with primary or recurrent Dupuytren’s disease affecting one or more 
fingers requiring surgery, and for whom the treating surgeon considers either 
fasciectomy or dermofasciectomy to be technically possible. 
Exclusion criteria will be patients under 18 years old, those with thumb or first 
web disease requiring treatment and those who are unable to give informed 
consent.  Other variables, such as a diagnosis of diabetes mellitus, will be 
captured, as this thesis has demonstrated that they are likely to affect 
outcome.  However, these patients will not be excluded, so that the external 
validity of the trial is optimised to NHS practice. 
 
11.3.2.2.6 Randomisation 
Randomisation will involve remote centralised randomisation process to 
minimise risks of bias identified in previous research regarding both 
randomisation and allocation concealment (see Chapter 4).  Given that 
blinding is not achievable, standard block randomisation will not be used.  
Patients will be randomised on the day of surgery immediately prior to 
anaesthesia. 
 
11.3.2.2.7 Intervention 
A pragmatic definition of fasciectomy will be adopted.  This will involve 
excision of Dupuytren’s disease responsible for the patient’s specific 
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symptoms followed by direct closure or local flap closure (e.g. z-plasties) at 
the surgeon’s discretion and based on their standard practice.  Smaller 
fasciectomies (such as segmental fasciectomy), where the aim is not to 
remove all of the disease responsible for a joint contracture, but to remove 
only a small segment of the disease across a joint, will be excluded. 
 
11.3.2.2.8 Comparator 
Conventional dermofasciectomy will be defined pragmatically, but with some 
criteria to distinguish it from firebreak dermofasciectomy (which has been 
shown to not affect outcome previously (Ullah et al., 2009)).  Skin grafts must 
cover the span of the joint affected and reach both midaxial lines of the digit in 
order to replace all of the glabrous skin covering the affected joint. 
 
11.3.2.2.9 Outcome measures 
Given the findings of the thesis, the URAM will be adopted as the primary 
outcome measure of the trial.  Although this outcome measure has limitations 
(see Chapter 7), it is the most contemporary measure of relevance, and its 
performance has surpassed that of the main alternative (the DASH) 
throughout this project.  However, given its limitations, secondary endpoints 
will be important.  These will include other patient-reported measures to 
capture the sequelae of surgery, such as a pain visual analogue scale (VAS).  
Formal recording of complications and satisfaction will also be measured.  
Finger joint angles will be assessed as a secondary outcome, but given the 
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effect of dynamism identified here (see Chapter 5), passive extension deficit 
will not be measured.  Instead, active finger extension and flexion will be 
measured, as this is not subject to dynamism and is more patient-centred.  
Health service opportunity costs will be captured for cost utility analysis.  
Return to work or baseline activity data and costing data (e.g. social care 
costs) will also be captured.  Further treatment will be recorded. 
 
11.3.2.2.10 Sample size 
A sample size calculation will be performed based on an MID between 
treatments of 8.3/45 in the URAM for the change score from baseline to one 
year after randomisation (as this represents the difference between treatments 
considered relevant, rather than the individual change considered relevant, or 
MID, see Chapter 9).  One year after randomisation in this trial equates to one 
year after treatment. 
 
11.3.2.2.11 Follow up 
Follow up will involve clinic assessments at six weeks, three months, six 
months and one year after randomisation.  This thesis has demonstrated that 
recovery takes longer than previous appreciated, hence the importance of 
taking measurements throughout the first year.  After this point, annual 
assessments will be made for five years. 
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11.3.2.2.12 Blinding 
Where possible, objective assessments such as measuring active finger joint 
angles will be performed by trained health care professionals who are not 
directly involved in the trial, though it is appreciated that formal blinding will not 
be possible here. 
 
The above trial proposal incorporates lessons identified from key findings of 
this project throughout.  The quality of future studies in this area is likely to be 
improved by this project, and areas for future research have been clarified.  
The key findings of the project will be summarised in the next and final 
section. 
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12 Project*Summary*
• There were few randomised controlled trials in Dupuytren’s disease, 
most of which have methodological flaws such that the quality of 
evidence available to guide practice is poor. 
 
• Patients have individual preoperative goals that they want improved by 
surgery, and these vary markedly from patient to patient. 
 
• Not all patient goals matched the impairments that are traditionally 
considered to be relevant in Dupuytren’s disease by clinicians, 
particularly loss of extension. 
 
• The URAM scale was not fully comprehensive for use in Dupuytren’s 
disease, particularly after treatment was completed. 
 
• Dynamism was common and large in magnitude in Dupuytren’s 
contractures crossing the proximal interphalangeal joint (PIPJ).  It might 
constitute a previously unquantified source of bias in unblinded studies. 
 
• The DASH was not unidimensional when used in Dupuytren’s disease, 
and the constructs that it reflects may not be relevant. 
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• The URAM appeared unidimensional in Dupuytren’s disease, though 
item nine behaved differently, as illustrated when the factor structure is 
analysed in conjunction with DASH items. 
 
• Limited interpretability data existed for outcome measures that might be 
used in trials of Dupuytren’s disease treatment, and the minimal 
important changes (MICs) and minimal important differences (MIDs) 
that did exist were mainly estimated using retrospective anchors. 
 
• The DASH was not interpretable after open surgery for Dupuytren’s 
disease. 
 
• The URAM showed acceptable interpretability, but with a much larger 
MIC for open surgery than was previously reported for aponeurotomy. 
 
• The factors associated with poor functional outcome were diabetes, 
revision surgery and female gender.  These differ from traditional 
diathesis factors. 
 
• After controlling for these factors (diabetes, previous ipsilateral surgery, 
female gender) and others, there was no significant difference in 
functional outcome between aponeurotomy and excisional surgery. 
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• Complication rates were considerably higher after excisional surgery 
than after aponeurotomy, which is likely to result in permanent 
functional limitation, and may explain the lack of difference in long-term 
functional outcome between the procedures, despite their markedly 
different recurrence rates. 
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13 Appendices*
Appendix 1: Nottingham University Hospitals R&D Approval 
 
 
 
 
 
 
 
 
 
 
 
 
6th April 2011 
 
 
 
Queen’s Medical Centre Campus 
Research and Development 
E11 Curie Court 
Derby Road 
Nottingham 
NG7 2UH 
 
Direct Dial: 0115 9709049 
 
Fax: 0115 8493295 
                                                        
www.nuh.nhs.uk
 
Dear R&D Office, 
 
Dupuytren’s disease: a clinical evaluation of the recurrence and 
complication rates of different surgical procedures. 
 
I can confirm we have reviewed the above project and can confirm that it is considered as a 
service evaluation. 
 
If any further details are required, please do not hesitate to contact me on the details below or 
the project lead Dr Tim Davis. 
 
Best regards, 
 
 
 
 
Charlotte Davies 
Research and Development Operations Manager 
E11 Curie Court 
Queens Medical Centre Campus 
Derby Road 
Nottingham 
NG7 2UH 
 
Tel; 0115 9249924 ext 61870 
Mobile; 07595284977 
Fax; 0115 8493295 internal 3295 
 
E-mail; charlotte.davies@nuh.nhs.uk 
 
For further information about R&D and a complete list of SOPs, processes and NUH sponsorship 
details please visit our new website; www.nuhrise.org 
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Appendix 2: Patient Information Letter 
 
 
BSSH$
Research$
 
 
Mr Jeremy Rodrigues BSc(Hons) MRCS MSc 
BSSH Research Fellow 
Division of Orthopaedic & Accident Surgery 
University of Nottingham 
C Floor, West Block 
Queen’s Medical Centre 
Nottingham 
NG7 2UH 
 
 
 
 
Dear Sir/Madam, 
 
The UK’s hand surgery society (The British Society for Surgery of The Hand (BSSH)) is carrying 
out a study of surgery for Dupuytren’s disease. 
 
This is a common condition that leads to the fingers bending up. 
 
We are keen to see how patients get along after standard surgery performed at the moment. This 
is a “Service Evaluation” of what is currently done in the NHS, not a trial of anything new. 
 
By doing so, we hope to be able to be able to improve the treatment of this condition for patients in 
the future, and to be able to plan studies comparing different treatments in the future. 
 
Taking part is voluntary. You do not have to take part, and your treatment now or in future 
will not be affected at all if you choose not to take part. 
 
We would like to invite you to take part in the project. 
 
All information collected will be treated confidentially, and will be stored securely. 
 
If you would like any further information, please feel free to contact the surgeon leading the project, 
Mr Jeremy Rodrigues, or my supervisor Professor Tim RC Davis.  
 
• My  postal address is at the top of the page 
 
• Or feel free to e mail me at: Jeremy.rodrigues@nuh.nhs.uk 
 
• Or make telephone contact by calling the Queen’s Medical Centre, Nottingham on 0115 924 
9924. This is the switchboard number. Once connected to the operator, ask for Professor 
TRC Davis’s secretary in Orthopaedics. She will pass on the message. 
 
 
Yours faithfully, 
 
 
Jeremy Rodrigues 
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Appendix 3: Rotherham Patient Contact Letter Content 
 
 
Dear …………………, 
 
I am writing to you to ask for your help with research into a 
condition called “Dupuytren’s disease.” It is a common condition 
and the UK’s national hand surgery organisation, the British 
Society for Surgery of the Hand (or BSSH) is keen to assess how 
people fare after having surgery for this. 
 
You may recall that you had an operation for this condition (which 
causes fingers to bend into the palm) either 1 year ago or 5 years 
ago. 
 
We would like to invite you to participate in this service evaluation. 
If you are happy to do so the BSSH will contact you by phone to 
arrange this. It will involve a visit to a clinic here. Your medical 
notes will be available in the clinic for the BSSH surgeon to review 
with you, if required.  
 
You will be reimbursed £5 to help cover transport costs. 
 
If you are happy to be involved, then please complete the enclosed 
consent form and return it using the stamped addressed envelope 
provided. The surgeon conducting the research will then contact 
you. 
 
There are a number of different research projects looking at this 
condition and you may be approached by other colleagues of mine 
also. Please be aware that all of this is entirely voluntary and, 
if you choose not to take part, your treatment will not be 
affected in any way. 
 
It is hoped that the results of this research will help hand surgeons 
to design and assess new treatments in the future. 
 
Many thanks. 
 
Yours sincerely, 
 
 
 
Mr Indranil Chakrabarti  
Consultant Hand Surgeon 
University of Nottingham   Appendices 
 429 
Appendix 4: Consent form 
 
 
BSSH$
Research$!
!
1.  I confirm that I have read and understand the letter 
dated XXXX. 
2. I understand that the study is being coordinated by 
Nottingham University Hospitals NHS Trust, The University of 
Nottingham and The British Society for Surgery of The Hand, 
and give permission for a surgeon working on their behalf to be 
given my details for this study. 
 
3. I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving any reason, without 
my medical care or legal rights being affected. 
 
4. I understand that sections of any of my medical notes may be 
looked at by responsible individuals where it is relevant to my 
taking part in research.  I give permission for these individuals to 
have access to my records. 
 
5. I understand that the data will be stored securely for at least 
10 years after which it will be disposed of securely.  Regulatory 
authorities from Research & Development department will have 
access to identifiable data for monitoring purposes. 
 
6. I agree to take part in the above study. 
 
 
 
  
SIGNATURE: ______________________________ 
 
DATE:  ____ / ____ / ____ 
 
PRINT NAME: ______________________________ 
 
TELEPHONE NUMBER: ________________________ 
(to arrange clinic appointment via phone) 
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Appendix 5: Cross Sectional Study Proforma 
 
 
!
!
!
!
!
Cohort!! 1yr!! 5yr!!!
Assessment!date! _____________________!!
Operation!date! ! _____________________!!
Operation!Hospital!&!Surgeon! ____________________________________!!
Operated!Hand! R!! L!!!
Operated!digits! TH!! IF!! MF!! RF!! LF!!!
Operation! Needle!! Blade!! Limited!! Fasciec!! Dermofasc!!! ! ! ! ! ! ! ! !!!!!!!MCP!/!P1!/!PIPJ!/!P2!! ! midAaxial!Y!!!!N!!
Graft!donor! ! _____________________________________!!
Splint!postop! ! Y!! N!! details! ____________________________________________!!
Previous!ipsilat!surgery! Y!! N!! details!____________________________________________!!
Previous!contralat!surgery! Y!! N!! details!____________________________________________!
Hand!dominance!! R!! L!!!
Occupation!since!op! ____________________________________________________________________!!
Main!Occupation!preop! ____________________________________________________________!!
Family!history! Y!! N!! details! _____________________________________!
!
Diabetic! Y!! N!,!! type!1!! ! type!2!,!meds!_____________________________!!
Steroids! Y!! N!!!
Smoker! ! Y!! N!!!
Epilepsy! Y!! N!! meds! ____________________________________________________!!
Weekly!alcohol!intake! ____________________________________________________________!!
Infection!requiring!antibiotics! Y!! N!! details! _____________________________________!!
2!point!discrim!intact!6mm! Y!! N!! details! RDN_____________UDN________________!!
Cold!intolerance!! ! Y!! N!! details! _____________________________________!!
CRPS! ! ! ! Y!! N!! details! _____________________________________!
!
Surgery!since!index!operation! Y!! N!! details! _____________________________________!!
Passive!extension! ! MCPJ!_________________!! PIPJ! ____________________!!
Active!flexion!digit! ! ! _____________________________________________!!
Active!flexion!other!digits! ! _____________________________________________!!
Operation!site:!palpable!disease! Y!! N!!! Cord!&!Contracture!! Cord!! Nodule!!!
Graft!recurrence:!! under!graft! ! ! lat!to!graft! ! prox!/!distal!to!graft! !!
Other!fingers!(same!hand)!with!disease! Th!! Web! ! IF!! MF!! RF!! LF!!!
Other!fingers!(other!hand)!with!disease!! Th!! Web! ! IF!! MF!! RF!! LF!!!
Knuckle!pads! Y!! N!! Lederhose!disease! Y!! N!!!
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Appendix 6: Cohort Study Baseline Data Capture Proforma 
 
 
!!Assessment!date!_____________________!!Operation!date! _____________________!!Operation!Hospital! ____________________________________!!Surgeon! ____________________________________!!Telephone!____________________________________!!!Operated!Hand! R! L!!Operated!digits! TH! IF! MF! RF! LF!!Operation! ! Needle! ! Limited!! Fasciec! ! Dermofasc!! ! ! ! ! ! ! ! !!!!!!!MCP!/!P1!/!PIPJ!/!P2!Previous!surgery! Y! N! details!____________________________________________!!!!Hand!dominance!! R! L!!Occupation! ____________________________________________________________________!!Diabetic!! Y! N! type!1! ! type!2,!meds!_____________________________!!Steroids! Y! N!!Smoker! ! Y! N!!Epilepsy! Y! N! meds! ____________________________________________________!!Other!PMH! _____________________________________________________________________________!!Current!angles! ! ! MCPJ!_________________! ! PIPJ! ____________________!!
Name!DoB!Number!!
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